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SCIENTIFIC OPINION  
Scientific Opinion on the assessment of allergenicity of GM plants and 
microorganisms and derived food and feed1 
EFSA Panel on Genetically Modified Organisms (GMO Panel)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The weight-of-evidence, case-by-case approach is considered the most appropriate way of assessing 
the allergenicity of genetically modified (GM) food and feed. This scientific opinion discusses various 
aspects to increase the strength and accuracy of this approach, including the latest developments 
pertaining to clinical aspects of allergic reactions, structural aspects of GM food and feed and in silico 
approaches, as well as IgE binding studies and cell-based methods, profiling techniques and animal 
models. In this context, conclusions and recommendations are provided to update and complement 
current risk assessment strategies for the allergenicity assessment of newly expressed protein(s) and 
whole GM food and feed. In summary, it is recommended that with regard to the search for sequence 
homology and structural similarities, the local alignment method with a known allergen with a 
threshold of 35% sequence identity over a window of at least 80 amino acids is considered a minimal 
requirement. When IgE binding tests are considered necessary, e.g. when there is sequence homology 
and/or structure similarity with known allergens, the use of individual sera from allergic individuals 
rather than pooled sera is recommended. In addition to the pepsin resistance test, it is recommended 
that the resistance to digestion of the newly expressed proteins is evaluated using other in vitro 
digestibility tests mimicking physiological conditions of humans. Finally, when the recipient of the 
introduced gene is allergenic, in order to compare the allergenicty of the whole GM plant with that of 
its appropriate comparator(s), it is recommended that relevant characterised endogenous allergens are 
included in the comparative compositional analysis of the GM plant and its appropriate comparator(s). 
Proposals for the use of additional testing that may improve the weight-of-evidence approach and 
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Wright, and Jean-Michel Wal. Opinion is shared by all members of the Panel. Correspondence: gmo@efsa.europa.eu  
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suggestions for further evaluation of new promising methods that are as yet in an early phase of 
development are also addressed. 
 
KEY WORDS 
Allergenicity, genetically modified organism, food, feed, safety, newly expressed protein, weight-of-
evidence approach. 
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SUMMARY 
 
This Opinion follows a request from the European Food Safety Authority (EFSA) to the Panel on 
Genetically Modified Organisms (GMO Panel) to establish a Working Group on “The Assessment of 
allergenicity of genetically modified foods”.  
 
The strategy summarised in this report for assessing the allergenicity of GM food and feed considers 
the allergenicity of the newly expressed proteins, the whole GM food and feed, and also other aspects, 
such as exposure. Particularly with regard to newly expressed proteins, it is based on a weight-of-
evidence, case-by-case approach, in line with the approach followed in the EFSA guidance document 
and the Codex Alimentarius guideline. Different aspects of the allergenicity risk assessment of GMOs 
are discussed in this report, and where relevant, additional recommendations are provided to further 
strengthen the weight-of-evidence approach. These include recommendations with regard to the 
search for sequence homology and structural similarities, IgE binding tests and testing of the 
digestibility of newly expressed proteins. The recommendations also pertain to the comparative 
analysis of endogenous allergens and their structural characteristics in whole GM food and feed. In 
addition, proposals have been made with regard to other additional testing that may improve the 
assessment, e.g. animal models, as well as suggestions for further exploring new promising methods 
that are as yet in an early phase of development, particularly on 3-dimensional structure of allergens, 
profiling technology, exposure assessment and post-market monitoring. 
 
The background information, scientific evidence and rationale on which the conclusions and 
recommendations are based, can be found in the annexes. 
 
Annex 1 (Clinical aspects of food allergy) deals with the mechanisms, the prevalence and clinical 
pictures of food allergy, as well as the diagnostic procedures. Within the assessment of allergenicity 
of GMOs, attention is paid to the risk for populations with a particular or altered digestive physiology 
such as infants. In addition, the possible role of GMOs as adjuvants, i.e. substances that, when co-
administered with a protein increases its immunogenicity and therefore might increase as well its 
allergenicity, is considered within the allergenicity assessment of GMOs. Where possible, the use of 
surveillance programmes such as post-market monitoring and survey of occurrence of occupational 
allergic reactions through different routes of exposure is proposed. 
 
Annex 2 (Structural aspects of food allergens: conformation, in planta processing and food matrix 
interactions) addresses the structure and biological properties of a newly expressed protein in an 
integrative approach for assessing its possible allergenicity. Current understanding of how the 
allergenic potential relates to protein structure, biological properties, post-translational modifications 
and plant processing, and how it may be affected by food processing and interactions with the food 
matrix is presented. This is discussed within the context of the natural variability and taking into 
account that genetics, environmental factors and post-harvest conditions may affect the expression of 
allergens in plants. Therefore, the considerations developed in this Annex do also pertain to the 
assessment of allergenicity of the whole plant. 
 
Annex 3 (Bioinformatics for the assessment of allergenicity of newly expressed proteins in GMOs) 
covers various bioinformatics methods available including allergen databases and algorithms for 
search of sequence identity of newly expressed proteins with known allergens and the assessment of 
the relevance of alignments observed. A recommendation is made that allergen databases are 
regularly updated and checked for accuracy (e.g. absence of irrelevant allergens and presence of 
minor true allergens with low frequency of sensitisation). Criteria for inclusion of proteins into 
allergen databases and for sequence identity searches are discussed as to improve the accuracy, 
sensitivity and specificity of current bioinformatics approaches. Bioinformatics analyses are not 
appropriate for the assessment of the de novo sensitisation potential of a newly expressed protein but 
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provide useful information on the possible IgE-cross-reactivity with known allergens. Such 
information should be confirmed by other tests to conclude on the likelihood of allergenicity of the 
newly expressed protein(s). 
 
Annex 4 (Assessment of allergenicity of newly expressed proteins in GMOs using in vitro and cell-
based tests) describes in vitro methods that can be used for assessing the allergenicity of newly 
expressed protein(s). This includes a discussion of different IgE binding assays and criteria for serum 
selection, and an overview of experimental conditions for performing and interpreting the outcome of 
in vitro digestibility tests. IgE-binding assays aim to test for possible IgE-cross reactivity of the newly 
expressed protein with known allergens. Specific serum screening is required if there is any indication 
of relationship or structure similarity with known allergens as evidenced in the previous step of the 
assessment, or if the source of the transgenic protein is considered allergenic, i.e. is known to produce 
one or more allergen(s). In view of the problems associated with the use of sera of human origin, the 
possibility of using well-characterised antibodies raised in animals for a pre-screening may be 
envisaged. Stability towards in vitro digestibility can provide additional information about the 
possible allergenic potential of the newly expressed protein. The conditions that should be observed 
for performing those tests and correctly interpreting the outcome are discussed in relation with the 
clinical considerations presented in Annex 1. Cell-based assays that employ either cells isolated from 
human or animal tissues or propagated from immortal cell lines are also considered.  
 
Annex 5 (Analytical and profiling technology/in vitro protein analysis and proteomics methods for the 
allergenicity assessment of the whole GM plant) addresses analytical methods and profiling 
techniques for assessing the potential increase of the intrinsic allergenicity of the whole plant and 
derived products as an unintended effect of the genetic modification. When the recipient of the 
introduced gene is known to be allergenic, a potential quantitative and/or qualitative change in the 
allergenicity of the whole GM food should be tested by comparing the allergen repertoire of the GM 
plant with that of appropriate comparator(s) taking into account the natural variability in the 
endogenous allergen expression. Allergens in whole plants can be analysed based on their 
immunochemical and biological properties with gel-electrophoresis followed by immunoblotting. 
Alternative proteomic methods using, e.g. mass spectrometry for identifying and quantifying allergens 
are also reviewed. High throughput analytical techniques are a promising tool for non-targeted 
profiling of differences in protein expression in the GM plant compared with its appropriate 
comparator(s). It is proposed that they should be thoroughly assessed for accuracy, sensitivity, 
specificity and feasibility before being routinely used for allergenicity assessment. 
 
In Annex 6 (Animal models) a review and a critical appraisal is made of the numerous animal models 
(including transgenic animals) that are currently available to test the capacity of a newly expressed 
protein to elicit an allergic reaction in allergic consumers already sensitised to a cross-reactive 
allergen or its potential to de novo sensitise predisposed individuals. Advantages and pitfalls of the 
different models are analysed. It is noted that none of these models fully reproduce either the diversity 
and variability of the IgE response in heterogeneous populations of allergic humans or the conditions 
of sensitisation that occur in the real life upon given conditions of exposure and environment. In 
addition, none of the current animal models has both enough sensitivity and specificity in order to 
guarantee the absence of false negative and false positive results. Animal models are, therefore, in 
general considered not validated and inconclusive for the assessment of the sensitising potential of a 
novel protein. However, they can provide useful information on the different mechanisms underlying 
the induction and development of an allergic reaction when there are indications of a sensitising or 
adjuvant potential of the newly expressed proteins.  
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PREAMBLE 
This “Scientific Opinion on the assessment of allergenicity of GM plants and microorganisms and 
derived food and feed“ addresses some aspects of food allergy and food allergens, and reviews the 
methods to assess the potential for allergenicity of newly expressed proteins and of whole GM food 
and feed.  
The EFSA GMO Panel wishes to emphasise that the allergenicity assessment of GM food and feed as 
described in this scientific opinion follows the same weight-of-evidence, case-by-case approach as 
described in the EFSA guidance document (EFSA, 2006b, 2009), the draft Commission Regulation 
(EC, 2009) and the Codex Alimentarius guideline (2003). This opinion discusses further developments 
in the area of allergenicity assessment which might be useful to increase the strength and accuracy of 
this approach for the assessment of the possible allergenicity of a GM food and feed. 
The weight-of-evidence, case-by-case approach implies that not all of the recommended testing 
methodologies are necessary in all cases. They should be performed depending on the characteristics 
and the set of information already obtained on the newly expressed proteins, on the source and on the 
recipient of the transgene in order to conclude on the likelihood of allergenicity. Although this 
scientific opinion contains recommendations, it has not the status of a regulatory document and is not 
binding in character. Recommendations should not be considered as general prescriptive requirements 
but as a help for the applicants to design and perform the allergenicity assessment of GM plants and 
microorganisms and for risk assessors to evaluate and interprete this assessment. 
Scientific evidence strengthening the weight-of-evidence approach may be based on experimental data 
provided by the applicant as well as on information from the available literature. In this sense the risk 
assessment process should be clearly distinguished from a regulatory process which includes risk 
management and control measures. It must be noted that, in contrast to what might be required for 
enforcement purposes in a regulatory context, relevant and useful information gained from the 
scientific field to strengthen the risk assessment may also be obtained using new methodologies. 
Therefore some of the methods described in this opinion are not standard methods and are thus not 
(yet) applicable for routine testing but can contribute to building a firmer platform on which to base an 
allergenicity assessment. 
 
With regard to the assessment of allergenicity of the whole plant, the EFSA GMO Panel is aware that 
little information is known regarding the natural variability of allergens in crops due to the effects of 
cultivars and various environmental conditions. Since the comparative assessment is the cornerstone 
for the safety assessment, reference data on allergen composition in allergenic crops needs to be 
created to allow accurate comparative compositional analysis of GM plants and appropriate 
comparators. It is also to be noticed that including relevant commercial varieties in the comparative 
analysis of known relevant endogenous allergens in plant tissues would also allow equivalence tests to 
be performed as recommended by EFSA (2010b) and draft Commission Regulation (EC, 2009). 
 
BACKGROUND 
The present Scientific Opinion follows a request from EFSA to the GMO Panel to establish a Working 
Group on “The Assessment of allergenicity of genetically modified foods”. The Working Group 
started its activities in December 2005, and has held 20 meetings in total.  On 21 October 2009, the 
EFSA GMO Panel endorsed a draft Opinion, which was published on the EFSA website from 1 
December 2009 until 14 February 2010 for a 10-week period of public consultation. A Scientific 
Report summarising the comments received through the public consultation (EFSA, 2010a) is 
published on the EFSA website along with this opinion. The Working Group has revised the draft 
opinion taking into account the comments from the public consultation and the final Opinion was 
adopted by the GMO Panel on 30 June 2010.  
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TERMS OF REFERENCE  
The EFSA GMO Panel was given the mandate to establish an ad hoc Working Group for a self 
mandate on “Assessment of allergenicity of GM foods”: 
- to review current strategies and test methods for the assessment of allergenic potential of GM 
plants/microorganisms as food or raw materials for food ingredients;  
- to consider new scientific developments and methodology in the area of allergenicity testing and 
assessment;  
- as appropriate, to propose new approaches for the assessment of allergenicity, including more 
accurate and sensitive tests as to increase the level of safety assurance of non-allergenicity of GM 
plants/foods and demonstrate that the genetic modification does not increase the allergy risk; 
- to invite external experts to the Working Group recognised for their competence in specific 
scientific fields and/or for their experience on case studies; 
- to organise workshops with the stakeholders;  
- to prepare recommendations to be used for the scientific assessment of allergenicity of GM plants 
and their products as an update/complement of the EFSA Guidance document for the risk 
assessment of genetically modified plants and microorganisms and derived food and feed (EFSA, 
2006a, 2006b, 2009). 
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ASSESSMENT OF ALLERGENICITY OF GM PLANTS AND MICROORGANISMS 
AND DERIVED FOOD AND FEED 
 
1. INTRODUCTION 
 
Allergenicity is the potential of a substance (e.g. food or food components such as proteins) to cause 
an allergy. Paragraphs 1.1 and 1.2 first summarise the main characteristics of food allergy, whereas the 
subsequent paragraphs address the issue how to identify and assess the different aspects of 
allergenicity of newly expressed protein(s) in GMOs and of foods derived from GMOs. 
 
1.1 Food allergy 
 
Food allergy is an adverse reaction to food and represents an important public health problem. Food 
allergy is different from toxic reactions and intolerance. Allergy is a pathological deviation of the 
immune response to a particular substance which affects only some individuals where a combined 
effect of variations in the environment and genetic predisposition has resulted in allergic sensitisation. 
In allergic individuals, sometimes minute amounts of a food that is well tolerated by the vast majority 
of the population can cause serious symptoms and death. It is not the allergen per se, but the allergic 
person’s abnormal reaction to the allergen that causes the adverse health effect. Food allergy can be 
caused by various immune mechanisms. However, IgE-mediated food allergy represents the main 
form of food allergy, that causes the most severe reactions and the only form causing life-threatening 
reactions. This IgE-mediated food allergy has been the focus in the risk assessment of allergenicity of 
GMOs and Novel foods (Codex Alimentarius, 2003; EC, 1997; EFSA, 2006b, 2009). With regard to 
food intolerance, the mechanisms are not well understood but in many cases is a consequence of a 
defect in digestion or metabolism. 
 
The assessment of allergenicity of a food or food component is the responsibility of scientific risk 
assessment bodies, and is a pre-requisite of marketing of GM foods (EC, 2003b). The prevention and 
management of food allergy is a responsibility of governmental regulatory bodies as well as the food 
industry and the food suppliers.   
 
1.2 IgE-mediated food allergy  
 
Importantly, food allergy consists of two separate phases: first sensitisation where no symptoms occur 
while the capacity of the immune system to react increases dramatically, and later elicitation 
(provocation) with clinical manifestations. When ingested, the allergen(s) i.e. the sensitising food or 
food component is to some extent degraded by digestive enzymes, absorbed by the gut mucosa (small 
amounts even by the oral mucosa), processed in specialised cells of the immune system and then 
presented to the reactive immune cells that produce an immune response. Sensitisation can also occur 
if the food allergen comes into contact with the skin or is inhaled (Lack et al., 2003). The mechanisms 
of IgE-mediated food allergy are described in Annex 1. In susceptible individuals, previous exposure 
to the incriminated food resulted in the synthesis of specific antibodies by lymphocytes, including 
antibodies of the immunoglobulin E (IgE) class. The specific IgE antibodies circulate in the body and 
bind to the surface receptors of blood basophils and tissue mast cells. Subsequent contact of the 
immune system with the same allergen, or with another molecule sharing common structures (so-
called epitopes) with the parent sensitising allergen, will cause more specific IgE to be produced and 
to bind to basophils and mast cells. This first phase of allergy is the sensitisation phase, during which 
the immune system responds with specific IgE production to the allergen in question, a process that by 
itself does not cause any symptoms. Finally, when the density of IgE antibodies on the mast cell and 
basophil cell surface is sufficiently high, the elicitation phase can occur. If the allergen now comes 
into contact with the IgE-coated immune system cells, the allergen molecule (as intact protein or at 
least bivalent immunoreactive fragments) will bind and cross-link the specific IgE present on the cell 
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membrane.  This cross-linking of IgE on mast cell and basophil cell membranes triggers the early 
phase of the immediate type allergic reaction. Pharmacologically active mediators, such as histamine, 
prostaglandins, and leukotrienes are released, causing the onset of the various symptoms of allergy.  
Some hours later, a second phase of inflammation may develop (“late phase reaction”), caused by a 
cellular reaction in which eosinophil granulocytes and T lymphocytes play a dominant role. The 
symptoms of the food allergic reaction are not limited to the oral cavity and the gastrointestinal tract 
but are also cutaneous and respiratory and even cardio-vascular. It is noteworthy that some individuals 
may get sensitised to an allergen i.e. produce detectable amounts of specific IgE antibodies to this 
allergens without developing any clinical symptoms of allergy upon exposure to this allergen.  
 
Because of structural similarity between certain allergens, the same food or allergen is not always 
required for both steps of the allergic reaction. Specificity is limited to the small part of the allergen 
(the epitope) directly binding to IgE.  Epitopes on different proteins, as a rule evolutionary related, 
may be identical or similar enough to bind to the same IgE molecules. When sensitisation to one 
allergen causes the immune system to respond to another allergen because of shared epitopes 
(identical or with a high degree of similarity) between the allergens, this is called cross-reactivity.  
 
It is important to note that there are two levels of cross-reactivity. Cross-reactivity may be limited to 
IgE binding without observed adverse effects (cross-sensitisation), or it may also confer clinical 
reactivity (cross-allergenicity). Cross-reactivity on the level of IgE binding is much more common and 
widespread than clinical cross-reactivity. The in vitro demonstration of cross-reactivity between two 
allergens in terms of IgE binding is no proof of clinical cross-reactivity, and only means that one 
important pre-requisite for clinical reactivity is present.  
 
Cross-reactivity complicates food allergy assessment, management and prevention. Cross-reactions 
exist between foods, between foods and pollen, and between foods and other substances like rubber 
latex, mite and insect allergens. As an example, frequent cross-reactions are observed between birch 
pollen and hazelnut, apple and more generally fruits of the Rosaceae family. Cross-reactions are also 
observed between pollen of Compositae (mugwort) and celery. Also important are foods that cross-
react with latex, e.g. chestnut, walnut, kiwi, banana, and avocado. Depending on their different epitope 
preferences, different individuals differ in their cross-reactivity patterns. 
 
 
1.3 Allergenicity assessment of GMOs 
 
Allergenicity is not an intrinsic, fully predictable property of a given protein but is a biological activity 
requiring an interaction with the immune system in predisposed individuals. It, therefore, depends 
upon the genetic diversity and variability in environmental exposures in the individuals. Given this 
lack of complete predictability it is necessary to obtain, from several steps in the risk assessment 
process, a cumulative body of evidence which minimises any uncertainty with regard to the protein(s) 
in question. In line with the recommendations of the Codex ad hoc Intergovernmental Task Force on 
Foods Derived from Biotechnology (2003) and the EFSA guidance document (EFSA, 2006b, 2009), 
an integrated, case-by-case approach, as described below, should be used in the assessment of possible 
allergenicity of newly expressed proteins.  
 
These new proteins can either de novo sensitise individuals particularly those with a predisposing 
genetic background (i.e. atopic individuals) and history of environmental exposure and/or elicit an 
allergic reaction in individuals already sensitised to another cross-reacting protein. Increased exposure 
to allergens already present in the conventional crop may also be part of the risk profile of GM plants, 
as the genetic modification may have resulted in unintended changes in the pattern of expression of 
endogenous allergens (e.g. over-expression of endogenous allergenic proteins naturally present in the 
recipient plant). 
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Consequently, when assessing the allergenicity of GMOs, two main issues are clearly to be addressed 
(EFSA, 2006b, 2009): i) the allergenicity of the newly expressed protein(s) that can be present in 
edible parts of the plants (an issue related to the source of the transgene/newly expressed protein, and 
ii) the potential increase of the intrinsic allergenicity of the whole plant and derived products as an 
unintended effect of the genetic modification (an issue related to the recipient). Another issue to be 
taken into account is a possible increase in the intake of / exposure to the GM food although its 
content of allergenic proteins has not been changed. Similar issues pertain to exposure to pollens of 
GM plants. 
 
Based on a comparative approach, the allergy risk assessment of GMOs aims to establish i) whether 
the newly expressed protein(s) are likely to be allergenic and ii) whether the allergenicity of the GM 
plant is similar or different to that of the appropriate comparator(s).  Since no single experimental 
method yields decisive evidence for absence of allergenicity, a weight-of-evidence approach is 
recommended taking into account all of the information of different nature obtained with various test 
methods. Methods used for the allergenicity assessment of newly expressed proteins in GMOs first 
investigate whether or not the source of the transgene/newly expressed protein has a history of 
allergenicity, then include a search for sequence homologies and/or structural similarities between the 
newly expressed protein and known allergens, in vitro tests to measure the capacity of specific IgE 
from serum of allergic individuals to bind the test protein and the resistance to degradation by the 
proteolytic enzyme pepsin. Where necessary, other additional tests may be used. These methods 
provide information on the risk of elicitation of an allergic reaction by the newly expressed protein in 
already sensitised individuals. Their contribution to the assessment of the risk of de novo sensitisation 
of atopic individuals is still a matter of scientific debate. 
 
As the pre-market assessment of GM products under Regulation (EC) 1829/2003 also considers the 
use of a GM product as animal feed besides its use as food, the potential for allergenicity in animals, 
both companion and livestock, should be considered.  Allergy and intolerance to feeds in animals may 
be due to several mechanisms and result in various clinical manifestations. The pathophysiology, the 
nature of the most common allergens, the level of exposure and digestive physiology in animals may 
be different from those in humans. Whilst animals and humans may share some allergens in common, 
no available source is known to exist to date that provides comprehensive information on specific 
compounds that would be allergic to some animals but not to humans. 
 
1.4 Scope of the report 
 
It is within the scope of this report to evaluate the robustness of currently used methods and to assess 
new scientific developments to refine the current allergenicity assessment approach, as well as the 
feasibility of incorporating these in the above mentioned weight-of-evidence approach. Emerging new 
tools, based on in vitro and in vivo methodology but not yet validated, will be evaluated for whether 
they are potentially appropriate to strengthen an accurate and sensitive assessment of allergenicity.  
 
The emphasis of this report is on the assessment of allergenicity in humans, defined as IgE-mediated 
or immediate-type hypersensitivity reactions. However, non-IgE mediated adverse reactions, 
immunogenicity, adjuvanticity, celiac disease and other food induced enteropathies have also been 
touched upon. Whilst the report focuses on allergenicity in humans mostly, it also considers 
allergenicity in animals, where applicable. 
 
The above mentioned considerations will be reviewed and evaluated for novel proteins expressed in 
GM plants and microorganisms, as well as for food and feed derived from such organisms. The 
assessment of whole food and feed is however difficult since food or feed products are complex. They 
may contain natural compounds, e.g. proteins that may be bioactive or allergenic per se. They may 
interact with the food matrix which would alter their functionality. In addition, processing may affect 
their structure, digestibility and therefore their allergenicity in the processed foods. The assessment of 
the allergenicity of the whole food or feed will mainly focus on the comparison of the qualitative and 
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quantitative patterns of expression of endogenous allergens in the GM plant and its appropriate 
comparator(s). 
 
2. STRATEGY FOR ASSESSING THE ALLERGENICITY OF GM FOOD AND FEED 
 
This section summarises the present strategy recommended by the EFSA GMO Panel for assessing the 
allergenicity of GM food and feed. It follows the same weight-of-evidence, case-by-case approach as 
recommended by Codex Alimentarius (2003) and as described in the EFSA guidance document 
(EFSA, 2006b, 2009). Following the analysis of the conclusions of its self mandate Working Group on 
”Assessment of allergenicity of GM foods”, the EFSA GMO Panel is still of the opinion that the 
weight-of-evidence approach is the most appropriate way of assessing the allergenicity of GM food 
and feed. With the purpose of updating and further refining this approach, a review has been made of 
the latest developments regarding clinical characteristics of food allergy, structural aspects of GM 
food and feed, in silico (or bioinformatic) approaches, IgE binding and cell-based methods, analytical 
“profiling” techniques and animal models. Recommendations to update and complement current risk 
assessment strategies and to strengthen the allergenicity assessment of GM food and feed are 
provided. Some of these recommendations do pertain to methods in an early phase of development, or 
to methods that have not yet been fully explored and validated in the area of allergenicity assessment, 
but which might be informative in certain cases to add to the weight-of-evidence approach. As 
mentioned in the preamble, they should be considered as suggestions to help performing and 
evaluating the allergenicity assessment and they should be used on a case-by-case basis, taking into 
account the characteristics of the introduced gene(s) and the recipient organism.  
 
So far, few tests have been validated for predicting the allergenicity of a (novel) protein or food. 
Validation may apply to the procedure in order to ensure the quality characteristics of the tests (e.g. 
sensitivity, specificity and reproducibility) and/or the relevance of the test. In this regard, the 
sensitivity of the test which reflects the rate of false negative results (i.e. the number of true allergens 
that would not be identified as such) and the specificity which reflects the rate of false positive results 
(i.e. the number of non-allergenic constituents that would be considered as allergens) are most 
important characteristics. No test with sufficient sensitivity, specificity and reproducibility is available 
to facilitate a definite conclusion on the allergenicity of a novel protein/food. However, the 
combination of a variety of tests may provide sufficient information on the likelihood of allergenicity.  
 
The recommendations are mainly aimed, where applicable, at applicants and risk assessors, and to a 
certain extent at risk managers, policy makers and the scientific community. They are not aimed at 
providing guidance to clinicians on protocols that should be performed in the diagnosis of an 
allergenic response of human consumers to a GM food. 
 
The scientific evidence and background information, on which the conclusions and recommendations 
are based, as well as a more extensive description of the recommendations, can be found in the 
annexes as indicated in the footnotes and in the different sections mentioned below.  
 
2.1 Assessment of allergenicity of newly expressed proteins 
 
The fact that a newly expressed protein belongs to a plant protein family known to include many 
allergens is not a definite evidence of allergenicity but it may be indicative of the need for further 
investigations. Also it is recognised that no direct relationship has yet been demonstrated linking the 
structure of a newly expressed protein with its allergenicity which would allow reliable prediction of 
allergenicity or non-allergenicity from structural considerations alone. In particular post-translational 
modifications, such as glycosylation, are not a predictive indication of an allergenic potential; 
similarly absence of glycosylation is not a demonstration of absence of allergenicity. However, post-
translational modifications may, in some cases, be an important issue to address because it can affect 
the stability of the newly expressed protein to digestion and thus have an impact on its allergenicity. It 
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also impacts on the interpretation of IgE binding studies; for example it is important to distinguish 
between IgE binding capacity linked with clinical significance versus positive IgE binding without 
clinical significance (e.g. N-linked glycans) (see Annex 2.8.3). In this sense, when studying the 
structural characteristics and the biological and physicochemical properties of a newly expressed 
protein, it is essential, as indicated in the EFSA Guidance Document (EFSA, 2006b, 2009), that the 
tested protein is equivalent with respect to structure and activity to the newly expressed protein in the 
GM plant. 
 
Studies carried out using purified target proteins prepared by expression in organisms such as 
Escherichia coli are acceptable as long as the properties of the microbial substitute protein are 
identical to those of the protein expressed in the plant, thus taking into account all post-translational 
modifications that specifically occur in the plant. The same remarks regarding the possible influence 
of in planta processing on structural modifications of the newly expressed protein also pertain to the 
influence of the environment of the newly expressed protein. Thus, the food matrix, and/or food 
processing may also impact on the structure and on the bioavailability of the protein and its 
digestibility. 
 
Therefore, it is a general recommendation to define the presence and nature of all post-translational 
modifications of the newly expressed protein in the plant. In this regard, the use of modern analytical 
methods using e.g. “-omics” technology and mass spectrometry is proven as a powerful method (see 
Annex 5.4 and 5.5).  
 
In addition, adjuvanticity, which is the capacity of a substance that when co-administered with an 
antigen increases the immune response to that antigen, has not been routinely considered in the 
assessment of allergenicity of GMOs. It should be assessed when there are indications that the newly 
expressed proteins functionally or structurally resemble a known adjuvant and are present at 
concentrations sufficient to be of concern.  
 
2.1.1 Search for sequence and structural similarities4 
 
Within the weight-of-evidence approach, a search for amino acid sequence and structural similarities 
between the newly expressed protein and known allergens shall be carried out using bioinformatics 
methods to identify potential IgE cross-reactivity between the newly expressed protein and known 
allergens. A typical in silico risk assessment of allergenicity minimally requires the following two 
resources: a repository of all known allergens with determined amino acid sequence (and, possibly, 3D 
structure) and an appropriate algorithm for searching relevant similarity between a query protein and 
the allergen database.  
 
Criteria for inclusion of allergens into databases are rarely stated and therefore the quality of most 
databases is difficult to assess. Moreover, most of the existing databases are likely to contain errors, 
such as presence of irrelevant allergens, and absence of true allergens (e.g. that might be minor 
allergens in a food). Other important features related to reliability of databases include good technical 
maintenance, regular curation, as well as a user-friendly retrieval system so that amino acid sequences 
can be easily extracted from the databases. 
 
The alignment-based criterion involving 35% sequence identity to a known allergen using a sliding 
window of 80 amino acids as proposed by FAO/WHO is still accepted as adequate for 
allergenicity/IgE-cross reactivity assessment also when compared to novel approaches. In addition, to 
optimise sensitivity versus specificity, a decision has to be made on the acceptability of false-negative 
rate since an overly strict adherence to sensitivity will result in an unreasonable number of false 
positives without completely avoiding all cross-reactivity risk. Peptide match of complete identity 
over 6 contiguous amino acids to known allergens is associated with very poor specificity (many false 
positives) and its relevance is doubtful. Complementary methods could also be considered to further 
                                                     
4 See annex 3 
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ensure absence of similarity to known allergens. For example, several web servers that rely on novel 
principles (based on motifs and peptides specific to allergens) have shown to be highly specific 
without loosing in sensitivity. In addition it is noted that the production of IgE antibodies depends on 
activation of specific T lymphocytes. A sequence homology search for T cell epitopes present in 
known allergens could therefore be carried out, identifying potentially immunogenic peptides. 
However, the predictive value of T cell prediction algorithms for allergic sensitisation is limited. In 
combination with cellular based tests, T cell epitope prediction may be useful for immunogenicity 
assessment and therefore hold prospects for further development. 
 
Conclusions: 
1. There is an important development in bioinformatics methods that are widely used for the risk 
assessment of newly expressed proteins in GMOs. They pertain to the assessment of cross-
reactivity with known allergens.  
2. The information provided by in silico tests is in principle considered useful and reliable for the 
search of amino acid sequence identity between newly expressed proteins and known allergens. 
However, many different bioinformatics methods are currently in use. 
3. Methods searching a complete identity over 6 contiguous amino acids to known allergens are 
associated with very poor specificity (many false positives). Therefore, it is in general not 
considered appropriate. 
 
Recommendations:  
1. Allergen databases used for the assessment of cross reactivity with known allergens should be 
as comprehensive and quality assured as possible (see Annex 3.3; 3.12), and they should be 
regularly updated by a competent independent body. To minimise the risk of overlooking 
potential IgE-cross reactivity due to incomplete databases, in silico consultation of several 
such repositories should be performed. 
2. There is a need for standardisation and harmonisation in search strategy and interpretation of 
results obtained. The alignment-based criterion involving 35 % sequence identity to a known 
allergen over a window of at least 80 amino acids is considered a minimal requirement for risk 
assessment, although the identity threshold is conservatively set. More details on how to 
conduct the alignment based criterion is explained in Annex 3.12.2. All sequence alignment 
parameters used in the analysis should be provided including calculation of percent identity 
(PID) (see Annex 3.6.1; 3.12). It is recommended that the calculation of PID is performed on 
a window of 80 amino acids with gaps so that inserted gaps are treated as mismatches. The 
details for the calculation of the PID can be found in Annex 3.12.2.  
3. In addition, with regards to clinical considerations as detailed in Annex 1, it is noted that there 
is a need to consider data regarding molecular structures of not only proteins known to be 
responsible for IgE mediated allergy but also for other types of immuno-mediated or immuno-
toxic reactions such as peptide fragments of gliadin involved in celiac disease (see Annex 
1.10.2). 
4. It is also proposed that the human allergen databases used for collecting allergen sequences for 
bioinformatics-supported comparisons of newly expressed proteins to allergens are extended 
with allergens for animals (see Annex 1.10.4). 
5. Future work should focus on complementary bioinformatics methods (see Annex 3.12.2) and 
on the completion of databases with information on 3-dimensional conformation of the 
allergens (see Annex 3.12.3). 
 
2.1.2 IgE binding tests5  
 
In vitro tests that measure the capacity of specific IgE from sera of allergic individuals to bind the test 
protein(s) are used for assessing the potential that exposure to newly expressed proteins in GMOs 
might elicit an allergic reaction in allergic individuals already sensitised to cross-reactive proteins. It is 
                                                     
5 See Annex 4.3 
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noteworthy that an IgE binding capacity which is identified for a newly expressed protein may not 
always imply that this protein would trigger an allergic reaction with clinical manifestations. 
 
If the source of the introduced gene is considered allergenic even if no sequence homology of the 
newly expressed protein to a known allergen is demonstrated or if the source is not known to be 
allergenic but there is any indication of relationship between the newly expressed protein and a known 
allergen, based on sequence homology or structure similarity, specific serum screening should be 
undertaken with sera from individuals with a proven allergy to the source or to the potentially cross-
reacting allergen using relevant immunochemical tests. IgE-binding assays (such as Radio or Enzyme 
Allergosorbent Assay (RAST or EAST), Enzyme Linked Immunosorbent Assay (ELISA) and 
electrophoresis followed by immunoblotting with specific IgE-containing sera) are adequate methods. 
It is noted that there is inter-individual variability in the specificity and affinity of the IgE response. In 
particular the specificity of the IgE antibodies to the different allergens present in a given food/source 
and/or to the different epitopes present on a given protein may vary amongst allergic individuals. In 
addition, sera from clinically well characterised allergic individuals that are the reference material for 
IgE binding studies may be available in limited number and quantity.  It is noted that phage libraries of 
human antibodies are currently available and could be used to create a GMO-specific library of human 
antibodies for pre-screening. In order not to test only the IgE binding capacity of the newly expressed 
protein but also its functionality to act as an allergen, the basophil degranulation assay is highly sensitive 
and specific. This test can be standardised using cell lines transfected with the human FcεRI receptor, 
such as rat basophil leukemia cells. 
 
Conclusion: 
1. IgE binding assays using sera from allergic individuals (i.e. specific serum screening) are 
required for the assessment of cross-reactivity when there are indications from the origin of 
the source or from bioinformatic studies. 
2. Relevant human sera may be difficult to obtain and are often limited in number and quantity.  
 
Recommendations: 
When the use of human sera is necessary, the following is recommended: 
1. Specific serum screening should be carried out with sera from well-characterised allergic 
humans taking into account information on their clinical manifestations and on their 
environment. Each serum should be tested individually in order to reflect the variability and 
wide pattern of specificity of the IgE response and to evidence potential IgE binding to minor 
allergens, as the latter would be masked if the test is performed on pooled sera because of 
dilution (see Annex 4.3; 4.5.2). 
2. Future work should focus on the development and standardisation of cell based tests for 
assessing the capacity of the newly expressed protein to bind IgE and provoke the 
degranulation of basophils (see Annex 4.4; 4.5.3). 
 
2.1.3 Additional testing 
 
As indicated in the EFSA GMO Guidance Document (EFSA, 2006b, 2009), additional testing, such as 
a pepsin resistance test, can add to the weight-of-evidence approach. This report provides some 
guidance on how these tests could be carried out to provide more accurate information. 
 
2.1.3.1 Pepsin resistance test and in vitro digestibility tests6  
The pepsin resistance test as currently used is not an in vitro digestibility test designed to mimic the 
physiologic conditions of gastric digestion but simply to determine the biochemical character of 
whether the subject protein is stable to pepsin degradation at pH 1.2 as has been established for some 
known allergenic proteins in food. As stated by FAO/WHO (2001) and Codex Alimentarius (2003) a 
correlation has been observed between the potential of a protein to act as an allergen and its resistance 
to pepsin degradation. A standardised procedure has been developed as to allow comparisons between 
                                                     
6 See Annex 4.2 
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different newly expressed proteins in experimental conditions (Thomas et al., 2004). However, 
numerous subsequent studies as quoted in Annex 4 have demonstrated that this correlation is not 
absolute and that proteins that are resistant to pepsin degradation might not be allergenic in normal 
conditions of exposure whereas labile proteins could be allergenic as well as the fragments that could 
be generated during the proteolysis. The result of this pepsin resistance test can therefore not be 
considered as a strong evidence of absence of intrinsic allergenicity of the protein or as a 
demonstration that the newly expressed proteins is likely to be degraded during the digestion in 
humans with (partly) loss of its toxic or allergenic potential. However a relationship between 
digestibility and allergenicity exists and many food allergens that sensitise through the oral route 
display some stability during gastric and/or intestinal digestion in physiological conditions.  
 
In addition to the pepsin resistance test, protein stability in in vitro digestibility tests reflecting 
conditions of human digestion are therefore recommended. The outcomes of the digestibility assays 
should be interpreted in conjunction with results of other assays and other properties of the protein 
under consideration. In addition, the outcomes of the in vitro digestibility tests should be interpreted 
with care as they represent model conditions. In vitro procedures usually do not reflect the fluctuations 
in pH values and enzyme to protein ratios that occur in vivo after consumption of a meal. Interpreting 
the outcomes of the in vitro digestibility studies on the isolated newly expressed protein in the light of 
other factors, such as the abundance of the protein within the food, interactions with the food matrix 
and possible structural/functional alterations occurring during food processing would be useful.  
 
The specific risk of allergenicity of GM foods in infants as well as in individuals with impaired 
digestive functions should be considered and therefore, the differences in the digestive physiology in 
these subpopulations should be taken into account. Primary sensitisation in the gut of young infants 
might be favoured by the immaturity of the local immunity and incomplete barrier function of the 
intestinal gut mucosa as well as incomplete protein degradation by pepsin in the stomach due to a 
gastric pH above values seen in adults.  
 
Given the information on the variability of i) the conditions occurring during the human digestion 
depending upon the age, the physiological status, the environment of individuals and ii) the resistance 
of proteins to proteolytic degradation (e.g. by pepsin) depending upon the nature and characteristics of 
the food matrix in which they are incorporated and to different processing they may have undergone, a 
single in vitro test of pepsin degradation performed on the purified isolated protein in aqueous solution 
under drastic conditions of pH and enzyme to protein ratio cannot provide sufficient information for a 
comprehensive assessment. It therefore does not allow concluding on the absence of allergenicity of 
the newly expressed proteins, particularly for some segments of the population such as infants and 
individuals with impaired digestive functions. 
 
Experience and information gained from research on in vitro digestibility tests could add to the 
weight-of-evidence approach and improve the assessment of allergenicity of newly expressed proteins. 
For instance, the EU funded RTD project EuroPrevall has developed and implemented elaborated in 
vitro digestibility tests and has investigated on how food processing and the matrix affect the release, 
digestibility and allergenicity of food proteins (Mandalari et al., 2009). Those tests may provide useful 
information on the impacts of such interactions on newly expressed proteins from a food derived from 
a GM plant and prepared as it is intended to be consumed. 
 
As already mentioned in Section 2.1, post-translational modifications, such as glycosylation, 
undergone by the protein during in planta processing may affect the stability to digestion and hence 
modify its allergenic potential.  
 
Although digestibility of a newly expressed protein is an important issue to address when assessing the 
risk of sensitisation via the oral route, it is to be noticed that sensitisation may result from respiratory 
or cutaneous exposure (see Annex 1.10.1). Where relevant those other possible routes of sensitisation 
should be considered. 
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Conclusions:  
1. Although several routes of sensitisation to a newly expressed protein (e.g. via oral, respiratory 
or cutaneous exposure) may be involved (see Annex 1.10.1), food intake represents a major 
route in the case of GMOs. The resistance to digestion may therefore be an important 
indication of an allergenic potential. The pepsin resistance test, as currently performed, is not 
fully predictive for the allergenicity of the newly expressed protein or for its digestibility in 
physiological conditions.  
2. Several in vitro digestibility tests mimicking the human gastric and intestinal digestion are 
available, and resistance of a newly expressed protein to digestion in relevant conditions is 
considered informative with regards to its potential allergenicity.  
 
Recommendations: 
1. In addition to the pepsin resistance test, other in vitro digestibility tests on newly expressed 
proteins are recommended to be performed in more physiological conditions in order to take 
into account variations of the pH value, the enzyme:protein ratio in the stomach and the 
impact of the food matrix and processing on the digestibility of the protein (see Annex 4.2; 
4.5.1). Measuring the resistance to digestion should also take into account the conditions of 
individuals with modified gastric digestion such as pH values > 2 (see Annex 1.10.1). Where 
relevant, other possible routes of sensitisation (e.g. via respiratory or cutaneous exposure) in 
which the protein is not processed by digestive enzymes should be explored. 
2. The occurrence of stable protein fragments and/or of potential larger fragments containing re-
associated peptides formed during digestibility testing should be considered as a risk factor. 
Peptide fragments and/or aggregates should therefore be investigated using conventional 
detection methods, such as gel electrophoresis, or alternative methods (e.g. HPLC and MS) 
(see Annex 4.5.1). 
3. Future work should focus on the need of data on the impact of relevant processing-induced 
modifications on the release, stability to digestion and allergenic potential of the newly 
expressed protein (see Annex 4.5.1).  
 
2.1.3.2 Targeted serum screening  
Targeted serum screening pertains to the use of sera in which IgE are present, directed towards 
allergens that are broadly related to the source of the transgenic protein. This approach may minimise 
the risk of introducing a transgenic protein that is homologous to an “unknown” allergen, i.e. an 
allergen that is not yet in the database and underscores the point that cross-reactive allergenic proteins 
are often not closely taxonomically related. This had been recommended by the FAO/WHO 
consultation in 2001. The technology to perform this kind of screening is well-established but the test 
has not been commonly used so far for the allergenicity assessment of GMOs. 
 
2.1.3.3 Animal models7  
Animal models may contribute to the assessment of allergenicity of newly expressed proteins. 
Whereas some models are more focused towards the study of the de novo sensitisation by a novel 
protein, other models are rather designed to study the potential capacity of a protein to elicit an allergic 
reaction in animals previously sensitised to a cross-reacting protein or whole food. It is noteworthy 
that none of these models fully reproduce either the diversity and variability of the IgE response in 
heterogeneous populations of allergic humans or the conditions of sensitisation that occur in real life 
upon given conditions of exposure and environment. In addition, no animal model has both high 
sensitivity and specificity in order to guarantee the complete absence of false negative and false 
positive results. Therefore, animal models are often considered not validated and inconclusive for the 
assessment of allergenicity. Indeed no single model can provide definite conclusion on the 
allergenicity of a novel protein or a GMO, neither in terms of likelihood/frequency nor in terms of 
severity. In case there is indication from the origin or from the structure of the newly expressed protein 
that it might act as or like a sensitiser, the potential of the newly expressed protein to sensitise de novo 
                                                     
7 See Annex 6 
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atopic individuals could be assessed only using animal models. Animal models might also be useful to 
study the cross-reactivity of the newly expressed protein with known allergens and the clinical 
relevance of observed immunological cross-reactions, e.g. by investigating the potential of the newly 
expressed protein to elicit an allergic reaction in animals previously sensitised to a cross-reacting 
allergen. All the different animal models available (e.g. using different species and/or different 
procedures of sensitisation) have advantages and pitfalls and therefore are not conclusive per se. 
However they can provide useful information on the different mechanisms underlying the induction 
and development of an allergic reaction. In the future, two types of animal models are likely to 
become of particular interest in the search for GMO allergenicity: humanised mouse models in which 
major histocompatibility class II complexes are entirely of human origin and mouse strains which have 
been made deficient in innate immunity components. They will provide information likely to be 
extrapolable to the human situation. 
 
The same considerations apply for the assessment of adjuvanticity of the newly expressed protein 
when indications exist for such a potential. Although there is no definite test for adjuvanticity and 
variability between species is observed, animal models may provide preliminary information.  
 
Conclusion: 
1. Many animal models (including transgenic animal models) have been and are currently 
developed for sensitisation, elicitation and adjuvanticity testing using different species and 
procedures. However, none of them fully reproduce either the diversity and variability of the 
IgE response in heterogeneous populations of allergic humans, or the conditions of 
sensitisation that occur in the real life upon given conditions of exposure and environment. 
Animal models are therefore frequently considered not validated and inconclusive for the 
assessment of allergenicity. Nonetheless, animal models can provide useful information on the 
different mechanisms underlying the induction and development of an allergic reaction.  
 
Recommendations: 
2. Antibodies with appropriate characteristics of specificity and affinity, obtained from animals 
experimentally sensitised in well-defined conditions could be used as a substitute for allergic 
human sera for a (pre-)screening of the immunological cross-reactivity of the newly expressed 
protein with known allergens (see Annex 6.3).  
3. In specific cases such as when indications for sensitisation or adjuvant potential exist, 
additional information gained from (combination of) animal models might be useful (see 
Annex 6.3).  
4. Future work should aim to improve the sensitivity and specificity of animal studies as to allow 
consistent and reliable conclusion on sensitisation and/or adjuvant potential and explore the 
use of transgenic animals which are likely to develop de novo sensitisation to newly expressed 
proteins and are extrapolable to the human situation (see Annex 6.3). 
 
2.2 Assessment of allergenicity of the whole GM plant 
 
As stated in the EFSA Guidance Document (EFSA, 2006b, 2009), when the recipient of the introduced 
gene is known to be allergenic, any potential change in the allergenicity of the whole GM food should 
be tested by comparison of the allergen repertoire of the GMO with that of its appropriate 
comparator(s).  This recommendation is based on the possibility that the genetic modification might 
have induced an unintended effect, e.g. resulting in an over-expression of natural endogenous 
allergen(s). The assessment of the allergenicity of the whole GM food does not directly refer to the 
weight-of-evidence approach as described above and it should be conducted in addition to the 
assessment of allergenicity of the newly expressed protein.   
 
In the case of allergenic plants or derived foods, that is to say those considered as most common food 
allergens that are defined and listed in the annexes of different regulatory texts published for labeling 
purposes and consumer health protection such as EU Directive 2003/89/EC (see Annex IIIa of EC, 
2003a), the comparative compositional analysis of the GM plant with that of its appropriate 
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comparator(s) should include known identified allergens, using targeted or possibly non-targeted 
profiling techniques. 
 
2.2.1 Quantification and characterisation of allergens within the compositional analysis  
 
When the recipient of the genetic modification is allergenic, the allergen repertoire of the GM plant 
and of its appropriate comparator(s) should be analysed and compared, taking into account the natural 
variation in the levels of expression of allergens in edible tissues (and pollen) of the plant and the 
possible presence of isoforms. Although the number of identified food allergens has increased 
tremendously in the recent past, little is known about actual concentrations of allergens for individual 
foods. Because of the great natural variability in the expression of the endogenous allergens, 
differences between non-GM cultivars may be higher than differences between the GM plant and its 
conventional counterpart. In order to assess the possible direct or indirect impact of the genetic 
modification, data on the level of expression of the endogenous allergens (as well as of the newly 
expressed proteins) in different tissues need to be established and used in the interpretation of the 
comparative compositional analysis. In addition, indications on how agronomic conditions, 
developmental stage and post-harvest storage alter expression levels in the GM plant and its 
appropriate comparator(s) and how the food matrix and technological processing may affect the 
allergenicity of the whole GM and non-GM food need to be further investigated (see Annex 2). These 
informations would need to be linked with an assessment of how the genetic modification may affect 
the levels and expression of allergens in the wild-type crop but also with data on thresholds regarding 
sensitisation and elicitation of allergic reactions in cross-reactive allergy syndromes. Establishing the 
qualitative and quantitative allergen profiles would require a set of appropriate analytical methods that 
may employ either targeted or non-targeted approaches for the analysis of whole protein extracts 
prepared from the GM plant and its appropriate comparator(s). 
When endogenous allergenic proteins have been identified in the recipient, analytical methods are 
available to allow a comparative and relative quantification of the relevant known endogenous 
allergens (e.g. “key allergens”8) in the GM plant and its appropriate comparator(s). Those methods, 
which may have not yet been “validated”, include immunochemical (Kerbach et al., 2009) and gel-
based methods allowing relative quantitation. There is even a lack of rigorously validated methods for 
absolute quantification of allergens in foods as defined by AOAC in their harmonised guidelines 
(Abbott et al., 2010) but efforts are underway through the MoniQA Food Allergens Working group9 to 
develop the reference materials currently lacking to allow such validation. Even without such 
validation allergen detection methods are used to allow allergen risk assessment and management of 
foods, and may be performed within the comparative compositional analysis. Available methods 
include specific (targeted) immunochemical techniques but also physicochemical techniques which do 
not require the use of allergenic human sera. Application of such methods to allow protein/allergen 
contents to be assessed relative to the appropriate comparator(s) would remove the necessity to use 
allergic human sera, thus sparing the precious resource for other IgE binding studies where it is 
necessary. 
 
Allergens can be analysed based on their immunochemical properties by different formats of direct 
and/or competitive inhibition immuno-assays such as ELISA and/or two dimensional electrophoresis 
in gel (2-DE) followed by immunoblotting using sera of individuals allergic to the recipient plant. It is 
considered that 2-D immunoblots or separated ELISA testing of specific proteins allow for separation 
of proteins that may co-migrate in 1-D blots and for identification of potential changes in these 
individual proteins.  However, the sensitivity of such tests may be too low to identify alterations in the 
expression of particular allergens in the GM plant versus its appropriate comparator(s) (see Annex 5). 
 
High throughput technologies including novel mass spectrometry-based methods are a potent tool for 
alternative non-targeted proteomics studies which may allow comparing the whole proteome of the 
                                                     
8 Key allergens can be defined in relation with their public health importance as identified allergens in allergenic 
food which are relevant with regards to their allergenic potency and abundance (Bjorksten et al., 2008). 
9 http://www.moniqa.org/allergens 
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GM plant with its appropriate comparator(s). However, even if promising, available data are still 
preliminary and the techniques in question need to be further investigated and evaluated before being 
routinely used in the allergenicity assessment process (see Annex 5).   
 
Conclusions: 
1. Data on the qualitative and quantitative patterns of expression of endogenous “key allergens” 
in commercial varieties would provide useful information in order to perform a comparative 
compositional analysis with GM plants.  
2. Appropriate analytical tools, such as ELISA and those for which IgE binding tests are 
required, are available to measure and compare the amounts of identified allergens expressed 
in the GM plant versus its appropriate comparator(s). High throughput analytical proteomic 
techniques are under development for non-targeted approaches. 
 
Recommendations: 
1. When the recipient of the introduced gene is allergenic, it is recommended that relevant 
identified endogenous allergens are included in the comparative compositional analysis of the 
GM plant and its appropriate comparator(s). Despite that great natural variability in expression 
of allergens may occur, this should not preclude identification of any consistent unintended 
effect due to the genetic modification.  Information on the level of expression of these “key 
allergens” in edible tissues and pollen, indications of the impact of variable environmental 
conditions, agronomic treatments, developmental stage and post-harvest storage on expression 
levels and structure of relevant endogenous allergens would allow an accurate interpretation of 
the outcomes of the comparative analysis (see Annex 2.8.1).  
2. To improve the available analytical tools for a comprehensive comparison of the allergenicity 
of the GM plant and its appropriate comparator(s), it is recommended to test appropriate 
protein extraction procedures in order to cover the different allergenic proteins present in the 
GMO and its appropriate comparator(s), including those not easily soluble in aqueous buffers 
(see Annex 5.8). With regard to IgE binding studies, a pre-screening might also be performed 
with the whole plant (protein extracts) using animal sera instead of human sera (see Annex 
5.8; 6.3). 
3. Future work should study the specificity, sensitivity and feasibility of new profiling 
technologies, particularly those based on so called “-omics” techniques, for the assessment of 
allergenicity. A thorough assessment needs to be made of their advantages and weaknesses in 
order to compare these modern techniques in terms of reliability of interpretation of the results 
with those classically used for targeted analysis, which require the use of human sera (see 
Annex 5.8). 
 
2.3 Other considerations 
 
Recent progress in our understanding of the pathogenesis of food allergy and related diseases has 
confirmed the key role of IgE antibodies, but also of regulatory mechanisms involved in natural and 
acquired tolerance to foods. It is generally recognised that the prevalence of food allergy is increasing, 
and the clinical pictures are changing (Rona et al., 2007). Accordingly, improved diagnostic 
procedures must be developed and also involve non-IgE-mediated reactions. They should be related to 
the clinical reactivity i.e. the outcome of standardised food challenges in selected allergic individuals. 
The clinical assessment of food allergies in relation to GM foods should rely on observations provided 
by doctors directly in charge with food allergic individuals. To obtain a high level of vigilance, clear 
information on GM foods need to be provided to the health professionals and allergic consumers. 
Inclusion of GM foods in prevalence studies designed in a general context of protection of public 
health and survey of allergic diseases could also provide useful information. 
 
Post-market monitoring programmes (PMM) aim to provide reliable information regarding actual 
intake of a novel food by different groups of consumers and occurrence of any expected or unexpected 
(adverse) effects in every day life conditions of consumption. It is recognised that there is a need to 
clearly inform medical doctors and consumers of the presence of GM and non-GM products, but in 
Assessment of allergenicity of GM plants and microorganisms and derived food and feed
 
 
22 EFSA Journal 2010; 8(7):1700 
line with the EFSA Guidance Document (EFSA, 2006b, 2009) the implementation of PMM can be 
recommended only on a case-by-case basis. Information should be recorded and provided on any case 
of occupational allergic reaction that would be observed in individuals in contact with the newly 
expressed proteins or the GMO through different routes of exposure. Although the number of 
identified food allergens has increased tremendously in the recent past, little is known about the 
potency of individual allergens with regards to routes and levels of exposure and particularly to 
threshold levels of allergens set for sensitisation and elicitation of allergic reactions by individual 
foods. This also pertains to GM foods. 
 
Conclusion: 
1. Little information is available with regard to the actual exposure and threshold for 
sensitisation or elicitation in different segments of the population consuming foods, including 
GM foods.  
 
Recommendations: 
1. PMM is recommended on a case-by-case basis, e.g. for GM food/feed with altered nutritional 
composition and modified nutritional value and/or modified to achieve specific health benefits 
(see Annex 1.9.3; 1.10.6). In case of remaining uncertainties on the allergenicity of the whole 
GM food, PMM may be considered by the risk manager. In case PMM is needed, future work 
should focus on the development of (a) protocol(s) to provide data on the actual intake of the 
GM food, to guarantee the relevance of the reported adverse effects and to allow establishing 
any relation/causalities with the consumption of GM foods. These protocols should provide 
guidance on which information on such GM foods to be placed on the market needs to be 
received by and from consumers and health professionals involved in allergy. In addition, it 
could be valuable to develop prevalence studies in which GM foods are included as potential 
source of allergens in order to get a quantitative estimation of the potential impact of 
cultivation and consumption of GM plants on the prevalence of allergies. 
2. Finally, a more general recommendation which does not only apply for GMOs but for all food 
allergens is that further research is needed to determine thresholds for sensitisation in man and 
thresholds for elicitation particularly in the case of cross-reactive allergies. This would allow 
identifying whether there is a level of expression of an allergen in a (GM) food that could be 
considered of no safety concern (see Annex 1.10.6).  
 
 
2.4 General conclusion 
 
The strategy summarised in this report for assessing the allergenicity of GM food and feed considers 
the allergenicity of the newly expressed proteins, the whole GM food and feed, and also other aspects, 
such as exposure. Particularly with regard to newly expressed proteins, it is based on a weight-of-
evidence, case-by-case approach, in line with the approach followed in the EFSA guidance document 
and the Codex Alimentarius guideline. The different aspects of the allergenicity risk assessment of 
GMOs are discussed in this report, and where relevant, additional recommendations are provided to 
further strengthen the weight-of-evidence approach. These include recommendations with regard to 
the search for sequence homology and structural similarities, IgE binding tests and testing of the 
digestibility of newly expressed proteins. The recommendations also pertain to the comparative 
analysis of endogenous allergens and their structural characteristics in whole GM food and feed. In 
addition,  proposals have been made with regard to other additional testing that may improve the 
assessment, e.g. animal models, as well as suggestions for further exploring new promising methods 
that are as yet in an early phase of development, particularly on 3-dimensional structure of allergens, 
profiling technology, exposure assessment and post-market monitoring. 
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ANNEX 1. CLINICAL ASPECTS OF FOOD ALLERGY 
 
1.1. Introduction 
 
“Food allergy” is often used to encompass many problems which do not involve allergic mechanisms.  
It is therefore important to put the problem into context.  An adverse reaction to foods may occur 
predictably in all the population to a greater or lesser extent when the food contains bioactive 
substances such as histamine which can accumulate in scromboid fish such as tuna and will produce a 
reaction identical to that seen during the course of an allergic reaction.  However, this will only occur 
if the tuna has been badly stored and will affect all people that ingest it.  Other foods contain 
pharmacologically active ingredients such as caffeine in coffee, theobromines in chocolate and of 
course alcohol.  Again the responses to ingestion of large doses are very predictable.  Other foods can 
become contaminated with toxins generated by bacteria such as that associated with Staphylococcus 
which will produce vomiting and abdominal pain soon after ingestion. These predictable reactions 
must be discriminated from those which only occur in some people but not others when exposed to the 
same food.  The most common reaction is psychologically based and might be described as food 
aversion. Thus known exposure to the food results in a range of bodily reactions including nausea, 
vomiting, abdominal pain, diarrhoea, and respiratory symptoms.  However, the reaction is not 
reproducible when the food is presented in a concealed form. If the reaction is reproducible then it can 
be termed as food intolerance where the mechanism is unknown or where it is associated with some 
form of error of digestion or metabolism.  This is best exemplified by lactose intolerance where the 
digestive enzyme for the milk sugar, lactase is missing from the bowel, particularly in adults.  This 
leads to the generation of lactic acid by bowel bacteria which in turn is intensely irritant to the bowel 
and produces abdominal pain, bloating and diarrhoea. Finally, the term food allergy may be applied to 
a reproducible adverse reaction to food where an immune mechanism can be implicated.  While this is 
generally assumed to be associated with the production of IgE antibodies to the relevant food other 
immune mechanisms may be involved.  This has led allergists to define two sub-groups of food 
allergy as IgE-mediated and non-IgE-mediated.  IgE-mediated reactions, including hypersensitivity, 
are an altered acquired specific capacity to react.  This implies that the immune system has modified 
its response following a primary exposure leading to an accentuated sequence of immune events which 
clearly is important in conferring immunity against repeated exposure to infectious agents but if the 
response is directed against innocuous factors such as foods then it can lead to the generation of a wide 
range of symptoms. 
 
The immune system is highly sophisticated and immensely complex.  It has evolved to handle attacks 
by damaging agents such as bacteria, viruses, fungi etc.  The system achieves this by recognising 
danger signals.  These are generated by two mechanisms, the first being as a consequence of the initial 
damage caused when the microorganism first enters the body.  The damaged cells release chemical 
messages which attract the immune cells to the site of the attack and activate them so that they begin 
to initiate an immune response which will eventually eliminate the organisms.  Secondly the immune 
active cells are able to recognise specific molecular patterns expressed by the infecting organisms.  
This is with receptors known as pattern recognition molecules.  These are present both in the 
circulation, on the surface of immune active cells and even inside cells.  The molecular patterns they 
recognise include infecting organism DNA sequences, molecules expressed in the cell wall of bacteria 
and many others.  Once the molecular pattern is recognised a sequence of events occurs which results 
in the immune system not only generating substances known as cytokines which aims at eliminating 
the organism by innate mechanisms but also initiates a so-called adaptive immune response.  This is 
the response by which the immune system becomes able to immediately recognise the invading 
organism and to rapidly mobilise the cells which will eliminate it before it is able to do any damage.  It 
is this component of the response that can sometimes be subverted to react to harmless factors and 
produce inappropriate inflammation and disease. Thus the mechanism underlying a hypersensitive 
response to an infection is no different to that of a hypersensitive response that might be associated 
with allergy.   
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1.2. Food allergens  
 
The term “food allergen” refers both to the complex whole food and to the chemically defined 
compounds that are responsible for allergenicity, i.e. the proteins. In the regulatory context, one 
usually deals with foods or classes of foods (e.g. “fish and products thereof”). However, the 
biochemical molecular entity causing most food allergies is proteins. Some protein breakdown 
products, i.e. peptide fragments, may conserve part of the allergenicity of the native protein and thus 
can also be considered as allergens. Food allergens are generally proteins of molecular weight of more 
than 9 kDa (but sometimes peptides may cause a reaction).  As soon as a protein is consumed, there is 
a potential risk of allergy in particular in a genetically predisposed (atopic) consumer. Allergenicity of 
a given complex food is very rarely due to a single protein component but rather to numerous different 
proteins which constitute the “allergen repertoire” of the food. Due to the diversity and variability of 
the human IgE response, all of the allergenic proteins are not always recognised by all individuals 
allergic to this food. Those allergens that are recognised by more than 50% of a population of 
individuals allergic to the food are called major allergens. This concept relates only to the frequency 
of recognition by IgE antibodies, and it is not related to the severity of the clinical manifestations of an 
allergic reaction. Major allergens may constitute a small proportion of the total protein content of the 
food concerned.  Clinical reactions may be similar whether they are triggered by major or minor 
allergens.  
 
The allergenicity of each single protein is due to a number of molecular immunoreactive structures, 
the IgE-binding epitopes. These epitopes comprise a limited group of amino acids.  
 
Most allergenic epitopes consist of amino acids as added during transcription/translation of DNA to 
RNA to protein (translational peptidic epitopes). However, epitopes may also be formed post-
translationally. Most information about such post-translational epitopes is available for glycosyl 
epitopes (consisting of sugars chains added to specific side chains in the protein), such as a structure 
called “Cross-reacting Carbohydrate Determinant, CCD, which will be discussed in more detail later. 
Other examples of post-translational modifications that may be part of an epitope are modifications of 
amino acids by hydroxylation (hydroxyproline or hydroxylysine) or deamidation (formation of 
glutamate from glutamine) or phosphorylation.  
 
Depending on their structure, two kinds of epitopes are often described. Some are termed 
conformational epitopes because their allergenicity (IgE-binding capacity) is tightly associated with 
the 3D structure of the protein. Once the protein is denatured so that the folding of the protein is 
disorganised, conformational epitopes are modified or destroyed. This is obviously the case with so-
called discontinuous epitopes, composed of amino acids in different parts of the protein molecule 
brought together by the folding of the protein chain. Other epitopes are called linear epitopes because 
they are (largely) formed by a continuous sequence of amino acids on one peptide chain of the protein. 
The distinction between these two types of epitopes is not absolute, as many “linear” epitopes are 
recognised with much higher affinity in the folded protein compared to the isolated peptide. 
 
Epitopes are widespread within the protein molecule. Similar to allergens, not all epitopes are 
recognised by all the individuals allergic to the protein, and some epitopes are immunodominant, i.e. 
recognised by the majority of these allergic individuals, while others are only recognised by a few 
allergic individuals. Thus, there is room for a tremendous variation between allergic individuals with 
regard to the precise targets of their allergic responses.  
 
It has been shown that some epitopes may have a particular clinical significance depending on their 
structure and location within the molecule. Short linear IgE-binding epitopes which may be located in 
hydrophobic parts of allergenic proteins could be used as markers of a persistent food allergy, i.e. to 
milk and to peanut (Beyer et al., 2003; Chatchatee et al., 2001; Jarvinen et al., 2001). Such 
characterisation of epitopes, and particularly IgE-binding epitopes, may in the future provide 
information allowing the prediction of persistence and severity of clinical reactions. However, there 
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remain methodological issues using short linear peptides, frequently attached to solid supports, to 
define what is essentially a three-dimensional structure only achieved by longer stretches of sequence. 
There are also instances where IgE epitopes have apparently been defined using such methods in 
regions of plant protein not normally found in mature proteins, such as signal peptides which are 
removed early during protein synthesis and are not usually found in the mature protein (Helm et al., 
1998).  
 
Stability to processing and resistance to proteolysis by digestive enzymes have long been considered a 
general characteristic of food allergens (Astwood et al., 1996). However recent studies showed that the 
relationship between resistance to digestion and allergenicity is less clear cut than originally thought 
(Astwood et al., 1996; Diaz-Perales et al., 2003; Eiwegger et al., 2006; Fu et al., 2002; Vassilopoulou 
et al., 2006). 
 
Allergenicity may be destroyed by processing (e.g. cooking) and/or digestion of the food. 
Alternatively, some epitopes may be unmasked and become available after denaturation or hydrolysis 
of the protein and neo-allergens or new immunoreactive structures may be created during processing 
including heat treatments (Berrens, 1996; Besler et al., 2001; Davis et al., 2001; Hansen et al., 2003; 
Maleki et al., 2000; Mondoulet et al., 2005; Nakamura et al., 2005). 
 
In sum, there are 3 levels of structures (whole food, protein and epitopes) involved in the interaction 
with IgE antibodies and responsible for the allergenicity of a given whole food. Different epitopes and 
thereby different proteins and different foods will respond differently to processing and digestion. 
Therefore, depending on the immunodominance of the different epitopes in a particular individual, the 
effect of processing on food allergenicity may also differ between individual consumers (see Annex 
2). 
 
1.3. Mechanisms 
 
Food allergy has to be understood as a disease where sensitisation can occur either by cross-reactivity, 
i.e. first sensitisation by a respiratory route to a common allergen (e.g. birch tree pollen allergens 
which have molecular homology with several fruit allergens), or primary sensitisation through the gut. 
The second issue appears to be particularly important and relevant to potential food allergy triggered 
by genetically modified foods. The gastro-intestinal tract provides various types of physical barriers to 
allergens (Adel-Patient et al., 2008). Normally, digestive enzymes and acid production in the stomach 
will denature most of the allergens before they have a chance to gain access to the immune system. 
However a fraction of them may be absorbed (partly) intact in the oral cavity and the gut and get 
directly into contact with the local mucosal immune system. Factors in the gut mucus secretions such 
as secretory IgA as well as the physical barrier of the gut also constitute a protection against antigen 
penetration. Antigen recognition by the gut immune system depends then, among other things, on 
protein size and on denaturation of major antigenic epitopes by digestion and proteolysis.  These 
protecting mechanisms are at least in part, less effective during the first months of life, possibly 
explaining a window of susceptibility at this age for sensitisation to common food allergens.  
 
Although those non-specific mechanisms of protection are efficient, it should be kept in mind that in 
some cases protein digestion may not necessarily be complete. Protein digestion is strongly linked to 
transit rate and the nature of concomitant food intake which has an effect on both the transit and 
absorption rate of potential allergens. Besides, the wide use of gastric acid inhibitors in the general 
population significantly alters the conditions under which food proteins are digested. It should be 
noted that proteolytic cleavage of proteins into peptides does not necessarily abrogate 
immunogenicity, and this applies in particular to food antigens submitted to peptic digestion in the 
stomach. Furthermore, if an allergenic epitope is heat and acid resistant it will have a greater potential 
to sensitise even in adults. There is also the potential for sensitisation to foods to occur by contact with 
inflamed skin and even by inhalation. Indeed recent studies have suggested that sensitisation to food 
allergens is more likely to occur through inflamed skin, such as occurs in eczema, than via ingestion 
(Adel-Patient et al., 2007; Adel-Patient et al., 2008; Lack et al., 2003). 
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Allergens interact with the innate immune system via multiple mechanisms, which constitute the first 
event occurring when an allergen comes into contact with a living body. The innate immune system is 
highly conserved on an evolutionary basis. Exposure to an antigen at mucosal level results in a 
cascade of events such as activation of the innate immune system, but not specifically for 
allergenicity. The contact of a food antigen with the intestinal mucosa is normally followed by 
sampling carried out by dendritic cells extending pseudopods into the intestinal lumen.  
 
When an antigen is processed by an antigen-presenting cell (APC) such as a dendritic cell for 
presentation in the context of major histocompatibility complex (MHC) class II molecules, the antigen 
is first taken up by the late endosome, in which a number of modifications occur. These include 
proteolytic cleavage at very discrete sites, reduction of disulfide bonds and trimming, so as to generate 
a family of peptides of approximately 20 amino acids. These peptides compete for the binding to 
nascent MHC class II molecules and are accommodated into the MHC cleft to ensure the best fit of 
amino acids between the peptide and MHC class II residues. The result is that only a very limited 
number of T cell epitopes are actually presented at the APC surface, among a large series of potential 
T cell epitopes. By contrast, pre-formed peptides, or a protein having been naturally submitted to 
peptic digestion, can bind to MHC class II molecule with no requirement for processing, reduction or 
trimming off. This result in a much larger panel of epitopes presented, with capacity to activate a large 
diversity of T cells. This establishes a fundamental difference in the repertoire of T cells activated by 
processing a whole protein as opposed to peptides. 
 
Under physiological conditions, dendritic cells (DC) of the mucosal immune system process the 
antigen for presentation to T cells in the context of MHC-class II determinants, which results in 
tolerance (Strobel and Mowat, 2006). Oral tolerance can result from a number of mechanisms, 
classified as intrinsic or extrinsic. Intrinsic mechanisms involve induction of apoptosis and clonal 
deletion (programmed cell death) and anergy. Apoptosis is induced by surface expression of receptors 
and ligands belonging to the family of “death receptors”, in particular Fas and its ligand, FasL. This 
leads to a cascade of intracellular events resulting in cell death. Anergy, which is lack of activation 
upon antigen recognition, is essentially induced in the absence of costimulatory signals, which in turn 
occurs in the absence of a danger signal. Under certain circumstances such as intestinal inflammation, 
or possibly in individuals with genetic susceptibility, tolerance is not established. This could result 
from antigen handling by activated dendritic cells or from the triggering of innate immunity 
mechanisms. Of major importance for innate immunity are a number of receptors located at the 
membrane of epithelial cells, such as the Toll-like receptors (TLRs), or inside epithelial cells, such as 
the NOD receptors. These receptors act as sensors to detect glycoproteins, polysaccharides, lipids or 
polynucleotides of diverse origin, including bacteria, viruses and parasites, which might be construed 
as danger signals. The signal resulting from receptor binding is followed by intracellular signaling 
leading to events which influence adaptive immune responses (Coombes and Powrie, 2008). There is 
therefore a first decision made at the level of the intestinal mucosa itself, whether tolerance or 
activation should occur. The synergy between innate immunity receptors and activation of DC is well 
established, since extension of DC pseudopods into the intestinal lumen depends on activation of 
TLRs. Yet, the precise mechanisms by which ligands of TLRs drive activation of DC remains poorly 
defined. A second decision will be made at the level of mesenteric lymph nodes, which is where the 
adaptive immune system is entering into action. Thus, DC instructed for tolerance induction or 
activation of an immune response migrate from the mucosa to mesenteric lymph nodes, where they 
encounter T cells. Depending on the message exchanged between DC and T cells in the context of 
antigen-specific, MHC-class II dependent cognate recognition, such T cells will be either activated or 
tolerised (Mowat, 2003). Activation through MHC-class II peptide presentation results in the 
recruitment of effector T cells (also known as effector T cells or Th cells) sharing the CD4 surface 
marker. These cells are therefore referred to as CD4+ Th cells (h stands for “helper”). Three types of 
CD4+ Th cells have been described: Th1, Th2 and Th17, whose function is explained below. 
Whenever tolerance is established and in particular oral tolerance, other CD4+ T cells can be 
recruited. 
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Extrinsic mechanisms involve the induction of regulatory T cells, among which two distinct subsets 
can be recognised: Th3 cells exert their suppressive activity through the production of TGF-β while 
natural regulatory T cells exert a contact-dependent suppressive activity, notably through over-
expression of CTLA-4. This surface molecule, when contacting its corresponding ligand on target 
cells, induces a catabolism of essential amino acids which deprive target cells of vital nutrients.     
 
Although the mesenteric lymph nodes serve a function of firewall to protect the systemic immune 
system from unnecessary activation or detrimental tolerance induction, it is noteworthy that when 
tolerance is established at the intestinal mucosal level, this is also translated into systemic tolerance. 
This seeming paradox most likely results from two distinct events. First, the passage of small amounts 
of antigens directly into the venous circulation towards the hepatic vein, short-circuiting lymphatic 
circulation drainage: antigens reaching the liver through the portal vein are known to induce tolerance 
instead of immune activation. Second, T cells educated to tolerance in the draining mesenteric lymph 
nodes migrate to other peripheral lymph nodes, resulting in lack of proliferation and absence of 
antibody production.    
 
Three subsets of adaptive effector T cells, with different properties are currently recognised, although 
it is likely that other subtypes will be described in the future. The Th1 subset is characterised by 
expression of the transcription factor T-bet and a receptor for Interleukin-12 (IL-12). The translocation 
of T-bet to the nucleus triggers the transcription of cytokines characteristic of the Th1 subset, 
including IFN-γ and IL-2. The Th2 subset expresses the GATA3 transcription factor and a receptor for 
IL-4. Translocation of GATA3 to the nucleus activates the transcription of IL-4, IL-5 and IL-13. The 
Th17 subset is characterised by the RORgammat transcription factor and a receptor for IL-23. Not 
much is known about the mechanisms by which RORgammat induces transcription of cytokines, but is 
associated to production of IL-6, TNF-α and IL-17. The link between soluble cytokines and T cell 
subset is, however, not very strict as, for instance, a number of Th1 cells produce IL-5. 
 
The differentiation of these T cell subsets depends on signals produced by antigen-processing cells, 
both soluble and surface-bound. For instance, Th1 cells differentiate upon binding of IL-12, Th2 upon 
binding of IL-4 and Th17 upon stimulation by IL-23, IL-6 and TGF-β. It should be noted that these 
subsets counteract each other. IFN-γ produced by Th1 cells inhibits the maturation of Th2 cells. IL-4 
blocks Th1 maturation and both IL-4 and IFN-γ block the maturation into Th17 cells.  
 
Effector CD4+ T cells exist at different stages of activation and are amenable to regulation by intrinsic 
and extrinsic mechanisms, as described above, which might also lead to unresponsiveness through 
either physical or functional elimination of specific Th cells. 
 
Each CD4+ effector T cells has been associated with pathology and, to some extent, specific isotype 
production. Crohn’s disease represents a typical Th1-driven disease, while ulcerative colitis 
exemplifies Th2 pathology. Th17 cells are associated with diseases characterised by chronic 
inflammation, such as Crohn’s and colitis, but also asthma. Th1 cells help in the production of 
immunoglobulins IgG1 and IgG3, while Th2 cells trigger the production of IgE and IgG4 antibodies. 
There is not yet an isotype associated with Th17. 
 
Antigen presentation in the gut can result in activation or tolerance induction involving various types 
of cells pertaining to either the innate or adaptive immune system. When activation prevails several 
outcomes are possible, though these are not mutually exclusive: 
• Activation of effector CD4+ T cells resulting in tissue inflammation and destruction in the absence 
of specific antibodies. T cell subsets producing inflammatory mediators such as IFN-γ (Th1 cells) or 
IL-6 (Th17 cells) predominate here. 
• Activation of effector CD4+ T cells producing interleukins required for helping B cells in producing 
specific antibodies. Here the Th2 cells play a determinant role as an obligate condition for the 
production of IgE antibodies.  
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Antibodies participate in the pathology of allergy but do not necessarily represent a main component 
of it. Apart from the role of IgE antibodies, which is well established, i.e. by activating basophils and 
mast cells, resulting in the liberation of mediators such as histamine, other isotypes of antibody may 
participate in the different pathologies of allergy but their role is not as well-established as for IgE.  
 
Both innate and adaptative immune responses are tightly regulated. A failure within these regulatory 
mechanisms could lead the immune reaction against antigens into becoming pathological. The 
mechanisms described above therefore can contribute to the pathogenic potential of a food antigen. An 
understanding of these cellular interactions occurring once the gut mucosa is in contact with a food 
antigen can facilitate the identification of early biomarkers of sensitisation.  
 
Natural resolution of food allergy occurs in up to 80% of milk allergy cases in early childhood in 
prospective studies (Host and Halken, 1990), egg (50%) and even peanut in 15% by the age of 3. 
There is currently no solid data to explain why and how the latter occurs but it is much less likely to 
occur beyond infancy. Many hypotheses, among which the maturation of the gut immune system, an 
increase in the number of regulatory T cells and modification of the gut flora elicited by qualitative 
changes in the diet have been suggested, but formal demonstration is still lacking. 
 
As mentioned before, antibodies of other isotype than IgE, e.g. IgG, can be involved in the immune 
response induced by food antigens. IgG4 needs specific attention, the first reason is that the production 
of IgE is more closely linked to that of IgG4 than to that of other immunoglobulin isotypes, mostly 
because both IgE and IgG4 depend on IL-4 or IL-13 for the isotype switch. Since Th2 cells are 
important producers of these cytokines this is often referred to as a Th2-type immune response. Such 
immune responses are not so strongly stimulated (and often even markedly down-regulated) by 
microbial factors (such as endotoxins and other Toll receptor ligands) as the more conventional Th1-
type immune responses. The second reason is that IgG4 antibodies to allergens have been described to 
be associated with allergic symptoms. 
 
A relationship exists between IgE and IgG4 from the immune regulatory point of view10. IgE 
producing B cells are descendants of IgM-producing B cells, either directly or indirectly.  In the latter 
situation, the intermediate B cell is often an IgG4-producing B cell, but B cells producing other IgG 
isotypes may also act as intermediate for IgE producing B cells. An IgE response invariably includes 
production of other antibodies. The reverse is, obviously but still remarkably, not true: it is very 
common to find IgG1 antibodies in the absence of IgE antibodies. This indicates that the isotype 
switch in B cell differs between IgG1 and IgE (and/or that the expansion and differentiation of the 
switched B cells depend on factors linked to the isotype switch). The best-known factor is the type of 
cytokines produced by the Th cell: Th1 cytokines, particularly interferon gamma, are potent inducers 
of the isotype switch to IgG1 and suppress the IgE switch, whereas Th2 cytokines, particularly IL-4, 
induce the switch to IgE (and to IgG4). However, the selectivity of these switch factors is often 
concentration-dependent. Low concentrations of IL-4 have been found to induce IgG1 switching in 
vitro (Kotowicz and Callard, 1993). Also in vivo, an association is found between IgE responses and 
IgG responses, particularly for classical atopic allergens, such as pollen allergens and mite allergens. 
For these allergens it is rare to find IgG responses in the absence of IgE responses (Aalberse, 2006; 
Aalberse et al., 2009; Chapman and Platts-Mills, 1978; Lichtenstein et al., 1992; Platts-Mills, 1979; 
Thomas and Hales, 2007). This association, which is particularly convincingly demonstrable with 
assays that use purified allergens (rather than whole allergen extracts) and that preferentially measure 
high-affinity antibodies, is found not only for IgG4, but also for IgG1. Because of the association 
between IgE and IgG4 responses, it has been suggested that IgG4 responses might be involved in 
allergic symptoms. 
                                                     
10 Note: in this document the isotype nomenclature refers to humans. The IgG isotypes in other species have 
often identical names without being homologous to the human isotype.  It is particularly confusing that the 
mouse IgG1 isotype is NOT equivalent to human IgG1, but (to some degree, in immune regulatory context) 
equivalent to human IgG4. 
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The suspicion about the involvement of IgG4 in allergy in general, and food allergy in particular, was 
largely raised by two sets of observations. Firstly, the evidence provided by Pepys et al. (1979) that 
human IgG antibodies (IgG-STS, for short-term sensitising IgG) could induce an allergic skin reaction 
in a passive transfer model in primates (the STS referred to the shorter duration of the sensitisation: 4 
hours, compared to >24 hours for IgE) . Whereas the first data suggested that IgG-STS activity resided 
largely in the IgG4 fraction, subsequent experiments failed to substantiate this (Malley et al., 1985). 
However, some support came from in vitro studies, in which anti-IgG4 antibodies were found to 
activate basophils from some human subjects. However, claims regarding allergen-induced IgG4-
dependent basophil activation could not be confirmed (Vantoorenenbergen and Aalberse, 1981). The 
anti-IgG4-induced basophil activation was probably due to IgG4 anti-IgE antibodies rather than to 
direct binding of IgG4 (Shakib and Smith, 1994). 
 
The other argument for implying IgG4 antibodies as a significant factor contributing to allergic 
symptoms was the increased presence of allergen-specific IgG4 in allergic subjects (Halpern and 
Scott, 1988; Stanworth, 1987).  Children with an atopic phenotype tend to have higher IgG antibodies 
to foods, also to foods that are well tolerated (Eysink et al., 1999), possibly due to a altered mucosal 
barrier function or to a general increased immune reactivity (Salvaggio et al., 1969). In the specific 
case of IgG4, the association between IgE and IgG4 is likely to reflect also the IL-4 dependency of 
both IgE and IgG4 production.  A main obstacle in accepting IgG4 as a contributing factor in allergen-
induced symptoms was the presence of often large amounts of allergen-specific IgG4 in the absence of 
symptoms. A striking example is provided by the beekeepers, who often have huge levels of venom-
specific IgG4 without any symptoms upon being stung and a negative skin test. Also the positive 
association between IgG4 to airborne allergens and protective effects of allergen-specific 
immunotherapy are more supportive of a protective than a pathogenic role of allergen-specific IgG4. 
 
There is no convincing evidence or mechanism to support the notion of IgG4 as a sensitising antibody. 
IgG antibody levels (including IgG4 antibodies) to foods tend statistically to be slightly higher and 
more prevalent in atopic subjects than in controls, but such antibodies (including high levels) are too 
common in the food-tolerant population to be of diagnostic use. The induction of IgG antibodies 
following the introduction of a novel protein into the diet can not be considered as an abnormal 
response. 
 
1.4. Prevalence  
 
Food allergies are a commonly suspected problem as up to 1/3 of a non-selected population believes 
they suffer from food allergy (Sloan and Powers, 1986; Young et al., 1994). Many individuals who 
believe they are allergic to foods do not have a reproducible response on double blind food challenge. 
They are described as having food aversion or psychological intolerance which is a common 
phenomenon. This emphasises the need for accurate assessment and diagnosis because food 
avoidance, in the mistaken belief about allergy, is not without potential complications, including 
nutritional imbalance and reduced quality of life. However, not all adverse reactions to food are 
attributable to food allergy, as by definition, the immune system has to be involved in pathogenesis of 
allergy (Johansson et al., 2001), other reproducible responses may be due to errors in digestion and/or 
metabolism (e.g. lactose intolerance). Epidemiological studies pinpointing the right diagnosis by 
standardised food challenges have demonstrated a prevalence of 5 to 8 % in infants and young 
children and less than 5 % in adults (Bock, 1987; Jansen et al., 1994). Most epidemiological studies 
were designed to detect IgE-mediated food allergy, and few data are available on non IgE-mediated 
food allergies. In infants, a prospective study on cow's milk allergy reported approximately half of the 
conditions (corresponding to approx 1-2%) to be non IgE-mediated (Host and Halken, 1990). In 
addition, data on non IgE-mediated food allergy can be extrapolated from population-based studies, 
suggesting that if adverse reactions to foods are suspected in up to 30% of the population, IgE-
mediated food allergy can only be diagnosed in up to 5 % of the population, a large part of the rest 
being intolerances or non IgE-mediated food allergy (Sloan and Powers, 1986; Young et al., 1994).  
 
Annex 1. Clinical aspects
 
 
32 EFSA Journal 2010; 8(7):1700 
Almost all edible proteins have been described either in large series or in case reports as a possible 
food allergen.  However, a relatively short list of foods is encountered as common food allergens 
around the world. Milk is a food allergen that was described already by physicians in ancient Greece. 
In addition, egg, peanuts and nuts, fish and crustacean, various grains, vegetables and fruits are 
commonly identified (Bock, 1987; Eigenmann et al., 1998) as  food allergens as defined by Directives 
2003/89/EC and 2006/142/EC  for labelling purposes (EC, 2003, 2006). There is a clear link between 
cultural eating habits and the foods most frequently encountered, e.g. in maritime countries, fish 
allergy is rather common, while South Korea has a high number of buckwheat allergic individuals, 
with buckwheat noodles being consumed in large amounts from early in life. As with all allergic 
diseases there is good evidence that food allergy prevalence has been increasing over the last 3-4 
decades, initially in developed countries but now also in the developing world (Rona et al., 2007). The 
geographical distribution of susceptibility to allergy has been associated with affluence, which has 
been explained as being due to reduced exposure to infections in early life. However, many other 
environmental influences are likely to be involved. So far, no scientific report has described allergic 
individuals with clinical reaction specific to GM food. However, it can be assumed that for crops such 
as soy that are consumed in relatively high quantities, including GM plants, allergic individuals react 
to constitutive proteins of the food. 
 
No information is available on whether or not an extensive cultivation and/or use of GM crops known 
to be allergenic e.g. soy, has changed the prevalence of inhalant or food allergy in the exposed 
populations. 
 
1.5. Clinical pictures 
 
Immune mediated adverse reactions to foods must be distinguished from intolerances due to errors in 
digestive or metabolic processing of the food. The first are most commonly associated with IgE 
generation but can sometimes occur in the absence of IgE, which is described as non-IgE-mediated 
food allergy. It may then either be mediated by activation of eosinophils which evolves between 4 and 
24 hours after exposure to the food or activated T-lymphocytes which takes several days to develop. 
However, some overlap might exist between the two classical forms, especially food allergies in the 
gastrointestinal (GI) tract with eosinophilic infiltration of mucosa where a subset of allergic 
individuals have positive IgE tests (Fig. 1). In describing the range of clinical features associated with 
food allergy it is important to be aware that there can be many other causes of the same presentation.  
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Figure 1: Clinical manifestations of food allergy classified according to the pathogenesis of the 
disease. Adapted from Rothenberg (2004). 
* Coeliac disease which is here included in a large definition of allergy is a form of hypersensitivity 
induced by gluten but with autoimmune mechanisms/ autoimmune disease. 
 
 
IgE-mediated food allergy can present with clinical signs limited to one system or involving several 
systems (anaphylaxis).  Skin is probably one of the most commonly involved systems in food allergy. 
Urticaria, sometimes known as hives, is a common reaction of mild food allergy as an isolated 
symptom, or in combination with other manifestations in anaphylaxis.  Urticaria usually manifests 
within minutes to 1 to 2 hours after ingestion of the food. Virtually, all foods eliciting IgE-mediated 
food allergy can provoke urticaria. The skin eruption is very similar to that seen after a nettle sting and 
is intensely itchy. It is a consequence of the release of mast cell mediators such as histamine. These 
irritate sensory nerves, cause dilatation of blood vessels and leakage of fluid from the circulation into 
the superficial layers of the skin.  Some allergic individuals might also present with a mixed clinical 
picture of urticaria and angio-edema, the latter being a reaction in the deeper layers of tissue below the 
skin, with swelling most characteristically round the eyes and lips. If it affects the tissues in the throat 
swelling may obstruct breathing and constitute a life threatening manifestation (laryngeal oedema). 
Atopic eczema/dermatitis is another common manifestation of food allergy. Food allergy associated 
flares of atopic dermatitis are seen most commonly in young children. Up to 40% of young children 
with moderate to severe atopic dermatitis can have an associated food allergy (Burks et al., 1998; 
Eigenmann and Calza, 2000; Eigenmann et al., 1998). However, food allergy is a less common 
association with eczema in older children and adults. The respiratory system might be involved 
leading to asthmatic symptoms and anaphylaxis. Acute rhinitis or broncho-constriction can be of rapid 
onset. Signs of asthma are of particular importance for the prognosis of food allergy.  Indeed it has 
been shown in several studies that near fatal and fatal reactions to foods are determined by pre-existing 
asthma (Bock et al., 2001; Sampson and McCaskill, 1985). Respiratory symptoms are present without 
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any other clinical symptoms in about 20 % of allergic individuals (Sampson and McCaskill, 1985). It 
is believed that isolated and chronic recurrent respiratory symptoms are uncommonly caused by food 
allergy alone. However, life threatening events can occur without prominent respiratory symptoms if 
massive basophil activation leads to extensive leakage of fluid from the circulation. This produces a 
drastic fall in circulating volume and blood pressure leading to collapse and cardiac arrest. 
Anaphylaxis is the word used to describe this life threatening reaction.  Symptoms of the gastro-
intestinal tract involvement including vomiting or diarrhea are often seen within the clinical picture of 
anaphylaxis. Finally, oral pruritus is one of the most common forms of IgE-mediated food allergy.  It 
is related to oral allergy syndrome, and this manifestation of food allergy is mostly seen in adolescents 
and adults and is linked to a primary sensitisation to a cross-reacting pollen protein (e.g. Bet v 1) 
which has sequence homology with crude apple and other tree fruit proteins (Amlot et al., 1987; 
Ortolani et al., 1988). 
 
Clinical manifestation can be provoked by the same foods as those involved in IgE-mediated food 
allergy but through different mechanisms. In young children, the diagnosis of non-IgE-mediated food 
allergy is mostly made by the history, showing a characteristic constellation of symptoms (Sampson 
and Anderson, 2000).  Food protein-induced enteropathies are diagnosed in infants usually less than 6 
months old. Classically they present as profuse and repeated vomiting after a symptom free interval of 
2 to up to 6 hours after ingestion of the food (Nowak-Wegrzyn et al., 2003; Powell, 1978; Sicherer et 
al., 1998).  The offending food is most often milk but can also be soy, egg or other solid foods.  The 
disease is self-limited in time and most often disappears after 2 to 3 years of a food elimination diet.  
Milk induced procto-colitis is a disease in which the child presents with isolated fresh blood in the 
faeces. It is seen in a few weeks old breast-feed infants and sometimes in bottle fed babies (Belli et al., 
1994; Lake et al., 1982) and it disappears after the milk has been removed from diet.  
 
Food-induced enteropathy is a pleomorphic disease in which an immunological mechanism is 
suspected but not always proven (Ford et al., 1983). However, where gut biopsies have been 
performed eosinophil or lymphocyte infiltration and occasionally subtotal villous atrophy (similarly to 
coeliac disease) is seen.  Adults and children with chronic diarrhea or vomiting, children with failure 
to thrive or other non-specific GI symptoms are most often diagnosed with this condition. Food 
induced enteropathy may be self-limiting and resolve after one or two years but on occasions can be a 
persistent problem.  Eosinophilic disease of the gastro-intestinal tract was first described only a few 
decades ago.  There is a clear trend towards increase of prevalence of these diseases.  They can present 
with eosinophilic infiltration of the lower esophagus (Kelly et al., 1995; Naylor, 1990) but this form of 
inflammation can be present at any level in the gastro-intestinal tract. Over the last few years an ever 
increasing range of gut motility disorders have been described in association with eosinophilic 
inflammation. In children and adolescents, this form of eosophilic disease is more often related to a 
specific food. The classical clinical picture is that of untreatable reflux with hyper-secretion of mucus 
and abdominal pain. However, chronic diarrhoea, constipation, abdominal pain, failure to thrive in 
children and weight loss in adults can be associated. 
 
Adults complaining of isolated gastro-intestinal symptoms may suffer from food aversion, intolerance 
or allergy. A recent cross-sectional study performed in Berlin showed an overall self-reported 
prevalence of adverse reactions to foods of 34.9% (Zuberbier et al., 2004) In the same studym, double-
blind, placebo-controlled food challenges identified reproducible adverse reactions to foods in 3.7% of 
the adult population, of which 1.1% were non-IgE-mediated. Other epidemiological studies in the UK 
and in the Netherlands have shown similar results (Jansen et al., 1994; Young et al., 1994). A specific 
clinical picture of non-IgE-mediated food allergy in adults is represented by eosinophilic esophagitis, a 
condition differing from the pediatric form described above by the lower rate of associated food 
allergy and by dysphagia being the leading symptom (Straumann et al., 2003). Animal models for 
eosinophilic disease of the gut have been established and should allow further mechanistic as well as 
therapeutic studies of this type of diseases (Mishra et al., 2001).  
 
Coeliac disease is well characterised by the clear involvement of food, i.e. gluten present in wheat and 
related cereals, in the pathogenesis of an immune reaction not mediated by IgE generally in absence of 
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IgE antibodies. The modification of gluten-derived peptides by tissue transglutaminase-mediated 
deamidation of glutamine residues increases the binding affinity to particular alleles of the major class 
II histocompatibility complex, i.e. HLA-DQ-2.5 and HLA-DQ-8, the expression of which is strongly 
associated with coeliac disease. Effector T cell reactivity is thereby increased. This mechanism serves 
as a basis to define coeliac disease as an auto-immune disease associated with local gut epithelium 
inflammation. The prevalence of the condition in communities varies with the frequency of the tissue 
types and in Europe is estimated to be between 0.2 and 1.2%. The proteins responsible for the 
response are prolamins, rich in proline and glutamine (gliadin from wheat, hordein from barley and 
sacalin from rye). There is some dispute as to whether the prolamin, avenin from oats may also cause 
the disease. Dietary exposure to the proteins, sometimes facilitated by simultaneous gut infection with 
rotavirus or adenovirus leads to the production of tissue transglutaminase (tTG) auto-antibodies.  tTG 
participates in the processing of gluten and there is a suggestion that there is an innate immune 
response to the gliadin. This results in a lymphocyte mediated inflammatory response with loss of the 
villus (folding) architecture of the small bowel wall, together with mucus gland hypertrophy. This 
results in mal-absorption of nutrients with resulting iron deficiency anaemia, failure to thrive in infants 
and weight loss in adults. The failure to absorb fat sometimes results in offensive diarrhoea known as 
steatorrhoea, abdominal bloating and pain. Many individuals particularly children with coeliac disease 
recovered once gluten is excluded from the diet. Several types of animal models with disease 
expression mimicking coeliac diseases have been established. They include MHC II transgenic mice 
(Mangalam et al., 2008), as well as gluten-sensitivity animal models in various types of animals 
including non human primates (Bethune et al., 2008). 
 
The treatment is primarily life-long avoidance of gluten, and for the rare refractory case immune 
modulation with steroids or other immune suppressants.  
 
It should be noted that gluten also is a potent food allergen, and gluten intolerance/celiac disease must 
not be confused with gluten allergy which may cause life-threatening anaphylactic reactions. 
 
1.6. Diagnostic procedures  
 
The diagnosis of food allergy is largely based on the clinical history.  In fact, a history of repeated 
ingestion leading to rapid occurrence of typical symptoms is highly suggestive of an adverse reaction 
to food. Furthermore, the clinical picture as described in the section above will increase the degree of 
suspicion for a food allergy. In suspected IgE-mediated food allergy, the diagnosis is supported by 
positive skin prick tests with commercial food extracts or native food extracts.  Furthermore, serum 
specific IgE can be measured to most potential food allergens. Interpretation of positive tests can be 
difficult as a positive test can often be due to sensitisation without clinical relevance. Various studies 
have provided cut-off levels for specific foods (Boyano-Martinez et al., 2002; Celik-Bilgili et al., 
2005; Osterballe and Bindslev-Jensen, 2003; Sampson, 2001).  It is now well established that these 
cut-off levels depend on the food, the type of symptoms, as well as the population age. Thus cut-off 
levels should be interpreted with caution (Eigenmann, 2005).  
 
It has been suggested that an atopy patch test can aid diagnosis in non-IgE mediated food allergy. The 
food is applied to a small patch of skin under an occlusive dressing for 48 hours. The skin is examined 
for a reaction 24 hours after the dressing has been removed. A positive response has a characteristic 
eczematous appearance. However, techniques have not been standardised and this approach has not 
yet undergone sufficient validation to be considered a routine diagnostic test.   
 
Diagnosis of non-IgE-mediated reactions mostly relies on the clinical history as described previously. 
Few reports have shown that activation of peripheral blood mononuclear cells by antigen can be of 
some help for the diagnosis. The diagnosis of coeliac disease is based on detection of circulating IgG 
and IgA tissue transglutaminase antibodies and the presence of villus atrophy and lymphocyte 
infiltration in a small bowel biopsy. More recent developed diagnostic tests included leucotriene 
release assays or CD63 activation or basophilic histamine release. However, these procedures are not 
yet clinically validated. 
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Thus, the diagnosis of food allergy has to be confirmed by resolution following withdrawal of the 
food(s) and the reoccurrence of symptoms during food challenges. Standardised food challenge 
protocols have been developed for the different clinical pictures.  They are currently the gold standard 
for the diagnosis of food allergy (Bindslev-Jensen et al., 2004; Bock et al., 1988; Niggemann et al., 
1994), but not without problems. During challenges factors which might otherwise promote a 
response, such as concurrent infection, heavy exercise etc. are eliminated. Furthermore, in order to 
disguise the taste of the food in a double blind procedure the immediate effects on the buccal mucosa 
(lining of the mouth) are lost. Assessing the response can also be difficult if only subjective symptoms 
occur.  
 
Double-blind, placebo-controlled food challenges (DBPCFC) have been elaborated firstly to diagnose 
food allergy in children with atopic dermatitis (Sampson, 1983). However, this procedure has quickly 
evolved to become the standard diagnostic test for food allergy in research protocols as well as in 
many clinical situations. If performed routinely in centres with well trained staff, these procedures can 
be easily performed in one- or two- day protocols. Although most centres use slightly different 
procedures, which need to be adapted to each allergic individual's own situation, wide efforts have 
been recently undertaken to standardise the procedure (Bindslev-Jensen et al., 2004; Bock et al., 1988; 
Niggemann et al., 1994; Sampson, 1983).  
 
In particular issues related to clinical assessment of foods derived from GMO designed to constitute a 
hypoallergenic food (e.g. a food with an allergenic potency which is decreased to a certain extent but 
not totally abolished), for example by decreasing the expression of endogenous allergens, the need for 
DBPCFC could be considered, although this would rather be a substantiation of health claims than a 
safety assessment. 
 
1.7. What happens when a new food is introduced into the diet? 
 
For as long as we know history, the diet of the population has been changing more or less rapidly with 
new foods being taken into use. New allergens certainly have been introduced many times. Some fifty 
years ago kiwi fruit was introduced from New Zealand into California and USA in general, and later 
into Europe. During the last decade, the use of lupin flour has become much more common than 
before in Europe and has spread to several countries where lupin never before was part of the diet. 
 
What will happen after introduction of a new or newly allergenic food, will depend on whether it 
elicits clinical reactions by cross-allergenicity, or whether clinical reactions depend on primary 
sensitisation to the new allergen.  Reactions due to cross-reactivity will occur as a “first wave” as soon 
as the food has been introduced, while reactions depending on primary sensitisation will come later as 
a “second wave”.  Totally novel allergens without cross-reactivity may only manifest themselves 
following primary sensitisation. The two types of reactions may differ clinically, and reactions due to 
primary sensitisation generally tend to be more severe than reactions caused by cross-allergenicity.  
 
Thus, after introduction of a new or newly allergenic (modified) food, there will first be clinical 
reactions due to cross-allergenicity (if any) that tend to appear early after introduction of the food, 
because the consumers are already allergic (Fig. 1). These reactions will take place from day 1 after 
introduction of the food, and their true frequency will depend on the extent to which the food is 
consumed, as well as the prevalence of cross-reacting allergies and the potency of the newly 
introduced allergen. However, the observed frequency will tend to be low in the beginning and 
increase as awareness of the problem increases among the population and among health care 
providers. These reactions will schematically tend to be less severe because they are due to cross-
reactivity. Later, because primary sensitisation has first to take place, reactions caused by primary 
sensitisation to the new allergen will gradually appear (Fig. 2). The true frequency will probably 
increase rather slowly, because different individuals are likely to be sensitised at different speeds 
depending on individual factors and patterns of food consumption. Also, it is likely that the observed 
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frequency will develop slowly, because recognition of the allergenic properties of the food and 
awareness of the problem most likely will take a long time to develop. 
 
 
                                                                                                              
 
                        
Figure 2: Schematic illustration of how, after introduction of kiwi fruit into UK in 1970 clinical 
allergic reactions to kiwi exposure appeared in the population. Initially, it was predominantly 
eaten by adults and most who developed allergic reactions did so as a consequence of cross 
reactivity in those with pre-existing pollen and latex allergy. Most adults had relatively mild 
symptoms. Only after around 20 years did kiwi begin to appear in infant feeds. This was 
followed by increasing numbers of children presenting with allergic reactions to kiwi with a 
significant percentage having severe manifestations including anaphylaxis (Lucas et al., 2004).   
 
On most of the European market, lupin is in effect a new allergenic food, and the picture of its 
allergenicity in the population is still evolving. Severe food allergic reactions caused by lupin 
appeared fairly soon after lupin flour was used to fortify wheat flour, and most of the food allergic 
reactions to lupin observed so far have apparently been caused by cross-allergenicity with peanut 
(Faeste et al., 2004; Moneret-Vautrin et al., 1999). Many of the reactions have been relatively severe 
(Radcliffe et al., 2005; Smith et al., 2004; Wuthrich, 2008). The extent of clinically important cross-
allergenicity between lupin and peanut has been reported and is still a matter of debate and further 
investigations are needed (Lindvik et al., 2008). Primary lupin allergy has been reported (Faeste et al., 
2004; Peeters et al., 2007; Quaresma et al., 2007; Wassenberg and Hofer, 2007; Wuthrich, 2008), but 
it remains to be seen whether primary lupin allergy will develop into a significant clinical problem.  A 
difficulty hampering a good understanding of the development of food allergy to lupin after its 
introduction into the general diet in Europe is the lack of information about the amount of lupin 
consumed at the national and individual levels. An early warning sign that lupin was allergenic was 
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that people working with the lupin sometimes developed asthmatic reactions due to inhalation of the 
flour. 
 
Thus, we can learn from history that if a novel food product cross-reactive with a common food 
allergen were introduced into the diet, clinical food allergic reactions would be expected to appear 
almost instantly. The further development of reaction frequency would depend on the extent of 
product intake and exposure, as well as the prevalence of cross-reacting allergies and the potency of 
the newly introduced allergen. If cross-reactivity were with a less common pre-existing food allergen, 
reactions still would occur early but the frequency would develop to lower levels. Recognition of 
cross-reactivity with a common allergen is likely to be rapid given the awareness of the potential 
problem among the population and caregivers whilst the recognition of cross-reactivity with a less 
common allergen is likely to be slow and less clear. In contrast, if reactivity to the GM food would 
depend on primary sensitisation, it would take months and possibly years before a significant number 
of clinical reactions appeared, and the recognition of the problem might develop very late and slowly. 
Moreover, primary sensitisation is more likely to occur early in life when the immune system is 
immature and become apparent when the food is eaten by infants.   
 
1.8. Specific assessment for children 
 
Food allergy in childhood is clinically different from adult food allergy. In infants and children, 
symptoms consist of skin reactions (i.e. urticaria and flares of atopic dermatitis), as well as digestive 
and/or respiratory reaction, while in adults symptoms are mostly related to foods cross-reacting with 
pollen proteins (i.e. oral allergy syndrome). Primary sensitisation to the incriminated foods largely 
explains the different type of clinical response. In infants, primary sensitisation occur through the gut 
(although it has been previously noticed that sensitisation might also occur through dermal or 
respiratory exposure) or also possibly prior to birth. Primary sensitisation in the gut of infants might be 
favoured by the immaturity of the local immunity and incomplete barrier function of the intestinal gut 
mucosa as well as incomplete protein degradation by pepsin in the stomach due to a gastric pH above 
values seen in adults. Gastric acid secretion attains adult levels only after one month of age (Hyman et 
al., 1985). For instance, it has been shown that at the pH in the stomach of an infant the major 
allergenic proteins in kiwi fruit are not digested, thus increasing the potential for primary sensitisation. 
This does not occur in older children and adults with more acidic conditions in the stomach (Lucas et 
al., 2008). The potential of allergy sensitisation in a gastric environment with increased pH is further 
corroborated by the increased risk for allergic sensitisation found in allergic individuals treated with 
anti-acid medications (Lucas et al., 2008; Untersmayr and Jensen-Jarolim, 2008). 
 
In adults, primary sensitisation can occur through the gut, but mostly by cross-reaction between fruit 
and legume proteins with common pollens (e.g. apple and birch pollens). This is exemplified by 
reactions to kiwi fruit which have been seen progressively more frequently over the last 30 years in 
Europe.  The commonest adult manifestation is with minor symptoms of the oral allergy syndrome. As 
it was more recently manifested in young children severe generalised allergic reactions including 
anaphylaxis occurred. The presumption is that the children were primarily sensitised with the potential 
for severe reaction while adults had cross-reactivity with prior pollen allergy and consequently milder 
responses.  
 
1.9. Other considerations 
 
1.9.1. Immunogenicity and adjuvanticity  
 
Immunogenicity is the capacity of proteins to induce an immune response and particularly activation 
of T cell lymphocyte subsets and the production of antibodies of different isotypes in humans and 
animals after exposure under appropriate conditions. Peptide fragments generated after proteolytic 
cleavage of the protein may retain (part of) the immunogenicity or acquire new immunogenic 
properties (see Annex 1.3).  
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Adjuvants (from Latin adjuvare, “to help”) are substances that, when co-administered with an antigen, 
increase the immune response to that antigen. By modifying the microenvironment in which antigen-
presenting cells (APC) are active, an adjuvant activates the innate immune system leading to increased 
efficiency of antigen presentation to T lymphocytes. This can be achieved by many different 
pathways, including increased surface expression of MHC molecules, co-stimulatory molecules, 
adhesion molecules, as well as production of soluble cytokines such as IL-12. 
 
Adjuvants activate APC by triggering signaling as a result of recognition of receptors of the innate 
immune system, Toll-like receptors (TLRs) and NOD receptors, in particular. Aluminium salts exert 
their adjuvant effect by a combination of depot-effect and activation of the inflammasome through 
caspase 1 and the release of IL-1b. The hallmark of such receptor recognition is the activation of the 
transcription factor NF-kB and its translocation to the nucleus.  
 
The adjuvant itself often is not immunogenic but injection of some adjuvant such as Freund’s 
complete adjuvant (CFA) or lipopolysaccharides (LPS) alone can profoundly affect the immunological 
status of an animal. Some adjuvants can activate NK and NKT cells resulting in increased natural 
“killer activity” in absence of any antigen. Some adjuvants can also elicit strong regulatory T cell 
responses. However, some proteins, e.g. choleratoxin are potent adjuvants and at the same time are 
also antigens that may trigger an immune response against themselves (Holmgren et al., 1994; Lebens 
and Holmgren, 1994; Moreno-Fierros et al., 2000; Pizza et al., 2001). The immune response facilitated 
by an adjuvant may sometimes be predominantly of one particular type qualitatively, e.g. a Th1-
response or a Th2-response, in which case the adjuvant would be called a “Th1-adjuvant” or a “Th2-
adjuvant”, respectively.  The qualitative polarisation of the immune response caused by an adjuvant 
may be more or less marked, but may sometimes be strong and may override a pre-existing immune 
response. For example, CpG olignucleotides (components of bacterial DNA) are strong Th1 adjuvants, 
and may overrun a pre-existing Th2-type response against an antigen (Senti et al., 2009; Serebrisky et 
al., 2000) and lead to a strong Th1-type response against that antigen. Many vaccines contain an 
adjuvant to obtain the desired immune response quantitatively as well as qualitatively. In the field of 
vaccinology, much work is focused on the development of safe and effective adjuvants (Chiarella et 
al., 2007; Guy, 2007; Kwissa et al., 2007). 
 
The term “adjuvant” is correspondingly used in environmental medicine to characterise factors that 
increase the development of immune responses, sometimes causing adverse effects (“environmental 
adjuvants”). For example, tobacco smoke is an adjuvant for allergy development (Nielsen et al., 2005), 
and there is an abundant literature on the adjuvant effects of diesel exhaust particles in relation to the 
increase of specific IgE production leading the development of allergy (Fernvik et al., 2002; Lovik et 
al., 1997; Samuelsen et al., 2008). The adjuvant effect of diesel exhaust particles has been found to be 
mediated both by adsorbed chemical substances and by the carbonaceous particle core itself (Granum 
and Lovik, 2002). Further, chemically inert particles in the fine and ultrafine (nano) size range have 
been found to have an adjuvant effect on antibody production (Granum et al., 2001a; Lovik et al., 
1997; Nygaard et al., 2009; Nygaard et al., 2004). Thus, it appears that physical as well as chemical 
properties may determine adjuvanticity (Granum and Lovik, 2002). 
 
The antigen and the adjuvant have to be injected or applied together to achieve maximal adjuvant 
effect (Granum et al., 2001b). The precise mechanisms underlying adjuvant activity are incompletely 
understood, and different mechanisms may contribute. One probable main type of mechanism is the 
focussing of antigen at a site where lymphocytes can react to it, and maintenance of antigen exposure 
at this site (“depot” effect). The other main type of mechanism is alteration of cellular functions (e.g. 
cytokine production) leading to a stronger immune response. The adjuvant may increase antigen 
capture and processing by antigen-presenting dendritic cells, and promote migration of dendritic cells 
to the lymph node. Released stress molecules may be of importance. Generally, it is thought that the 
capacity to induce local inflammation is important, because this will increase the local availability of 
both lymphocytes and antigen-presenting cells in a setting of cellular activation. Adjuvants may 
represent a “danger signal” to the immune system (Gallucci and Matzinger, 2001), and interact with 
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pattern recognition receptors of dendritic cells, in particular Toll-like receptors (TLRs) and NOD 
receptors (Franchi et al., 2009; Lahiri et al., 2008; Trinchieri and Sher, 2007). Thereby the adjuvants 
may influence the magnitude and quality of the immune response by increasing the efficiency of 
antigen presentation to T lymphocytes. This can be achieved by different pathways, including 
increased surface expression of MHC molecules, co-stimulatory molecules, adhesion molecules, as 
well as production of soluble cytokines such as IL-12.  
 
In addition to substances having a direct adjuvant effect, other substances may exert an indirect 
adjuvant effect by reducing food protein enzymatic degradation (Untersmayr et al., 2003) or by 
increasing antigen uptake (e.g. saponins in foods) (Maharaj et al., 1986).  
It is nowadays feasible to detect in vitro an adjuvant activity by assessing, in cultures of APC, a few of 
the multiple parameters that characterise activation, both at genomic and phenotypic levels. The 
formation of an inflammasome within cells can be evaluated for instance by detecting the activity of 
caspases (Franchi et al., 2009). The precise pathway through which a putative adjuvant is exerting its 
activity can be determined using cells from genetically-modified animals (mostly knocked-out mice), 
silencing RNA and neutralising antibodies. Such experiments are becoming commonly used.  They 
may not detect all mechanisms for adjuvanticity/ types of adjuvants nor allow distinguishing IgE and 
cytotoxic adjuvanticity from IgA/IgG/IgM but they would provide useful information for assessing the 
adjuvant effect of newly expressed proteins or any product derived from GMOs (Marrack et al., 2009). 
Such in vitro models can be used in association with animal models (see below). 
 
There are several classes of adjuvants.  
• Mineral oil emulsions with or without killed mycobacteria (Freunds complete and incomplete 
adjuvant, respectively) have been much used in animals but can not be used in man (Claassen 
et al., 1992; Stills, 2005). 
• Some cytokines may be used as adjuvants, and administration of cytokines such as IL-2, GM-
CSF and IL-12 has in human volunteers and animals been found to enhance the development 
of a mucosal immune response by an antigen (Toka et al., 2004; Wright et al., 2008).  
• So-called CpG motifs, sequences about 20-fold more common in bacterial than in mammalian 
DNA, are effective Th1- and cytotoxic immune response adjuvants in mice, but results have 
not been found directly transferable to humans and other base sequences are needed for 
optimal function in humans (Gupta and Cooper, 2008; Klinman, 2006).  
• Alum, a gel composed of aluminium potassium sulphate, aluminium hydroxide or aluminium 
phosphate also refererred to as alum, was one of the first adjuvants used and is still the only 
one commonly used in humans. It is extensively used e.g. in vaccines for children. The 
mechanism of action is beginning to be understood (Kool et al., 2008; Lambrecht et al., 2009). 
Alum promotes a Th2-biased antibody response (Lindblad, 2004) and is less good at 
supporting a cell-mediated immune response.  
• Finally, some bacterial toxins or their components and modified versions have been found to 
be potent adjuvants in experimental animals and in humans, e.g. cholera toxin, pertussis toxin, 
staphylococcal enterotoxin B and heat-labile enterotoxin (HLT) from E. coli.  To produce a 
molecule that is no longer toxic but still retain adjuvant activity, modified versions of cholera 
toxin have been made by point mutation or removal of the A chain (Pizza et al., 2001; 
Sanchez and Holmgren, 2008; Vazquez et al., 1999; Zhou et al., 2009).  
 
While adjuvanticity, in particular for the IgG, IgM and IgA isotypes, is beneficial in some settings like 
in vaccines, an increase of IgE production resulting from an adjuvant activity may increase the risk of 
allergy. With vaccines, this has in practice turned out not to be a problem of practical significance. In 
contrast, in relation to respiratory allergy, exposure of the mucosa of the airways to environmental 
adjuvants like tobacco smoke (Nielsen et al., 2005) and diesel exhaust particles (Diaz-Sanchez et al., 
1999; Lovik et al., 1997) has been convincingly demonstrated to increase the development of IgE-
mediated allergy. Interestingly, it has also been demonstrated that a very important cause of allergy, 
pollen grains, in addition to their protein allergens carry with them substances that function as 
adjuvants. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and 
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augment T helper type 2 cell polarisation (Traidl-Hoffmann et al., 2005). The combined exposure to 
pollen allergens and substances with pronounced adjuvant activity may, at least in part, explain the 
high prevalence of pollen allergy and points to the importance of adjuvants in a normal physiological 
mucosal exposure setting when it comes to IgE-mediated allergy. Also in the intestines, adjuvant-
facilitated IgE responses in experimental systems lead to food allergy and therefore clearly may cause 
adverse effects (Li et al., 2000; Untersmayr et al., 2003), and the same appears to be the case in man 
(Scholl et al., 2005; Untersmayr et al., 2005). In an epidemiological study, food allergy was linked to 
exposure to staphylococcal enterotoxin from infected sinuses (Liu et al., 2006). An adjuvant-induced 
increase in production of antibodies of the IgA isotype would supposedly protect the mucosa both in 
the airways and in the intestines. It is less clear whether an increased production of IgG subclasses 
because of adjuvant activity would be beneficial or might lead to adverse health effects. An IgG 
response has a protective role against infections in the airways, and an IgG response against food 
proteins appears to be a normal response in the gut. However, whereas in the lung a strong IgG 
response against innocuous antigens may cause severe symptoms in so-called extrinsic allergic 
alveolitis (farmer’s lung, pidgeon-breeder’s lung, etc), it is still unclear whether an adjuvant-enhanced 
strong IgG response against food components would cause adverse effects. Also, it is still 
controversial whether an induction of strong Th1 immunity would protect against Th2-dependent 
allergic responses or lead to inflammatory conditions. Immunisation experiments in rodents with 
subcutaneous injection may serve for screening and hazard identification (Lovik et al., 2007). 
However, considering the presumably most relevant route of exposure, peroral immunisation models 
in mice have also been developed at the experimental level (see section on in vivo models; (Brunner et 
al., 2009; Li et al., 2000; Untersmayr et al., 2003; Vinje et al., 2009)). As previously mentioned, an 
increased IgE response effect is strongly linked to allergy development and should be considered an 
adverse effect, whereas an IgA reponse may be beneficial and in general not adverse. With regard to 
IgM and IgG, it is still speculative whether an increased response to food allergens may cause adverse 
effects. Considering the fact that no condition is known in which IgG and IgM antibodies are the 
primary cause of adverse effects in the intestines, an IgG or IgM adjuvant effect not accompanied by 
increased IgE production probably should not be considered an adverse effect. However, further 
research addressing this issue should be undertaken.  
 
In relation to foods, a food component with (strong) adjuvant activity would be expected to increase 
the development of allergy not only against that particular food. Instead, the effect would probably be 
stronger against other foods eaten concomitantly, if these were strong allergens (like milk, eggs, nuts, 
peanuts, etc.). 
 
1.9.2. Food allergy in food-producing and companion animals. 
 
Food allergy in farm animals has been reported in veal calves from dairy herds and piglets after 
weaning (review by Dreau and Lalles, 1999). Such food adverse reactions developed in baby calves 
when milk protein was replaced in milk formulas by insufficiently processed plant proteins, including 
sources like soya bean (Glycine max.) and field pea (Pisum sativum). The process of early weaning 
onto non-milk dry diets leads to adverse reactions to food in baby pigs. In both animal species, 
gastrointestinal signs of reactions to food are the most common. In farm-reared fish, including salmon 
and rainbow trout many attempts have been made for replacing fish protein with plant proteins, from 
soya bean mostly. Food-mediated disorders have long been suspected based on gastrointestinal tissue 
alterations with such vegetal-based diets. However, little evidence exists presently to indicate whether 
these disorders are allergy or even immune-mediated in the fish. 
 
Immune reactions to food in companion animals (mostly dogs and cats) involve primarily skin and 
secondly gastrointestinal tract clinical manifestations (review by Verlinden et al., 2006). Some models 
of natural sensitisation to particular foods (e.g. cow’s milk in guinea pigs and wheat gluten in Irish 
Setter dogs) in companion animals do exist and are particularly relevant to studying similar diseases in 
humans.  
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Although an eviction regimen is an important element for the diagnostic of immune reactions to foods, 
appropriate treatments of food ingredients have been developed for reducing such adverse reactions. 
 
1.9.2.1. Food allergy in farm animals 
 
One major limitation for studying true IgE-mediated food hypersensitivity reactions in veal calves and 
baby pigs has been the unavailability of anti-bovine IgE and anti-porcine IgE reagents. A murine 
monoclonal antibody specific for bovine immunoglobulin E was produced in 1988 (Thatcher and 
Gershwin, 1988) and has been used essentially for studying responses to parasites in bovines. Two 
papers reported the production of hyper-immune anti-porcine IgE reagents (Roe et al., 1993; Rupa et 
al., 2008b). Skin passive cutaneous anaphylaxis (PCA) tests were developed as an alternative to IgE 
assays for studying immune-mediated adverse reactions to food components in young calves. 
 
Milk formula-fed calves 
Immune-mediated gastro-intestinal disorders in calves fed milk formulas containing heated soya bean 
flour were reported for the first time in the early sixties in The Netherlands. The major clinical signs 
were loss of appetite, diarrhoea and body weight reduction (review by Lalles, 1993). Earlier work in 
the U.K. based on PCA skin testing concluded to the involvement of either type I (IgE-mediated) or 
type III (immune-complex mediated) hypersensitivity reactions (Barratt and Porter, 1979; Barratt et 
al., 1978, 1979; Kilshaw and Sissons, 1979b). The very rapid (< 1 hr) onset of motility disturbances of 
the small intestine following a challenge with antigenic soya bean in calves already sensitised to this 
food was also consistent with an IgE-mediated reaction (Lalles et al., 1995a; Lalles et al., 1998; 
Sissons et al., 1982). Disruption of myoelectric complexes migrating along the small intestine 
occurred for incorporation rates of soya bean representing 17.5% or more of the total protein in the 
diet (Lalles et al., 1995a). Histamine via H-1 receptors appeared to be the main mediator involved in 
motility disorders (Lalles et al., 1995a). 
 
Sensitive calves developed very high levels of circulating IgG1 antibodies against the major soya bean 
proteins, namely glycinin and β-conglycinin. Detailed investigations with a set of purified soya bean 
proteins led to the conclusion that glycinin and β-conglycinin were probably the major adverse food 
molecules involved but that other minor proteins, including α-conglycinin, Bowman-Birk inhibitor and 
lectin also induced skin reactions (Lalles et al., 1996b). β-Conglycinin, but not glycinin was also able 
to induced in vitro proliferation of lymphocytes collected from sensitised calves. This, together with 
long-lasting skin reactions after intradermal injection of β-conglycinin suggested this protein to be 
involved in type IV, cell-based hypersentivity reactions in calves (Lalles et al., 1996b). 
 
Histology revealed strong intestinal villous atrophy (Barratt et al., 1978, 1979; Kilshaw and Sissons, 
1979a; Lalles et al., 1995a; Seegraber and Morrill, 1982, 1986) associated with increased permeability 
and decreased absorptive capacity (Kilshaw and Slade, 1980; Lalles et al., 1995a; Seegraber and 
Morrill, 1979). Increased mast cell numbers and eosinophilia in sensitive calves were reported earlier 
(review by Lalles et al., 1993). Infiltration of mucosal tissues with T lymphocyte subsets [CD4+ and 
WC1(γδ)+ T cells in the lamina propria and CD8+ and WC1(γδ)+ T cells in the epithelium] was 
reported later (Lalles et al., 1996a).  
 
β-Conglycinin was shown to resist gastric digestion in vivo (Lalles et al., 1999) and both glycinin and 
β-conglycinin were detected in small intestinal digesta (Sissons and Thurston, 1984). Treating soya 
bean products appropriately (e.g. with heat, proteases or hot water-ethanol mixture) reduced 
considerably clinical signs of food-related disturbances and improved growth performance (Lalles et 
al., 1995b; Sissons et al., 1979). The immunogenicity of soya bean products, their digestibility and calf 
performance could be predicted from the levels of immunoreactive glycinin and β-conglycinin in soya 
bean products as determined by ELISA (Lalles et al., 1996c; Sissons et al., 1982). 
 
Beside soya bean, veal calves were shown to digest raw field pea flour poorly and to develop severe 
immune-mediated gastro-intestinal disorders and diarrhoea (Bush et al., 1992). By contrast, fish 
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protein sources (Guilloteau et al., 1986) as well as wheat gluten and potato protein (Branco-Pardal et 
al., 1995) are well digested and tolerated by young calves.  
 
Baby pigs 
Allergy to food (e.g. soya bean) components is suspected to be an aetiological factor involved in the 
post-weaning diarrhoea syndrome in young pigs (reviews by Dreau and Lalles, 1999; Lalles and 
Salmon, 1994; Lalles et al., 1993). However, food-specific IgE responses have been studied in piglets 
only recently (Fu et al., 2007) because of the unavailability of anti-porcine IgE reagents before. 
Responses to food components were mostly studied regarding the other Ig isotypes and systemic 
antibodies to food were consistently observed in studies with pigs fed antigenic soya bean products 
after weaning (Dreau et al., 1994; Friesen et al., 1993; Li et al., 1990). Specific IgM and IgG were 
found in plasma, and IgM, IgA and IgG in intestinal secretions, in piglets previously fed antigenic 
proteins (Dreau et al., 1994; review by Lalles and Salmon, 1994). The numbers of plasma cells in the 
lamina propria of the small intestine were drastically increased following antigenic soya bean 
consumption (Dreau et al., 1995). Attempts to identify immune mechanisms by direct skin testing 
suggested that glycinin, by not α- or β-conglycinin were involved in immediate reactions (Dreau et al., 
1994). This is consistent with the IgE-mediated reactions to glycinin demonstrated recently (Sun et al., 
2008). Gastric administration of glycinin was able to induce dose-dependently an IgE-mediated 
response in pigs, resulting in diarrhoea and reduced growth performance (Sun et al., 2008). This 
response was of the Th2 type and was associated with increased numbers of intestinal mast cells, 
increased histamine release and increased plasma concentrations of IL-4 and IL-10 (Sun et al., 2008). 
Another recent study identified antigenic (but not allergenic) epitopes of the other soya bean storage 
globulin, β-conglycinin recognised by pig plasma IgG (Fu et al., 2007). Finally, other proteins from 
legume grains are immunogenic in pigs but adverse food-related reactions have not been reported 
against these legumes (Salgado et al., 2002). 
 
Regarding cellular aspects of immune responses to food, lympho-proliferation tests carried out in vitro 
with circulating and intestinal cells added with soya bean extracts or purified proteins remained largely 
unsuccessful (Dreau et al., 1995; Li et al., 1990; Li et al., 1991). However, histological investigations 
demonstrated an infiltration of the intestinal mucosa by T cells of the CD4+ (lamina propria) and 
CD8+ (epithelium) phenotypes (Dreau et al., 1995). 
The neonatal piglet also served to develop models of gastrointestinal allergy (e.g. to peanut and 
ovomuccoid) (Helm and Burks, 2002; Helm et al., 2003; Helm et al., 2002; Rupa et al., 2008a). 
 
Fish 
Adverse reactions to soya bean proteins are suspected to cause deleterious effects on the distal 
intestine of rainbow trout and Atlantic salmon. However, little evidence is available to date for 
concluding to particular immune-mediated specific mechanisms. Rumsey et al. (1994) reported 
increased leukocyte cell numbers and concentrations of plasma protein and immunoglobulin and 
increased non-specific immunity (activities of neutrophils, monocytes and macrophages) in rainbow 
trout fed soya bean products, ‘possibly indicating an inflammatory or hypersensitivity response’. In 
another study, high dietary levels of soya bean were shown to suppress non-specific immunity and to 
favour the appearance of alterations in distal intestinal tissues in salmon (Burrells et al., 1999). Two 
studies, one in rainbow trout (Kaushik et al., 1995) and one in salmon (Burrells et al., 1999) reported 
that no circulating antibody responses to dietary soybean proteins could be found. A Norwegian group 
noted increased levels of IgM (Bakke-McKellep et al., 2000) and T-cell-like responses to soya bean 
(Bakke-McKellep et al., 2007) in intestinal tissues of salmon. One possible aetiological factor may be 
the presence of lectin that binds intestinal epithelium and cause its disruption in rainbow trout (Buttle 
et al., 2001).  
 
Horses and birds 
Fadok (1995) reported the possibility for pruritic dermatoses ‘caused by allergies, including food 
allergy/intolerance’. However, the lack of recent publications in this area suggests a low incidence of 
this disease in horses. To the best of our knowledge, immune-mediated reactions to food in poultry 
have not been reported in the literature thus far. 
Annex 1. Clinical aspects
 
 
44 EFSA Journal 2010; 8(7):1700 
 
1.9.2.2. Food allergy in companion animals 
 
Food allergy in dogs and cats is difficult to diagnose accurately because levels of total and specific IgE 
in plasma are of low predicting value in these animals (review by Day, 2005). Also, as far as 
dermatological manifestations are concerned, cross clinical signs with responses to frequently carried 
parasites are common (review by Verlinden et al., 2006). A food trial comprising elimination and 
reintroduction of the incriminated food/s is probably the best diagnostic tool (Verlinden et al., 2006). 
 
Dogs 
Clinical manifestations of food allergy in dogs are mostly dermal, with less than 10-15% 
gastrointestinal non-specific signs (vomiting, diarrhoea) but other manifestations (e.g. rhinitis, 
conjunctivitis) can be seen occasionally. Food allergy with dermal manifestation may represent 
approximately 10 % of all skin diseases, excluding those caused by parasites (review by Verlinden et 
al., 2006). It is often considered that gender, age, season and breed do not influence the incidence of 
food allergy in dogs. However, various pure breeds (e.g. Boxer, Collie, German Shepard, Irish Setter) 
may have a higher risk, contrary to crossbreeds that appear less sensitive. The age of first occurrence 
of food allergy may vary widely (a few months to > 10 years) but it is generally comprised between 1-
2 years. Adverse reactions may happen after 1-2 years of consumption of the incriminated allergens. 
The most frequent clinical sign of food allergy in dogs is pruritus, although it can resemble other skin 
diseases (e.g. pyoderma). Otitis interna is a good indication of food allergy in dogs. Diet exclusion is 
considered the best option for recovery from food allergy. However, the duration of the exclusion 
treatment can vary widely (from 3 to 13 weeks). Thus, well nutritionally balanced diets are needed for 
long periods of incriminated food elimination in order to cover the nutritional requirements of the dogs 
(review by Verlinden et al., 2006). 
 
The food ingredients most frequently incriminated in food sensitivity in dogs are beef and dairy 
products, followed by cereals, eggs and chicken (Day, 2005; Verlinden et al., 2006). Also reactions to 
processed (canned or dry) foods are increasingly observed, in connection with the increased 
consumption of such preparations. Bovine serum albumin, IgG heavy chain and the enzyme phospho-
glucomutase were recently identified as major meat allergens in dogs (Martin et al., 2004; Ohmori et 
al., 2007). Food ingredient (e.g. soya bean protein) hydrolysis is a promising way of preparing hypo-
reactive foods for dogs (Biourge et al., 2004; Cave, 2006; Cave and Guilford, 2004; Jackson et al., 
2003; Serra et al., 2006). 
 
The Irish Setter dog is a natural model of gluten-sensitive enteropathy occurring at 4-7 months of age 
and being caused by a type IV cell-mediated hypersensitivity to wheat gluten (review by Verlinden et 
al., 2006). It is genetically linked to a single major autosomal recessive locus (Batt et al., 1984; Garden 
et al., 2000; Hall et al., 1992). Various HLA-DQ haplotypes of the canine major histocompatibility 
complex class II were characterised, one being absent from healthy dogs (Polvi et al., 1997). This 
disease is characterised by partial to total jejunal villous atrophy associated with a selective reduction 
in brush border enzyme activities (e.g. alkaline phosphatase, aminopeptidase N and dipeptidyl-
peptidase IV; disaccharidase activities are unchanged) and changes in the activity of various intra-
cellular enzymes (Batt et al., 1984; Pemberton et al., 1997). Abnormal intestinal permeability is 
frequently recorded and often precedes the onset of gluten-sensitive enteropathy, suggesting its 
aetiological role in the disease (Hall and Batt, 1991). Affected dogs display elevated serum levels of 
IgA, low anti-gliadin antibodies that correlate with immune complex formation, and increased 
intestinal mucosa densities of lymphocytes (Hall et al., 1992). Disease relapse can be obtained 
following a gluten-free diet or a diet with hydrolysed gluten (Hall and Batt, 1992).  
 
Rare diseases, including protein-loosing enteropathy and protein-loosing nephropathy have been 
described in Soft Coated Wheaten Terrier dogs. They may involve immune complex-mediated, type 
III hypersensitivity reactions to food (review by Verlinden et al., 2006). Finally, experimentally-
induced food allergy models have been developed in dogs (review by Day, 2005). 
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Cats 
Food allergy is rare in cats and when it happens it displays skin manifestations mostly, with less than 
10-15% of gastrointestinal disorders (Guilford et al., 2001). The influence of gender, age or breed 
appears low but some breeds (e.g. Birman and Siamese cats) may be more sensitive (review by 
Verlinden et al., 2006). The age of first occurrence of allergy and the duration of consumption of the 
incriminated allergens before the onset of the disease are within the same ranges as in dogs. 
 
The major clinical sign of food allergy in cats is also pruritus showing regional distribution (often 
head, neck and ears) and being associated with eosinophilia in 20-50% of the cases. Many other 
clinical signs have been observed at a low frequency (review by Verlinden et al., 2006).  
 
The food ingredients the most frequently incriminated in dietary sensitivity in cats are beef and dairy 
products, fish and processed (especially dry) foods. Adverse reactions to food additives and to 
unspecified food components are also relatively high. 
 
Guinea pigs, rats and mice 
The young guinea pig is a well known model of natural allergy with high levels of reaginic antibodies 
and altered intestinal permeability following oral consumption of cow’s milk (Heyman et al., 1990; 
Suzuki et al., 1987). Many other rodent, non-natural (induced) models of allergy have been developed 
for research purpose (reviews by Fritsche, 2003; Helm and Burks, 2002). 
 
To sum up, immune-mediated reactions have been detected in young farm animals (calves, pigs) and 
in intensively reared fish species (salmon, trout) in the context of replacing expensive animal proteins 
(from cow’s milk or fish) with cheaper vegetal protein sources, mainly soya bean in food formulas. 
Food ingredient composition for pets is still diversified which probably explains the corresponding 
diversity in reported offending foods. Such food-mediated diseases in animals can be overcome by 
using food ingredients that underwent appropriate treatments, including heat, enzymes or organic 
solvents. Interestingly, some immune reactions to foods develop naturally in some animal species (e.g. 
cow’s milk allergy in the guinea pig; gluten sensitive enteropathy in the Irish Setter dog). These have 
been used as relevant experimental models for humans. Finally, additional work is still needed in fish 
and pets for understanding better the underlying immune mechanisms involved in adverse reactions to 
food. 
 
1.9.3. Post-Market Monitoring of Allergenicity of GM foods. 
 
Novel foods in general and food derived from GMOs in particular are submitted to a comprehensive 
risk assessment before they are approved and launched on the market place. However reactions of 
consumers may be highly variable, depending on genetic diversity, exposure, geographic, 
socioeconomic and environmental conditions and all possible situations are difficult to mimic in pre-
market risk assessments. In addition some (small) segments of the population who may be very high 
consumers or particularly susceptible to develop adverse effects when exposed to a novel/GM food 
may not have been sufficiently accounted for during pre-market assessments. For these reasons the use 
of post-market monitoring programmes (PMM) that aim to provide accurate information regarding 
actual intake of the novel food by different groups of consumers and occurrence of any expected or 
unexpected (adverse) effects in relation with the consumption of the novel foods in every day life 
conditions has long been proposed.  
 
Wal et al. (2003) and Hepburn et al. (2008) noted that large study populations should be used to ensure 
a statistically valid interpretation and emphasised that allergenicity could be a relevant hypothesis 
driven case for PMM because allergic individuals constitute targeted groups of the population that 
may be well identified, organised and informed and who can be motivated to participate actively in a 
PMM study. 
 
However, many difficulties have been identified with regard to PMM of foods and particularly of 
foods derived from GM plants (commodities) as compared to post launch monitoring programmes that 
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are currently performed for medicinal products. Among others this particularly pertains to the need for 
adequate traceability and identification of the food products derived from the GM source which may 
be impossible if the GM ingredient is incorporated in a wide range of foods. This is why the EFSA 
guidance document (EFSA, 2006, 2009) recommends the implementation of such PMM only when the 
GM food has no traditional comparator and is intended for an improved nutritional and health value. 
 
Nevertheless, there is a need to inform medical doctors and consumers of the presence of GM- and 
non-GM- products, so that case reports can be specifically related to either category of food that has 
been consumed. In order to have a reliable information between the different stakeholders (e.g. 
consumers, health professionals, food industry, risk assessors and risk managers), it is crucial that the 
collection, validation and recording of case reports is carefully checked for relevance (correct clinical 
diagnosis versus self-reported reaction, link to food consumed). Models of such registries of allergic 
reaction to foods and allergo–vigilance systems have already been developed in some countries and 
they will certainly be of a great help for risk assessment and risk management. With regards to the 
possible effects of long term exposure due to the development of cultivation and consumption of new 
food products on the frequency/severity of allergic sensitisation and reaction, more  data should be 
collected to precisely define what the reference “base-line” actually is. 
 
1.10. Conclusions and recommendations 
 
Food allergy is an adverse immune response where sensitisation can occur either by cross-reactivity or 
primary sensitisation through the gut, skin and respiratory tract. While allergy is generally assumed to 
be associated with the production of IgE antibodies to the relevant food other immune mechanisms 
may sometimes be involved. Epidemiological studies have indicated a food allergy prevalence of 5 to 
8 % in infants and young children and less than 5 % in adults; however, some recent studies have 
found the incidence of severe or lethal reactions to be highest in teen-agers and young adults (Bock et 
al., 2001; Lovik et al., 2002; Pumphrey and Gowland, 2007; Worm et al., 2010). The diagnosis of food 
allergy is largely based on the clinical history.  In suspected IgE-mediated food allergy, the diagnosis 
will rely on positive skin prick testing with commercial food extracts or native food extracts and serum 
specific IgE can also be measured to most potential food allergens. Interpretation of positive tests can 
be difficult as a positive test can also indicate presence of a sensitisation without clinical relevance. In 
addition, food allergy in farm animals has been reported. Some models of natural sensitisation to 
particular foods in companion animals do exist and are particularly relevant to studying similar 
diseases in humans. Furthermore, adjuvants are substances that may increase the immune reaction to a 
protein. An increased IgE response effect is strongly linked to allergy development and should be 
considered an adverse effect, whereas an IgA response may be beneficial and in general not adverse. 
Finally, there is a need to inform medical doctors and consumers of the presence of GM- and non-GM- 
products, so that case reports can be specifically related to either category of food that has been 
consumed.  
 
1.10.1. Specific assessment in infants and individuals with altered digestive functions 
 
Conclusions 
The specific risk of potential allergenicity of GM products in infants as well as individuals with 
impaired digestive functions (e.g. elderlies, or individuals on antacid medications) should be 
considered, taking into account the different digestive physiology and sensitivity towards allergens in 
this subpopulation. Whilst young children may be prone to sensitisation with GM derived allergens, 
this cannot be verified experimentally and clinically due to ethical issues, for which reason the further 
development of appropriate animal models to provide information on the issue of primary sensitisation 
is recommended. The recommendation provided here should not exclude any age group or patients on 
medications affecting the protein digestion, but include these individuals to provide safe GM products 
to all. 
 
Recommendations 
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• In addition to the pepsin resistance test, other in vitro digestibility tests in more physiological 
conditions are recommended in order to take into account the variations of the pH values of 
individuals with a modified digestion, e.g. sub-optimal, higher pH.  Besides the oral route of 
sensitisation, also other routes may be considered such as sensitisation by aerosolised foods or 
foods in contact with the skin.  
 
1.10.2. Non-IgE-mediated food allergy 
 
Conclusions 
Non-IgE-mediated food allergy is in many ways different with regard to mechanisms from IgE-
mediated food allergy, although several syndromes might derive from dual immune reactions, i.e. 
including IgE-type antibodies as well as other mechanisms (e.g. in eosinophilic diseases).  
 
Recommendations 
• In the frame of the allergy risk assessment of GM products there is a need to include known 
data regarding molecular structures of proteins known to be responsible for IgE-mediated 
allergy but also for other types of immuno-mediated or immuno-toxic reactions such as 
peptide fragments of gliadin involved in celiac disease. 
 
1.10.3. GM products specifically designed to be either hypoallergenic, adjuvant or 
vaccinating 
 
Conclusions 
For GM products that have specifically been designed for specific functions (e.g. to be either 
hypoallergenic, adjuvant, or vaccinating), such as by gene-silencing of the expression of allergenic 
proteins, clinical studies will have to be performed in order to substantiate the claim.  
 
The outcomes of such clinical studies, including those collected for therapeutic/diagnostic purposes, 
may also be useful for risk assessment.  The design of such studies should therefore also comprise the 
collection of data useful for risk assessment, such as the inclusion of dose ranges. 
 
1.10.4. Food allergy in food-producing and companion animals 
 
Conclusions 
As the pre-market assessment of GM products under Regulation (EC) 1829/2003 also considers the 
use of a GM product as animal feed besides food, the potential for allergenicity in animals, both 
companion and livestock, should also be considered.  Whilst animals and humans may be sensitised to 
the same common allergens, no public source is known to exist to date that provides comprehensive 
information on specific compounds that would be allergic to some animals but not to humans. In 
addition, allergy and intolerance to foods in animals may be due to several mechanisms and result in 
various clinical manifestations. The pathophysiology, the nature of the most common allergens, the 
level of exposure and digestive physiology in animals may be different from those in humans. Positive 
indications of a newly expressed protein being similar to an animal allergen may be followed-up with 
further testing in the pertinent animal, which has to be decided for on a case-by-case basis considering 
the feasibility of such trials and the intended use.   
 
Recommendations 
• It is proposed that the human allergen databases used for collecting allergen sequences for 
bioinformatics-supported comparisons of newly expressed proteins to allergens is extended 
with allergens for animals. Therefore, it is recommended that in parallel with the human 
allergen databases, databases for animals are developed and that the level of allergenicity 
shared between humans and animals is further investigated. 
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• In relation to allergy in animals, livestock animals may serve as “sentinel” given their large 
and less variable intake of certain feeds, including those derived from GM plants. This might 
also provide information for allergy in humans. 
 
1.10.5. Adjuvanticity 
 
Conclusions 
Adjuvanticity has not been routinely considered in the assessment of potential allergenicity of GMOs. 
Based on analogy with respiratory allergy, findings in experimental models and limited 
epidemiological studies, consideration of adjuvanticity may seem pertinent particularly in two 
situations. When a food contains a substance known to functionally or structurally resemble a known 
strong adjuvant, or to belong to a class of proteins known often to have allergy adjuvant activity (e.g. 
bacterial toxins) the possibility of adverse immune responses being caused by the adjuvant should be 
considered. Further, in cases when adverse immune responses actually are found to be triggered by a 
product, it may be appropriate to consider the presence of strong adjuvants in that product.  
 
There is no definite test for adjuvanticity, and examples of species differences in adjuvanticity are 
known. However, because the substance properties and the mechanisms causing adjuvant activity are 
not well known, experimental work to reveal adjuvant activity of a substance must first of all consist 
of immune function studies in the intact host. Immunisation experiments in rodents with subcutaneous 
injection may serve for screening and hazard identification (Lovik et al., 2007). However, considering 
the presumably most relevant route of exposure, the mucosal route, peroral immunisation models in 
mice have also been developed at the experimental level (see section on in vivo models; (Brunner et 
al., 2009; Li et al., 2000; Untersmayr et al., 2003; Vinje et al., 2009). An increased IgE response effect 
is strongly linked to allergy development and should in the presence of appropriate controls be 
considered an adverse effect, whereas an IgA response may be beneficial and, at least, not adverse. 
With regard to IgM and IgG, it is still speculative whether an increased response to food allergens may 
cause adverse effects. Considering the fact that no condition is known in which IgG and IgM 
antibodies are the primary cause of adverse effects in the intestines, an IgG or IgM adjuvant effect not 
accompanied by increased IgE production probably should not be considered an adverse effect. 
However, further research addressing this issue should be undertaken.  
 
It is possible that in a near future adjuvant activity of newly expressed proteins or any product derived 
from GMOs may be assessed also using in vitro test such as cultures of APC in which a few of the 
multiple parameters that characterise activation, both at genomic and phenotypic levels can be 
determined. To date, such tests may not detect all mechanisms for adjuvanticity/ types of adjuvants 
nor allow to distinguish IgE and cytotoxic adjuvanticity from IgA/IgG/IgM but they would provide 
useful information particularly when used in association with animal models (see Annex 6.2.4; 6.3). 
 
1.10.6. Post-market monitoring and prevalence studies 
 
Conclusions 
The possibilities for setting up post-market monitoring (PMM) programmes for potential allergies 
towards GM products should be further explored and particularly the means to clearly identify GM 
from non-GM products in order to collect accurate data on the actual exposure and significantly and 
specifically relate any adverse effect to the intake of the GM food in order to substantiate or rule out 
potential differences of allergies to GM- versus non-GM- products. 
 
There is a need for exchanges of clear and reliable information between stakeholders with regards to 
the introduction of new food products derived from GMOs, their identification and the adverse effects 
that their consumption might have caused in consumers. This involves consumers, health 
professionals, food industry, risk assessors and risk managers. Networks of these groups such as 
professional and patients’ organisations might serve as primary contact point for dissemination and 
validation of pertinent information.  
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Occupational allergies of workers exposed repeatedly to relatively high levels of a particular GM 
product should serve as a sentinel for allergenicity, in particular in relation to   respiratory allergy, but 
with some relevance also for food allergy. 
 
Recommendations 
• PMM is recommended on a case-by-case basis, e.g. for GM food/feed with altered nutritional 
composition and modified nutritional value and/or modified to achieve specific health 
benefits. In case of remaining uncertainties on the allergenicity of the whole GM food, PMM 
may be considered by the risk manager. In case PMM is needed, future work should focus on 
developing (a) protocol(s) to provide data on the actual intake of the GM food, to guarantee 
the relevance of the reported adverse effects and to allow establishing any relation/causalities 
with the consumption of GM foods. It could for instance be valuable to develop prevalence 
studies in which GM foods are included as potential allergens in order to have a quantitative 
estimation of the potential impact of cultivation and consumption of GM plants on the 
prevalence of allergies. In this regard, information needs to be provided to the consumers and 
health professionals on such GM foods to be placed on the market. 
• Finally, a more general recommendation which does not only apply for GMOs but for all food 
allergens is that further research is needed to determine thresholds for sensitisation in man and 
thresholds for elicitation particularly in the case of cross-reactive allergies. This would allow 
identifying whether there is a level of expression of an allergen in a (GM) food that could be 
considered of no safety concern.  
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ANNEX 2. STRUCTURAL ASPECTS OF FOOD ALLERGENS: CONFORMATION, 
IN PLANTA PROCESSING AND FOOD MATRIX INTERACTIONS 
 
 
2.1. Introduction 
 
One of the key questions that remains to be answered is why some food proteins, and not others, 
become allergens. Whilst the immune status and genetics of an individual play a role in this, 
indications are that structural features and biological properties of some proteins predispose them to 
becoming allergens. Structure-function studies are a major aspect of protein science because they can 
provide a theoretical framework within which effective predictions can be made. Such relationships 
and knowledge underlie the in silico bioinformatic approaches for predicting the allergenic potential of 
newly expressed proteins in GMOs as described in Annex 3. Our knowledge base is currently 
incomplete with regards predicting whether a protein is likely to become allergen through 
sensitisation, an aspect of research hampered by our lack of effective animal models for food allergy 
(Annex 6). However, our knowledge about the basis of IgE cross-reactivity between known allergens 
is much greater and hence similarities in structure (both at the sequence level and three-dimensional 
structures) can be used to predict such cross-reactive allergenicity of newly expressed proteins with 
much greater assurance. This Annex summarises current understanding of how allergenic potential 
may be affected by protein structure, biological properties and post-translational processing. This has 
been placed within the context of how genetics, environmental factors and post-harvest processing 
may affect expression of allergens in plant foods, and how genetic modification has been used to 
down-regulate allergen gene expression in food plants to produce low allergen alternatives (see 2.7.3). 
Similarly our knowledge of how food processing and the food matrix modulate allergenic potential has 
been summarised. This Annex concludes by identifying gaps in our current knowledge and making 
recommendations on how information on the structure and biological properties of a novel protein can 
be used in an integrative fashion to support an assessment as to its likely allergenic potential.  
 
2.2. Classification of allergens based on their structural attributes  
 
The advent of gene cloning led to an explosion in the availability of proteins sequences which allowed 
more molecular approaches to classifying proteins based on sequence similarities. At the same time 
there has been an increase in the number of proteins with a defined three-dimensional structure, which 
has allowed even those proteins with poor sequence similarities to be compared, allowing 
identification of proteins with low homology levels but super-imposable three-dimensional structures 
to be identified, such as has been the case for the 11S and 7S seed storage globulins (Lawrence et al., 
1994). Using this knowledge, and driven by the need to ascribe possible functions to proteins 
identified simply on the bases of sequenced genomes, has led to the development of several 
bioinformatic approaches to classifying proteins into families such as  the “Pfam” database. This is a 
large collection of protein sequences (version 24.0 comprises around 11,912 families) which have 
been classified into protein families using multiple sequence alignments and hidden Markov models” 
(http://pfam.sanger.ac.uk/; for further information see Annex 3, (Finn et al., 2006). It is distinct from 
the allergen sequence databases discussed in Annex 3. In parallel with such developments there has 
been an explosion in the identification and sequencing of many allergens. The number of different 
allergen sequences for is approaching 200 for food alone. Such a data set makes the classification of 
allergens based on the structural attributes and biological properties feasible (Mills et al., 2004a). 
Previous studies (Aalberse, 2000) have indicated that there is no clear relationship between specific 
types of tertiary structure element and allergenicity but since the properties of proteins are generally 
conferred by virtue of their overall three-dimensional structure protein family analysis may pave the 
way to answering the question what makes one protein, and not another, an allergen. 
 
Protein family analysis of known plant food allergens indicates that the majority fall within just four 
families accounting for over 65% of the sequences (Jenkins et al., 2005). This pattern has been found 
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to hold for animal food allergens (Jenkins et al., 2007) and pollen allergens (Radauer and Breiteneder, 
2006). The dominant plant food allergen family is the prolamin superfamily, which comprises the 
cereal seed storage proteins, 2S seed storage albumins, cereal inhibitors of trypsin and α-amylase and 
the non-specific lipid transfer proteins (nsLTP). This is followed by the cupin superfamily, primarily 
comprising the 7S and 11S seed storage globulins, the Bet v 1 superfamily, comprising homologues of 
the major birch pollen allergen, Bet v 1 and profilins.  There is a long “tail” in the classification which 
includes other important allergens such as the class I chitinases involved in the fruit-latex cross-
reactive allergy syndrome and the cysteine protease family which includes the kiwi fruit allergen 
actinidin and the soybean allergen Gly m Bd 30K. It is interesting to note that all these proteins have 
either seed storage or protective functions. Despite the widespread consumption of vegetative tissues 
by humans there is little evidence that either the major photosynthetic enzymes or the less abundant 
structural and metabolic proteins are important allergens, see appendix. 
 
Fewer food allergens of animal origin have been identified to date, reflecting the fact that humans 
consume a less diverse range of animal-derived foods. Nevertheless these allergens also fall into a 
relatively small number of structurally-related families. The majority of animal food allergens can also 
be classified as belonging to one of three families, tropomyosins, EF-hand proteins (with a specific 
helix-loop-helix motif, which is also present in an important group of pollen allergens) and caseins, 
with a tail of 14 families containing only one to three reported allergens each. It is of note that several 
of these “minor” families include allergen families that have been identified as being important 
inhalant allergens, such as the lipocalin allergens (Virtanen, 2001).  
 
Such a structural classification of allergens is distinct from other classifications which can be based on 
assessments of allergenic potency. Thus, the Official IUIS Allergen Nomenclature database employs 
the terms “major” and "minor" for allergens depending on whether more or less than 50% of patients 
tested react with the corresponding allergen-specific IgE in the given test-system (Larsen and 
Lowenstein, 1996). This definition is also useful since allergic individuals rarely display a reaction 
towards only one type of protein. However, inevitable such a functional definition is dependent on the 
panel of patients being studied and hence the definition of major and minor allergens is likely to vary 
between different allergic patients with different allergic phenotypes or geographic origin (for further 
details see below).  
 
2.3. Structure-function relationships of allergens 
 
Using structural relatedness expressed in protein family membership, proteins can also be classified on 
the basis of putative function. This is because common properties of proteins are usually conferred by 
common structures. One large group are the structural, metabolic, proteins, of which many are 
regarded as “housekeeping” proteins being essential for the structure and function of all cells.  This 
group includes enzymes involved in biosynthesis and catabolism, structural proteins present in 
membranes and (for plants) cell walls, transporters and components of signaling cascades. Others may 
have a protective function whilst in plants there is a large group of storage-related proteins which are 
especially relevant when considering food as they contribute significantly to the human diet through 
the consumption of various seeds, nuts and grains.  
 
Several properties conferred by these common structural features have been proposed (Breiteneder and 
Mills, 2005). However, membership of one of a limited number of protein families in itself is not 
sufficient to determine allergenic activity. It seems that at least four factors work together to result in 
the sensitisation of an atopic individual with any given allergen, such as (i) the genetic make-up of the 
exposed person, (ii) the abundancy of the allergen, (iii) the structure of the allergen, and (iv) the 
biochemical and physicochemical properties of the allergen. This section seeks to summarise 
observations and current knowledge regarding the latter two points.  
 
2.3.1. Stability  
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One definition of stability is the ability of a protein to either retain or regain its original native three 
dimensional structure following treatments (chemical, such as urea, or physical, such as temperature) 
or to resist attack by proteases. No single type of structure is associated with stability but one 
structural feature that clearly contributes is disulfide bonds, with both intra- and inter-chain disulfide 
bonds constraining the three-dimensional scaffold. These covalent links limit the extent to which the 
protein structure can be disrupted by heat or chaotropic agents and assist the protein to regain its 
original folded structure once the perturbation is removed. Some notable food allergens are highly 
disulfide bonded, including members of the prolamin superfamily (nsLTP, 2S albumin, inhibitors of 
trypsin and α-amylase found in cereals), together with the thaumatin-like proteins (TLPs). However, 
the absence of disulfide bonds does not indicate a lack of stability since the cupin barrel, for example, 
is highly stable and possesses no disulfide bonds. Stability also affects the extent to which proteins are 
attacked by proteases. For example, aspartyl proteases such as pepsin, require a certain degree of 
flexibility in their substrates since they act on six to eight residue stretches of polypeptide chain which 
must lie across their active site in an extended conformation. Thus, structural features that increase 
protein stability, such as extensive disulfide bonding and compactness with few mobile loops, will also 
render them poor substrates for proteases such as pepsin. However, not all proteins have well-defined 
three-dimensional structures, and it is now evident that many proteins contain large domains or 
regions of disordered structure (Dunker et al., 2001). Such proteins are dynamic, with polypeptide 
chains adopting an ensemble of secondary structures which are in equilibrium with each other.  They 
therefore structurally resemble unfolded, denatured, or partially-folded proteins and have been termed 
rheomorphic (Holt and Sawyer, 1993). As a consequence of their dynamic nature, rheomorphic 
proteins do not undergo a sharp transition from one conformational state to another on heating and 
hence possess many potential thermo-stable epitopes. However, this same flexibility makes them 
highly susceptible to proteolytic attack. Caseins are examples of unstructured allergens. A more in-
depth summary of the current state-of-the-art regarding the role of susceptibility to digestion in 
determining the allergenic potential of proteins, including the pepsin resistance test, can be found in 
Annex 4.  
 
2.3.2. Ligand binding 
 
A number of the allergen families described above are able to bind a variety of ligands, ranging from 
metal ions (such as the parvalbumins) to lipids (such as the nsLTP). Metal ions often become 
integrated into the three-dimensional structure of a protein with their loss disrupting protein folding 
and in some instances even resulting in the formation of a partially-folded intermediate. Ligand 
binding can have an overall effect of reducing mobility of the polypeptide backbone, increasing both 
the thermal stability and resistance to proteolysis.  This is important as many proteases require 
flexibility in their substrate proteins. Proteins such as the lipocalins and nsLTP which possess a lipid-
binding pocket show increased stability when the pocket is occupied (Creamer, 1995; Douliez et al., 
2001) .  
 
2.3.3. Lipid/membrane interactions 
 
Many plant food allergens are also able to associate with cell membranes and other types of lipid 
structures formed in foods. One commonly observed mode of action of proteins that protect plants 
against microbial pathogens is the destabilisation of bacterial or fungal membranes resulting in 
leakage. Proteins acting in this way include thionins, thaumatin-like proteins, two types of prolamin 
superfamily members (2S albumins and nsLTPs) and some defensins (Breiteneder and Mills, 2005). In 
addition to interactions with membrane lipids, many food proteins can interact with other lipids to 
form emulsified and other structures. Such interactions may be deliberately introduced during the 
preparation of foods – for example egg proteins with oil to form emulsified sauces such as 
mayonnaises. Many allergenic food proteins, including whey proteins and caseins are eaten in such 
emulsified forms. When proteins adsorb to a lipid layer in an emulsion they unfold, revealing 
hydrophobic regions of the molecules which favour interactions with lipids. The proteins also 
aggregate to form a two-dimensional gel-like layer which has the elastic properties necessary to 
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stabilise oil droplets effectively in an emulsion. While emulsions and other lipid structures are widely 
used as adjuvants in the raising of antibodies, nothing is known on the effect of such interactions on 
the allergenic potential of foods but it is clear that any protein presented in this form to the immune 
systems will be at least partially denatured (Breiteneder and Mills, 2005).   
 
2.3.4. Oligomeric and repetitive structures 
 
There is evidence from studies on recombinant therapeutics that aggregation of proteins can enhance 
immunogenicity (Chirino et al., 2004), even leading to the breakdown of self-non-self discrimination 
(Rosenberg, 2006). Furthermore elicitation potential may be affected by formation of oligomers and 
aggregates by providing multiple IgE epitopes which are more effective at cross-linking surface-bound 
IgE and hence triggering histamine-release in mast cells. Furthermore it appears that aggregates are 
able to break tolerance to recombinant self- therapeutic proteins such as IFN-α (Braun et al., 1997). 
For example, dimerisation of the birch pollen allergen, Bet v 1, only gives a positive skin test in 
sensitised mice when presented in a dimeric, rather than a monomeric state and dimerisation was 
found to potentiate Bet v 1 specific IgE production (Scholl et al., 2005). It is also intriguing to note 
that one major epitope site recognised by parasite-neutralising antibodies in malaria corresponds to a 
serine-rich repeat sequence region (Fox et al., 2002). Food allergens with repeating structures include 
the tropomyosin allergens of shellfish and seed storage prolamins, oligomeric cupins and many of 
these proteins are also able to form aggregates. 
 
Impact of modification on structural features and/or on biochemical, physicochemical properties of 
proteins on allergenicity can not be approached in a general way but on a case by case basis. As 
knowledge about individual protein families and identification of allergenic epitopes evolves, a more 
precise risk assessment can be performed. 
 
2.3.5 Pathogenesis-related proteins and allergenic potential  
 
It is interesting to note that many plant food allergens appear to have a role in defending plants form 
attack by pests and pathogen (Hoffmann-Sommergruber 2002) and have been termed pathogenesis 
related (PR) proteins according to the criteria defined by van Loon and van Strien (1999, 2006). This 
includes the PR-10 proteins from the Bet v 1 family of allergens, the nsLTPs which belong to PR-14 
family, the gene-expression of these proteins being controlled by stress-response elements, often being 
upregulated in response to pathogen attack and abiotic stress. Many others including cereal α-amylase 
inhibitors, thuamatin-like proteins and the 2S albumins may have a protective function, and may 
affect, for example membrane integrity,  although it is often less defined than that of the PR proteins. 
It is possible that the properties that make a protein effective in protecting a plant from pathogen 
attack, including pH changes and secretion of proteases associated with, for example, invasion of plant 
tissue by fungal hyphae may also play a role in potentiating their allergenic activity (Hoffmann-
Sommergruber, 2002; Mills et al., 2004b). 
 
2.4. Protein structure and IgE cross-reactivity 
 
The molecular mechanism of IgE cross-reactivity, like that of any other type of immunoglobulin, is 
based on the physico-chemical interactions between an antibody’s binding site and a target molecule. 
Like any molecular recognition event, antibody-antigen interactions are a dialogue between the 
antibody’s binding site and the region on the antigen to which it binds – the epitope (see Annex 1.2).  
 
Given the knowledge on conformational versus linear epitopes, it is apparent that on the basis of 
molecular mimicry, allergens belonging to proteins with both conserved three-dimensional structures 
and homologous sequences, such as the Bet v 1 family and the profilins, will exhibit a high degree of 
IgE-cross reactivity simply because of the way in which they resemble each other. Thus, primary 
sensitisation to birch pollen Bet v 1 elicits an IgE repertoire which is highly likely to recognise one of 
the many homologues in fruits and vegetables that resemble Bet v 1 so closely (Jenkins et al., 2005). 
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The Bet v 1 family in particular exhibits extraordinary conservation of both surface residues and main 
chain conformations. In addition, the presence of conserved domains, such as the hevein domain found 
in the class I chitinases, is also sufficient for IgE cross-reactivity.  
 
Besides the whole protein also fragments of the proteins might be responsible for cross-reactivity.  
 
2.4.1. Cross-reactive carbohydrate determinants  
 
Carbohydrates represent post-translationally derived epitopes (see also Annex 1.2.). According to the 
work of Mari (Mari, 2002) IgE-linkage to carbohydrates are mostly prevalent in patients with multiple 
pollen sensitisations, varying from 31% of the pollen allergic patients to 71% in the case of multiple 
pollen sensitisations. However, the prevalence of IgE to carbohydrates varies from 16-55% in food 
allergic patients and from 56-79% among patient allergic to hymenoptera (Fotisch and Vieths, 2001). 
Most of the reports on pollen allergen glycosylation focused on the asparagine-linked carbohydrate 
moieties (N-glycans) and showed that α(1-3) fucose and β(1-2) xylose are the major cross-reactive 
carbohydrate determinants (CCDs) (Andersson and Lidholm, 2003; Fotisch and Vieths, 2001). These 
N-glycans may be shared by pollen of taxonomically unrelated species (Iacovacci et al., 2001), by 
pollens and food proteins (Petersen et al., 1996) as well as by plants and insects (Aalberse et al., 1981; 
Altmann, 2007). However, they are distinct from N-glycans present on mammalian proteins (Altmann, 
2007). In helminth infections these fucosylated determinants are known to induce a strong immune 
response.  
 
IgE responses directed towards plant N-glycans show high cross-reactivity as mentioned above 
(Aalberse et al., 2001). However, there is debate in the scientific community as to whether IgE-linkage 
to CCD’s is biologically relevant that is translated into clinical significant allergic symptoms (van der 
Veen et al., 1997). Plant protein extracts displayed much lower ability to stimulate histamine release 
when compared to purified allergens without N-glycans (Altmann, 2007; Fotisch et al., 1999). The 
reasons for the low clinical significance is the absence of divalency of glycans that can trigger 
crosslinking of IgE receptors, low binding affinity of IgE or the presence of blocking antibodies that 
downregulate the allergic response. Recent data by Jin et al. (2008) favour the theory of blocking 
antibodies, and thus induce tolerance induction, against ubiquitous N-glycan structures.  
 
However, in the past individual allergens have been identified where glycan structures were involved 
in allergenic activity as it was shown in the case of celery allergy (Bublin et al., 2003) and tomato 
allergy (Westphal et al., 2003). Apart from the N-glycans, less frequently, O-glycans can be present on 
plant proteins and single β-arabinosyl residues linked to hydroxyproline residues play an important 
role in IgE binding in Art v 1 from mugwort pollen (Leonard et al., 2005). Whether these O-glycans 
are important in determining the IgE-reactivity of other plant species remains to be identified. 
 
In contrast, little is known about IgE binding to carbohydrates on proteins of animal origin. However, 
recently, IgE antibodies directed against galactose-α−1,3-galactose, expressed on a range of non-
primate mammals, have been shown to cause severe side effects during cetuximab therapy (Chung et 
al., 2008). In addition, delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in 
patients with IgE antibodies specific for galactose-alpha.1,3-galactose have also been observed 
(Commins et al., 2009). 
 
2.5. Allergenicity of microbial and fungal proteins 
 
A wide range of fungal allergens have been identified in basidiomycota as well as from ascomycota. 
They include many housekeeping proteins such as enolases, HSP 70, ribonucleases, manganese-
dependent superoxide dismutase (MNSOD) and serine proteases just to name a few (Simon-Nobbe et 
al., 2008). In general they cause inhalant allergies but there are several case reports of a cross-reactive 
allergy to the novel food Quorn which is based on Fusarium-derived mycoprotein (Hoff et al., 2003; 
Katona and Kaminski, 2002; Tee et al., 1993; Van Durme et al., 2003).  In general individuals were 
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sensitised to respiratory mould allergens and suffered from, sometimes severe, hypersensitivity 
reactions on consumption of Quorn. In one instance the allergen responsible was identified as a 60S 
acidic ribosomal protein P2 from F. culmourum, which is highly conserved in a number of fungal 
species (Hoff et al., 2003).  Allergic reactions to ingested fungi (mushrooms) (Ho and Hill, 2006; 
Ichikawa et al., 2006) and mould consumed in fermented foods (Morisset et al., 2003) have been 
reported but are not generally well documented and no allergens associated with such reactions have 
been characterised.  
 
Other proteins of microbial origin that can act as respiratory sensitisers following occupational 
exposure to dusts are enzymes (such as lipases and proteases) used, for example, in the detergent 
(Baur, 2005).  Severe side effects and production of specific IgE antibodies have also been described 
following vaccination using diphtheriae and tetanus toxoid (Martin-Munoz et al., 2002; Mayorga et 
al., 2003).  Furthermore certain microbial proteins, such as Stapyhlococcus aureus protein A, can act 
as superantigens, inducing IgE responses observed in atopic dermatitis (where it is associated with a 
dysfunctional epidermal barrier) and is thought to play a role in chronic nasal diseases with nasal 
polyps (Bachert et al., 2008).  
 
2.6. Post-translational processing of plant proteins and allergenicity 
 
Many plant proteins are processed after synthesis, by the addition of carbohydrate or other chemical 
groups or by proteolysis.  In many cases this occurs within the endomembrane system of the cell and 
this is particularly important in relation to plant food allergens as the vast majority of these are 
“secretory” proteins which pass through the endomembrane system to reach their final destination.  
These include the major plant food allergen families that have been described: the prolamin 
superfamily, the cupins, cysteine proteinases, Kunitz inhibitors, chitinases and thaumatin-like proteins.  
Many of these proteins undergo various types of post-translational processing which may affect their 
allergenic potential. However, we lack experimental data indicating the extent to which post-
translational modification may affect allergenic potential, even in model systems. In GM plants there 
is the potential for the transgenic protein to undergo post-translational processing, which may be 
different depending upon the host. This, coupled with the gaps in our knowledge, make it difficult to 
relate studies of allergenic potential of purified transgenic proteins, to the form in which they are 
found in the GM plant.   
 
2.6.1. Glycosylation 
 
Of the various modifications carried out by enzymes located in the ER and the Golgi apparatus, 
glycosylation is probably one of the most complex and most relevant regarding allergenic potential 
given the ability of carbohydrate moieties to act as cross-reactive epitopes (see above). It may also 
affect protein stability (Wang et al., 1996; Wormald and Dwek, 1999) and many highly glycosylated 
proteins appear to be more resistant to proteolysis (Gu et al., 1989). N-glycosylation only occurs on 
asparagine residues in a specific sequence context, i.e. within the three-amino-acid sequence 
asparagine-any amino acid-serine or threonine. However, the presence of such a site does not always 
result in glycosylation.  Similarly, the extent of glycosylation may vary between two sites on the same 
protein, as in the bean 7S storage protein phaseolin (Bollini et al., 1983). Modification of N-linked 
glycans may occur as the proteins move through the stacks of the Golgi, leading to a greater range of 
complexity, but this is affected by the protein conformation and will not occur if the glycan is 
inaccessible to the enzymes. The final “trimming” of glycans to remove one or two terminal N-
acetylglucosamine residues, occurs soon after the glycoproteins arrive in the vacuole from the Golgi 
(Kermode and Bewley, 1999). 
 
A second important modification which may occur within the ER is hydroxylation of proline residues.  
This is particularly important in proteins destined for secretion into the cell wall where the 
hydroxyproline residues are O-glycosylated in the Golgi apparatus. Hydroxylation of proline residues 
depends on their sequence context and is catalysed by a specific prolyl hydroxylase enzyme 
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(Kieliszewski, 2001). These residues, along with serine and threonine residues can undergo O-
glycosylation in the Golgi. Hydroxyprolines may be modified by arabinoxylation or galactosylation, 
depending on their sequence context. Thus, contiguous hydroxproline residues appear to be 
preferentially arabinosylated while clustered but not contiguous residues are preferentially 
galactosylated (Kieliszewski, 2001; Shpak et al., 2001).  Shimizu et al. (2005) also showed that a 
single proline residue in the sweet potato storage protein sporamin was hydroxylated and modified 
with arabinogalactan when expressed in tobacco cells, although there is no evidence that this 
modification occurs in the sweet potato plant (Matsuoka et al., 1995). Differences in the pattern of 
glycans attached to hydroxyproline have also been observed when an α-amylase inhibitor from bean 
was expressed in seeds of transgenic pea (Prescott et al., 2005).  In this case the recombinant protein 
was more immunogenic than the native form when fed to mice. In addition to glycosylation, it has 
been shown that post-translational phosphorylation increased the IgE-binding capacity of caseins. 
 
2.6.2. Post-translational proteolysis 
 
The major protein modification which occurs in the storage vacuole of seeds and other plant storage 
organs is proteolytic processing. Where vacuolar transit sequences are present as N- or C-terminal 
peptides these may be removed by specific proteinases.  For example, the sweet potato protein 
sporamin contains a prosequence of 16 residues which directs the protein into the vacuole where it is 
cleaved between alanine and serine residues (Matsuoka et al., 1990). Many proteins undergo 
proteolytic processing inside the vacuole, including the 7S and 11S storage globulins and the 2S 
storage albumins (see chapters in Shewry and Casey, 1999).  These storage protein processing events 
are catalysed by a specific group of cysteine proteinases, called legumains, which cleave at the C-
terminal side of asparagine residues (Muntz, 1998) although other proteases have also been implicated 
(Gruis et al., 2004). One example of this is the presence of both an unprocessed and a processed 2S 
albumin isofoms of Ara h 6. The processed isoform has undergone a limited proteolysis with a loss of 
an internal dipeptide. The impact of the processing on the allergenicity was low since the structure of 
the protein was maintained by the disulfide bonds (Bernard et al., 2007). In addition, other trimming at 
the N- and C-termini is responsible for further heterogeneity in this group of proteins (Moreno et al., 
2004). Thus, proteolytic processing could result in the exposure of different parts of the protein to 
those in the intact forms and inauthentic processing could result in the presentation of different 
epitopes with impacts on allergenicity. 
Any mutations which result in failure of the proteins to fold correctly may result in the protein being 
removed from the endoplasmic reticulum (ER) and degraded (Napier, 1999; Pedrazzini et al., 1997), 
although accumulation may occur if the protein remains tethered to the ER membrane (Gillikin et al., 
1997; Kim et al., 2004). Such proteins may expose different residues to the immune system leading to 
altered immunogenicity/allergenicity compared with the native, correctly folded protein. 
 
2.7. Whole plant allergenicity 
 
As indicated in Annex 1.2, a hierarchy of different levels of structures running from whole food to 
protein molecules to epitopes located within proteins has to be taken into consideration when 
investigating the allergenicity of a food.  
 
This section deals with the allergenicity of the whole plant and derived products and particularly with 
regards to possible alterations, e.g. due to over-expression of natural endogenous allergens, as an 
unintended effect of the genetic modification 
 
2.7.1. Natural genetic variation and allergen abundancy  
 
In the recent past the variation in allergenicity in a range of cultivars within one plant species has been 
characterised. Thus, out of a panel of 18 date cultivars 5 highly allergenic lines were identified by 
means of SPT and IgE ELISA reactivity (Kwaasi et al., 2000). Bell pepper cultivars (n=8) were 
analysed for the presence and levels of the IgE binding Bet v 1 homologue, an osmotin-like protein 
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(PR 5 protein), and profilin which showed differential expression patterns (Jensen-Jarolim et al., 
1998). Koppelman and colleagues (2001) analysed 13 different peanut samples (4 varieties) derived 
from different geographical locations. No significant difference could be found between these samples 
concerning the allergenic activity. Since the 1960s the green kiwi, A. deliciosa is on the market in 
Europe. In the last few years another kiwi species, Actinidia chinensis cv. Hort 16 ZESPRI Gold, more 
commonly known as golden kiwi, has become available. Actinidin, Act c 1, previously identified as 
the major allergen from the green kiwi, has not been identified as IgE binding component in the 
golden kiwi (Bublin et al., 2004). In contrast other allergens e.g. the thaumatin-like protein are 
common in both species. For 10 soybean cultivars clear differences in IgE binding potencies could be 
identified in vivo and in vitro (Codina et al., 2003). A total of 88 apple cultivars has been analysed for 
allergenicity by in vitro IgE tests and in vivo tests (SPTs, and oral challenges in a smaller number of 
cultivars) (Sancho et al., 2008). Significant differences in allergen levels regarding Mal d 1 and Mal d 
3 translated into IgE dependent reactivities in vitro as well as in vivo (Bolhaar et al., 2005; Sancho et 
al., 2008).  
 
However, the IgE reactivitiy to individual allergens can differ between individual patient groups as it 
has been shown for the apple allergens. IgE reactivity to Mal d 1 is based on previous sensitisation to 
the birch pollen homologue Bet v 1, and is predominant in areas where birch trees are flowering, that 
are Northern and Central Europe. Usually this pollen related fruit allergy is linked with rather mild 
allergic symptoms of the oral allergy syndrome as it has been shown in an EC funded project SAFE 
(Fernandez-Rivas et al., 2006; Hoffmann-Sommergruber, 2005). A different sensitisation pattern is 
observed in apple allergic patients from Southern Europe. These patients display IgE reactivity 
predominantly to the non-pollen related nsLTP, Mal d 3. In addition, Mal d 3 was identified as a risk 
factor for developing severe symptoms upon consumption of fruits (Fernandez-Rivas et al., 2006). 
Similarly different sensitisation patterns have been reported for cherry allergens, Pru av 1 and Pru av 3 
(Reuter et al., 2006) and for hazelnut allergens (Pastorello et al., 2002). All these studies provide 
evidence that allergic patients groups differ in their sensitisation patterns due to exposure to different 
inhalant allergens, due to different consumption habits and maybe additional environmental factors. 
These different sensitisation patterns may in turn influence the severity of reported symptoms as it is 
observed for the pollen-related food allergens versus the non pollen-related food allergens. Therefore, 
fruit cultivars low in one allergen presenting a benefit of one allergic patients’ group may still 
represent a risk for another different allergic consumer group.  
 
Identification of allergen encoding genes and their genomic mapping provides additional information 
about the potential allergenicity of a cultivar and or species. So far, gene mapping has only been 
performed on the apple genome locating the four identified allergens, Mal d 1 (a Bet v 1 homologue), 
Mal d 2 (a profilin), Mal d 3 (a lipid transfer protein) and Mal d 4 (a thuamatin-like protein). The gene 
families of the respective allergens were determined (Gao et al., 2005a; Gao et al., 2005b; Gao et al., 
2005c) and Mal d 1 related markers were identified which could help in new breeding programs 
aiming at low allergen variants (Hoffmann-Sommergruber et al., 2007). 
  
2.7.2. Post-harvest treatments and allergen abundancy  
 
In addition to genetic variation, environmental factors also affect plant gene expression including 
allergens. Thus site-to-site variation can affect levels in expression, with agronomic factors, and 
climate all playing a part. Furthermore the stage of ripening of fruits, such as apples, may also affect 
the allergen content in fruits and vegetables.  Post-harvest treatment such as storage conditions 
(temperature, modified atmosphere) of fruits and vegetables can also increase or decrease the allergen 
load as it has been shown for apples regarding Mal d 1 and Mal d 3 concentrations in relation to 
normal air versus controlled atmosphere versus upon ambient conditions (Sancho et al., 2006a; Sancho 
et al., 2006b). For example, within a single apple cultivar the allergen levels can differ from individual 
fruits up to ten-fold.  
In contrast, postharvest ripening treatment on mango did not exert changes in the levels of the 2 
known allergens, Man I 1 and Man I 2 (Paschke et al., 2001). These few examples show a broad 
variation range of allergen levels in raw plant food which makes it difficult to pinpoint general 
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acceptable allergen levels in certain allergenic fruits and vegetables even if the necessary detection 
assays are available.  
 
Furthermore, in most plant food allergies a multiplicity of allergens has been implicated and hence a 
decreased concentration of a single protein may not be sufficient to make a food safe of allergic 
consumers to eat. Therefore, detailed information on the allergenic repertoire of a given food is 
mandatory, as well as an in-depth characterisation of the individual allergens and their performance 
during storage and food processing. In addition, the allergen recognition pattern may vary among 
different populations according to their exposure, dietary habits and environmental factors such as 
pollen exposure.  
 
2.7.3. Transgenic plants down-regulating expression of allergens  
 
Genetic modification has also been applied to down-regulate levels of allergens in plant foods with the 
aim of developing low allergen alternatives. Single-site mutagenesis of two IgE binding peptides of 
the soybean allergen, Gly m Bd 30 kDa has been proven to be effective in producing a hypoallergenic 
soybean protein (Herman et al., 2003). An alternative approach was taken using antisense RNA for the 
14 kDa and 16 kDa allergenic proteins in rice, which repressed the allergen gene expression in 
maturing seeds and resulted in the reduced allergenicity (Nakamura and Matsuda, 1996; Tada et al., 
1996). The same method was applied to the soybean, targeting the Gly m Bd 30 kDa gene and after 
successful transformation, this protein could no longer be detected (Herman et al., 2003). Further 
examples were shown for downregulating the major apple allergen, Mal d 1 (Gilissen et al., 2005) and 
apple plantlets were virtually free of Mal d 1 as shown by immunoblots and skin prick tests. Recently 
transgenic tomato fruits suppressing expression of tomato profilin (Le et al., 2006) and non-specific 
lipid transfer protein (Lorenz et al., 2006) were obtained by applying the double-stranded RNA 
interference (dsRNAi) technology. Although these ”hypoallergenic” plants represent valuable 
alternatives for the allergic consumer the acceptance of such beneficial GMOs is rather low as 
evaluated by a survey performed in 3 European countries (Miles et al., 2006). At present these 
approaches are of scientific value and highlight the possibility to down-regulate individual allergen 
levels through genetic modification. However, the impact on the allergenicity of the whole food 
remains to be demonstrated on a case-by-case basis.  
 
2.7.4. Food processing and the matrix 
 
Food processing can impact on the allergenicity of foods (Mills and Mackie, 2008; Mills et al., 2006). 
For example the removal of tissues containing allergens may reduce allergenicity of foods, as has been 
found for peaches where removal of the skin which contains the nsLTP allergen, reduced their 
allergenicity (Brenna et al., 2000). Another example is the leaching of peanut 2S albumins into the 
cooking water during boiling (Mondoulet et al., 2005). Processing of ingredients and preparation of 
finished foods may also affect allergenicity by altering the structure and properties of food proteins. 
Most studies to date have focused on the effect of processing on elicitation of allergic reactions in 
sensitised individuals and there is little data on effects on sensitisation potential. Effects appear to 
depend on the structural characteristics of the allergen, with highly stable proteins, such as members of 
the prolamin superfamily such as 2S albumins and nsLTP tending to retain their allergenic properties 
after severe processing procedures, such as fermentation (Asero et al., 2001) whilst others, notably the 
Bet v 1 homologues appear to be more labile, frequently loosing their allergenicity in processed foods. 
Thus, processing of fresh fruits, such as apple, removes the ability of the apple Bet v 1 homologue, to 
elicit allergic reactions in sensitised individuals (Asero et al., 2006) but for other foods, such as celery 
root (celeriac), the Bet v 1 homologues (Api g 1 in this instance) retains its eliciting potential after 
cooking (Ballmer-Weber et al., 2002). Recent studies of Bet v 1 itself show it is relatively 
thermostable, the protein unfolding only at temperatures above 68°C (Mogensen et al., 2007), 
implying that differences in the plant tissue matrix of apple compared to celeriac may modulate the 
stability of this family of proteins to food processing.  
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The role of the food matrix in determining allergenicity is not generally well understood. It has been 
shown during double blind placebo controlled food challenge that the form in which a protein is given 
can affect the development and severity of allergic reactions to peanut (Grimshaw et al., 2003). How 
the food matrix might impact on the sensitisation phase of food allergies is not understood. Studies in 
this area are in their infancy because of the complexities presented by food structures and components 
interactions, and the problems presented by a lack of truly effective animal models for food allergy. 
Indications are that food component interactions may affect the way in which allergens are released 
from foods, the way in which they are digested and subsequently taken up and interact with the 
immune system. Certainly it appears the co-administration of a mixture of lipids from Brazil nut is 
essential for the sensitising potential of the Brazil nut 2S albumin allergen, Ber e 1, in particular 
animal models (Dearman et al., 2007). It remains to be determined whether this is a synergistic effect 
of lipids acting on the immune system in conjunction with the protein, and/or effects of lipid structure 
on release and presentation of the allergen.  
 
Within the food matrix a protein may undergo Maillard modification i.e. non-enzymatic glycosylation 
of proteins during food processing. Maillard reactions takes place between free amino groups 
(generally lysine residues) on proteins with reducing sugars (such as glucose and lactose) and the 
subsequent rearrangements lead to formation of a complex mixture of products. N-glycosylated forms 
of proteins may be more allergenic than their unmodified counterparts (Davis et al., 2001). The 
Maillard reaction was shown to play a possible role in the allergenicity of foods such as peanuts 
(Beyer et al., 2001; Maleki et al., 2000) and appear to enhance the IgE-binding capacity of the 
shellfish allergen, tropomyosins (Nakamura et al., 2005). However, different allergens appear to 
respond in different ways. Thus, Maillard reactions significantly reduced IgE reactivity of the 
allergenic Bet v 1 homologue of cherry, Pru av 1 (Gruber et al., 2004), whilst this reaction was found 
to protect the IgE-binding capacity of the allergenic nsLTP of apple following harsh thermal treatment 
(Sancho et al., 2005). Maillard modifications are only one of a range of chemical changes that can take 
place in foods during cooking.   
 
Another modification catalysed by the polyphenol oxidase, is responsible for enzymatic browning 
reactions in fresh fruits and vegetables. Modification of Pru av 1 with epicatechin and caffeic acid 
reduced IgE-binding capacity although the extent to which it was reduced was highly dependent on the 
polyphenol involved, quercetin and quercetin glycoside, rutin, having a lesser effect (Gruber et al., 
2004).  
 
2.8. Conclusions and recommendations 
 
The risk assessment of GMOs is based on a comparative approach with regards to allergenicity. It 
aims to establish whether the potential allergenicity of the GM plant is less, equal or increased 
compared to that of its appropriate comparator(s) (EFSA, 2006, 2009). A prerequisite for assessing 
any potential increase in allergenicity of a GMO should be to define allergen levels in wild-type 
species and cultivars as a “baseline” reference. Data on quantitative allergen expression levels from 
either raw or processed food are scarce. Our knowledge on the impact of both natural (plant tissue) 
and processed structures on allergenic potential (sensitisation or elicitation) is poor. Consequently, it is 
difficult to predict how processing and the matrix may affect allergenic potential. Whilst it is difficult 
to predict the likelihood of a newly expressed protein in a GMO to sensitise an individual, we can 
predict, based on sequence and structural similarity the ability of proteins to elicit an allergic reaction 
in individuals already sensitised, such as in the cross-reactive pollen-fruit/vegetable and latex-fruit 
allergy syndromes. Based on the existing knowledge about three dimensional properties of known 
allergenic protein families there is good evidence to predict a potential new allergen if this protein 
displays one or more of such identified characteristics. Recent findings in the area of protein structure 
(determination of 3D structures by X-ray crystallography and NMR) coupled with modern 
computational methods enabling effective molecular modeling have provided a new means of 
classifying proteins and provide the opportunity to link structure with function (allergenicity). Such 
knowledge is a prerequisite for prediction of allergenic potential although this can only be fully 
realised when a potential allergen meets the immune system of an atopic individual. Working towards 
Annex 2. Structural aspects of food allergens
 
 
70 EFSA Journal 2010; 8(7):1700 
a better understanding why some proteins and not others can become allergens several aspects need to 
be addressed and considered. 
 
2.8.1. Endogenous allergenicity and references for the comparative assessment of the 
whole GMO 
 
Conclusions 
The risk assessment of GMOs is based on a comparative approach with regards to allergenicity 
(EFSA, 2006, 2009). In order to assess the “allergenic” potency of a GMO, its endogenous allergen 
repertoire needs to be compared in a qualitative and, where possible, (semi-) quantitative fashion with 
that of the wild-type counterpart; i.e. in a comparative safety assessment. This principle applied to 
allergenic risk assessment of GMOs requires that the allergenic repertoire of the host plant is known, 
including the natural variation in the levels of expression of allergens in the different (edible) tissues 
(and pollen) of the plant and the possible mixture of isoforms (if applicable) found in the appropriate 
comparator(s). The effect of the genetic modification on the expression of the natural endogenous 
allergens can be set within the context of expression in the unmodified crop. A pre-requisite for 
assessing any potential increase in allergenicity of a GMO is to define allergen levels in wild-type 
species and cultivars as a “baseline” reference.  
 
When the recipient of the introduced gene is allergenic, a comparison of the allergen repertoire of the 
GM and its appropriate comparator(s) should be performed using individual human allergic sera. This 
is still considered a reference procedure in order that the comparison does not overcome minor 
allergen(s). However, modern proteomic and mass spectrometry methods, including high throughput 
analytical techniques of proteins, are also able to provide qualitative and quantitative information on 
the levels of the different allergens and have the major advantage of not depending on reagents of 
human origin (see Annex 5).  
 
In the case of recipient plants known to be common allergenic foods, the test, control and reference 
crops should be grown, samples stored and processed under conditions that are as identical as possible 
because agronomic and post-harvest treatments are known to have a considerable effect on allergen 
expression levels. When the allergens of clinical importance are limited, identified and recorded, a 
thorough comparison between the GM plant and its appropriate comparator(s) should not be precluded 
because of natural variability. 
 
Information should be provided on the contents and/or qualitative and quantitative profiles of 
endogenous allergens in multiple commercial varieties that are commonly grown for food and feed 
production and in the GM plant varieties containing the GM event that are to be commercialised. The 
outcomes of the comparison of the GM plant and its appropriate comparator(s) should be interpreted 
in the light of the natural variability in intrinsic allergenicity and with regards to the strategy used for 
the genetic modification (e.g. choice of the recipient cultivar for the GM event) on a case-by-case 
basis. Significant differences should be identified even if they range within the natural variability of 
commercially available cultivars. 
 
The choice of the reference crops used for establishing the natural range of variability should be 
limited to the most commonly grown cultivars and thus reflecting the expected range of human and 
animal exposure. 
 
Although the number of identified food allergens has increased tremendously in the recent past, little 
is known about actual allergen concentrations in plant foods and even less is known about the potency 
of individual allergens with regards threshold levels of allergens set for sensitisation and elicitation of 
allergic reactions by individual foods. The allergen repertoire of individual plant food species and the 
variation in levels of allergen expression in edible tissues of plants needs to be defined. This should be 
linked to indices of potency for different allergen molecules. Integration of such data sets will allow 
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any changes in the allergen repertoire of a GMO to be quantified and linked to potential changes in 
sensitisation/elicitation potential.  
 
Recommendations 
• When the recipient of the introduced gene is allergenic, it is recommended that relevant 
identified endogenous allergens are included in the comparative compositional analysis of the 
GM plant and its appropriate comparator(s). Despite that great natural variability may occur, 
this should not preclude identification of any consistent unintended effect due to the genetic 
modification.  Information on the level of expression of relevant identified endogenous 
allergens in edible tissues and pollen, indications of the impact of variable environmental 
conditions, agronomic treatments, developmental stage and post-harvest storage on expression 
levels and structure of relevant endogenous allergens would allow an accurate interpretation of 
the outcomes of the comparative analysis. 
 
2.8.2. Structure, biological properties and allergenicity prediction of the newly expressed 
proteins 
 
Conclusions 
The frequency of a protein family in a given genome is not reflected in the frequency distribution of 
food allergens. The distribution observed for food allergens is similar to that of pollen allergens 
(Radauer and Breiteneder, 2006); its highly restricted nature is striking and emphasises the fact that 
whilst, in theory, all proteins have the potential to become allergens, in practice this is not the case. 
Membership of a particular protein family is indicative of a protein being more likely to be an 
allergen, than a protein which does not belong to a proteins family. It is not predictive per se but is 
related to the properties of proteins which are conferred by their three-dimensional structures.  
 
Whilst it is difficult to predict the likelihood of a novel protein as represented by a newly expressed 
protein in a GMO to sensitise an individual, we can predict, based on sequence and structural 
similarity the ability of proteins to elicit an allergic reaction in individuals already sensitised, such as 
in the cross-reactive pollen-fruit/vegetable and latex-fruit allergy syndromes. Based on the existing 
knowledge about three dimensional properties of known allergenic protein families there is good 
evidence to predict a potential new allergen if this protein displays one or more of such identified 
characteristics. Reversely, if a certain protein does not display already known structures linked with 
allergenicity it does not mean total absence of potential allergenicity. This applies especially to 
proteins that human mucosal surfaces have not been exposed to before. In this case allergenic risk 
assessment may need to be re-evaluated after a few years of consumption of the GMO. 
 
We need to understand why some proteins, and not others, can become allergens. As part of 
addressing this question we need to understand how routes of exposure, levels of exposure and 
digestion affect sensitisation potential. Thresholds for sensitisation and tolerisation need to be 
identified in man and related to thresholds for elicitation in cross-reactive allergies to identify whether 
there is a level of expression of an allergen in a food that could be considered “safe”. This is especially 
important for making allergenic risk assessment of proteins expressed in low amounts versus those 
expressed to a significant proportion of the plant tissue. Studies carried out using purified target 
proteins prepared by expression in organisms such as Escherichia coli need to be related to the 
properties of the protein as expressed in the plant, thus taking into account all post-translational 
modifications, such as proteolysis and glycosylation that only occur in the plant. Modern protein mass 
spectrometry methods can enable such comparisons to be made. 
 
Recommendations 
• Without a knowledge of the mechanisms whereby one protein, and not another, becomes 
allergenic, prediction will always be uncertain. However, on a case-by-case basis, information 
on protein scaffolds found in protein families that contain many non-homologous allergens 
may be informative when used in combination with other factors such as stability to 
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processing, proteolysis and levels of consumption.  They may be especially important in 
understanding IgE cross-reactivity as it is the conformational relationships which underlie and 
explain much of this phenomenon (Breiteneder and Mills, 2006). Where possible structural 
aspects need to be considered (using appropriate experimentally-determined or modeled three-
dimensional structures) in conjunction with information on sequence identity/similarity with 
regards assessing potential IgE-cross reactivity (see Annex 3 recommendations 3.12.2). 
 
2.8.3. Impact of post-translational processing and expression in the plant of the trait 
proteins 
 
Conclusions 
Evaluating allergenic potential needs to take account of effects of post-translational modifications and 
relevant processing-induced modifications on either the background allergen repertoire of a food crop 
or the trait itself. Whilst methods for direct analysis of N-linked carbohydrates on proteins are well 
developed, those for mapping of relevant O-linked carbohydrates are complex and require large 
amounts of material and complex chemistry for their analysis; they also show more heterogeneity than 
N-linked glycans. Furthermore given the difficulty of predicting the impact of a given plant tissue or a 
different plant species on the post-translational processing of a novel protein, any assessment of 
allergenic potential needs to be done on the tissues as it would be eaten and not simply on a purified 
protein. It is clear that plant proteins may undergo highly specific processing (including proteolysis, 
glycosylation and a number of other post-translational modifications) within the endomembrane 
system.  Furthermore, the pattern of processing is determined by the sequence context of the potential 
processing sites, the accessibility of the sites to the processing enzymes and the endomembrane 
compartment in which the protein is retained or passed through.  When the test material used for 
assessment of allergenicity of the newly expressed protein has been produced in a microorganism, it 
should be verified that its structure is the same as the structure of the protein expressed in the GM 
plant, including all post-translational modifications. Furthermore, it is not always possible to predict 
what modifications will take place and direct analyses are required.  Finally, because the endoplasmic 
reticulum and vacuole provide convenient destinations for the targeting of proteins in transgenic plants 
these events may occur more frequently with expressed foreign proteins than would be expected based 
on their overall occurrence in vivo. Our knowledge of how post-translational processing may affect 
allergenic potential is largely confined to effects of glycosylation and influence of cross-reactive 
carbohydrate determinants.  
 
Improved methods for mapping of O-linked carbohydrates would facilitate more effective analysis of 
these post-translational modifications.  
 
Recommendations 
• Therefore it is a general recommendation to define the presence and nature of all post-
translational modifications of the newly expressed protein in the plant. This information is 
required since post-translational modifications, such as glycosylation, may affect stability of 
proteins to digestion and hence modify their allergenic potential. It also impacts on the 
interpretation of IgE binding studies; for example it is important to distinguish between IgE 
binding capacity linked with clinical significance versus positive IgE binding without clinical 
significance (e.g. N-linked glycans). In this regard, the use of modern analytical methods 
using e.g. “-omics” technology and mass spectrometry is proven as a powerful method (see 
Annex 5.4 and 5.5).  
• Future work should aim to establish data on the level of expression of the newly expressed 
proteins in edible tissues. This should include expression levels in different tissues, and 
indications of how agronomic conditions, developmental stage and post-harvest storage affect 
these. These then need to be linked with data on thresholds regarding sensitisation and 
elicitation of allergic reactions in cross-reactive allergy syndromes. This also needs to be 
linked to an assessment of how genetic modification may affect the levels and expression of 
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allergens in the wild-type crop in order to assess the effect of genetic modification on the 
intrinsic allergenicity of the crop.  
 
2.8.4. Impact of food processing and the matrix on the allergenicity of newly expressed 
proteins 
 
Conclusions 
Depending on the food or tissue in which a novel protein might be consumed the effect of the food 
structure on allergen release in the alimentary tract, bioaccessibility, digestion and allergenic potential 
should be assessed. Our knowledge on the impact of both natural (plant tissue) structures and 
processed structures on allergenic potential (sensitisation or elicitation) is poor. Consequently it is 
difficult to predict how processing and the matrix may affect allergenic potential.   
 
We need a better understanding of the mechanisms underlying what makes some proteins more 
allergenic than others and how some food structures (such as lipid-rich foods) may affect release and 
immunological properties of allergens in foods, as well as their stability to digestion. Such knowledge 
would allow any risk assessment to be better informed and hence offer greater assurance to consumers. 
Such knowledge would also help underpin the development of bioinformatic methods with an 
improved capability of predicting allergenic potential. In addition protein mass spectrometry methods 
need to be developed and applied to mapping processing-induced modifications.  
 
Recommendations  
• Future work should focus on the need of data on the impact of relevant processing-induced 
modifications, (such as Maillard modifications) on stability to digestion and allergenic 
potential of the newly expressed protein. This needs to be complemented by data on how food 
processing and the matrix affect the release of a newly expressed protein from a food derived 
from GMO and prepared as it is intended to be consumed. Such data needs to be linked to 
assessing how the digestibility and immune-reactivity is affected.  
 
2.9. Appendix  
 
Plant food allergen families 
 
Prolamin superfamily 
First identified on the basis of visual comparison of amino acid sequences, this protein superfamily is 
characterised by a conserved pattern of cysteine residues, which are located within a sequence of about 
100 amino acids. Either six (for the 2S albumins and ns LTPs) or eight (in the trypsin and α-amylase 
inhibitors) such cysteine residues are present, which form three or four intra-chain disulphide bonds. 
Most of the proteins contain characteristic Cys Cys and Cys X Cys motifs, where X represents any 
other residue, and can be defined by the formula: 
 
 Cys-(X=7-13)-Cys-(X=8-26)-Cys-Cys- (X=8-30)-Cys-X-Cys-(X=20-48)-Cys-Cys   
 
This “cysteine skeleton” has been disrupted in some cereal seed storage prolamins (notably the high 
molecular weight subunits of wheat glutenin) by the insertion of a repetitive domain, with the 
component cysteine residues being present in the N- and C-terminal portions of the proteins. Whilst 
the degree of sequence identity between the conserved regions of prolamin superfamily members is 
low they are structurally conserved with very similar three-dimensional structures (Mills et al., 2003).  
 
Whilst the pattern of cysteine residues is conserved, they are connected to form different disulphide 
bonds in the nsLTP sub-family compared with the 2S albumin of α-amylase inhibitors. This difference 
reflects the fact that only the nsLTPs possess a central lipid-binding tunnel and is a rare example of the 
protein sequence being more highly conserved than the 3D protein structure. At present members of 
the superfamily have only been identified in plants and it has not been possible to identify its 
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evolutionary origin in primitive organisms. Most members function as either seed storage proteins 
(such as the cereal seed storage prolamins) or in plant protection such as the α-amylase inhibitors and 
nsLTPs, the latter belonging to pathogenesis-related (PR) protein group 14 (Van Loon and Van Strien, 
1999), or a combination of the two (2S albumins). However, they also include a group of structural 
cell wall proteins (Jose-Estanyol and Puigdomenech, 2000).      
The prolamin seed storage proteins also trigger an immune-mediated food intolerance disease known 
as coeliac disease which is thought to affect around 1% of the population in Western Europe. This has 
a different immune mechanisms to type I IgE-mediated allergic reactions and symptoms can take 
much longer (hours, days) to manifest themselves compared to IgE-mediated reactions which usually 
take place more rapidly (minutes, hours). Coeliac disease results from an abnormal cellular-mediated 
immune response which causes an inflammatory reaction in the small bowel and results in flattening 
of the mucosa and an associated malabsorption syndrome (Walkersmith et al., 1990). It is a complex 
disorder which has many manifestations unrelated to the gastrointestinal tract which include defective 
tooth enamel and myocardiopathy amongst many others (Hischenhuber et al., 2006). Gluten 
intolerance is thought to arise as a consequence of deamidation of glutamine residues in peptides 
resulting from activity of the tissue transglutaminase present in the gut mucosa. The modified peptides 
are able to bind to class II human histocompatibility leucocyte antigen (HLA) molecules DQ2 and 
DQ8. This recognition event appears to orchestrate an inflammatory response which results in the 
flattened mucosa characteristic of coeliac disease (Hischenhuber et al., 2006; Qiao et al., 2004; Stern, 
2008). 
 
Cupins 
The cupins are a superfamily of proteins which possess a common β-barrel structure which are thought 
to have evolved from a common ancestor on the basis of two shared sequence motifs, 
[G(X)5HXH(X)11G] and [G(X)5P(X)4H(X)3N], (where X is any amino acid residue) which 
correspond to a metal binding site in many, but not all, members of the superfamily (Dunwell et al., 
2004). The structure is thought to have evolved from an ancestral protein present in prokaryotes 
through fungi, to flowering and non-flowering plants. Sub-families include the germins and sporulins, 
which possess only single β-barrel domains with enzymatic activity and a metal ion (manganese) 
located at the centre of the barrel (Woo et al., 2000). Germins from bell-pepper (Leitner et al., 1998) 
and orange (Ahrazem et al., 2006) have been identified as allergens. Another important sub-family are 
the bicupin seed storage globulins where two β-barrel domains have been fused to form subunits 
which are then assembled into either trimeric (7S globulins) or hexameric (11S globulins) structures 
(Mills et al., 2003).  
 
Bet v 1 family 
Bet v 1 was one of the first cloned allergens and is the major allergen in birch pollen (Breiteneder et 
al., 1989) and now 23 homologues with known sequence 
(http://www.meduniwien.ac.at/allergens/allfam/) in a wide variety of plant species have been 
characterised indicating the ubiquitous allergenic nature of this protein in the plant kingdom. The Bet 
v 1 proteins have no clearly ascribed biological function but may be involved in plant protection, 
belonging to the PR 10 group of pathogenesis related proteins (Van Loon et al., 2006; Van Loon and 
Van Strien, 1999). A striking sequence motif GXGXXG is present in most Bet v 1 proteins but is 
reduced in some cases to GXG.  This is known as a P-loop (phosphate binding loop) and is frequently 
found in protein kinases and nucleotide binding proteins (Saraste et al., 1990). However, the 
nucleotide binding function was determined experimentally for Bet v 1. The protein Bet v 1 possesses 
a central tunnel which appears to bind plant steroids (Markovic-Housley et al., 2003; Neudecker et al., 
2001) but the physiological role of this property has not been established. However, the high degree of 
homology of Bet v 1 proteins across diverse plant species (Jenkins et al., 2005), which even extends to 
surface features which are generally highly variable between species, indicates that they do have a 
conserved function.  This high level of structural conservation is also important for their cross-
reactions as allergens. 
 
Profilins 
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Profilins are small (12-15 kD), ubiquitous cytosolic proteins, which are present in all eukaryotic cells 
and act as actin-binding proteins (Witke, 2004). As such they may play a key role in regulating 
intracellular transport processes and cell morphogenesis and division. Despite having low sequence 
similarity these proteins are structurally homologous across lower eukaryotes, plants and animals, with 
a compact globular structure consisting of a central seven-stranded anti-parallel β-sheet enclosed by 
the N- and C-terminal α-helices on one side and one or two helices on the other side. The plant 
homologues are somewhat divergent, notably with a slightly longer solvent exposed loop between the 
N-terminal α-helix and the first β-strand which is more variable and represents part of an IgE epitope 
in the allergenic profilin from birch pollen, Bet v 2 (Fedorov et al., 1997). The profilins are also 
involved in the cross-reactive pollen-fruit allergies. However, the clinical significance of IgE reactivity 
to either pollen and fruit profilins differs.  
 
Animal allergen families 
 
Fewer animal allergens have been identified to date, which perhaps reflects the fact that humans 
consume a less diverse range of animal-derived foods. Nevertheless these allergens fall into a 
relatively small number of structurally-related families (Jenkins et al., 2007).  
 
Tropomyosins 
Tropomyosins have highly conserved structures, which relate to the regulatory role that they play in 
muscle contraction, in combination with actin and myosin. They are rod-shaped coiled-coil dimers 
which form head-to-tail polymers along the length of an actin filament (Phillips et al., 1979). Like 
profilins, they are present in all eukaryotes but the allergenic tropomyosins are confined to 
invertebrates (Ayuso et al., 1999), primarily two groups, crustaceans and molluscs, generally referred 
to as shellfish (Wild and Lehrer, 2005). As a result of sequence similarity between tropomyosins from 
different species, the IgE from the sera of some allergic individuals who are allergic to crustaceans 
may also bind to tropomyosins from several molluscan species (Leung et al., 1996) but not to 
vertebrate tropomyosins (Ayuso et al., 1999). The introduction of mutations to “humanise” the 
sequence reduces or abolishes IgE binding (Reese et al., 2005).  
 
Parvalbumins 
The parvalbumins are a class of denaturation-resistant calcium-binding proteins that are important for 
the relaxation of muscle fibers by binding free calcium in cells. They are present in high amounts in 
white muscle of fish and amphibians, and in lower amounts in fast twitch muscle of birds and 
mammals. They contain calcium-binding E-F hand motifs (Pauls et al., 1996) that are related to motifs 
for other allergenic calcium-binding proteins such as polcalcins from pollen (Ledesma et al., 2006)  
and troponin c from cockroaches (Hindley et al., 2006). Fish β-parvalbumins have been identified as 
allergens in a large number of fish species and in frog (Hamada et al., 2004; Hilger et al., 2004; Wild 
and Lehrer, 2005). It is not clear whether fish parvalbumins are the primary sensitising agent, and that 
homologues from molluscs and frog are allergenic because of IgE cross-reactivity or whether non-fish 
parvalbumins are able to sensitise per se. It is possible that the cross-reactivity between 
β−parvalbumins results from the conservation of surface structures, as has been suggested for some 
plant food allergens (Jenkins et al., 2007; Jenkins et al., 2005). 
 
Caseins 
Caseins are exclusively mammalian proteins. Casein, Bos d 8, is actually an association of different 
proteins that constitute the coagulum, i.e. the solid fraction of proteins obtained after coagulation of 
milk. Each individual casein, αS1-, β-, αS2- and κ-casein, represents a well-defined chemical 
compound but they cross-link to form ordered aggregates: micelles. They are structurally mobile 
proteins. α s1 - , α s2- and β-caseins have a dipolar-type structure, comprising a globular hydrophobic 
domain and a highly solvated and charged domain, with amphipatic properties and bind calcium 
through clusters of phosphoserine residues. The caseins form a shell around amorphous calcium 
phosphate to form microstructures called nanoclusters allowing calcium levels in milk to exceed the 
solubility limit of calcium phosphate. These nanoclusters are assembled into the casein micelles found 
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in milk, which are in turn stabilised by κ-casein (Tuinier and de Kruif, 2002). Because of their 
structure caseins are very susceptible to all proteinases and exopeptidases but not significantly affected 
by severe heat treatments. The heterogeneity in structures of casein is complicated by their genetic 
polymorphism resulting in several variants for each casein. These variants are characterised by point 
substitutions of amino acids or by deletions of peptide fragments of varying size or by post-
translational modifications such as phosphorylation and glycosylation. 
In most patients with cow’s milk allergy, a high IgE cross-reactivity occurs between the different 
caseins of cow’s milk and between the whole casein fraction of the milk of ruminant species including 
cow’s, goat’s and sheep’s milk and cows’ milk (Bernard et al., 1999; Restani et al., 1999). However, 
IgE response and clinical reaction may also be quite specific and allergic reactions to goat’s and ewe’s 
milk without cow’s milk allergy were recently described (Ah-Leung et al., 2006). 
 
Other Food Allergen Families 
 
Cysteine proteases 
The C1, or papain-like, family are part of a much larger family of cysteine proteases, which were 
originally characterised as having a cysteine residue as part of their catalytic site. The C1 family was 
identified as having conserved Gln, Cys, His and Asn residues at the active site and includes many 
endopeptidases, aminopeptidases, dipeptidyl peptidases, some enzymes having both both exo- and 
endo-peptidase activities (Rawlings and Barrett, 1993). Sequence comparisons show a high degree of 
relatedness of the residues surrounding the catalytic site across the family. Thus, in papain, the 
catalytic residues are Cys-25 and His-159, other important residues being Gln-19, which helps form 
the 'oxyanion hole', and Asn-175, which orientates the imidazole ring of His-159.  
 
A number of CI protease allergens have been identified including inhalant allergens such as the dust 
mite allergen Der p 1, a β-expansin which is a major allergen of timothy grass pollen, Phl p 1 (Grobe 
et al., 2002) and a number of food allergens. Despite these structural similarities the C proteases have 
only low levels of overall sequence homology, the dust mite allergen, Der p 1 having only 
approximately 30% identical to the plant cysteine proteases. Notable food allergens are actindin, the 
major kiwi fruit allergen (Fahlbusch et al., 1998; Pastorello et al., 1998) and the soybean 34kD (oil 
body-associated) protein, known variously as Gly m Bd 30K, Gly m 1, or P34. They haave been 
reported as the major allergen involved in soybean-induced atopic dermatitis (Ogawa et al., 1993) and 
it is actually associated with the storage vacuoles of soybean (Kalinski et al., 1992). There is evidence 
that the protease activity of the dust mite allergen Der p 1 is important in its allergenicity as it can 
cleave the human IgE receptor, CD23 and may thereby ablate the feedback mechanism which 
normally regulates IgE synthesis (Hewitt et al., 1995; Schulz et al., 1995). 
 
Lipocalins 
The lipocalins are diverse proteins sharing about 20% sequence identity but with conserved three 
dimensional structures characterised by a central tunnel which can accommodate a diversity of 
lipophilic ligands (Flower, 1996). They are thought to function as carriers of odorants, steroids, lipids, 
pheremones and other compounds. The majority of lipocalin allergens are respiratory, having been 
identified as the major allergens in rodent urine, animal dander and saliva as well as in insects such as 
cockroaches. The only lipocalin which acts as a food allergen is the cow’s milk allergen, β-
lactoglobulin (Virtanen, 2001). 
 
Lysozyme family 
The O-glycosyl hydrolases are a widespread group of enzymes that hydrolyse the glycosidic bond 
between two or more carbohydrates, or between a carbohydrate and a non-carbohydrate moiety. Like 
many of the other protein families described here their three-dimensional structures are better 
conserved than their sequences. They are grouped by structural similarity into clans, one of which is 
the glycoside hydrolase family 22 which comprises lysozyme type C and α-lactalbumins which have 
both probably evolved from a common ancestral protein. However, they have distinctly different 
functions with lysozyme acting as a muramidase, hydrolysing bacterial cell wall peptidoglycan whilst 
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lactalbumin is involved in lactose synthesis in milk. In addition, unlike lysozyme, α-lactalbumin binds 
calcium. Two food allergen belong to this clan, the minor hens’ egg allergen, lysozyme (Gal d 4) and 
the minor cows’ milk allergen α-lactalbumin having little sequence homology but superimposable 
three-dimensional structures (Nitta and Sugai, 1989).  
 
Transferrin family 
Transferrins are eukaryotic sulphur-rich iron-binding glycoproteins which function in vivo to control 
the level of free iron. They have arisen by duplication of a domain, with each duplicated domain 
binding one iron atom. They include blood serotransferrin (siderophilin); milk lactotransferrin 
(lactoferrin); egg white ovotransferrin (conalbumin); and membrane-associated melanotransferrin. 
Both lactoferrin and ovotransferrin have been identified as minor allergens in cows’ milk and egg 
respectively.   
 
Serpins 
The term serpin is derived from the fact that these proteins are SERine Proteinase INhibitors and are 
present in all groups of organisms with apart from fungi. They are involved in a variety of 
physiological processes including blood clotting, inflammation amongst many others. Many of the 
family members have no inhibitory activity but those that do may act as suicide substrate inhibitors, 
forming acyl intermediates which bind irreversibly to a protease (van Gent et al., 2003). Food 
allergens belonging to this family are the hens’ egg allergen, ovalbumin and Z4 from barley, a beer 
allergen. 
 
Arginine kinases 
Argingine kinase belongs to a family of structurally and functionally related ATP: guanido 
phosphotransferases that reversibly catalyse the transfer of phosphate between ATP and various 
phosphogens. They have highly conserved active sites including cysteine residues which may be 
important in catalysis.  They have been identified as allergens in invertebrates including food allergens 
in shrimp (Yu et al., 2003), and non-food allergens in Indianmeal moth house dust mite, cockroach, 
king prawn, lobster, and mussel (Binder et al., 2001).  
 
Kunitz inhibitors 
The Kunitz/bovine pancreatic trypsin inhibitor family is active against serine, thiol, aspartic and 
subtilisin proteases. They are generally small (~50 residue) proteins with three intra-chain disulphide 
bonds stabilising a tightly folded three-dimensional structure. They belong to a superfamily of 
structurally-related proteins but share no sequence similarity. Members of this family have also been 
identified as allergens in in cows’ milk, Bos d TI and tentatively in Anisakis simplex (Shimakura et al., 
2004). From the second plant protein family, not related to the animal protein family, food allergens 
have been identified in soybean (Moroz and Yang, 1980) and potato (Seppala et al., 2001).  
 
Chitinase 1 
Chitinases hydrolyse chitin, a major polymer component of fungal cell walls, the cuticles of 
arthropods and exoskeletons of crustacean and a may therefore play a role in plant protection against 
pests and pathogens. Based on their sequence and structural homologies they have been divided into 
six classes with class I chitinases having an N-terminal chitin-binding domain which is homologous 
with the latex protein hevein. This may explain why class I chitinases from avocado, chestnut and 
banana have been identified as cross-reactive allergens in the latex-fruit syndrome. 
 
Thaumatin-like proteins 
The family of thaumatin-like proteins (TLPs), also designated PR-5 play an important role in the 
plant’s defence and are thought to be produced in response to pathogen infection or to osmotic stress 
but are also a group of highly stable plant food allergens. Their eight disulphide bridges contribute to 
their exceptional stability, allowing them to both resist thermal denaturation and digestion (Smole et 
al., 2008). A number of TLP allergens have been identified in fruit including apple, kiwi, grape and 
cherry (Breiteneder, 2004). 
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ANNEX 3. BIOINFORMATICS FOR THE ASSESSMENT OF ALLERGENICITY OF 
NEWLY EXPRESSED PROTEINS IN GMOS 
 
 
3.1. Introduction  
 
Atopic individuals have an intrinsic tendency to develop type I hypersensitivity allergic reactions 
against one or several common environmental allergens. Proteins with potential to provoke allergic 
reactions can be divided into two subcategories, complete and incomplete allergens, i.e. those which 
can educate the immune system (sensitisation) to a full response including the induction of 
immunoglobulin E (IgE) antibodies and those which only have the ability to trigger release of 
inflammatory mediators through cross-reactive IgE binding, respectively (Aalberse et al., 2001; Vieths 
et al., 2002; Weber, 2001). The ability of incomplete allergens to elicit allergic reactions in individuals 
already sensitised to another allergen through cross-reactive IgE-antibodies is mostly due to properties 
inherent in their structure, i.e. they have the ability to mimic conformational or linear IgE-binding 
epitopes on the complete allergens. The ability to initiate the synthesis and induce the secretion of IgE 
antibodies can, however, not be explained by protein structure alone, since the duration, amount and 
conditions of exposure (matrix surrounding the allergen, nature of the host tissue, etc) to the allergen 
probably are just as important factors. 
 
Over the last decade, bioinformatics methods have been widely used for collecting, storing, and 
analysing molecular and/or clinical information of importance for allergy (Mari, 2005). Several 
databases holding information on allergenic proteins, including their amino acid sequence or structural 
features, are publicly available on the Internet. Some of these web resources also contain platforms 
enabling the user to subject a query amino acid sequence to computational assessment trials to 
estimate its level of potential allergenicity, based on algorithms especially designed for this purpose.  
 
A typical in silico risk assessment of potential allergenicity minimally requires the following two 
resources: a repository of all known allergens with determined amino acid sequence and/or 3D 
structure as well as an algorithm for searching relevant similarity between a query protein and the 
allergen database. With the purpose of improvement of bioinformatic approaches relative to the 
current guidelines for in silico assessment, the various databases and algorithms, primarily used by 
different applicants and researchers within this field, are reviewed and discussed.  
 
This annex deals essentially with the assessment of IgE cross-reactivity of newly expressed proteins 
with known allergens. 
 
3.2. Current in silico guidelines  
 
In 1996, the joint International Life Sciences Institute – International Food Biotechnology Council 
(ILSI/IFBC) presented a decision-tree for a comprehensive safety assessment of GM foods in the 
context of allergenicity, which encompasses several principally dissimilar testing methods including 
an amino acid sequence comparison for xenoproteins, obtained from sources with known allergenic 
potential, to allergen sequences (Metcalfe et al., 1996). Several years later, the joint Food and 
Agriculture Organisation and World Health Organisation (FAO/WHO) Expert Consultation on 
Allergenicity of Foods Derived from Biotechnology presented a revised scheme, in which a similar 
bioinformatics analysis is a mandatory initial step regardless of transgene origin. The recommended in 
silico protocol holds a two-part procedure wherein a warning flag is raised by either a match of six 
consecutive amino acids or an identity of more than 35 % (as measured with sequence alignment, see 
next section) over an 80-amino acid window of the query protein, in both cases to a documented 
protein allergen (FAO/WHO, 2001). The first of these FAO/WHO criteria is conducted to identify 
potential linear IgE epitopes or possibly also T-cell epitopes, whereas the second criterion aims at also 
detecting potential conformational IgE-epitopes. 
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The identical peptide match method using a peptide length of six amino acids has attracted much 
criticism in recent years, since it generates too many false positives in testing of potential allergenicity 
(Bjorklund et al., 2005; Gendel, 2002; Goodman, 2006; Hileman et al., 2002; Kleter and Peijnenburg, 
2002; Silvanovich et al., 2006; Soeria-Atmadja et al., 2006; Stadler and Stadler, 2003). Moreover, 
even in linear B cell epitopes some amino acids can be replaced without loss of antibody binding. 
Consequently, the Codex Alimentarius Commission did not adopt the criterion of six identical amino 
acids in their guideline (Codex Alimentarius, 2003), but rather concluded that the scanning peptide 
size should be based on a scientifically justified rationale. In 2006 and 2009, the European Food 
Safety Authority (EFSA) released a guidance which is in line with the recommendations of the Codex 
Alimentarius as regards the assessment of the allergenicity of GM foods and in which improved in 
silico testing for prediction of potential allergenicity is recommended (EFSA, 2006, 2009). 
 
3.3. Allergen online databases 
 
Several reviews on allergen databases have been published during the last five years (Brusic et al., 
2003; Gendel, 2009; Gendel and Jenkins, 2006; Mari, 2005; Schein et al., 2007). An excerpt of these 
publicly available and searchable repositories is listed in Table I (see Appendix 3.13). There are large 
differences between the databases as regards the number of molecules listed as allergens (or 
isoallergens), as well as the information available on these molecules and their source organism. Most 
of these publicly accessible online repositories contain information on allergens as well as links or 
accession numbers to general databases, such as UniProt (Bairoch et al., 2005), in which the actual 
amino acid sequence of the corresponding allergen can be found and retrieved. Some databases also 
contain links and accession numbers to structural or domain information on the allergen molecules, 
whereas other include experimentally verified IgE-epitopes and/or computationally derived motifs (a 
motif can be described as a substructure in a protein that can be connected to function).  
 
The following features of an allergen database are desirable for risk assessment usage: 
1. Selection criteria for inclusion of allergens in the databases should be given. There are several 
important issues regarding the database design and quality for usage in development, 
performance estimation and utilisation of in silico assessment methods. For example, not all 
listed allergens in the databases may be clinically relevant and/or relevant for the purpose of 
amino-acid-sequence-based comparisons (some may have been included solely because they 
have an IgE-binding post-translational modification, such as cross-reactive carbohydrate 
determinants) and certain allergens may only occur as protein fragments lacking the amino 
acid positions crucial for their allergenicity. Currently, the selection criteria of entering 
allergens into most on-line databases are not fully transparent. Thus, reasons for molecules 
appearing in the database could range from information on structural similarity to known 
allergens to documentation on binding to IgE-antibodies in individuals allergic to their source. 
Proteins, for which the suspected allergenicity/IgE-cross-reactivity is founded on weak 
documentation, should be excluded during development and validation of new in silico 
methods. In risk assessment trials, on the other hand, the aim is to reduce the risk of 
introducing new allergens on the consumer market. Therefore, to reduce the risk of 
overlooking possible IgE cross-reactivity to any allergen during an actual risk assessment, 
different allergen databases could be used to identify potential allergenic proteins. It is 
recognised that these databases may differ in the extent by which the allergenicity/IgE-cross-
reactivity of particular allergenic proteins contained by these databases has been documented. 
2. Possibility to directly perform bioinformatics risk assessment using the listed allergens or 
extract/export data necessary for that purpose. Reported methods for in silico assessment of 
allergenicity/IgE-cross-reactivity are nearly always based on amino acid sequence 
information. Thus, meaningful usage of an allergen database in risk assessment exercises 
requires either that such methods are already implemented as tools in the repository or that 
amino acid sequences easily can be downloaded in appropriate formats (so that they can be 
used in stand-alone implementations of the aforementioned methods). Several allergen 
databases contains on-line tools for directly assessing allergenicity/IgE-cross-reactivity of a 
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query protein using various algorithms and criteria based on submission of the corresponding 
amino acid sequence (see Annex 3.9). An expedient downloading procedure of (selected 
excerpts of) these databases is also a preferred feature.  
3. Maintenance and upgrading of databases. Some of the databases listed in Table I (see 
Appendix 3.13) have not been updated for a long time. Continuous curation is, however, 
important, thereby giving access to recently discovered allergens (being either sensitising or 
cross-reactive). Moreover, it is desirable that old versions of databases are stored in an 
accessible form, thereby facilitating possibility to go back and analyse earlier assessments. 
Therefore, bioinformatics risk assessments should also be accompanied with date of 
consultation and/or version number of database. 
 
An allergen database designed specifically for risk assessment should include amino acid sequences of 
all characterised allergens. To increase the usefulness of the database for future bioinformatics 
protocols, it should preferably be associated with available molecular information, such as knowledge 
on epitopes and 3D-structure. Moreover, information available on quality of documentation on 
allergenicity/IgE-cross-reactivity of the allergen, such as binding to IgE antibodies in allergic 
individuals, is also valuable. Ideally, all records should be searchable according to what kind of 
allergenicity documentation there is entailed to it so that users could export datasets tuned to their own 
quality criteria. The Allergome platform is one of the most comprehensive on-line database available, 
both as regards the number of characterised molecules, as well as the amount and diversity of 
information (including documentation on allergenicity in many cases) on individual allergens (Mari et 
al., 2006). However, several records that have been included may not be suitable for risk assessment 
since they lack publications demonstrating IgE binding. Moreover, Allergome does currently not allow 
in silico risk assessment of query amino acid sequences. Therefore, risk assessment using this 
repository requires that all amino acid sequences first are downloaded and thereafter used as input to a 
stand-alone assessment tool. Like several other databases (see Table IV, Appendix 3.13), the 
AllergenOnline database allow comparisons of query proteins according to the 35 % sequence identity 
criterion (see Annex 3.2). Moreover, inclusion of allergens into the database is supervised by a peer 
review panel and overall inclusion criteria are stated on the website. Since none of the databases listed 
in table I (see Appendix 3.13) is complete, as regards numbers and diversity of allergens, a search 
against a single database might overlook important similarities to a known allergen. To reduce this 
risk, bioinformatics risk assessment trials should include searches to several databases. 
 
3.4. Performance estimation of in silico methods 
 
Accurate prediction of protein allergens using bioinformatics methods would be an invaluable help in 
the risk assessment of GM foods. A prediction model typically consists of a prediction procedure in 
combination with a dataset (allergens and sometimes also presumed non-allergens). There are mainly 
two measures that are used to describe the performance of an allergenicity prediction model; 
sensitivity and specificity, which are defined as follows: 
 
Sensitivity = Negatives False  Positives True
Positives True
+  
Specificity = Positives False  Negatives  True
Negatives True
+  
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Another performance measure commonly used in several reports instead of specificity is false alarms 
(1-specificity), whereas the term sensitivity is also referred to as recall. It is easy to understand that 
there is a trade-off between 
sensitivity and specificity. Forcing 
an algorithm (by changing its 
detection statistic threshold) to 
perform with 100% sensitivity i.e. 
all allergens are correctly 
predicted, will automatically imply 
an increased risk of generating 
more false positive results. This 
trade-off can be visualised using 
receiver operating characteristic 
(ROC) curves, which depict 
sensitivity on the ordinate versus 
the fraction of false positive scores 
(1 – specificity) on the abscissa, as 
they vary with incremental 
alterations of the detection statistic 
thresholds for a given algorithm. 
Among the different existing 
techniques to assess sensitivity and 
specificity, the two most commonly used approaches in allergen prediction are holdout validation and 
k-fold cross validation (CV). In holdout validation, a set of examples (in this case amino acid 
sequences) is kept outside all parts of the prediction method design and is only used for testing the 
accordingly designed prediction system. In k-fold CV, all data examples are partitioned in k equally 
sized fractions. In each of k iterations, each fraction is used for performance estimation, whereas the 
other k-1 fractions are allowed to design the prediction method. After all k iterations have been 
conducted, the average sensitivity and specificity is computed. Thus, both techniques evaluate a 
prediction model, as regards sensitivity and specificity, using test data not earlier used in design of the 
prediction model. 
 
3.5. Sequence homology bias and its impact on performance 
 
As mentioned earlier, dedicated and publicly available repositories of protein allergens have proven 
indispensable for the development of computational methods for identifying potentially cross-reactive 
molecules. An appreciable part of the allergens occurring in these specialised databases are referred to 
as isoallergens. Moreover, a high degree of similarity between allergens may also occur across species 
boundaries. If an amino acid sequence, occurring in the reference database, has an isoform in the set of 
test examples used for performance evaluation, the accordingly designed prediction algorithm will 
easily identify also this isoform as potentially allergenic. Therefore, if redundant sequence datasets are 
used in the design and performance estimation of a prediction system, there is a large risk of obtaining 
overly optimistic performance estimates. Although, this issue is well known in most bioinformatics 
areas it has, however, not yet been extensively discussed in the literature in the context of allergen 
prediction. Moreover, as reported by Aalberse (2005), it is not clear how many of the hitherto reported 
algorithms for allergenicity prediction have taken this source of bias into consideration. Non-
redundancy is commonly obtained by firstly clustering amino acid sequences so that no examples 
between clusters share more similarity than a cut-off limit. Thereafter, one representative sequence 
from each cluster is selected to constitute the non-redundant set. There is currently no general 
sequence identity redundancy threshold for performance estimation of allergenicity prediction systems 
but its influence on sensitivity performance was recently described for various computational methods 
(Soeria-Atmadja et al., 2006). It should be mentioned that redundant databases only impose a problem 
during estimation of a method’s performance (sensitivity/specificity). Therefore, in the actual risk 
assessments, redundancy is (for most methods) not an issue. 
 
A simulated example of the shape of a ROC curve 
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3.6. Computational methods for risk assessment of potential allergenicity/IgE-cross-
reactivity 
 
Most of the methods reviewed below have been developed with the purpose to predict the allergenic 
potential of a protein. As mentioned earlier, however, de novo sensitisation is not only determined by 
the structural properties of the allergen, but other factors are also important. Therefore, computational 
protocols and algorithms mentioned in the following subchapters could be considered as methods 
primarily for assessment of IgE-cross-reactivity rather than allergenicity in general. 
 
3.6.1. Methods based on alignment to entire allergen amino acid sequences 
 
Sequence alignment is a method to compare and represent similarities and differences between 
sequences of biomolecules. It is a fundamental technique in biology since high sequence similarity 
usually means structural and/or functional similarity. Sequences can principally be aligned in two 
different ways, globally or locally. Since local alignment aims at finding shorter sequence regions of 
highly conserved residues, it is preferred for bioinformatics assessment of allergenicity/IgE-cross-
reactivity. The two most commonly used local alignments methods for searching sequence databases 
are FASTA (Pearson and Lipman, 1988) and BLAST (Basic local alignment search algorithm) 
(Altschul et al., 1990), which both are fast approximations of the Smith-Waterman algorithm for 
optimal local alignment (Smith and Waterman, 1981). A local alignment involves two symbolic 
sequence representations of DNA or protein arranged next to each other so that their most similar 
elements are juxtaposed. Every element in the trace of an alignment is a gap, match or mismatch. 
Matches and mismatches involve alignment of two identical and different amino acid residues, 
respectively, whereas a gap represents a deletion/insertion in one of the amino acid sequences.  
 
Sequence 1: -IRASAGFDL--AGVHYYVTA 
             || | ||||  |||| ||| 
Sequence 2: HIRSS-GFDLLVAGVHTYVT- 
 
The example above contains five gaps, marked with ‘-‘, several matches, marked with ‘|‘, and a few 
mismatches (empty space between the two sequences). Two major (often user-defined) parameters 
affecting an alignment procedure of two amino acid sequences are gap penalty setting and substitution 
matrix, both being important in guiding the algorithm to indicate matches, mismatches or gaps. The 
former parameter includes both a penalty for opening a gap, as well as for extending it, and is 
implemented to avoid excessive insertion of gaps in the alignment. Substitution matrices contains 
scoring values for aligning two amino acids to each other, wherein matches (of two identical amino 
acids) typically correspond to high scores, whereas mismatches are assigned low values. The category 
of substitution matrices based on evolutionary analysis of related proteins families, such as the 
BLOSUM series, have different grading on mismatches, where those involving two evolutionary 
similar amino acids are assigned higher scores than others. The impact of alignment parameter setting 
(gap penalties and substitution matrix) on the FAO/WHO alignment recommendation has not been 
extensively studied. As regards gap opening penalty, it has been concluded that the change of FASTA 
default value from 12 to 10 did not significantly alter the results (Ladics et al., 2007). Although not 
evaluated, it is likely that similar conclusion could be drawn as regards choice of substitution matrix, 
at least if default substitution matrices of different local alignment tools are considered (such as 
BLOSUM50 or BLOSUM62). Thus, until a specific alignment parameter setting has been proven to 
outperform other alternatives (based on proper evaluations), use of default alignment parameter 
settings should be adequate for risk assessment. 
 
As mentioned earlier, current bioinformatics protocol for IgE-cross-reactivity testing recommends 
identity of more than 35 % over an 80-amino acid window of the query protein to a known protein 
allergen as a criterion for further testing. The proposed procedure for analysing similarity involves an 
initial segmentation of the query protein into a complete (overlapping) set of 80 amino acid long 
sequences. Thereafter each 80-mer is compared to an allergen database using the local alignment tool 
Annex 3. Bioinformatics
 
 
92 EFSA Journal 2010; 8(7):1700 
FASTA to reveal the best alignments (FAO/WHO, 2001). Finally, these outputs are analysed to 
identify matches that meet the abovementioned similarity criterion. There are several different 
methods to calculate the crude measure percent identity (PID) from an alignment of two amino acid 
sequences (Raghava and Barton, 2006), where some methods neglect gaps and others treat them as 
mismatches. If gaps are neglected in the calculation, a heavily gapped alignment (which often 
indicates poor similarity) can still return an overly high PID. If such an alignment is evaluated by a 
PID calculation method considering gaps as mismatches the PID will decrease, which better reflects 
the poor similarity between the two sequences. The gap opening penalty is more severe than the gap 
extension penalty. This might be used as an argument in favour of counting each gap as one, without 
taking the number of amino acids in the gap into account. However, in the conventional approach the 
“number of gaps” is interpreted as “the sum of the numbers of amino acids missing in each gaps”, 
rather than as the number of gaps. This approach lowers the homology score, particularly if sequence 
identity is calculated over the total protein length and there are large gaps. A marked effect will, for 
example, be found in protein families with splicing variants (in which whole domains are often 
lacking). However, using the proposed sliding window approach, the effect is much smaller. The 
sequence percent identity would thus be calculated as follows: 
 
GapsAligned
IdenticalPID += , where Identical is the number of identical positions in the alignment, 
Aligned is the number of all aligned positions in the alignment (including mismatches) and Gaps is the 
number of positions in the inserted gaps in the alignment. N-terminal as well as C-terminal truncations 
are discarded.  
 
 
The identity limit of 35 % is considered conservative, since allergenic cross-reactivity usually requires 
more than 50-70 % sequence identity (Aalberse, 2000) although exceptions to this rule-of-thumb exist. 
Moreover, a recent report by Ladics et al., (2007) disputes the 80-mer sliding window approach, since 
it can generate both more false positives, as well as less statistically significant alignments than results 
derived from a database search with the entire query amino acid sequence only. The former issue was 
demonstrated by comparing the assessment results of the two procedures, when tested with different 
datasets of presumed non-allergens. Since FASTA searches, using the entire query amino acid 
sequence, overlook some of the presumed false positives identified with the sliding-window 80-mer 
search, it is reasonable to argue that the former approach is more specific. The second criticism against 
the sliding window approach relates to the statistical significance of the resulting top alignments. An 
alignment derived from a FASTA search of a database is accompanied with an E-value, which 
represent the number of times the corresponding alignment score is expected at chance. FASTA 
alignments with the entire query amino acid sequence corresponded to lower E-values than those using 
the 80-mers, thereby having higher statistical significance. On the other hand, the identified 
alignments obviously meet the criterion of at least 35 % identity over a window of minimum 80 amino 
acids. From that perspective, the conservatively set sequence identity criterion rather than the 80-mer 
approach is responsible for the false positives. Moreover, it is plausible that some of these false 
positives also would have been recognised, using alignment of the entire query sequence, at a slightly 
lower sequence identity threshold. Nonetheless, the added value of initial amino acid sequence 
segmentation into overlapping 80-mers prior to alignment is questionable. It is, however, an important 
aspect in the calculation of the PID, particularly if the query protein has (or is predicted to have) a 
multi-domain structure, since a single domain with similarity to a known allergen theoretically could 
escape detection if inserted into an otherwise non-allergenic protein, or if splice variants of the protein 
exist in which the deletion of a whole domain might markedly reduce the PID if it is calculated over 
the whole sequence rather than over 80-mers. 
 
Regardless sequence identity threshold and method for searching similarity (either using the entire 
amino acid sequence or the complete set of the corresponding 80-mers) it should be noted that matches 
slightly below the limit may be just as important as those slightly above. Thus, the sequence identity 
threshold should be used as guidance rather than strictly discriminatory for further testing. Moreover, 
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it would be valuable to evaluate a match between a query protein and allergen more quantitatively than 
the simple categories “above limit” or “below limit”.  
 
Another core issue, not yet raised in the literature, is the use of PID as a discriminatory criterion in 
IgE-cross-reactivity risk assessment. According to the current recommendations this criterion equals to 
occurrence of 35 % pairs (or more) of identical amino acids over a window of at least 80 amino acids 
in the top alignments to allergens obtained with FASTA. The initial FASTA searches, based on 
evolutionary substitution matrices (being the default setting of most local alignment tools) are, 
however, set to identify the best alignments according to a different criterion, since also partial 
matches (evolutionary similar mismatches) are assigned high scores (see above). Therefore, the 
resulting alignments are optimised to include pairs of both identical and similar amino acid residues. 
In the following procedure, however, only the identical matches are included, whereas the high-
scoring partial matches (being mismatches of similar amino acids) of the alignment are ignored. Thus, 
since evolutionary substitution matrices are used to find best alignments of a query protein to an 
allergen database, the criterion in the subsequent analysis of the alignment should be analogously 
based, i.e. on sequence similarity rather than sequence identity. Such criteria could, for example, be 
based on other local alignment output, such as Z-scores or E-values. In a recent report, use of a 
threshold based on method to calculate an E-value for assessing query alignments to allergens is 
suggested, which results in fewer false positives among corn proteins when compared to application of 
the 35% identity criterion (Silvanovich et al., 2009). Further research and evaluations of more and 
larger datasets may prove this threshold (or alternative thresholds also based on sequence similarity) 
being superior to those founded on percent identity. 
 
Apart from the recommendations by FAO/WHO and Ladics et al. (2007) several other procedures 
have been suggested (Gendel, 1998b; Soeria-Atmadja et al., 2004; Zorzet et al., 2002), which are also 
founded on features from sequence alignment procedures against entire amino acid sequences of 
allergen proteins. In the first of these papers, Gendel suggested an initial alignment search using an 
identity matrix, followed by an additional search using either a biochemical or an evolutionary 
substitution matrix. The two latter papers describe the use of supervised learning algorithms, which are 
trained to discriminate between alignment-based features typical for allergens and presumed non-
allergens, respectively.  
 
Although many allergens appear to cluster into relatively few protein families (Aalberse et al., 2001; 
Breiteneder and Ebner, 2001; Jenkins et al., 2005; Radauer and Breiteneder, 2006), most members of 
such protein families seem to be devoid of allergenic properties (Mills et al., 2004). Therefore, there is 
a risk that algorithms searching for similarities against an allergen database of entire amino acid 
sequences may find similarities characteristic for other functional features than IgE-cross-reactivity. 
 
3.6.2. Methods based on similarity to computationally generated motifs/peptides from 
amino acid allergen sequences 
 
To reduce false positives due to similarity matches against parts of the allergens unimportant for 
allergy, several recent studies have focused on the construction of algorithms for automated motif 
generation. The purpose of these algorithms is to create a peptide set, wherein only motifs common for 
allergens are supposed to be included. Thereafter, a similarity search is performed between the query 
protein and the allergen motif set, which replaces the original dataset of entire allergen amino acid 
sequences. Stadler and Stadler have reported the iterated use of the Multiple EM for Motif Elicitation 
(MEME) algorithm (Bailey and Elkan, 1994) to generate motifs that are present within two or more 
allergens (Stadler and Stadler, 2003), whereas Li et al. (2004) have presented an alternative algorithm, 
in which the motif-finding method is founded on wavelet analysis. Since both these approaches fail to 
extract motifs for 10-20 % of the allergens, an add-on procedure has also been suggested, wherein a 
similarity search (using alignment) against the entire amino acid sequences of these (unmatched) 
allergens is performed. In a recent report, Kong et al. (2007) described a procedure that uses a 
combination of several MEME-derived motifs, which showed higher specificity than employing single 
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motifs only. Mari et al. (2006) showed that generated motifs may, in some cases, be useful for 
identifying IgE epitopes. 
 
Although algorithms developed to solely recognise common inter-allergen motifs might return an 
overall reasonably good prediction performance in regular test procedures, there is still a risk that they 
target motifs specific for protein family although these motifs have little or no relevance to 
allergenicity/IgE-cross-reactivity. This issue is most important in those cases where protein allergens 
have relatively closely related human homologues. For example, in the study by Li et al. (2004) it is 
stated that some of the motifs generated from allergen tropomyosins are specific to the tropomyosin 
family itself rather than the allergen counterparts. Hence, algorithms solely searching for motifs that 
are common in allergens may suffer (although to a lesser content) from the same problems as those 
using similarity searches in entire amino acid sequences. As an alternative to algorithms searching for 
inter-allergen motifs, Björklund et al. (2005) have reported an algorithm based on a novel principle, 
wherein allergen-representative peptides are obtained by selecting peptide sequences of allergens that 
occur infrequently in presumed non-allergens. A drawback with this method is that it is restricted to 
choose the same amount of peptides from each allergen and that the obtained peptides are constrained 
to having the same length. These two issues were addressed in the refinements of this method (Soeria-
Atmadja et al., 2006). The latter method was also able to discriminate between allergens and 
presumable non-allergens in tropomyosin and parvalbumins protein families. A drawback with both of 
the latter methods is that they require a dataset of presumable non-allergens to select the peptides (see 
Usage of negative examples in modeling and evaluation of in silico methods). 
 
3.6.3. Methods based on similarity to experimentally verified IgE-epitopes 
 
As mentioned earlier, the identical peptide match criterion, using 6 amino acids long peptides as 
proposed by FAO/WHO, has been substantially criticised for being too unspecific. In order to increase 
the specificity, Kleter and Peijnenburg (2002) have proposed a 2-step strategy wherein the positive 
outcomes, as revealed by the aforementioned criterion, are further screened for the presence of 
potential linear IgE-epitopes. This approach includes comparison of these peptides with known IgE-
epitopes and/or evaluating their potential antigenicity with computational methodology (see epitope 
prediction section).  
 
Saha and Raghava (2006) evaluated the use of similarity to experimentally verified IgE-epitopes for 
prediction of allergenicity/cross-reactivity and found that 11 % of an independent allergen data set 
could be correctly assigned. Thus, at the present time there are too few characterised IgE-epitopes for 
these methods to be sensitive enough as stand-alone in silico testing procedures, but may be useful as 
complement to other bioinformatics algorithms. 
 
3.6.4. Methods based on amino acid composition or physico-chemical properties 
 
An interesting alternative to both the identical peptide match method, as well as alignment criteria, has 
been proposed by Ivanciuc et al. (2002). Amino acid sequences are firstly transformed into a numerical 
representation based on five-dimensional physico-chemical descriptors of amino acid properties 
(Venkatarajan and Braun, 2001), and similarity between the numerical vectors is thereafter calculated 
as Euclidean distance. Although this method may be useful for the search of potential epitopes in 
known allergens (Schein et al., 2005), it has not yet been sufficiently evaluated in the context of risk 
assessment of a query protein’s allergenic potential. In a report, Saha and Raghava (2006) suggested 
(among several other methods) the use of amino acid composition and dipeptide composition as 
features in combination with supervised machine learning for prediction of allergenicity/IgE-cross-
reactivity. This approach did, however, show low specificity when evaluated with Swiss-Prot. 
 
Recently, Cui et al. (2007) presented a method based on supervised machine learning in combination 
with sequence-derived structural and physicochemical properties by using different propensity scales 
(see B-cell epitope prediction). More specifically, proteins are converted into numerical vectors based 
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on their amino acids’ hydrophobicity, normalised Van der Waals volume, polarity, polarisability, 
charge, surface tension, secondary structure and solvent accessibility. The authors describe global 
(over the whole protein) composition of each of these properties using three descriptors, firstly 
introduced by Dubchak et al., (1995) for predicting protein-folding class. This approach seems very 
promising since it yields overall good accuracy but foremost since it correctly assigns also several 
allergens lacking sequence similarity to other allergens. A possible drawback, though, is that currently 
no information is given on which of the known allergens the query is most alike. Thus, this makes it 
difficult for a risk assessor to further investigate the allergenic potential through in vitro or in vivo 
methodology. 
 
3.6.5. Usage of negative examples in modeling and evaluation of in silico methods 
 
As mentioned earlier, dose and route of exposure, which may be just as important as characteristics 
inherent to the protein, are not considered in bioinformatics testing. Thus, a change of the quantity of a 
protein in a GM-food could be sufficient to change its allergenic potential. Therefore, screening for 
true non-allergenicity of a protein is currently not possible. Nevertheless, a dataset of presumed 
negative examples (non-allergens) is a prerequisite for estimating specificity (see above). Moreover, 
some of the prediction methods mentioned above, also requires the use of presumed non-allergens in 
either the procedure for generating motifs/peptides or training a supervised learning algorithm. 
Accordingly, in the following section the term “presumed non-allergens” refers to proteins with 
presumably low allergenic potential under normal conditions/exposure. 
 
In the reports by Stadler and Stadler (2003) and Li et al. (2004), presumed non-allergens, used as one 
way of measuring specificity, are simulated by shuffling the order of amino acid positions in allergen 
protein sequences. It is, however, unclear if these virtual amino acid sequences are representative for 
non-allergens or even for proteins. In the study by Björklund et al. (2005) presumed non-allergens 
were selected from several commonly consumed commodities, a dataset that is also used by Saha and 
Raghava (2006). Since most of these proteins were of plant origin the dataset is probably not 
representative for all presumed non-allergens. Moreover, for some of the proteins, such as those 
belonging to the rice proteome, it is very uncertain if they are good candidates as negative examples. 
The risk of allergens contaminating the non-allergen dataset should be considerably higher in the work 
by Furmonaviciene et al (see “Future studies”), since the presumed non-allergens are homologous to 
known allergens. In the report by Soeria-Atmadja et al. (2006), the human proteome (with some 
exceptions) is employed as a negative filter to generate peptides presumably important for 
allergenicity/IgE-cross-reactivity. Cui et al., (2007) suggested very recently an interesting procedure to 
obtain presumably non-allergens to be used in their evaluation. Protein families in the Pfam database 
(Finn et al., 2006) that are absent of any documented allergens are selected and representative 
members from human, bovine, chicken, pear, apple, peanut (and some others) are then chosen as 
presumed non-allergens. Another important aspect is that none of the abovementioned methods for 
selecting presumable non-allergens have considered their abundance in their source, which is an 
important factor as regards allergenicity. 
 
3.6.6. Comparison of performance estimates for different methods 
 
Since the amount of allergen that can be used as examples is relatively scarce, k-fold CV has been the 
most commonly used method for sensitivity evaluation of an allergenicity/IgE-cross-reactivity 
prediction method (Bjorklund et al., 2005; Li et al., 2004; Stadler and Stadler, 2003; Zorzet et al., 
2002), although several of the most recent studies have used an independent holdout test set (Cui et al., 
2007; Saha and Raghava, 2006; Soeria-Atmadja et al., 2006). CV has also been used to reveal the 
predictor’s estimated specificity (Li et al., 2004; Stadler and Stadler, 2003; Zorzet et al., 2002). The 
most thorough procedure for specificity assessment, however, is to estimate the ratio of allergens in 
the entire SwissProt database (Cui et al., 2007; Kong et al., 2007; Li et al., 2004; Saha and Raghava, 
2006; Soeria-Atmadja et al., 2006; Stadler and Stadler, 2003).  
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Table II (see Appendix 3.13) lists studies where both sensitivity and SwissProt estimation have been 
assessed. Some of the aforementioned methods have been compared with the two FAO/WHO criteria 
mentioned earlier. In only a few studies new algorithms have, however, been bench-marked to each 
other. Since the performance of the algorithms reviewed here has been estimated using different 
datasets, it is difficult to discriminate between them. 
 
3.6.7. B-cell epitope prediction algorithms 
 
Various methods exist to predict the parts of the protein molecule that are likely to be antigenic and 
recognised by antibodies, i.e. epitopes. These methods do commonly not discriminate between the 
different classes of immunoglobulin antibodies, such as IgE, IgA, IgG, or IgM. Epitope prediction 
methods can be divided into two subcategories: those that use the linear amino acid sequence of the 
protein as input and those that consider the three-dimensional structure of the protein (Greenbaum et 
al., 2007). 
 
The classical way of predicting linear B-cell epitopes is by the use of propensity scale methods, which 
assign a propensity score to every amino acid, based on studies of their physico-chemical properties. 
These methods usually use a sliding window of a fixed number of contiguous amino acids, for which, 
at each step of sliding, separate propensity scores are combined or averaged into a score assigned to a 
specific point within the sliding window (Hopp and Woods, 1981). Most propensity scales are based 
on the hypothesis that amino acid residues on the surface of the three-dimensional structure of a 
protein molecule are more accessible to antibodies and therefore more prone to binding. 
Hydrophilicity of the amino acids indicates the likelihood that they will be exposed at the protein 
surface to the aqueous environment, whilst hydropathicity indicates the likelihood that residues will be 
buried inside the hydrophobic core of a protein. Another, more empirical approach is to consider the 
relative frequency with which specific amino acids have been observed to occur at the surface of 
known three-dimensional protein structures. It should be borne in mind, though, that some epitopes of 
allergens are known to occur in the inside of proteins, where they become accessible after denaturation 
or protein degradation into peptides. Moreover, Blythe and Flower have evaluated the performance of 
484 propensity scale methods for B cell epitope prediction and found that even the best performing 
methods could marginally outperform random prediction (Blythe and Flower, 2005).  
 
Another approach is to consider the surface of the three-dimensional structure of a protein, if 
available, and to identify those residues exposed on the surface that are accessible to antibody binding. 
Groups of accessible residues that occur within a confined area of the surface that can interact with an 
antibody binding site are considered epitopes. In contrast to the linear-sequence-based methods, this 
approach pertains to non-linear, discontinuous epitopes. In addition to the surface of the antigenic 
protein, also knowledge about residues involved in specific antibody-protein interactions can be 
exploited, such as derived from crystallographic data on the bound complex or derived using 
mimotope technology. For more information on 3D-structure-based B-cell epitope prediction, see 
Greenbaum et al (2007). 
 
3.7. T-cell epitope prediction algorithms 
 
There are several bioinformatics tools available for identification of T-cell epitopes to certain specific 
MHC alleles including those of MHC class II, such as MULTIPRED (Zhang et al., 2005), 
SYFPEITHI (Rammensee et al., 1999), EpiMer (Meister et al., 1995) and TEPITOPE (Sturniolo et al., 
1999). Moreover, T-cell epitope prediction methods are considered more reliable, as regards both 
specificity and sensitivity, than those designed for identification of B-cell epitopes. Prediction of one 
or several peptides of the query amino acid sequence as being potential MHC class II binders 
indicates, however, immunogenicity in general, rather than allergenicity. It is doubtful whether these 
algorithms can predict T cell epitopes being specific for the proliferation of TH2 cells, which are 
associated with allergic sensitisation. Therefore, it is currently not straightforward how results from in 
silico T cell epitope predictions should be viewed upon in risk assessment of allergenicity. 
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3.8. Future studies 
 
Since there are relatively few allergens with determined tertiary structure as compared to those with 
known primary structure, most efforts in allergenicity prediction have been founded on similarity 
searches on the amino acid sequence level. There has, however, been much research recently aiming to 
reveal correlations between structure and protein allergenicity rather than to create a prediction system 
for allergenic potential (Barre et al., 2005; Furmonaviciene and Shakib, 2001; Jenkins et al., 2005; 
Johannessen et al., 2005; Neudecker et al., 2001; Roy et al., 2003; Schirmer et al., 2005). A recent 
report by Furmonaviciene et al (2005) describes the employment of the ConSurf server (Glaser et al., 
2003), which is founded on phylogenetic relationships between sequence homologues, to identify 
functionally important regions of the surface on allergens with known 3D structure. In analogy with 
the work of Björklund et al (2005), presumed non-allergens belonging to the same families as the 
allergens, have also been included to prevent generating motifs specific for protein family rather than 
allergenicity. Although this approach is very interesting, no suggestions how it could be used as a 
prediction tool has been presented. Furthermore, as mentioned earlier, there are so far relatively few 
allergens where the 3D structure has been determined. As more structural information on allergens is 
revealed, the search for common structural motifs is, however, likely to improve the quality of 
assessment of IgE-cross-reactivity and allergenicity. Moreover, different state-of-the-art algorithms for 
structure prediction (Petrey and Honig, 2005), applied on allergens, which only have their amino acid 
sequence determined, could further improve prediction accuracy. For example, a two-step protocol to 
identify potentially cross-reactive peanut-lupine proteins has been described that firstly performs 
FAO/WHO in silico criteria and thereafter a visual comparison of the matching sequences’ predicted 
three-dimensional structure models (Guarneri et al., 2005). The described procedure needs substantial 
refinements before it could be used as a bioinformatics risk assessment tool, such as implementing it 
as an automated process, providing a computational measurement for describing relevant structure 
similarities, and most importantly, it must be validated using the methods described earlier (see Annex 
3.4). 
 
3.9. Bioinformatics tools available over the Internet 
 
3.9.1. Risk assessment based on FAO/WHO guidelines 
 
Table III (see Appendix 3.13) lists websites where a search using the complete or parts of FAO/WHO 
bioinformatics protocol can be carried out, although each website uses different repositories as the 
allergen reference dataset. Some of these servers hold only the 35 % sequence identity criterion, 
revealed using alignment of whole query amino acid or of its corresponding set of overlapping 
peptides, whereas other also include the identical peptide match criterion. 
 
3.9.2. Risk assessment based on similarity to generated motifs/peptides 
 
Alternatives or complements to FAO/WHO-based bioinformatics risk assessment tools are listed in 
table IV (see Appendix 3.13). The prediction method based on motifs generated by wavelet analysis, 
as described by Li et al (2004), is publicly available on the WebAllergen server (Riaz et al., 2005), 
whereas both ADFS (Nakamura et al., 2005) and AlgPred (Saha and Raghava, 2006) hold a prediction 
method based on the MEME motif discovery tool similar to that reported by Stadler and Stadler 
(Stadler and Stadler, 2003). The aforementioned AlgPred web server also offers the possibility to 
predict IgE-cross-reactivity through similarity searches to experimentally verified IgE epitopes, either 
as a separate method or in conjunction with additional methods. Other prediction algorithms available 
at this server include the supervised machine-learning methods based on either amino acid or dipeptide 
composition over the entire protein’s amino acid sequence, of which the former can be accessed also 
at AllerTool (Zhang et al., 2007). EVALLER (version 2.0) is an executable on-line implementation of 
the principles presented by Soeria-Atmadja et al (2006) in conjunction with allergens of the FARRP 
AllergenOnline database and is available at the Swedish National Food Administration (Barrio et al., 
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2007; Bongcam-Rudloff et al., 2007). The web server Allergen Protein Prediction E-Lab (APPEL) 
holds one of the most recent prediction methods, which is founded on supervised machine-learning in 
combination with a global description of the protein based on amino acid propensity scales (Cui et al., 
2007).  
 
3.9.3. Other tools that could be useful for risk assessment  
 
There are also other bioinformatics tools that are not directly focused towards predicting IgE-cross-
reactivity/allergenicity potential of proteins but that still may be useful for in silico risk assessment. 
For example, SDAP offers the possibility to do a search with a known epitope to reveal epitope 
candidates among the allergens available at the server, either using an identical match as criterion or a 
match based on similarity, whereas Allergome, AllerTool and ALLERDB hold a visual tool to display 
graphical representation of allergens known to be cross-reactive.  
 
3.10. In silico prediction of the allergenicity potential of open reading frames (ORFs) 
 
Risk assessments of genetically modified plants must also consider the possible formation of short 
peptides, being the result of translated small open reading frames (ORFs). These putative peptides are 
often very short (typically shorter than 40 amino acids), and are therefore not readily analysed with the 
FAO/WHO alignment criterion (35% identity over 80 amino acids). Even though the FAO/WHO 
identical peptide matching has attracted a lot of criticism for risk assessing full length protein 
sequences, this method may be applicable to assess ORFs. Thus, if an ORF shares an identical peptide 
of 8 (or even 7) amino acid residues with any allergen, this ORF should be subject to further 
evaluation. Presence of contiguous identical peptides as criterion is sensitive to gaps, i.e. an insertion 
or deletion of an amino acid residue in any of the amino acid sequences. Since insertion/deletion of 
one amino acid within an epitope does not automatically mean inhibition or reduction of IgE-binding, 
it is important that the method of choice also can handle gaps. A scientifically more sound in silico 
analysis would be to perform similarity searches (using alignment) to databases of experimentally 
verified IgE epitopes or to motifs common in allergens. However, evaluations of resulting high-ranked 
alignments can not be conducted using the criterion for full length protein sequences, i.e. 35% identity 
over 80 amino acids. Since the ORFs can differ much in length relative to each other, it is difficult to 
set a fixed criterion for the evaluation of alignments (between ORFs and known allergens). Therefore, 
judgement on high similarity of an ORF to an allergen must at the present time be performed case by 
case. An alternative method to the identical peptide match approach is the peptide similarity tool 
available at the SDAP server, which is based on similarities of physico-chemical properties rather than 
simple identity. It is, however, not clear if this peptide matching method can also compensate for gaps. 
 
In conclusion, possible inroads for assessing cross-reactivity or allergenicity potential of these short 
sequences include: a) Alignment to experimentally verified IgE epitopes or to motifs common in 
allergens. Judgements on whether the resulting alignments show sufficient similarity between ORF 
and an allergen must be performed case by case; b) Search for identical contiguous peptides of length 
8 (or at shortest 7) to known allergens; or alternatively, a search for contiguous peptides using the 
peptide-similarity tool at the SDAP server. 
 
3.11. In silico prediction of potential involvement in coeliac disease 
 
Coeliac disease is an autoimmune disorder of the small bowel that occurs in genetically predisposed 
individuals. The immunological reaction is caused by prolamins, which are storage proteins rich in 
proline and glutamine, such as gliadin and hordein from wheat and barley, respectively. The proline-
rich peptides that are released by the enzymatic action of proteases during digestion are recalcitrant to 
further breakdown and are thereby able to reach the immune system of the gut mucosa. Upon exposure 
to these proteins, the body's immune system cross-reacts with the enzyme tissue transglutaminase, 
causing an inflammatory reaction. In addition, the enzymatic action of transglutaminase itself also 
deamidates specific glutamine residues, yielding glutamic acid residues, that further increase the 
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sensitisation capacity of the coelic-disease-associated proteins. Currently, the only effective treatment 
is a gluten-free diet. 
 
Although the BIFS database has listings of gluten-associated proteins there are so far no in silico 
prediction procedures publicly available over the Internet. Literature indicate that a limited number of 
common protein motifs of gluten proteins, including the α-, γ-, and ω-gliadins and low-molecular 
weight glutenins, are involved with the sensitisation of T-cells. These motifs have so far been used for 
screening amino acid sequences of gluten proteins in cereals for their presence and linkage with 
potential celiac-disease-causing properties (van Herpen et al., 2006). 
 
3.12. Conclusions and recommendations 
 
There is an important development in bioinformatics methods that are widely used for the risk 
assessment of newly expressed proteins in GMOs. They pertain to the assessment of cross-reactivity 
with known allergens. Computational screening for potential allergenicity/IgE-cross-reactivity is both 
expedient and inexpensive, compared to laboratory experimentally studies, since the only 
requirements are a computer and, as mentioned earlier, a feasible algorithm and data repository. 
Moreover, many of these algorithms accomplish good discrimination between known allergens and 
proteins presumed to have a lower allergen potential. It should, however, be stressed that all the 
various computational algorithms available (and reviewed here) are designed to search for (presumed) 
allergenicity features that are inherent in the protein’s sequence/structure, whereas external factors, 
such as exposure or post-translational modifications (except for search for N-glycosylation sites) are 
not taken into account. These algorithms are therefore generally well suited for predicting cross-
reactivity but currently not for identification of de novo sensitisation potential, which is a much more 
challenging task. Accurate prediction of the latter feature requires more knowledge on the primary 
sensitisation procedure and possibly also further algorithmic refinement to include exposure data in 
the models.  
 
If computational testing suggests the protein of interest being a potential allergen, further testing, 
which may be of in vitro or in vivo character, should be performed in the risk assessment procedure.  
 
3.12.1. Employment of allergen databases 
 
Conclusions 
Several reported allergen databases, as outlined in specific and review-type articles, are accessible 
through the Internet. When used for risk assessment purposes such repositories should be as 
comprehensive and quality assured as possible. Generally, criteria for inclusion of allergens into 
databases, are, however, rarely stated and therefore the quality of most databases is difficult to assess. 
Moreover, none of the existing databases are complete since they all contain errors, as regards 
presence of presumed non-allergens, as well as absence of true allergens. For example, it is plausible 
that a significant number of “minor” allergens have not yet been identified and characterised. On the 
other hand, IgE binding to some among the listed allergens is mainly due to post-translational 
attachment of glycans, rather than the protein itself. Other important features of databases include 
good technical maintenance, regular curation, as well as a user-friendly retrieval system so that amino 
acid sequences can be easily extracted from the databases.  
 
Recommendations 
• Allergen databases used for the assessment of the risk of cross-reactivity with known allergens 
should be as comprehensive and quality assured as possible, and they should be regularly 
updated by a competent independent body. To minimise the risk of overlooking potential IgE-
cross-reactivity due to incomplete databases, in silico consultation of several such repositories 
should be performed. 
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3.12.2. Amino acid sequence based bioinformatics protocols 
 
Conclusions 
As mentioned earlier, bioinformatics prediction methods of potential protein allergenicity/IgE-cross-
reactivity is an initial screening step before in vitro or in vivo testing. Over the last decade, various 
bioinformatics methods for the abovementioned purpose have been developed. In the review of state-
of-the-art, only methods that have undergone some standard bioinformatics (large-scale) performance 
estimation regarding specificity and sensitivity have been considered. Peptide match of complete 
identity over 6 contiguous amino acids to known allergens is associated with very poor specificity 
(many false positives), which has been reported in numerous studies. Moreover, the relevance of an 
identical match criterion, regardless of length, is doubtful, since replacement of one amino acid within 
a potential epitope does not necessarily imply loss of reactivity. The alignment based criterion using a 
sliding window of 80 amino acids as proposed by FAO/WHO, is still accepted as reasonably adequate 
also when compared to novel approaches for allergenicity/IgE-cross-reactivity prediction. The 35% 
identity cut-off level may seem overly conservative and 50% identity cut-off has been suggested. 
Nonetheless, significant cross-reactivity can occur well below 50% identity. The relevance of the 
sliding window approach as opposed to alignment of the full-length query protein has been disputed in 
the literature. The former approach seems to be more conservative, in the sense that more amino acid 
sequences meet the 35% sequence identity criterion using this method. A special concern is attached to 
the sequence identity criterion, since this strategy neglects partial matches (evolutionary favourable 
substitutions). Therefore, alternative criteria to assess similarity may prove more useful. In recent 
years, a range of enhanced algorithms, founded on more advanced principles have been reported. 
Several among those are associated with both high sensitivity and favourable specificity and are also 
publicly available over the Internet. A selected fraction of these tools are therefore well qualified to 
complement the alignment-based method, as suggested by FAO/WHO. Moreover, a decision has to be 
made on the acceptability of false-negative rate since an overly strict adherence to sensitivity will 
result in an unreasonable number of false positives (sensitivity versus specificity), without completely 
avoiding all cross-reactivity risk. 
 
Recommendations 
There is a need for standardisation and harmonisation in search strategy and interpretation of results 
obtained. The alignment-based criterion involving 35 % sequence identity to a known allergen over a 
window of at least 80 amino acids is considered a minimal requirement for risk assessment, although 
the identity threshold is conservatively set. This procedure could be conducted as follows: 
• All sequence alignment parameters used in the analysis should be provided including 
calculation of percent identity (PID). It is recommended to employ default settings for 
substitution matrix and gap penalties, (e.g. BLOSUM 50 as substitution matrix, range of 10-12 
as gap opening penalty and 2 as gap extension penalty).  
• It is recommended that calculation of PID is performed on a window of 80 amino acids with 
gaps so that inserted gaps are treated as mismatches. If the highest value of the PIDs thus 
calculated for all alignments is indeed above 35%, then it will have to be checked which parts 
of the sequences of both proteins (i.e. the query protein and the aligned allergenic protein) are 
covered by the windows showing a PID>35%. 
GapsAligned
IdenticalPID += , where Identical is 
the number of identical positions in the alignment, Aligned is the number of all aligned 
positions in the alignment (including mismatches) and Gaps is the number of amino acids in 
the inserted gaps in the alignment. N-terminal as well as C-terminal truncations are discarded. 
For alignments where the alignment length (Aligned + Gaps) is shorter than 80 amino acid 
residues, sequence percent identity should be recalculated to an 80-mer window. 
• For further development, more research is required to reveal if there are more favourable 
alternatives for assessing sequence similarity than sequence identity. Complementary methods 
could also be considered to further ensure absence of similarity to known allergens. For 
example, several web servers that rely on novel principles (based on motifs and peptides 
specific to allergens) have shown to be highly specific without loosing in sensitivity. When 
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novel bioinformatics methods are proposed, they should preferably be compared with other 
methods by means of adequate performance estimation procedures using the same datasets.  
 
3.12.3. Future bioinformatics methodology 
 
Conclusions 
Even though epitope prediction algorithms may add information as a part of an in silico weight of 
evidence, no reports on performance studies on specificity and sensitivity in terms of allergens have 
been presented. At the present time, B-cell epitope prediction is seemingly not yet suitable for risk 
assessment. Moreover, even though accurate T cell prediction algorithms may identify potentially 
immunogenic peptides, they are currently not directed to allergic sensitisation, specifically. Therefore, 
T-cell epitope prediction may be more suitable for assessment of immunogenicity, whereas the 
predictive value for allergic sensitisation is limited. However, in combination with cellular based tests, 
T cell epitope prediction may hold prospects for development to usefulness for immunogenicity 
assessment. 3D motifs are likely to hold information of higher relevance to IgE-cross-reactivity, 
compared with linear motifs. Gradually increasing numbers of structurally determined allergens in 
combination with advanced algorithms for structure prediction should enable searches for such 
structural motifs. There is not yet any report on thoroughly evaluated protocols for measuring 
similarity to known allergens on the 3-dimensional level. Algorithms to predict epitopes or structural 
motifs of importance to allergenicity/IgE-cross-reactivity need further evaluation before these may be 
recommended for risk assessment.  
 
Recommendations 
• Future work should focus on the completion of databases with information on 3-dimensional 
conformation of the allergens and on the development/validation of relevant algorithms to 
identify structural homology with T cell epitopes. Since recent studies suggest alternative 
similarity criteria to the 35% identity for assessing the sequence alignment to an allergen, this 
needs to be further evaluated. 
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3.13 Appendix 
 
The following tables list the main websites/databases that were available (and consulted) during the preparation of the scientific opinion, but some of them (as 
indicated with a *) were no longer available at the moment of the publication of the opinion.  
 
Table I: Allergen online databases 
 
Database URL Type of  
allergens 
Clinical 
information 
Sequence 
information 
Structural 
information 
Epitopes Domain 
information 
Last update 
IUIS Allergen 
Nomenclature Sub-
Committee 1 
http://www.allergen.org/Allergen.aspx All No Yes Accession names to 
external website 
No No On regular 
basis  
2009-05-27 
AllergenOnline 
(FARRP)2   
http://www.allergenonline.org All Links to 
external 
website 
Links to external 
website 
No No No Yearly 
version 10.0 
2010-01 
IMGT allergen page  http://imgt.cines.fr/textes/IMGTeducation/IMGTle
xique/A/AllergensBiochemicalData.html 
Food No Accession 
names to 
external website 
Accession names to 
external website 
No No 2007-02-13 
The Allergen Database 
(CSL)9 
http://allergen.csl.gov.uk 
 
All No Links to external 
website 
No No No Not stated 
Allergen Database for 
Food Safety (ADFS) 3 
http://allergen.nihs.go.jp/ADFS/  
 
All No Links to external 
website 
Links to external 
website 
Yes Links to 
external 
website 
2009-03-10 
Bioinformatics for 
Food Safety (BIFS) 4 
http://www.iit.edu/~sgendel/fa.htm * All No Links to external 
website 
No No No Not stated 
The InformAll 
Database 
http://foodallergens.ifr.ac.uk/ Food Yes Links to external 
website 
Links to external 
website 
Yes Links to 
external 
website 
2006-10-18 
Allergome 5 http://www.allergome.org All Yes Yes + links  to 
external website 
Links to external 
website 
No Links to 
external 
website 
On regular 
basis  
2009-06-30 
ALLERDB 6 http://research.i2r.a-
star.edu.sg/Templar/DB/Allergen/ * 
All No Yes + links  to 
external website 
Links to external 
website 
No Links to 
external 
website 
Not stated 
Structural Database of 
Allergenic Proteins 
(SDAP) 7 
http://fermi.utmb.edu/SDAP/sdap_src.html 
 
All No Links to external 
website 
Yes + links  to 
external website 
Yes Links to 
external 
website 
2009-06-25 
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AllerMatch 8 http://www.allermatch.org/ All No Links to external 
website 
Links to external 
website 
No No 2007-12-21 
Allfam database 9 http://www.meduniwien.ac.at/allergens/allfam/ All No Links to external 
website 
Links to external 
website 
No Yes 2009-05-11 
Allergen ATLAS10 http://tiger.dbs.nus.edu.sg/ATLAS/ All No Links to external 
website 
Links to external 
website 
Yes Yes Not stated 
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Table II: Studies assessing both sensitivity and SwissProt estimation  
Study Method 
Sensitivity 
(%) 
SwissProt estimate 
(%) 
Stadler and Stadler 1 Similarity to generated motifs (MEME) 86,2 4,0 
Stadler and Stadler 1 
Alignment 35% over 80 aa OR peptide 
match (length = 6) 97,0 67,3 
Stadler and Stadler 1 
Alignment 35% over 80 aa OR peptide 
match (length = 8) 92,2 8,0 
Li et al 2 
Similarity to generated motifs (wavelet 
transform) 70,6 3,5 
Soeria-Atmadja et al 3 Similarity to selected peptides (FLAPs) 86,6 1,5 
Soeria-Atmadja et al 3 Similarity to selected peptides (ARPs) 83,2 3,1 
Soeria-Atmadja et al 3 
Alignment 35% over 80 aa OR peptide 
match (length = 6) 96,6 75,4 
Soeria-Atmadja et al 3 
Alignment 35% over 80 aa OR peptide 
match (length = 8) 88,9 6,2 
Saha and Raghava 4  Amino acid composition 84,2 43,1* 
Saha and Raghava 4  Dipeptide composition 84,8 38,1* 
Saha and Raghava 4  Similarity to selected peptides (ARPs) 66,6 2,0* 
Saha and Raghava 4  Similarity to generated motifs (MEME) 12,4 3,4* 
Saha and Raghava 4  Similarity to IgE epitopes 10,8 1,8* 
Cui et al 5 Physico-chemical properties 93,0 2,9 
Kong et al 6 
Similarity to combination of motifs 
(MEME) 75,3 3,8 
 
 
1. Stadler MB and Stadler BM (2003). Allergenicity prediction by protein sequence. FASEB 
Journal, 17, 1141-3. 
2. Li KB, Issac P and Krishnan A (2004). Predicting allergenic proteins using wavelet transform. 
Bioinformatics, 20, 2572-8. 
3. Soeria-Atmadja D, Lundell T, Gustafsson MG and Hammerling U (2006). Computational 
detection of allergenic proteins attains a new level of accuracy with in silico variable-length 
peptide extraction and machine learning. Nucleic Acids Res, 34, 3779-93. 
4. Saha S and Raghava GP (2006). AlgPred: prediction of allergenic proteins and mapping of 
IgE epitopes. Nucleic Acids Res, 34, W202-9. 
5. Cui J, Han LY, Li H, Ung CY, Tang ZQ, Zheng CJ, Cao ZW and Chen YZ (2007). Computer 
prediction of allergen proteins from sequence-derived protein structural and physicochemical 
properties. Molecular Immunology, 44, 514-20. 
6. Kong W, Tan TS, Tham L and Choo KW (2007). Improved prediction of allergenicity by 
combination of multiple sequence motifs. In Silico Biol, 7, 77-86. 
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Table III: FAO/WHO-based bioinformatics risk assessment tools  
Webtool URL Peptide 
match 
Alignment 
AllerPredict1 http://research.i2r.astar.edu.sg/Templar/DB/Allergen/Predict/Predict.html * Yes (length = 
6) 
BLAST 
AllerTool2 http://research.i2r.a-star.edu.sg/AllerTool/ * Yes (length = 
6) 
BLAST 
Structural Database 
of Allergenic 
Proteins (SDAP) 3 
http://fermi.utmb.edu/SDAP/sdap_who.html Yes (length = 
userdefined) 
FASTA or 
FASTA 
sliding 
window 
AllerMatch4 http://www.allermatch.org/ Yes (length = 
userdefined) 
FASTA or 
FASTA 
sliding 
window 
Allergen Database 
for Food Safety 
(ADFS) 5 
http://allergen.nihs.go.jp/ADFS/ Yes (length = 
userdefined) 
FASTA 
The Allergen 
Database at the 
Central Science 
Laboratory (CSL) 
http://allergen.csl.gov.uk No FASTA 
AllergenOnline 
(FARRP) 6 
http://www.allergenonline.org Yes (length = 
8) 
FASTA or 
FASTA 
sliding 
window 
Allergome 7 http://www.allergome.org No BLAST 
Allergen ATLAS 8 http://tiger.dbs.nus.edu.sg/ATLAS/ Yes (length = 
userdefined) 
BLAST or 
BLAST 
sliding 
window 
1. Zhang ZH, Tan SCC, Koh JLY, Falus A and Brusic V (2006). ALLERDB database and integrated bloinformatic tools for assessment of allergenicity 
and allergic cross-reactivity. Cellular Immunology, 244, 90-96. 
2. Zhang ZH, Koh JL, Zhang GL, Choo KH, Tammi MT and Tong JC (2007). AllerTool: a web server for predicting allergenicity and allergic cross-
reactivity in proteins. Bioinformatics, 23, 504-6. 
3. Ivanciuc O, Schein CH and Braun W (2003). SDAP: database and computational tools for allergenic proteins. Nucleic Acids Res, 31, 359-62. 
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4. Fiers MW, Kleter GA, Nijland H, Peijnenburg AA, Nap JP and van Ham RC (2004). Allermatch, a webtool for the prediction of potential 
allergenicity according to current FAO/WHO Codex alimentarius guidelines. BMC Bioinformatics, 5, 133. 
5. Nakamura R, Teshima R, Takagi K and Sawada J (2005). [Development of Allergen Database for Food Safety (ADFS): an integrated database to 
search allergens and predict allergenicity]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku, 32-6. 
6. Hileman RE, Silvanovich A, Goodman RE, Rice EA, Holleschak G, Astwood JD and Hefle SL (2002). Bioinformatic methods for allergenicity 
assessment using a comprehensive allergen database. International Archives of Allergy and Immunology, 128, 280-91. 
7. Mari A, Scala E, Palazzo P, Ridolfi S, Zennaro D and Carabella G (2006). Bioinformatics applied to allergy: Allergen databases, from collecting 
sequence information to data integration. The Allergome platform as a model. Cellular Immunology, 244, 97-100. 
8. Tong JC, Lim SJ, Muh HC, Chew FT and Tammi MT (2009) Allergen Atlas: a comprehensive knowledge center and analysis resource for allergen 
information. Bioinformatics, 25, 979-80. 
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Table IV: Alternatives or complements to FAO/WHO-based bioinformatics risk assessment tools  
Webtool Underlying algorithm URL 
WebAllergen 1 Similarity to generated 
motifs (wavelet transform) 
http://weballergen.bii.a-star.edu.sg/ * 
AlgPred 2 Similarity to generated 
motifs (MEME) 
http://www.imtech.res.in/raghava/algpred/  
AlgPred 2 Similarity to selected 
peptides (ARPs) 
http://www.imtech.res.in/raghava/algpred/ 
AlgPred 2 Similarity to experimentally 
verified IgE epitopes 
http://www.imtech.res.in/raghava/algpred/ 
AlgPred 2 Supervised learning based 
on either amino acid or 
dipeptide composition 
http://www.imtech.res.in/raghava/algpred/ 
AllerTool 3 Supervised learning based 
on amino acid composition 
http://research.i2r.a-star.edu.sg/AllerTool/ * 
EVALLER (2.0) 4, 5 Supervised learning  based 
on similarity to selected 
peptides (FLAPs) 
http://bioinformatics.bmc.uu.se/perl/run?script=evaller&standalone=1  
ADFS 6 Similarity to generated 
motifs (MEME) 
http://allergen.nihs.go.jp/ADFS/ 
APPEL 7 Supervised learning based 
on global physcio-chemical 
descriptions of proteins  
http://jing.cz3.nus.edu.sg/cgi-bin/APPEL  
1. Riaz T, Hor HL, Krishnan A, Tang F and Li KB (2005). WebAllergen: a web server for predicting allergenic proteins. Bioinformatics, 21, 2570-1. 
2. Saha S and Raghava GP (2006) AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res, 34, W202-9. 
3. Zhang ZH, Koh JL, Zhang GL, Choo KH, Tammi MT and Tong JC (2007). AllerTool: a web server for predicting allergenicity and allergic cross-
reactivity in proteins. Bioinformatics, 23, 504-6. 
4. Barrio AM, Soeria-Atmadja D, Nister A, Gustafsson MG, Hammerling U and Bongcam-Rudloff E (2007). EVALLER: a web server for in silico 
assessment of potential protein allergenicity. Nucleic Acids Research, 35, W694-W700. 
5. Bongcam-Rudloff E, Edsgärd D, Barrio AM, Soeria-Atmadja D, Gustafsson M and Hammerling U (2007). A guide to EVALLER (2.0) web server: A 
new tool for in silico testing of protein allergenicity. EMBnet.news, 13, 32-37. 
6. Nakamura R, Teshima R, Takagi K and Sawada J (2005) [Development of Allergen Database for Food Safety (ADFS): an integrated database to 
search allergens and predict allergenicity]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku, 32-6. 
7. Cui J, Han LY, Li H, Ung CY, Tang ZQ, Zheng CJ, Cao ZW and Chen YZ (2007). Computer prediction of allergen proteins from sequence-derived 
protein structural and physicochemical properties. Molecular Immunology, 44, 514-20. 
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ANNEX 4. ASSESSMENT OF ALLERGENICITY OF NEWLY EXPRESSED 
PROTEINS IN GMOS USING IN VITRO AND CELL-BASED TESTS   
 
 
4.1. Introduction 
 
The guidelines for food safety assessment of GMOs published by Codex Alimentarius (2003) 
recommend various in vitro methods as part of the "weight-of-evidence" approach for assessing the 
potential allergenicity.  These methods include the following tests with newly expressed proteins: 
• The degradation of the newly expressed proteins by the proteolytic enzyme pepsin in defined 
conditions (referred to as "pepsin resistance test") 
• The binding by newly expressed proteins of IgE-containing sera from patients who are 
allergic towards an allergen of interest, such as: 
o the source of the transgene, if this happens to be an allergen, or  
o an allergen with which the newly expressed protein shows a relevant degree of 
structural similarity. 
 
In the following sections, current practice and recently acquired knowledge are considered, and further 
directions are discussed in this area of allergenicity assessment. 
 
Commonly, given the low expression levels of transgenic proteins in genetically modified crops, 
recombinant equivalents of these proteins are produced in microorganisms, such as Escherichia coli, 
which are amenable to the production of sufficient quantities. It is this protein which is usually used 
for in vitro tests.  Codex Alimentarius' and EFSA GMO Panel's guidance requires that these proteins 
be equivalent to that expressed in the genetically modified crop.  This usually entails a comparison 
between the two different proteins with regard to molecular mass (e.g. electrophoretic mobility, mass 
spectrometry), glycosylation, immunoreactivity (e.g. Western blot), and enzymatic or biological 
activity. 
 
In this Annex, a review of current knowledge and use of these methodologies is presented, as well as 
other potentially valuable tools.  In particular, cell-based assays that employ either cells isolated from 
human or animal tissues or propagated from immortal cell lines appear promising. 
 
4.2. Resistance of proteins to in vitro digestion by proteases 
 
4.2.1. Background 
 
Two approaches have been taken to studying the digestibility of proteins in relation to allergenic 
potential. The first uses conditions that are often far from physiological and give a biochemical 
measure of a protein’s overall physiocochemical stability (see Annex 2.3.1).  One example of this is 
the in vitro digestibility test proposed by Astwood and co-workers (1996) as a method that could be 
used to predict likely allergenic potential of a newly expressed protein based on its resistance towards 
degradation by pepsin.  The rationale underlying the use of pepsin resistance tests performed under 
standardised conditions, as proposed by FAO/WHO (2001) and Codex Alimentarius (2003), is that for 
some known food allergens, there appeared to be a correlation, even if no direct causal relationship, 
between their resistance to pepsin and their allergenic properties.  A second approach seeks to discover 
the role that simulated, physiologically relevant digestion plays in the mechanisms of oral 
sensitisation. Such studies characterise the repertoire of digestion products to which the gut mucosal 
immune system is exposed. 
 
4.2.2. Pepsin resistance test 
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As mentioned above, incubations of transgenic proteins in a solution containing the proteolytic 
enzyme pepsin, which occurs naturally in the stomach of man and animals, are commonly used to test 
the resistance of these proteins against degradation.  Usually, samples from the incubation are taken 
after different time intervals and analysed for the integrity of the test protein.  The rationale underlying 
the pepsin resistance test is that for some known food allergens, there appears to be a correlation, but 
no direct causal relationship, between their resistance to pepsin and their allergenic properties.  The 
outcomes of the pepsin resistance tests, rather than seeking to model physiological processes, can be 
interpreted as a biological measure of protein stability.  This is because aspartyl proteases, such as 
pepsin, require a certain degree of flexibility in their substrates as they act on six to eight residue 
sections of a protein substrate, which must lie across their active site in an extended conformation. 
Pepsinolysis tests employ conditions which are far from physiological (Astwood et al., 1996) and are 
based on a standard “simulated gastric fluid” employed for pre-clinical testing of pharmaceuticals, 
such as described by the US Pharmacopoeia (1995). It is widely used, for example, to measure the rate 
of dissolution of tablets and other solid forms containing orally administered pharmaceuticals.  The 
ability of the pepsin resistance test is to distinguish between allergenic and non-allergenic proteins was 
initially described by Astwood and co-workers (1996) and whilst not completely confirmed by 
subsequent studies (Fu, 2002; Fu et al., 2002), it is still considered to have some utility when used in 
integrative risk assessment (EFSA, 2006, 2009). 
 
Besides “simulated gastric fluid", supplementary models that are used for testing degradation of 
potentially allergenic proteins include "simulated intestinal fluid" and isolated ruminal fluid.  
Sequential treatments with the stomach protease pepsin and the duodenal proteases trypsin and 
chymotrypsin may be applied, such as it has been done by Mouécoucou et al. (2004).  Such models do 
also have applications outside the field of allergenicity research.  For example, sequential incubations 
with ruminal fluid and pepsin solutions are widely used as an in vitro model for the digestibility of dry 
matter and organic matter of animal feeds (Tilley and Terry, 1963). 
 
Such in vitro models have been employed in allergenicity testing in a limited manner, focusing on 
purified target transgenic proteins and known allergens, incubated with the proteases at a gross excess 
of enzyme to target protein compared with those that might be encountered in vivo.  Thus, many 
protocols have employed pepsin: substrate ratios in the range 1/5 – 1/10 (Astwood et al., 1996; Fu et 
al., 2002).  Such ratios may be considered far in excess of those likely to be found in the stomach.  
Pepsin secretion has been estimated between 20 – 30 kUnits of enzyme activity / 24h at 37ºC in adults 
(Documenta Geigy, 1973). A typical adult dietary intake of protein around 75g / 24h gives an 
indication that approximately 1 unit pepsin is secreted for every 3 mg of protein consumed.  This 
compares with approximately 1 unit pepsin/μg protein used in the pepsin resistance assays.  Usually, 
the pepsin resistance assays monitor the integrity of the test protein during the time period of digestion 
using SDS-PAGE (Thomas et al., 2004), Western blotting, or, less commonly, enzymatic or other 
indicators of biological activity.   
 
4.2.3. Conduct of pepsin resistance tests 
 
The report of the expert consultation convened by FAO/WHO (2001) on potential allergenicity of 
transgenic foods provided detailed directions for the conduct of the pepsin resistance test.  These 
details pertained to, for example, the conditions of protein incubation in pepsin solution (e.g. pH 2) 
and subsequent electrophoresis and staining or blotting of protein bands in the electrophoresis gel.  
Nonetheless, the guidelines of the Codex Alimentarius Commission (2003) on the in vitro digestibility 
test employing proteolytic enzyme such as pepsin were of a more general nature and mentioned the 
need for consistent and well validated protocols (Herman et al., 2006).  Various studies have sought to 
ameliorate current practice by either standardisation or incorporation of additional features.  These 
include studies focusing on the pepsin e.g. pepsin: protein ratio, pH of incubation mixture, purity of 
pepsin etc.  For example, ILSI Health and Environmental Science Institute has undertaken a ring test, 
in which allergenic and non-allergenic proteins were submitted to digestion in simulated gastric fluid 
at two pH values, i.e. pH 1.2 and 2.0, and at a pepsin: protein ratio of 10 units per microgram of test 
protein, corresponding to a pepsin:protein weight ratio of 3/1 (Thomas et al., 2004).  Samples taken in 
Annex 4. In vitro and cell-based tests
 
 
114 EFSA Journal 2010; 8(7):1700 
time series up to 60 minutes after the incubation integrity were analysed by SDS-PAGE.  An 
agreement was obtained between laboratories regarding the time before disappearance of whole 
proteins, in particular at pH 1.2.  Various conditions that varied between laboratories, such as type of 
electrophoresis gel and fixation technique, influenced the quality of the results, such as the detection 
of peptide fragments (Thomas et al., 2004).  
 
Two other studies have been carried out on the kinetics of the degradation of transgenic Cry proteins 
from Bacillus thuringiensis and two labeled model proteins (Herman et al., 2005; Herman et al., 
2003).  Their results show that, while experimental conditions and velocities of degradation may differ 
between separate experiments, the kinetics follow first-order kinetic behavior.  In addition, half-lives 
of these proteins, e.g. the time point were 50% has been degraded, can serve as a good parameter for 
comparison between proteins and results from different experiments. 
 
4.2.4. Models for gastrointestinal digestion of allergenic proteins 
 
Detailed features of stomach function have been revealed recently by modern imaging and 
computational techniques with respect to the transport of fluids and solids within the stomach under 
influence of gastrointestinal muscle contractions and movement of solids within the stomach.  
Calculations thus show that with the intake of foods that have a high content of fluid, the passage time 
for a dissolved compound to the duodenum can be as short as 10 minutes due to the presence of a fluid 
“stomach road” within the mixed stomach contents, whilst for solid particles, the passage can be in the 
order of hours (Pal et al., 2007).   
 
Technological innovations have allowed for the continuous non-invasive monitoring of gastric pH 
through the use of capsules bound to the gastric wall with nylon suture threads and containing 
sensitive pH meters and radio transmitters logging the measured data to external receivers.  This has 
been used to monitor the intra-gastric pH in non-human primates and it was found that whilst the pH 
in the fasted stomach is indeed around pH 2, this rises to a peak above pH 4 (median around pH 5) 
within 30 minutes after a meal and gradually returns within several hours to the fasted state pH (Chen 
et al., 2008).  This pattern is similar to that previously observed in humans.  At present, we have little 
or no information on the patterns in infants and elderly people with probably less acidic conditions in 
the fasted state.  Such fluctuations and differences in intragastric pH are especially important given the 
pH-dependent nature of pepsinolysis (Christensen, 1955) and can affect digestion of allergens such as 
those from kiwi fruit (Lucas et al., 2008). It has long been known that pepsin specificity, as 
determined using model peptide substrates, changes markedly as a function of pH (Cornish-Bowden 
and Knowles, 1969). 
 
Various recent publications indicate that proteins that are commonly degraded in the stomach may 
actually survive passage through the stomach and become allergenic in patients that use medicines that 
impair the action of pepsin as a consequence of raising gastric pH. For example, intra-gastric pH is 
raised above 2.5 in peptic ulcer patients following acid-suppression medication and newborns and may 
reduce or stop the digestion of proteins by pepsin (Untersmayr and Jensen-Jarolim, 2008; Untersmayr 
et al., 2005; Untersmayr et al., 2007; Yoshino et al., 2004).  This phenomenon in newborns is 
accounted for by the fact that their stomachs are not completely functional yet, as has also been 
discussed in section 2.6, which provides a possible explanation for increased occurrence of allergies in 
children that disappear in later life stages.  Conversely, this may also apply to aged people with 
impaired stomach function due to ageing (Untersmayr et al., 2008). 
 
A fraction of the proteins and peptide fragments that sustain during digestion can subsequently be 
absorbed from the intestine, as has been demonstrated by the presence of small amounts of orally 
ingested stable proteins in the serum of human volunteers and experimental animals (Untersmayr et 
al., 2007; Yamada et al., 2006).  A number of factors can influence the uptake of proteins and peptides 
from the intestine, such as food constituents (surfactants, alcohol), physiological stress and intestinal 
diseases (Thomas et al., 2007). 
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The interaction of a given protein present within consumed foods with the host’s immune system not 
only depends on the degradation of the protein during passage but also upon the uptake from the 
gastrointestinal tract.  Various mechanisms exist by which proteins and other antigens are taken up 
from the intestines and subsequently processed and exposed.  These mechanisms include the uptake by 
M cells in Peyer patches, dendritic cells in the epithelial cell layer with protrusions in contact with the 
intestinal content, and uptake through endocytosis by epithelial cells (reviewed by Chehade and 
Mayer, 2005).  Despite the fact that many proteins are degraded to short peptides by the action of 
intestinal exo- and endo-proteases before uptake and metabolism, the uptake of intact forms of specific 
proteins from the intestinal tract into body fluids and tissues has been observed, e.g. bovine lactoferrin 
by mice as reported by Fischer et al., (2007).  The intestinal uptake of intact proteins is probably 
mediated by binding of these proteins to receptors on intestinal cells, such as M cells (Fischer et al., 
2007).  Also endocytosis of intact proteins by epithelial cells can be mediated by receptor-binding, 
such as has been observed for soybean ferritin on the apical membrane of human epithelial Caco-2 
cells in vitro (San Martin et al., 2008).  The relationship between stability to simulated digestion and 
uptake in vivo in animal models has been demonstrated for the α-amylase inhibitor allergens from rice 
(Yamada et al., 2006). 
 
The considerations above highlight the need to consider the stability of protein fragments formed 
under conditions of digestion besides the stability of the intact protein.  Of particular interest are 
peptides of which the size would be sufficient to allow containing at least two epitopes for binding by 
multiple IgE-antibodies and their cross-linking to receptors on the surface of mast cells, eventually 
leading to release of histamine and other elicitors of allergic reactions.  For example, Honma and co-
workers (1996) have observed that 20-mer peptides derived from the egg allergen ovalbumin are still 
able to elicit histamine release from basophils. Another possibility is that peptides that are too small to 
be allergenic by themselves may associate to form aggregates of sufficient size to trigger an allergic 
reaction. It has been well documented in the literature pertaining to preparation of hydrolysates of 
many protein preparations, including food ingredients such as whey, casein or gluten hydrolysates, 
that the resulting peptides, whilst often of low molecular weight, are able to assemble into much larger 
aggregates.  That such aggregates can form following gastrointestinal proteolysis is being observed, 
with, for example, large aggregates of casein peptides forming following pepsinolysis (Qi et al., 2007). 
The formation of such aggregates may explain why even readily digested allergens, such as Ara h 1, 
can retain their capacity to elicit histamine release after extensive digestion (Eiwegger et al., 2006) and 
are thought to play a role in the residual allergenicity of some extensively hydrolysed infant formulas 
(Rosendal and Barkholt, 2000). 
 
4.2.4.1. In vitro models for gastrointestinal digestion 
 
In order to sensitise an individual via the gastrointestinal tract, an allergen must have properties which 
preserve its structure from degradation (such as resistance to low pH, bile salts and proteolysis), thus 
allowing enough allergen to survive in a sufficiently intact form to be taken up by the gut and sensitise 
the mucosal immune system (Mills et al., 2004; Taylor and Hefle, 2001).  Studies investigating how 
digestion affects the integrity and immunological activity of allergens in this context use more 
physiologically relevant models of digestion.  These models need to take into account a range of other 
factors which affect the gastro-intestinal passage of proteins besides proteolysis.  A number of factors 
can namely influence the uptake of proteins and peptides from the intestine, such as food constituents 
(surfactants, alcohol) and physiological stress (Thomas et al., 2007).  Factors such as intra-gastric pH 
also need to be taken into account.  In order to investigate the role of stability to gastroduodenal 
digestion on allergenic potential, model systems which mimic physiological conditions have been 
developed using appropriate levels of proteases and including biosurfactants such as vesicular 
phosphatiduyl choline secreted by the gastric mucosa and bile salts.  This system has been used to 
study the stability to digestion of a number of food allergens including the 2S albumin allergen from 
Brazil nut and sesame (Moreno et al., 2005b; Moreno et al., 2005c), the LTP allergen from grape 
(Vassilopoulou et al., 2006), peanut Ara h 1 (Eiwegger et al., 2006), the allergenic thaumatin-like 
protein from kiwi fruit (Bublin et al., 2008) and the milk allergens α-lactalbumin, β-lactoglobulin and 
β-casein (Macierzanka et al., 2009; Moreno et al., 2005a).  This model system has undergone a multi-
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laboratory trial through the FP VI EU funded EuroPrevall project (Mandalari et al., 2009). It is 
noteworthy that the fate of a protein during an in vitro digestibility test would be likely to change if the 
test protein is present as a purified protein in solution in a buffer or included in a complex food matrix. 
 
The gastrointestinal tract also involves physical mixing of foods with progressive addition of digestive 
secretions of which several physical/mechanical modeling approaches have been described (Mitea et 
al., 2008a; Wickham and Faulks, 2007).  Such “Dynamic models” may or may not remove the 
products of digestion but have the advantage of mimicking the physical processing and temporal 
changes that actually occur in the gut lumen in vivo.  This is particularly useful where the physical 
properties of the digested food changes over time, with regards for example viscosity and particle size 
and can take account of the formation of unstirred layers and the formation of colloidal phases in the 
digesta. They are derived from the devices used by the pharmaceutical industry to measure tablet 
dissolution, which can be compared to the stomach emptying rate, providing an indicator of 
bioavailability (Galia et al., 1998). These approaches can be important for testing the "bioequivalence" 
of pharmaceutical preparations.  They are usually performed in special apparatus filled with fluids 
such as simulated gastric fluid. These apparatus contain devices, such as paddles or moving 
concentrated rings that mimic the physical forces exerted upon these solid forms but it is becoming 
acknowledged that they provide only a primitive simulation of the in vivo processes. 
 
There are currently two types of dynamic model available which haven extensively used to study food 
digestion.  The TNO Gastro-Intestinal Model (TIM) model takes into account the mixing of 
gastrointestinal contents under influence of peristaltic muscle contractions and is composed of various 
sequentially linked compartments representing the stomach, duodenum, jejunum, and ileum, lined 
with membranes.  Enzyme solutions representing the in vivo gastrointestinal fluids are added to the 
pertinent compartments.  The uptake from the contents of this artificial gut is measured by their 
presence of diffusates through the membranes of each compartment.  A food sample is introduced and 
subsequently samples are taken at various stages of the model at specific time points (Mitea et al., 
2008a).  It is cautioned, though, that this model focuses on passive diffusion and that active uptake by 
intestinal tissues is not accounted for in this model (Yoo and Chen, 2006).   
 
A second model is built on a modular design of three stages (Wickham and Faulks, 2007).  The first 
part simulates the main body of the stomach, mimicking the mixing dynamics, diffusion profiles of 
both acid and enzymes and emptying cycles measured within the main body of the human stomach.  
This is followed by a unique emptying routine into a second module simulating the antrum (the lower 
part of the stomach).  Here the digesta are subjected to high shear (as measured using magnetic 
resonance imaging), forcing mechanical breakdown of the food structure.  The final stage of the model 
provides a simulation of the small intestine, with integrated intestinal mixing dynamics and diffusion 
with the addition of bicarbonate, phospholipids, bile, and digestive enzymes simulating the complex 
environment of the small intestine.  Whilst not applicable to studies using purified allergens, such 
physical models are highly relevant to the study of allergens within the food matrix. 
 
4.2.5. Interpretation of in vitro protein resistance test outcomes 
 
A key aspect in the interpretation of the results of digestion studies is whether they relate to the pepsin 
resistance test or investigations into the role of physiological gastrointestinal digestion and the 
allergenicity of foods.  With regard to the former, the resistance of a food protein to degradation by 
proteases has been proposed as an indicator for enhanced likelihood of allergenicity (Astwood et al., 
1996).  However, subsequent studies have indicated that the relationship between resistance to pepsin 
and allergenic potential is not clear-cut with some notable allergens being susceptible to digestion 
under certain conditions (reviewed by Bannon et al., 2003; Fu et al., 2002), whilst several food 
proteins not known to be allergens show resistance to degradation (Herman et al., 2007).  However, 
the lack of a standardised protocol regarding differences in the pH of the assay, enzymes to protein 
ratios, target protein purity and method of analysis may cause the variability in these digestibility 
studies and makes interpretation of the results from digestion studies difficult to interpret (Thomas et 
al., 2004). 
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A much larger body of work relates to studies seeking to define the relationship between 
gastrointestinal digestion and the mechanisms of allergy regarding both sensitisation and elicitation 
potential. Using more physiologically-relevant digestion protocols, many researchers have shown that 
peptide fragments derived from the degradation of allergens may still be reactive with IgE from 
patients' sera.  This has been demonstrated, for example, with hen egg's ovomucoid exposed to 
simulated gastric fluid (Takagi et al., 2005) and grape-derived lipid transfer protein sequentially 
exposed to simulated gastric and intestinal fluids (Vassilopoulou et al., 2006).  Other studies indicate 
that known IgE epitopes can sustain digestion in the form of such large fragments, such as Ber e 1, the 
allergenic 2S albumin from Brazil nut.  A major degradation product of Ber e 1 is composed of three 
peptide fragments bound by disulphide bridges (Moreno et al., 2005c).  However, there are also 
studies which indicate that some allergens, such as the major peanut allergen Ara h 1 and the avocado 
allergen Prs a 1, retain their allergenic activity with regards elicitation potential even after extensive 
degradation (Diaz-Perales et al., 2003; Eiwegger et al., 2006).  Allergens associated with Oral Allergy 
Syndrome, such as the apple allergen Mal d 1, are generally liable to gastroduodenal digestion and 
whilst the IgE reactivity of such proteins is destroyed, it appears that T-cell reactive peptides remain 
(Schimek et al., 2005).  The differential resistance of the Bet-v-1- and lipid-transfer-protein- (LTP) 
types of food allergens has been well documented in foods such as apple and hazelnut (Akkerdaas et 
al., 2005) and is now being extended to fruits such as kiwi (Lucas et al., 2008), possibly relating to the 
differential susceptibility of kiwi Bet v 1 homologues and allergens such as the thaumatin-like proteins 
and actinidin, which are highly resistant to digestion (Bublin et al., 2008). 
 
Such differences have led some, such as Jiang and co-workers (2007), to propose that it is possible to 
distinguish between food allergens that sensitise through the oral route and those that do not sensitise 
through the oral route, as is the case for pollen-food and latex-fruit cross-reactive allergens.  These 
authors conclude that most of the allergens with a comparatively large size of predicted peptide 
fragments after digestion belong to the allergens that sensitise through the oral route.  Interestingly, 
Lucas and co-workers (2008) found that kiwi-allergic patients that show either Oral Allergy Syndrome 
or systemic allergies also react differently, i.e. the first with pepsin-sensitive proteins and the latter 
with resistant proteins.  Others, such as Moreno (2007), suggest that digestibility should be considered 
in conjunction with the abundance of the protein in a food, with a higher abundance indicating 
increased likelihood that some of the protein will escape from intestinal degradation. 
 
For the interpretation of the results, it should also be considered that various experimental conditions 
have their influence on the resistance of proteins towards physiological measures of digestion: 
 pH: similar to the in vivo conditions in peptic ulcer patients on medication and newborns, 
raising the pH of simulated gastric fluid above pH 2.5 may reduce or nullify the digestion of 
proteins (Lucas et al., 2008; Untersmayr et al., 2005; Yoshino et al., 2004).  
 The ratio between pepsin and protein can substantially affect the resistance of the intact 
protein and derived fragments.  Takagi et al. (2005), for example, incubated hen egg white 
ovomucoid with pepsin at 10, 1 and 0.1 units of pepsin per microgram of ovomucoid.  These 
authors observed that the stability of part of the intact protein and derived fragments, 
including IgE-binding ones, increased substantially to more than 30 minutes at the lower 
incubation ratios of 1 and 0.1 units of pepsin per microgram of ovomucoid (Takagi et al., 
2005). 
 Food processing and the food matrix will both affect the susceptibility of proteins to digestion, 
their release and presentation to the immune system and hence their allergenic potential.  Pre-
heating proteins, as a model for food processing prior to consumption may also influence 
digestibility (Takagi et al., 2003).   In addition, the conditions of heating may also influence 
the presence of allergenic proteins in the consumed end product, such as it has been observed 
in boiled versus roasted peanut with less allergens in the first caused by extraction into the 
boiling solution (Mondoulet et al., 2005).  The matrix can influences digestibility.  For 
example, when presented in an emulsified form, large polypeptide fragments of casein, which 
are normally rapidly broken down to small peptides, can resist gastric digestion (Macierzanka 
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et al., 2009).  Other food components, such as polysaccharides may also modulate digestion 
(reviewed by Moreno et al. (2007); see also Annex 2.7.4 on food processing and the matrix). 
 
Codex Alimentarius and EFSA guidance acknowledge that digestibility cannot be completely 
predictive.  As discussed within this Annex, many food allergens that sensitise through the oral route 
display stability to digestive conditions as demonstrated by the intactness of the protein or derived 
peptide fragments under these conditions. This stability to in-vitro digestibility should therefore still be 
considered a risk factor but not in isolation, i.e. the outcomes of the digestibility assays should be 
regarded in conjunction with the results of other assays and the other properties of the protein under 
consideration. 
 
4.3. IgE binding tests 
 
Various tests for the binding of IgE-containing sera from allergy patients to a test protein are available, 
and their application for the assessment of potential allergenicity of proteins has been reviewed by 
Goodman and Leach (2004) and by Goodman (2008).  This in some cases may be a variation on the 
clinically exerted routine assays of testing IgE binding to standardised allergens as a tool for diagnosis 
of allergies towards these specific allergens.  The use of binding tests in which patients' serum is 
incubated with allergens and the IgE antibodies bound by allergen subsequently measured is provided 
by various suppliers as an automated assay.  These tests may also include positive controls consisting 
of well-characterised, IgE-containing sera from allergy patients.  Less-characterised sera used, for 
example, in experimental research may also show weak reactions due to the presence of low-affinity 
antibodies and non-specific binding.  The results of IgE-binding assays provide valuable indications 
for the potential occurrence and intensity of sensitisation to allergens.  However, the presence of IgE 
in some cases may not concur with clinical reactions to allergenic foods (van Ree et al., 2006).  In 
addition, sensitive reactions to foods may occur through non-IgE-mediated mechanisms. 
 
IgE-binding assays require the availability of sera from multiple patients, given the variability in 
specificity and affinity of IgE antibodies between patients allergic to the same allergenic food.  
Specificity towards specific allergenic proteins is important if, for example, the protein to be tested has 
shown similarity to a specific allergenic protein in the bioinformatics-supported comparisons with 
allergens.  In cases of rare allergies, the number of sera that are available may be less than optimal, a 
problem which is also encountered by manufacturers of commercial IgE-detection kits (Hamilton and 
Franklin Adkinson, 2004).  In fact, the OECD's International Co-ordination Group for Biotechnology 
performed a survey among its members regarding the availability of centralised repositories or stocks 
of sera that are medically documented and suitable for testing the allergenicity of foods in 1997 
(OECD, 2002).  It turned out that a number of member states already had such sera banks in place, 
while some others either had non-centralised points where such sera were kept (e.g. companies), or 
none at all.  For the selection of sera, the clinical data of the patients are important.  Patients whose 
sera are used should have a confirmed history of allergic reactions to food allergens (van Ree et al., 
2006).  In addition, care should be taken to avoid non-specific binding to the sorbent on which the 
allergen is coupled, for example by diluting sera containing high levels of IgE. 
 
Based on the abovementioned considerations, the characteristics of the sera should be checked with 
regard to IgE- binding to specific allergenic proteins (e.g. by ELISA and/or immunoblotting), the 
allergic reactions in the patient (case history and recent confirmation clinical tests, including skin prick 
test and double-blind placebo-controlled food challenge), and a sufficiently high IgE titer (yet not 
derived from patients showing broad-spectrum reactivity, such as atopic dermatitis and lupus patients) 
(Ballmer-Weber and Fernandez-Rivas, 2008; Goodman, 2008). 
 
Guidance from FAO/WHO Expert Consultation (2001), the Codex Alimentarius Commission (2003) 
and the EFSA GMO Panel (EFSA, 2006, 2009) discern "specific" and "targeted" serum- screening. 
"Specific" pertains to serum IgE antibodies that are specifically directed towards an allergen. This 
allergen may be the newly expressed protein or an allergen whose structure is sufficiently similar to 
this protein to provoke a cross-reaction with IgE antibodies. It also may be the source of the transgene 
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used in the genetic modification. "Targeted" serum- screening pertains to the use of sera whose IgE are 
directed towards allergens that are broadly related to the source of the transgenic protein.  This 
approach is important to minimise the risk of introducing a transgenic protein that is homologous to an 
“unknown” allergen, i.e. an allergen that is not yet in the database (as still is the case for many 
allergens, for example from moulds, yeasts and invertebrates). 
 
For this kind of serum screening a very restricted definition of the target is practical nor wise. If the 
transgene comes from some mould to which humans are not generally exposed, it is scientifically 
sound and a realistic option to test sera from patients with an allergy to the common allergenic moulds 
and yeasts. A practical advantage of defining the target species in a broad way is that suitable sera are 
(much) more common than sera with IgE reactivity to a very narrowly-defined target species.  
 
Several such cross-reactive allergen clusters have been well described, for example, rubber latex with 
banana, birch with apple and snail with mite and shrimp. This underscores the point that cross-reactive 
allergenic proteins are often not closely taxonomically related. These allergens are usually referred to 
as “pan-allergens”. 
 
Codex Alimentarius states that targeted screening is still in preliminary phase of development. 
However, there is no doubt that cross-reactivity often crosses taxonomical boundaries and that this has 
consequences for allergenicity assessment. The technology to perform this kind of screening is well-
established. 
 
One example of an IgE-binding assay is the Radio Allergosorbent Assay (RAST), in which an allergen 
has been absorbed onto a paper disc.  This disc is incubated with sera, after which the non-bound sera 
is washed off and the bound IgE antibodies detected by subsequent binding with 125I-labeled anti-IgE 
antibodies.  The amount of 125I on the disc, which is an indirect measure for IgE bound to the allergen, 
is measured by its scintillation.  Automated versions of this type of assay are currently on the market, 
which allow for quantitative analysis and which employ standardised allergens absorbed to the discs, 
and in several cases the paper and the radioactive label substituted by alternatives as to finally measure 
an absorbance or fluorescence. 
 
In the case of the testing of a purified novel protein, it can be envisioned that this protein is absorbed 
to the disc and exposed to sera from allergic patients to determine whether it is recognised and bound 
by these sera.  In case any possible changes in the crop's own allergenicity due to genetic modification 
are tested, both discs with whole protein extract from the GM crop and its non-transgenic comparator 
are exposed to the same sera in order to determine whether a change in the reactivity towards the sera 
has occurred.  However the precision of the quantitative determination allowed by the test may not be 
sufficient to evidence differences between the two proteins/extracts.  If two proteins or extracts are to 
be compared, an "inhibition assay" may be thus performed in which the antisera are pre-incubated 
with increasing concentrations of the comparator protein or extract, after which exposure of the 
allergosorbent disc is to take place.  In case that the comparators compete with the allergosorbent for 
binding by IgE, the first incubation will decrease the amount of unbound IgE antibodies that are still 
available for binding to the allergosorbent in the second incubation, which is measured as diminished 
binding to the disc. Comparison of the inhibition curve plotted with increasing concentration of 
competitors, i.e. the protein or extract from the GM and the non-GM crops, provide useful information 
on their respective IgE binding capacity. 
 
Variants to the RAST assay include, among others, the Enzyme Linked Immunosorbent Assay 
(ELISA), which largely follows the same principle as the allergosorbent assay, albeit that it involves 
the use of plastic tubes or titre plates, colored or fluorescent substrates, and dilution series.  Annex 5 
provides a more detailed treatise of the ELISA technique as it can also be applied for testing whole 
extracts of proteins.  Moreover, the CAP system may currently be preferred over RAST by various 
users because of higher sensitivity and lower non-specific binding.   
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Another method is the use of electrophoresis, followed by immunoblotting with IgE-containing 
antisera, by which the reactivity with specific protein bands can be discerned.  This may be applied to 
a protein of interest in order to verify whether it is bound by IgE antibodies or not.  It may also be 
applied on a whole protein extract to determine whether any changes in the profiles of IgE-binding 
proteins have occurred in case the crop that has been genetically modified is allergenic in its own 
right.  A popular technique for protein electrophoresis is SDS-PAGE (sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis) for which usually reducing conditions are applied that cause the 
cleavage of disulfide bonds between proteins or peptides during gel electrophoresis.  Several allergens, 
however, are known to be post-translationally cleaved into peptides that are still held together by 
disulfide bonds.  The detection of the correct whole protein form of such allergens requires the use of 
non-reducing conditions.  In addition, experimental conditions, such as the use of different blocking 
agents to prevent non-specific binding on the immunoblot, may influence the quality of the results 
(Goodman and Leach, 2004). 
 
Both for immunoblotting and ELISA, the use of additional control inhibition assays may be warranted 
in order to verify the specificity of antibody binding.  This can be done by inclusion of inhibitors (such 
as the purified allergen to which the IgE is known to bind) in the incubation solution during the 
binding of the IgE- antibodies to the protein of interest.  This kind of inhibition assays can also be used 
to further explore cross-reactivity by using the potentially cross-reactive protein as the inhibitor 
(Goodman, 2008). 
 
Various rapid techniques that may substitute gel electrophoresis and that are amenable to automation 
have been developed, such as capillary electrophoresis but these are not commonly used yet for the 
purpose of allergenicity assessment. Capillary electrophoresis (CE) has been used in combination with 
mass spectrometry (MS) for the analysis of intact proteins since 1989 (Haselberg et al., 2007). For the 
analysis of allergens it has been used so far by Punzet et al (2006) for the profiling of preparations of 
recombinant birch allergen Bet v 1A. In that case, the concentration of the recombinant allergen was 
very high and the sequence was known. It has not been used to detect and characterise allergens in 
food. 
 
Protein fragments, i.e. peptides, may also be tested for IgE-binding such as for identification of 
epitopes.  Usually overlapping fragments of the sequence of the protein of interest are synthesised, for 
example as fusion peptides with larger proteins or covalently linked to beads.  Binding of the single 
peptides by IgE-containing antisera is tested by incubation in wells of microtitre plates or dot-blots on 
membranes, followed by detection of bound complexes, such as by colorimetry.  This technique may 
be particularly suited to find linear epitopes of a number of contiguous amino acids. 
 
A similar technique to detect non-linear conformation technique is described by Untersmayr et al. 
(2006).  In this case, random peptides were generated as part of recombinant bacteriophage proteins 
with the "biopanning" technique.  Phages that produced proteins that were recognised by IgE directed 
against the cod allergen parvalbumin, i.e. Gad c 1, were isolated and further purified.  The peptide 
sequences that had been inserted into these phages were then identified.  Using bioinformatics, these 
sequences were aligned with amino acid residues, particularly the charged ones that occur on the 
surface of the known three-dimensional structure of parvalbumin.  This combination of IgE-binding 
with bioinformatics, which is discussed elsewhere in this document, thus enabled identification of 
non-conformational epitopes.  This study also shows that linear sequences can act as "mimotopes" of 
non-linear counterparts in antibody-binding. 
 
4.3.1. Detection of potential cross-reactivity with known allergens by using sera from 
sensitised animals  
 
The problem of using patient’s sera is that the quantity is limited and the variation in reactivity and 
recognition of allergens between patient sera is high. The antibodies of different patients might 
recognise different epitopes in an allergen. Furthermore, the epitopes of allergens can be linear but 
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also conformational. Processing of an allergen-containing product or the matrix in which the allergen 
is present might diminish the allergenicity for one patient, but not for the other. Instead of using sera 
from patients which are very variable and limited in quantity for the detection of allergens in GMOs, a 
pre-screen of detecting putative allergens could be by using antibodies raised in mice or in rabbits. A 
model of sensitisation to purified food allergen such as b-lactoglobulin or to whole foods (cow’s milk 
and peanut) was developed using a T helper Th2-biaised strain of mouse, i.e. the BALB/c mouse and 
showed that intra-peritoneal (i.p.) and intra-gastric (i.g.) sensitisations in presence of adjuvant induced 
the production of IgE antibodies specific to the same proteins, and even to similar epitopes on the 
different proteins, as human IgE from allergic patients (Adel-Patient et al., 2005). 
By over-exposure of mice against the native known allergen as well as the linear (denatured) allergen 
it is possible to raise specific monoclonal antibodies with known and reproducible characteristics of 
specificity and affinity whereas polyclonal antibodies characteristics are multiple and variable. The 
mice antibodies could be used as a detection for putative allergens, either by immunoblot screening 
after 1-D or 2-D protein gel electrophoresis, or by immuno-capturing or immuno-purification. They 
might recognise a different epitope than the ‘real’ epitope, and therefore an in depth analysis of the 
amino acid sequence of the epitope of the putative allergen is necessary. This could be performed by 
mass spectrometry sequencing (MSMS). 
Small amino acid sequence variation in an epitope of an allergen can make the difference in being 
allergenic or not (Gao et al., 2008; Schenk et al., 2009; Vader et al., 2002), therefore it will be 
necessary to characterise the allergen, after the primary screening, in more detail 
The method of raising mAbs in mice against immuno-toxic epitopes has been performed for wheat 
gluten epitopes that can stimulate binding and proliferation of T-cells in celiac disease patients 
(Spaenij-Dekking et al., 2004). Since gluten intolerance does not develop via IgE, but via T-cell 
mediated immune response, human sera of celiac disease patients could not be used to detect immuno-
reactive epitopes in an immunoblot screening after 1-D or 2-D protein gel electrophoresis. Although 
the T-cell epitopes are known and used in raising the mAbs in mice, differences may exist in the 
affinity and specificity of the mice antibodies compared to the human T-cell lines in relation to the 
specific amino acid sequence of the gluten epitopes (Mitea et al., 2008b). 
 
4.4. Cell-based assays 
 
4.4.1. Basophil assays 
 
Diagnostic relevance of basophil activity 
As described in section 1.2, basophils are involved with the elicitation of allergic reactions by 
releasing mediators, such as histamine, after contact with IgE-bound allergens.  These cells can be 
used in vitro after collection of blood specimens containing these cells from allergic patients.  
Basophils carry a high-affinity receptor for IgE antibodies.  Dimerisation of such receptors at cell 
surface through the binding of two IgE antibodies to 2 distincts epitopes on a single allergen molecule 
or to 2 identical epitopes on an allergen with repetitive moieties or present in a polymerised form 
transduces a signal of activation to the cell.  This results in the liberation of preformed mediators, 
including histamine, heparin and various enzymes such as tryptase, and in cell activation leading to de 
novo production of mediators including leucotrienes. 
 
The system may be sensitive, but suffers a number of drawbacks, among which: 
 
 the number of circulating basophils is low, both in man and in animal models; 
 the extent of degranulation in the presence of a given concentration of an allergen is inversely 
proportional to the degree of allergen polysensitisation, which reduces the likelihood of 
having 2 IgE of the same specificity in sufficiently close proximity as to dimerise;  
 basophils can degranulate in the absence of IgE antibodies. Complement breakdown products 
such as anaphylatoxins (C3a and primarily C5a) are potent activator of basophils; 
 the inherent susceptibility to degranulate can be altered by medications such as morphine and 
derivatives; 
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 more recently, receptors of natural immunity, called TOLL-like receptors, have been shown to 
modulate the reactivity of basophils and mast cells. TOLL-like receptors signal down the cell 
after ligation of many different ligands, from viruses, bacteria, fungi and endotoxins. 
 high variance of outcomes depending on the conditions under which the test is performed, 
including the choice of individual human serum with which the basophils are coated as well as 
of the donor basophils themselves (Pedersen et al., 2008).  
 setup of the assay may be demanding, for example in terms of logistics (e.g. sampling and 
transport of donor cells), laboratory facilities (e.g. skilled and experienced staff), and costs 
(Kleine-Tebbe et al., 2006). 
 
Attempts to circumvent these difficulties include alteration of the protocol for testing, such as 
introducing a washing step by which all IgE antibodies are eliminated from cell surface.  Cells can 
then be incubated with any serum that putatively contains IgE antibodies to the relevant allergen 
(passive sensitisation assay).  
 
Basophil degranulation tests, which require a processing of blood samples immediately after 
collection, may also not be suitable. Several cell lines have been derived, primarily from rat basophil 
leukemias (RBL).  However, the rodent alpha chain of the sFcReI does not bind to human epsilon 
chain.  This has prompted researchers to transfect RBLs with the different chains of the human 
receptor.  An in vitro functional test using a humanised stable mast cell line is of great interest to study 
the biological activity of purified proteins or to study the effect of processing or digestion on their 
allergenic potential. RBL SX-38 cells are derived from rat mast cells that have been transfected to 
stably express the α, β and γ chains of the human high-affinity receptor for IgE, FcεRI, allowing IgE 
of allergic patient sera to bind on their surface (Blanc et al., 2009; Dibbern et al., 2003; Wiegand et al., 
1996). 
 
In the future, transfected RBLs could become the reference cell for basophil activation test, provided 
technical difficulties inherent to the use of human serum can be resolved. 
 
Assays of basophil activity 
Histamine release can be evaluated by radioimmunoassay or ELISA.  Histamine is highly susceptible 
to degradation upon storage, particularly at room temperature, and stabilisation of histamine by 
acylation is a recommended step before carrying out the assay.  The determination of tryptase 
concentrations, i.e. the serine proteinase enzyme occurring in secretory granules of mast cells, is of 
interest as a kit is commercially available to evaluate very low concentrations of tryptase.  In addition, 
tryptase is much more stable than histamine.  The mediator release can also be quantified by the 
determination of β-hexosaminidase activity. 
 
An alternative to evaluation of mediators such as histamine and tryptase, is the determination of the 
number and intensity of basophil activation using surface markers.  Thus, surface molecules such as 
CD63 and/or CD203c show much increased expression after basophil activation and this can be 
accurately measured with a specific antibody and fluorescence sorting.  In fact, the CD63 molecule is 
associated with the membrane of granules which are expelled after cell activation. 
 
Yet, very large differences between individuals are observed, inter alia because the number of 
receptors for IgE varies as a function of circulating total IgE.  This leads to variable transduction and 
tyrosine kinase phosphorylation and, consequently, variable degrees of degranulation.  CD63 is not 
specific for basophils and contamination of the cell suspension by activated platelets can indeed 
generate falsely positive results.  It is therefore suggested to combine two antibodies, one directed 
towards CD63 and another towards IgE.    
 
On the whole, the basophil activation/degradation test is commendable in situations in which different 
allergens or forms of allergens (e.g. natural versus recombinant) have to be compared for their 
capacity to bind IgE.  This pertains in particular to scenarios in which a transgenic protein has been 
found to cross-react with IgE from sera, and which therefore needs further confirmation of the 
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capacity of the pertinent protein to elicit allergic responses. Scientific literature provides accounts of 
encouraging results obtained through studies into the potential cross-reactivity with passively 
sensitised basophils with other allergens.  For example, De Leon et al. (2005) observed the activation 
of basophils coated with anti-peanut IgE with extracts from peanut, walnut, and Brazil nut, measured 
as CD63 induction by means of flow cytometry.  Wallowitz et al. (2007) also showed that basophils 
sensitised with sera from a patient allergic to both sesame and walnut were activated to recombinant 
analogues of the 11S globulins from both sesame (rSes I 6) and walnut (rJug r 4) and with whole 
extracts from both as well, which also had shown cross-reactivity in IgE-binding assay.  If basophils 
were sensitised with sera from a patient allergic to sesame but tolerant to walnut, despite IgE-cross-
reactivity to both, the basophil assay only showed activation in response to incubation with sesame 
extract or rSes I 6, thus demonstrating the potential utility to discern between relevant and irrelevant 
IgE-binding (Wallowitz et al., 2007). Basophil tests, once their applicability has been established and 
validated, would make a valuable contribution to testing transgenic proteins for their potential 
allergenicity. 
 
4.4.2. Other assays under development 
 
The T cell systems discussed below are in a particularly advanced stage of development, as is the 
current understanding underlying the mechanisms of their activity. 
 
Diagnostic relevance of T cell activity 
As described in Annex 1, T cells play a central role in the sensitisation phase of the development of 
allergies besides their role in the effector phase.  T cells are key components of the allergic immune 
response.  It is classically considered that Th2 cells are prominent by their capacity to produce IL-4, an 
essential cytokine in the production of IgE antibodies.  However, not all experimental evidence can be 
explained by Th2 involvement and there is good data to show that Th1 cells could well be a key 
player.  Whatever the case, the situation is likely to change according to the allergen considered and it 
is therefore safe to design methods by which specific T cells can be detected without a priori 
conception on their lineage.  This section further discusses the distinction between various lineages of 
T-helper (Th) cells with regard to its applicability for cell-based assays for allergenicity, whilst the 
Th17 subset, including both effector and regulatory types of Th17, is not further elaborated here given 
that its existence has only recently been discovered (see Annex 1.3 on mechanisms). 
 
The development of T helper cells into either Th1 or Th2 categories has been found to depend, among 
others, on the activity of two specific transcription factors, GATA3 and T-bet1.  Transcription factors 
activate genes by “switching on” their transcription.  GATA3 binding to consensus sequences triggers 
the transcription of canonical cytokines belonging to the Th2 lineage, such as IL-4, IL-5 and IL-13. 
These cytokines are associated with physiological events including isotype switch to the production of 
IgE antibodies, migration and maturation of eosinophils and mast cells, and inhibition of apoptosis in 
such cells. The overall result typifies a so-called Th2 response. By contrast, translocation of T-bet 
drives the transcription of IL-2, IL-12 and IFN-gamma, typical of a Th1 response with production of 
IgG antibodies and antigen-presenting cell activation. Importantly, T-bet is dominating in the sense 
that activated T-bet binds to GATA3 and inhibits the function of the latter. Therefore, GATA3 
activation and its consequences on immediate hypersensitivity reaction develop only in the absence T-
bet activation. 
 
A further degree of complexity arises from the observations that the emergence of an allergic reaction 
could in fact be due to a lack of suppression.  Suppressor or regulatory T cells belong to 2 different 
categories, although some of their characteristics overlap such categories. Natural regulatory T cells 
are actively selected in the thymus, while induced regulatory T cells are generated in the periphery 
upon antigen challenge.   
 
A classical example of induction of regulatory T cells, which can also be useful for the assessment of 
GMO allergenicity, is the induction of Th3 cells obtained by mainly oral administration of antigen in 
animal models. Th3 cells produce high levels of TGF-beta, a regulatory cytokine, and various amounts 
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of IL-4 and IL-10. Such cells are found in mesenteric lymph nodes after tolerance induction. It is 
expected that at least part of the mechanisms by which tolerance to food antigens is established is 
through the elicitation of such Th3 cells. Although the exact role of TGF-beta in such tolerance is still 
controversial, conditions required for expanding Th3 cells are being investigated.   
 
Assays of T cell activity 
Assays for specific T cells include proliferation tests, phenotypic characterisation including cytokine 
production and single cell analysis. 
 
The capacity to proliferate upon antigen presentation is evaluated using either radioactive or 
fluorescent markers, which incorporate into dividing nuclei and can be readily measured by gamma 
counting or fluorescence emission.  T cells are obtained from the spleen of mouse immunised by 
conventional methods with either the transgenic protein or its appropriate controls. 
 
A phenotypic evaluation can be carried out on the same cells.  Cell surface markers such as ICOS can 
be detected using specific antibodies and a fluorescence cell sorter.  The production of cytokines can 
be evaluated by either measuring them in the supernatants using an ELISA, or directly within 
permeated cells.  This can easily be combined to an evaluation of the activation stage of several 
transcription factors; the latter include mainly GATA3 and Bet1, respectively characteristic of the Th2 
and Th1 lineage as described above. Methods for the evaluation of transcription factor activation are 
routinely available using specific antibodies, Western blotting or immunoprecipitation assays. 
 
The ELISPOT assay is a capture assay in which cytokines produced by activated cells are trapped onto 
membranes coated with specific anti-cytokine antibodies.  This method allows an enumeration of 
activated T cells and therefore allows a direct comparison between transgenic proteins and their 
counterparts, i.e. positive and negative controls.  
 
Assessing the capacity to expand regulatory T cells or elicit induced regulatory cells is usually 
performed by functional assays.  Yet, specific phenotypic markers are being identified, as for instance 
surface expression of the IL-7 receptor (CD127).  Functional assays are based on the property of 
regulatory T cells to suppress the activation of bystander T cells, i.e. T cells of unrelated specificity 
but sufficiently close to the regulatory T cells as to be affected either by cytokine production or cell-
cell contact.  
 
Evaluation of allergen-specific T cells activity 
Peripheral blood mononucleated cells (PBMC) are prepared by gradient density centrifugation and 
mixed for 5 to 7 days with the allergen under scrutiny. Cells are then washed and cultured for an 
additional 18 h with tritiated thymidine, followed by further washing and counting of radioactivity. 
The intensity of radioactivity is proportional to the proliferation of cells. By comparison with a control 
culture in which no allergen is included, it can be determined whether or not peripheral blood cells 
contain allergen-reactive T cells. 
By measuring the cytokine concentrations in the supernatants of such cultures, it is possible to assign a 
phenotypic signature to such cells. In particular, the presence of IL-4, IL-5 and IL-13 in such 
supernatants indicate that activated cells pertain to the Th2 polarised CD4+ T cell subset, which is 
implicated in the production of IgE antibodies. In contrast, the presence of IFN-gamma indicates that 
such cells can participate in chronic inflammation through the secretion of various inflammatory 
mediators. 
 
Polyclonal T cells contained in the PBMC sample can be further purified by limiting dilution until cell 
lines or even clones are obtained. Such cell lines or clones can be further activated by exposure to 
allergen presented by autologous antigen-presenting cells. This allows not only to evaluate at single 
cell level the phenotype of allergen-reactive cells, but also to identify the epitope(s) recognised. To 
this end, synthetic peptides of ± 20 amino acids are produced, which encompass the entire allergen 
sequence with an overlap of ± 5 amino acids. The activation properties of peptide(s) can then be 
further refined by the use of mutated peptides including single amino acid substitution.  
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Interpretation 
As with antibodies, including IgE antibodies, the mere presence of allergen-reactive T cells in 
peripheral blood does not per se establish a diagnosis of allergy. The potential harmful effect of such T 
cells can be harnessed by intrinsic and/or extrinsic mechanisms of tolerance, namely anergy or 
apoptosis occurring in gut lamina propria, or by the local presence of regulatory T cells, respectively.  
Large variations in extend of proliferation are expected between individuals, and it is therefore 
mandatory to include a control with unstimulated cells for each assay, which has to be carried out in 
triplicates.      
 
4.5. Conclusions and recommendations 
 
Various in vitro assays have been considered above, some of which have already become a 
commonplace in the comprehensive testing of transgenic proteins in the risk assessment of GMO.  
Examples of this are the in vitro digestion of proteins in simulated gastric fluid and the use of IgE 
binding tests to measure potential cross-reactivity of the new protein with known allergens to which 
the serum donors are allergic.  Other assays, such as the cell-based assays are not yet routinely used 
for this purpose, but appear to be promising as they can mimic the in vivo cascade of sensitisation and 
elicitation, whilst obviating the need for clinical testing. 
 
It is noted that the choice and design of the experiments performed for this purpose depend upon other 
items considered in the “weight-of-evidence” approach.  For example, if bioinformatics studies show 
that a transgenic protein indicates relevant similarities to a known allergen, this would trigger further 
serum screening of the protein with sera from patients allergic to the pertinent allergen combined with 
other in vitro assays.   
 
4.5.1. Resistance to in vitro protein degradation 
 
Conclusions 
The stability of a protein against the action of protein-degrading enzymes that occur within the gastro-
intestinal tract is a feature of various food allergens and is generally considered one of the risk factors 
for allergenicity. 
 
Not all allergens, such as apple allergen, are known to be stable to digestion and also degraded 
fragments of proteins can act as allergens.  In addition, other factors, such as the abundance of the 
protein in a food, the way it is contained within the food matrix, and the effect of food processing on 
the protein may affect the likelihood that a protein will survive passage through the gastrointestinal 
tract.  Moreover, the in vitro models used may not reflect the fluctuations in pH and enzyme:protein 
ratios that occur in vivo after consumption of a meal.  Combination of the outcomes of the in vitro 
digestibility studies with other information, such as the abundance of the protein within the food and 
the stability towards food processing may therefore provide useful hints of how the outcomes can be 
interpreted.  In addition, besides the intact protein, also peptide fragments derived from protein 
degradation still may have the capacity to elicit allergic reactions.  The analytical methods to detect 
the degradation of proteins in in vitro digestibility models should therefore allow for the detection of 
peptide fragments. In polyacrylamide gel electrophoresis (PAGE), for example, the resolution of 
peptide bands depends on the degree of cross-linking of the gels.  Gradient gels are commercially 
available that allow for a good separation and detection of low-molecular-weight protein fragments.  
In addition, attention may have to be paid to the choice of stain used for these fragments in the gel in 
order to ensure sensitivity without artefacts. 
 
In addition, there has apparently been a wide-felt need to standardise the conditions under which in 
vitro digestibility assays are performed so that results from tests carried out in different laboratories 
can be compared.  For example, the half-life of a protein in simulated digestive fluids may provide for 
a comparable parameter.  In addition, the outcomes of the ring trial published by Thomas et al. (2004) 
Annex 4. In vitro and cell-based tests
 
 
126 EFSA Journal 2010; 8(7):1700 
has shown that the reproducibility is enhanced at pH 1.2 compared to pH 2.0, such as for the time until 
disappearance of a protein.  The pH value of 1.2, however, does not reflect the pH ranges commonly 
encountered in stomachs. The pepsin resistance test as currently used is therefore not an in vitro 
digestibility test designed to mimic the physiologic conditions of gastric digestion but simply to 
determine the biochemical character of whether the subject protein is stable to pepsin degradation at 
pH 1.2 as has been established for some known allergenic proteins in food. 
 
The outcomes of in vitro digestibility tests should be interpreted with care as they represent model 
conditions. In vitro models used may not reflect the fluctuations in pH and enzyme:protein ratios that 
occur in vivo after consumption of a meal.  Combination of the outcomes of the in vitro digestibility 
studies with other factors, such as the abundance of the protein within the food and the stability 
towards food processing may therefore provide useful hints of how the outcomes can be interpreted. 
 
Recommendations 
• In addition to the pepsin resistance test, other in vitro digestibility tests on newly expressed 
proteins are recommended to be performed in more physiological conditions in order to take 
into account variations of the pH value between pH 2.0 and pH 4.0, reflecting the in-vivo 
fluctuations in gastric pH values, the enzyme:protein ratio in the stomach and the impact of 
the food matrix and processing on the digestibility of the protein.  This test could also include 
the non-physiological pH of 1.2, which is considered to yield comparable results between 
different laboratories and which is frequently used for this purpose.  This enables the analysis 
of the pH dependence of the pepsin resistance of the intact protein and derived fragments.  
The time intervals at which samples are taken should reflect the natural passage times of 
ingested food in the stomach (e.g. in the range of a minute up to an hour).  Also the pepsin 
activity:protein ratio should be varied, including assay conditions of 10, 1, and 0.1 units of 
pepsin per microgram of test protein.  Both positive controls of proteins known to be stable 
under these conditions and negative controls of proteins known to be labile should be 
included.  In order to enhance comparability of the outcomes from assays carried out at 
different time points or in different laboratories, the half-life of a protein showing first-order 
degradation kinetics should be reported.  Measuring the resistance to digestion should also 
take into account the conditions of individuals with modified gastric digestion such as pH 
values > 2 (see Annex 1.10.1). Where relevant, other possible routes of sensitisation (e.g. via 
respiratory or cutaneous exposure) in which the protein is not processed by digestive enzymes 
should be explored. Proteins of a particular interest, including those showing stability towards 
pepsin, can also be checked for their stability towards other gastro-intestinal enzymes and to 
food processing.  In addition, the food- or feed-matrix containing the newly expressed protein 
and processing are likely to have an impact on the proteins’s degradation by proteases (e.g. 
because of interactions with other constituents and/or structural modifications during 
processing). The information gained and the value of the in vitro pepsin resistance test or other 
digestibility tests would thus be much increased if they were performed in the presence of 
food- or feed-matrix extracts. 
• Besides the intactness of the test protein in the pepsin resistance test, also the occurrence of 
stable protein fragments should be considered as a risk factor. Therefore should detection 
methods, such as gel electrophoresis, be insufficient to detect low-molecular-weight fragments 
of proteins, then alternative methods, like HPLC and MS should be performed. If the test 
protein contains disulphide bridges, the presence of potential larger fragments containing re-
associated disulphide-bonded fragments should be verified by isolation and detection under 
non-reducing conditions.   
• Future work should focus on the need of data on the impact of relevant processing-induced 
modifications on the release, stability to digestion and allergenic potential of the newly 
expressed protein. 
 
4.5.2. IgE binding tests 
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Conclusions 
IgE binding tests using allergic human sera may be required in various specific circumstances when 
potential cross-reactivity of a transgenic protein with known allergens is considered possible.  For this 
purpose, sera from patients allergic to the allergen of interest are needed.  It is noted, though, that there 
is inter-individual variability in the protein-specific IgE responses amongst patients sensitised to the 
same allergenic food.  If sera are pooled prior to carrying out any of these assays, there is a risk that 
antibodies reacting with less frequently recognised allergens may be diluted to an extent that their 
cross-reactivity with the test protein can be overlooked.  Therefore, the reactivity of individual sera 
should preferably be checked. 
 
Serum screening for testing possible IgE-cross-reactivity is required if there is any indication of 
relationship or structure similarity between the newly expressed protein and a known allergen, for 
example if sequence homology is evidenced in the bioinformatics study, or if the source of the 
transgenic protein is considered allergenic,  
 
Recommendations 
When the use of human sera is necessary, the following is recommended: 
• Specific serum screening should be carried out with sera from well-characterised allergic 
humans so as to individuate potential responses with IgE antibodies that recognise only minor 
allergens, which may be diluted if sera pooling is done. Appropriate individuals should be 
selected whose allergy to the source of the transgene or to a known allergen similar to the 
newly expressed protein has recently been clinically confirmed. Where possible the 
individuals should come from geographic regions where the GM plant is expected to be grown 
and consumed. The individuals should be representative of the allergic subpopulations of the 
populations that may be exposed to the GM plant through its cultivation within their domicile 
(respiratory allergy) or consumption (food allergy).  
 
4.5.3. Future methodology, cellular assays 
 
Early inflammatory events leading to food hypersensitivity 
The link between allergen exposure and the development of an adaptive immune response 
characteristic of allergy, including Th2 cell activation and production of allergen-specific IgE 
antibodies is poorly understood. Deciphering the mechanisms involved in allergen recognition and in 
the effector arm of inflammation would shed light on the very reason as to why hypersensitivity 
develops with only some antigens.  In fact, many allergens exhibit biological properties unrelated to 
immunogenicity, such as binding of lectins to glycan chains on the surface of human intestinal cells.  
 
In vitro cultures of intestinal epithelial cells can easily be established. Such cells can be exposed to 
different extracts of GMOs or their natural counterpart. The consequence of such an exposure can be 
measured at different levels. These include identification of activated metabolic pathways by kinome 
analysis, i.e. the ensemble of the kinase enzymes that regulate protein activity through protein 
phosphorylation, and identification of RNA transcripts by full transcriptome evaluation. Whether or 
not different pathways of activation by GMOs and their natural counterpart would be easily 
determined, the relative importance of identified activation pathways can be established by using 
reporter genes for transcription factors and antibodies to phosphorylated kinases.  
 
Selective pathways can be blocked by silencing RNA. This consists in silencing specific genes by 
addition of RNAs that are complementary to the corresponding mRNA. A particular application of 
such a technology will be the evaluation of silencing gene coding for receptors of innate immunity 
such as TLRs and NODs. It is indeed likely that such receptors “sense” allergens and represent a 
necessary step towards effective immunity.   
 
A further step would be to evaluate intracellular protein formation. This is of importance since many 
proteins are regulated at the post-transcriptional level. Intracellular staining after membrane 
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permeation and labelling of the intracellular target is detected by Facs analysis. In particular, it can be 
anticipated that in the very near future the transduction of signals within T cells will become routine in 
the evaluation of T cell activation.  One example of this is the evaluation of the nuclear translocation 
of NF-kb, a main transcription factor for a number of pro-inflammatory cytokines and anti-apoptotic 
factors. 
 
Basophil-based assays measuring the activation of these B-cells based on CD63 production have 
already been validated for the diagnosis of a number of allergies.  Their application to the assessment 
of potential allergenicity of transgenic proteins and genetically modified foods has not been widely 
reported in scientific literature as yet.  Further research is therefore warranted so as to explore the 
potential applicability to allergenicity assessment of genetically modified products. 
 
In vitro cellular assays are not yet routinely used for the purpose of testing for potential allergenicity 
of transgenic proteins, yet appear promising.  Further research should investigate the possibilities to 
accommodate predictive cellular assays into the allergenicity assessment of GMOs, such as basophil 
assays confirming cross-activation of these cells by proteins showing cross-reactivity in IgE-binding 
assays.  For some of these assays, such as basophil assays, usually human materials (e.g. isolated cells, 
sera) are needed.  Also the potential utility of T-cell activation should be further explored.   
 
It is noted that phage libraries of human antibodies are currently available and could be used to create a 
GMO-specific library of human antibodies for pre-screening. In order not to test only the IgE binding 
capacity of the newly expressed protein but also its functionality to act as an allergen, the basophil 
degranulation assay is highly sensitive and specific. This test can be standardised using cell lines 
transfected with the human FcεRI receptor, such as basophil rat leukemia cells. 
 
Recommendations: 
• Future work should focus on the developement of cell based tests for assessing the capacity of 
the newly expressed protein to bind IgE and provoke the degranulation of basophils. 
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ANNEX 5. ANALYTICAL AND PROFILING TECHNOLOGY / IN VITRO PROTEIN 
ANALYSIS AND PROTEOMICS METHODS FOR THE ALLERGENICITY 
ASSESSMENT OF THE WHOLE GM PLANT 
 
 
5.1. Introduction 
 
The assessment of allergenicity of GM plants should ensure that no unintended effects of the genetic 
modification will negatively impact on the allergenicity of these plants.  For example, the genetic 
modification should not alter the profile of naturally occurring allergenic proteins of the whole GM 
plant and derived tissues of interest in an undesirable way. An example of an undesirable alteration is 
the over-expression of naturally occurring allergens. It should also be noticed that, as a corollary to the 
intended effect of the genetic modification, newly expressed proteins may be identical or very similar 
to known allergens that naturally occur in plants. This will be particularly the case when the purpose is 
to modify the content of proteins, such as some defense and seed storage proteins, which also are 
typical allergens. In such cases, the newly expressed protein may be identical to the native protein that 
occurs in the host plant, or qualitative changes may occur when it is expressed in a recipient plant that 
belongs to another plant species than the source. In particular, changes in the glycosylation pattern can 
have an effect on the allergenicity or immunogenicity of the protein. Changes were found, for 
example, in the structure of N-linked glycans of bean alpha-amylase inhibitor when the gene was 
expressed in pea (Prescott et al., 2005). Although there was no evidence for altered allergenicity, the 
protein showed enhanced immunogenicity when tested in an animal model (Prescott et al., 2006; 
Prescott and Hogan, 2006). The newly expressed protein may also be targeted to a particular secretion 
pathway in the recipient plant. The analytical method should then be adapted to detect and quantify the 
modified allergenic newly expressed protein. 
 
Besides qualitative changes in the newly expressed protein, both qualitative and quantitative 
alterations in endogenous proteins may take place that influence the allergenicity of the whole plant. 
They may affect the pattern of expression of naturally occurring allergens, i.e. the allergen repertoire 
of the recipient plant. Some of these natural allergens may then be over- or under-expressed as 
compared to the conventional counterpart, leading to a quantitative change. Qualitative changes may 
affect structural features including post-translational modifications on some allergens. The potential 
emergence of new allergens which had not been identified in the non-GM recipient plant before is a 
situation that can be predicted by bioinformatics, for example by comparing the sequence of 
hypothetical peptides encoded by newly formed open reading frames (ORFs) with the sequences of 
known allergens (see Annex 3). Significant differences were for instance observed among GM potato 
lines in the levels of tuber proteins that are potential allergens, such as aspartic protease, Kunitz-type 
enzyme inhibitor and patatin (Kärenlampi and White, 2009; Lehesranta et al., 2005). Increased content 
of allergenic storage proteins were found in the proteome of GM pea expressing a bean alpha-amylase 
inhibitor gene (Chen et al., 2009). There is also an example from wheat where proteome analysis 
showed that the amount of allergenic proteins were lower in the GM plants compared to the non-GM 
comparator (Scossa et al., 2008). 
 
When investigating the potential allergenicity of whole plants, special attention needs to be drawn to 
identify the natural variability in expression levels of identified proteins in wild type plants and to 
compare the composition of the wild type and the GM plant (Baker et al., 2006; Natarajan et al., 2009; 
Ruebelt et al., 2006; Shewry et al., 2006, see also Annex 4). All observed changes in the proteins 
should be assessed against natural variation caused by plant genotype and cultivation environment 
(including location and season). Lehesranta et al. (2005) compared tuber proteomes of 32 potato 
genotypes representing a range of genetic variation: 21 named cultivars of tetraploid potato, eight 
landraces and three diploid genotypes. Genotypic variation was extensive, with 97% of the proteins 
showing significant qualitative and quantitative differences between one or more varieties and 
landraces. Of the nearly 2000 polypeptides detected, only 34 did not appear to differ significantly 
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between the genotypes. Some of the most striking differences occurred in the various isoforms of 
patatin. Environmental factors can cause even higher variation in protein profiles than does the 
genotype (Barros et al., 2010).  
 
Actually, other comparative studies on the proteome and transcriptome of several GM plants, 
including tomato, potato, wheat and soybean, have found very few differences between the GM and 
wild-type forms. Di Carli et al (2009) examined the proteomes of GM plants that were designed to 
present antiviral resistance. They compared the protein profiles of two plants expressing different 
recombinant antibodies with those of their unmodified forms. Tomato was modified to express the 
antibody scFv(G4) against the cucumber mosaic virus (CMV) coat protein, and Nicotiana 
benthamiana was engineered to express the antibody scFv(B9) against the G1 envelope protein of 
tomato spotted wilt virus. The differences in protein profiles between leaf protein extracts from the 
GM and control plants were highlighted by two-dimensional gel electrophoresis, using imaging 
techniques and a statistical analysis to identify proteins that were differentially expressed. A total of 
1818 spots were detected on the tomato gels but only 10 were differentially expressed. Similarly, 8 
proteins out of 1989 for N. benthamiana were apparently affected by genetic transformation. However, 
the differences in expression were low with an average ratio of less than 2.4. The proteins were 
identified by mass spectrometric techniques. The majority were single expression products involved in 
photosynthesis or defence processes rather than metabolic pathways, and therefore could have been 
caused by "minimal environmental stimuli". Taken together with the low expression ratios, the data 
led the researchers to conclude that "the proteomic differences observed between GM and control 
plants are negligible, defined and more likely due to physiological variations". Fewer differences 
between the GM plant and its conventional counterpart may be found than between plant varieties. 
However, each genetic modification should still be examined case by case. 
 
Allergens are usually only a small fraction of the proteins of a given plant. As an example grasses 
have only 11 allergenic groups of isoforms described so far in their pollen and maybe up to 25 
allergenic groups in their seeds (Brodard et al., 1993). A few allergens have been described in their 
leaves and roots most of them being common to the pollen or the seeds. These numbers are very small 
as compared to the total number of expressed and detectable proteins in grasses. The techniques 
required to analyse the allergens therefore have to be able to analyse and screen a great number of 
proteins to be able to detect a very small number of allergens. This detection, as allergens, is achieved 
through a specific recognition by human IgE antibodies. 
 
When the allergens of a particular plant species are well characterised, more or less specific methods 
can be used for their quantitative analysis. The situation becomes more complicated if qualitative 
changes in known allergens or any changes in unknown allergens need to be identified. In those cases, 
more sophisticated non-targeted methods become increasingly useful. This Annex briefly describes the 
principles of these techniques and discusses their advantages and limitations. All methods presented 
here are based on the structural properties (sequence, size, charge etc.) of the proteins and on their 
immunoreactivity. 
 
5.2. ELISA and derived immunoassays 
 
Enzyme-linked immunosorbent assay (ELISA) is a commonly used method for the targeted analysis of 
known allergens and their quantification in a sample using specific antibodies. It is noteworthy that for 
diagnostic purposes different formats of ELISA may also be used for determination of antibodies, e.g. 
of the IgE class.  
 
Derived from the radio-immuno assays, ELISA became very popular by the use of enzyme-labelled 
tracers and by its miniaturised format: the microtiter plate, allowing a rapid screening of numerous 
samples in a reduced amount. Its principle consists in immobilising one partner of the Antigen-
Antibody (Ag-Ab) reaction on a solid surface (e.g. the bottom and the walls of a plastic well) and let it 
be recognised by the other one in the liquid phase then quantitated by using enzyme-labelled antigen 
or antibody. Allergen recognition may be obtained by immobilising a potential allergen and letting it 
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be recognised by human IgE antibodies from an individual with a known characterised allergy. The 
immobilised allergen-IgE complex is then detected and quantified by a second antibody, e.g.  an anti-
human IgE antibody raised in animals and labelled by covalent linking to an enzyme. Several 
improvements and different procedures to this basic format have been introduced such as the nature 
and labelling of capture antibody, the development of immunometric tests (i.e. “sandwich ELISA”) or 
competitive inhibition assays. Most of the critical steps have been automated allowing high throughput 
and routine dosages and high dynamic ranges are achievable with a limited amount of reagents.  
 
The selectivity is a key point of the method. Allergens have to be water-soluble for their extraction 
from the plant/food and their binding to the polystyrene surface of the plates requires some 
hydrophobic properties at their surfaces. In neutral buffers without detergent, the cell membranes often 
form vesicles with hydrophilic portions of the integral membrane proteins trapped inside. Also when 
detergents are added in the extraction buffer, they may interfere with the ability of the protein to 
interact with the antibody. 
 
The specificity of the method is also a major issue which depends on the quality of the reagents that 
are used. Also, interfering confounding compounds such as carbohydrates have been reported. They 
may act as haptens present on molecules that may be abusively detected as allergens by IgE antibodies 
to these motives called cross-reactive carbohydrate determinants (CCD). 
 
Another aspect is the sensitivity of the method linked to the immunologic detection by IgE antibodies 
of allergic individuals. Allergens are frequently present under different isoforms or isoallergens and 
some allergic individuals do recognise only a few of these isoforms. In order to avoid the risk of 
overlooking some allergens, particularly minor allergens, individual sera should be used instead of 
pooled sera. Also, if human sera are used, the serum concentration may be critical and the test should 
be performed with dilution series. This is because of the variability in concentrations of specific IgEs 
and of the possible presence in the serum of inhibitory antibodies such as auto anti-IgEs, which may 
create steric hindrance and interfere with complex formation. The availability of human sera from 
sufficient number of clinically well-characterised allergic individuals may be limited for a number of 
reasons (including ethical reasons). Using affinity-purified antibodies raised in experimentally 
sensitised animals against the allergenic proteins might overcome this problem and allows performing 
a pre-screening in certain applications. 
 
The development of future immunoassays for allergen testing is likely to go into certain directions so 
as to improve their performance, e.g. they will be miniaturised, allowing a great number of allergens to 
be tested by the same single allergic individual serum, and purified allergens will be preferred over 
crude source mixtures, particularly for the purpose of diagnostic of allergy. 
 
Similarly to the development of microarray systems to quantify whole transcriptomes, protein 
(micro)arrays can be expected to be used increasingly in the future (Harwanegg and Hiller, 2005; 
Lebrun et al., 2005). The most common protein microarray is the antibody microarray, where 
antibodies (e.g. those raised against the newly expressed proteins of the GM plant and against 
endogenous allergens of that plant species) are spotted onto the protein chip (e.g. microscopic glass 
slide or nano-well array) and are used as capture molecules to detect and quantify the respective 
proteins in plant protein samples. The arrays also allow a great number of allergens (protein extracts 
from the GM plant, purified newly expressed proteins or protein fragments) to be tested for cross-
reactions with the serum of an allergic individual (50 µL serum for a chip of 80 allergens). Even a few 
purified allergens (“allergenicity markers”) may be sufficient if chosen among the most frequently 
recognised allergens of the particular plant species. The advantage is that only small quantities of 
serum are needed and it is possible to detect simultaneously cross-reactivity towards many allergens. 
As for ELISA, limitations in the protein microarray method, which is based on solid phase matrix, is 
the differential binding to the matrix of proteins present in crude extracts. While the assays can be 
optimised for individual proteins (as in the ELISA assay), a single chemistry will favour the binding of 
some proteins (allergens) but may be completely inefficient for other proteins which may be important 
allergens for a subpopulation of allergic individuals. Selecting chemistries that efficiently immobilise 
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two major allergens as purified, recombinant or synthesised proteins may be more practical than trying 
to select conditions to immobilise all proteins in the crude extract. It is important that they have the 
same structure (including post-translational modifications) and conformation as the native allergen 
produced in the plant (Swoboda et al., 1995). 
 
5.3. Two dimensional gel electrophoresis combined with immunoblotting  
 
When the purpose is to screen the GM plant for unintended changes in the expression of proteins that 
are (possible) allergens but for which specific assays are not available, other methods may be applied. 
These methods first involve separation of the proteins. The most commonly used protein separation 
method, although not routinely applied for the characterisation of GM plants, is the 2-dimensional 
electrophoresis in gel (2-DE) (Batista et al., 2007; Natarajan et al., 2009; Thelen, 2009). 2-DE is the 
combination of two electrophoretic techniques based on complementary principles, isoelectric 
focusing (IEF) followed by SDS PAGE, a polyacrylamide gel electrophoresis (PAGE) in a buffer 
containing a detergent, sodium dodecylsulfate (SDS). IEF separates the protein following their 
isoelectric point and SDS PAGE separates them following their molecular size relatively to the 
migration of standard protein markers increasing the resolution of the analysis. Once the proteins of a 
complex crude extract of a plant are separated by the 2-DE technique the best way to detect the few 
allergens present among circa a thousand of proteic spots displayed in one 10 x 10 cm gel is to 
perform a blot (or print) of this gel on a membrane, usually made of nitrocellulose or a hydrophobic 
polymer PVDF. The transferred allergens and proteins are thus immobilised on a solid surface. Their 
detection is then made possible by incubation with a relevant antibody solution, usually a human 
allergic individual serum. It could also be incubated with antibodies raised against the allergen or 
against a particular epitope of the allergen in animals. The use of monoclonal antibodies with well 
defined characteristics of specificity and affinity would allow a standardised (pre-)screening. A single 
10 x 10 cm blotting membrane may allow the detection and the identification of a few dozen of 
different spots by using a few mg of a crude allergenic extract. When using allergic patient serum, a 
minimum of 300 μL for a 10 x 10 cm blotting membrane is required whereas 1D electrophoresis in gel 
followed by blotting requires around 50 µL. The IgEs specific to the immobilised allergens are then 
detected by the incubation of the blot with enzyme labelled second antibody (i.e. an anti-human IgE 
antibody) followed by the addition of the enzyme substrate. The detected allergens are thus 
characterised by their isoelectric point and their relative mass. 
 
Confirmation of the identity of each proteic spot identified as an allergen is normally required in all 
cases to avoid false interpretation of the results. The protein spot is excised from the gel, digested by 
proteolytic enzymes (e.g. trypsin) into peptides, and subjected to mass-spectrometric (MS) analysis 
(see section 5.4). 
 
Techniques alternative to 2-DE, including miniaturised techniques, are available to separate proteins in 
complex biological samples (see section 5.5).  
 
5.4. Critical points of immunological based methods 
 
In spite of their great performances, ELISA and 2-DE followed by immunoblotting have some 
limitations or critical points (Vercauteren et al., 2007) which can be reviewed on each step of the 
method. 
 
Critical points due to the sample 
- Natural heterogeneity of some allergens: the major allergen Bet v1 appears usually in 2-DE as more 
than 20 spots corresponding to different isoforms. Most of the birch pollen-sensitive individuals 
recognise all of them as allergens. However some allergic individuals do recognise only a subset of 
these molecules corresponding to a limited number of common epitopes scattered on the different 
isoforms of Bet v 1. Therefore, in order to avoid the risk of overlooking some allergens, particularly 
minor allergens, individual sera should be used instead of pooled sera 
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A change in isoallergen content may be considered as an unintended effect of the genetic modification. 
 
- Protein extraction: 2-DE is performed in buffered aqueous solutions. The analysed samples have to 
be soluble in these buffers. IEF is a very critical step of the method as it eliminates in the very 
beginning of the separation all small ions from the sample. If these ions are needed for the solubility of 
the sample this one will precipitate out of the liquid phase and will not migrate at its isoelectric point. 
The best improvement found to increase the solubility of the sample is to use a mixture of chaotropic 
agents (thiourea / urea) and detergents (e.g. CHAPS).  This solution may induce a modification of the 
isoelectric point of the sample as well as some alteration of its immunodetectability by antibodies 
originally induced in vivo by native samples. Another major limitation lies in the molecular sizes of 
the proteins that can be studied in the range of 10 to 200 kDa as a consequence of the use of 
polyacrylamide gel as support of the electromigration with a limited porosity. Membrane proteins, 
highly charged (basic and acidic) proteins and very large proteins are difficult to resolve. 
 
- Matrix or process effect: samples of processed food may not be soluble anymore in water. Thermo-
labile epitopes may disappear during processing. Allergic individuals may be allergic only either to 
raw or cooked foods (such as shrimp or fish) involving in both cases different epitopes.  
 
- Carbohydrates on allergens (cross-reactive carbohydrate determinants, CCDs): many allergens are 
glycoproteins. Some allergic individuals do recognise glyco-moieties by their IgEs. IgE antibodies 
usually bind the glycated epitopes with low affinity. By immunoblotting the electrophoresis gel after 
1- or 2-DE in gels, many glycated molecules could be detected falsely as allergens. A 2-DE followed 
by a blot incubated with such sera may indicate whether CCDs or true allergens are involved because, 
instead of giving a few sharp allergenic spots, CCDs are present under numerous fuzzy spots. Some 
glycoproteins like horse radish peroxydase which are heavily glycosylated may serve as positive 
controls to detect non-specific background with sera having IgE antibodies to CCD. 
 
Critical points due to the analytical method 
One of the major reasons to use purified allergens versus crude extracts in the ELISA and the allergen 
chip format is their binding onto the solid phase matrix. It is rather easy to bind a well known purified 
protein on a solid phase by using a given ad hoc chemistry. The amount of bound protein can be 
estimated. Conversely, a complex crude allergenic extract will be difficult to immobilise on a unique 
surface. A single chemistry will favour the binding of some proteins but be totally inefficient for other 
components which might be important allergens for a subgroup of allergic individuals. Chosing 2 
major allergens efficiently immobilised by complementary chemistries may detect more allergic 
individuals than one single crude extract poorly immobilised. 2-DE in gels requires a skilful operator 
and has some essential manual steps, is rather time consuming and poorly reproducible. The use of 
precast gels and immobilised pH gradients contributes greatly to the improvement of the 
reproducibility of the method. 
 
Critical points due to the detection method 
The determination of the IgE binding capacity of a potential allergen may be highly dependent on the 
serum concentration used. Care should be taken to duplicate or triplicate these determinations by using 
several dilutions of serum. This effect of the serum dilution may be linked to the presence of inhibitory 
antibodies, such as auto anti-IgE in the serum. They may create a steric hindrance phenomenon and 
impair the IgE binding to allergens. Finally, an optimal choice of the length of time needed to make 
the optical density readings is important for the purpose of keeping a rather constant enzymatic 
activity of the enzyme used for converting a substrate into a spectrophotometrically detectable product 
during the time of incubation, and is an important contribution to the best IgE quantification. 
 
Limitations due to the use of human sera 
The availability of human sera from sufficient number of clinically well-characterised allergic 
individuals may be limited for a number of reasons (including ethical reasons). In addition, some 
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technical limitations such as variability in the specificity of the sera used, absence of reference sera 
and reproducibility of new sera collected are to be mentioned. 
 
5.5. Allergen detection and identification using mass spectrometry in combination with 
2-DE 
 
The past two decades have seen an increase of significantly improved mass-spectrometric devices, 
allowing precise analysis of biomolecules (Seibert et al., 2005). In general, the instruments are made 
up of three primary components: the source, which produces ions for analysis; the mass analyser, 
which identifies the ions based on their mass-to-charge ratios; and the detector, which quantifies the 
ions resolved by the analyser. The technique is sensitive to the picomole to femtomole range and may 
serve to detect any specific sequence belonging to a particular allergen and/or identify any given 
protein. 
 
Mass spectrometry (MS) may be used in combination with 2-DE alone as to identify some particular 
protein spots selected upon their molecular size and isoelectric points. It is commonly used in 
combination with 2-DE plus immunoblotting to identify the allergenic spots that bind IgE antibodies. 
This analytical method which associates 2-DE and MS is generally known as proteomics. 
 
Tandem mass spectrometry (MS/MS) or MSn is a stepwise fragmentation in which the ion fragments 
detected in the first step are further fragmented and detected in one or more additional steps. It allows 
the identification of amino acid sequence of peptides using computational methods to analyse the MS 
fragmentation patterns. For MS/MS identification of a protein spot from a 2D gel a relatively high 
amount of protein is needed (e.g. a clearly visible spot after Coomassie Brilliant Blue staining).  
Examples of MS/MS techniques through which the sequence identity of a protein can be assured 
include peptide mass finger printing (PMF) with Q-TOF-MS/MS (Quadrupole Time Of Flight Mass 
Spectrometry) or LC-MS/MS (Liquid Chromatography Mass Spectrometry).  Besides the amino acid 
sequences also other features of proteins can be revealed by MS-based methods.  For example, the 
glycosylation pattern can be revealed by MALDI-MS (Matrix Associated Laser Desorption Ionisation 
Mass Spectrometry) (Bakker et al., 2006), LC-ESI-MS (Liquid Chromatography Electron Spray 
Ionisation Mass Spectrometry) or by lectin binding assay (Kronsteiner et al., 2008).  
 
The probability and reliability of identification is higher in plant species whose genomes are 
completely sequenced. A few dozen of different spots may be detected and identified from a 10 x 10 
cm gel containing a few mg of crude protein extract. A limitation of 2-DE is the necessity of off-line 
detection. Low-abundance proteins are difficult to identify in the presence of highly abundant proteins. 
The method is rather labour-intensive, particularly when combined with 2-DE and aiming at 
characterising alterations among the levels of thousands of proteins in a whole GM plant compared to 
its conventional counterpart. 
 
5.6. Allergen detection and identification using mass spectrometry in combination with 
alternative methods of separation 
 
For the analysis of complex biological matrices generally multidimensional systems are needed based 
on combinations of different separation and/or detection systems. Today, various separation 
techniques are available for the qualitative and quantitative analysis of proteins. Frequently used 
techniques are slab-gel electrophoresis (SGE), liquid chromatography (LC) and capillary 
electrophoresis (CE) (Issaq et al., 2002). Limitations of SGE are the relatively long and labour-
intensive analysis, the necessity of off-line detection, and the lack of precise (and automated) 
quantitation. LC is advantageous due to its separation power, ease of automation and routine coupling 
with various detection principles, like mass spectrometry (MS).  
 
Capillary electrophoresis introduced in the 70’s has long been an intermediate method between the 
conventional (slab) gels and the miniaturised microchips. CE offers attractive features for the analysis 
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of proteins, as the analysis times can be relatively short and only minute amounts of sample are 
needed. An efficient cooling allows very fast electrophoretic migration in the capillary. All the 
separation steps can be automated. The recent progress in microfluidics will allow soon the capacity to 
perform fully automated analysis that requires nano-L of samples and a few µL of sera for immuno-
monitoring. Furthermore, CE analyses are carried out in fused-silica capillaries under aqueous 
conditions and in the absence of a stationary phase. This enables the study of proteins without causing 
conformational changes due to organic modifiers and/or a stationary phase (Haselberg et al., 2007).  
Kronsteiner et al. (2008) used capillary zone electrophoresis to characterise two recombinant products 
of the birch pollen allergen Bet v1a. However, in the case of putative (new) allergens present in GM 
crops it will be necessary to characterise the allergen on more than size and charge because small point 
mutation might render a non-allergenic protein an allergen or vice versa. This information can not be 
obtained with CE analysis alone. Therefore, amino acid sequence information will be needed for true 
characterisation. Chen et al. (1998) characterised latex allergens by capillary electrophoresis and 
combined it with N-terminal amino acid sequence analysis of the isolated allergens.  
 
There has been an increased interest in the development of chip-based analytical systems, as they may 
increase analysis speed and performance, and reduce cost, weight and size of the instrumentation. 
Successful efforts have been made to combine microfluidic CE systems with mass spectrometric 
detection (DeVoe and Lee, 2006; Sung et al., 2005). In the protein analysis field, applications of chip-
based CE-MS mainly focus on digests of proteins, but intact protein analysis has also been described 
in some cases (Haselberg et al., 2007). These chip based analytical systems that couple microfluidic 
systems with mass spectrometry give more identification of peptides or proteins, but still no sequence 
information. This could for instance be obtained when using MALDI-MS/MS. There are no examples 
however where this combined chip-based system with MALDI-MS/MS is used for allergen detection 
and identification. 
 
A combination of separation and detection based on immunochemical and physiochemical properties 
can also be used, as is performed in the SELDI-MS (Surface Enhanced Laser Desorption Mass 
Spectrometry) analysis method (Hsieh et al., 2005) or by making a combination of immunoblot 
screening or immunoprecipitation coupled to mass spectrometry (Bassler et al., 2009; Careri et al., 
2007). 
 
SELDI-TOF-MS (surface-enhanced laser desorption/ionisation time of flight mass spectrometry), first 
introduced by Yip and Hutchens (1992), is based on two powerful techniques, chromatography and 
mass spectrometry. It consists of selective protein/peptide extraction and retention on chromatographic 
chip arrays and their subsequent analysis using a simple laser desorption/ionisation mass spectrometer 
(Hsieh et al., 2005; Merchant and Weinberger, 2000) The ProteinChip arrays have chemically 
derivatised surfaces utilising classical chromatographic separation characteristics such as reversed 
phase, ion exchange, silica, immobilised metal affinity capture, and preactivated capture. The latter 
surface allows for covalent attachment of various molecules, such as antibodies, receptors, DNA, 
small molecules, and ligands. Bio-active proteins/peptides can thus be captured on these surfaces 
and/or identified through the recognition of their corresponding antibodies. 
SELDI-TOF-MS technology has thus far been successful in various applications ranging from protein 
profiling of complex biological mixtures (Issaq et al., 2002) to identification and characterisation of 
biomolecules (Caputo et al., 2003).  
SELDI-TOF-MS technology could be used for allergen detection in GM plants when a set of 
antibodies raised against the main allergens would be available that can selectively capture allergens 
present in an extract. The captured proteins can be characterised by mass spectrometry of intact 
proteins. Again, no sequence information becomes available.  
Examples of the SELDI-TOF-MS method where allergens are selectively captured by antibodies 
covalently attached to a protein chip array are not available yet, but could present a promising 
technique. For isoform identification, sequence information will be needed and MS/MS application 
therefore will be necessary. 
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Capture of known allergens with magnetic beads coupled to specific antibodies can also be combined 
with MALDI-TOF/MS. After release of captured allergens tryptic digestion should be performed.  
 
MS/MS analysis has been used to get sequence information for the identification of allergens and of 
their different isoforms, where MS/MS has been combined with immuno-affinity or immunodetection 
of the allergens in a complex protein mixture. Helsper et al (2002) used affinity purification of apple 
allergens in combination with Q-TOF-MS/MS for the identification and semi-quantification of 
different isoform compositions. Also non-allergenic proteins have been identified in such a way. 
Elvira et al (2008) used immunodetection by Western blot analysis of 2D protein gels of pathogenesis-
related (PR) proteins in compatible and incompatible viral infections of Capsicum chinensis plants to 
identify PR protein spots. These spots were excised from the membranes and sequenced by MALDI-
TOF spectrum and MS/MS spectrometry.   
 
In these above mentioned examples, the allergens or proteins are first purified by immuno-affinity or 
immunodetection in a 2D protein gel, and subsequently characterised by MS/MS peptide sequencing. 
This is a labour intensive method, but small sequence differences in isoforms can be detected. Since 
different isoforms can have different IgE-reactivity, this sequence information is very valuable.  
 
Bassler et al. (2009) used a multidimensional strategy combining immunodetection or 
immunopurification and LC-MS/MS for protein fractionation and molecular characterisation of tomato 
seed allergens. For protein separation they performed two-dimensional chromatography using 
chromatofocusing (CF) for the first dimension and reversed phase (RP) chromatography in the second 
dimension. The protein fractions were subjected to SDS-PAGE for further separation. Potential 
allergens were detected by IgE immunoblotting and analysed using LC-MS/MS. A legumin- and a 
vicilin-protein were identified as IgE-cross-reactive tomato seed proteins as new putative allergens 
showing a significant homology to other previously reported food allergens. Expressed sequence tag 
(EST)/Contig sequence alignments combined with tryptic peptide coverage analysis revealed a novel 
full-length vicilin protein in tomato. This combined method of multidimensional LC-MS/MS 
combined with immunodetection is again a targeted and labour-intensive method, but renders 
sequence information. In this example new putative allergens could be detected in a very complex 
protein mixture. 
 
Complex matrices commonly affect the sensitivity and selectivity of liquid chromatography-mass 
spectrometry (LC-MS) analysis. Thus, selective sample enrichment strategies are useful particularly to 
analyse proteins present in low abundance in samples. Known allergens can be selectively enriched 
from the samples for (semi)quantitative analysis based on their immunochemical properties 
(immunoaffinity enrichment). A similar approach can be used to enrich unknown allergen isoforms for 
identification. Careri et al. (2007) have developed a selective immunomagnetic extraction procedure to 
isolate trace peanut allergen protein Ara h3/4 from breakfast cereals combined with microwave-
assisted tryptic digestion and liquid chromatography-electrospray ion-trap tandem mass spectrometry 
(LC-ESI-IT-MS/MS) measurement. Using protein A-coated magnetic bead support, anti-Ara h3/4 
monoclonal antibodies were used as selective capture molecules. The results obtained by LC-ESI-IT-
MS/MS in terms of limit of detection (3 mg peanut/kg matrix) and a significantly reduced matrix 
effect by this enrichment step demonstrated that the Ab-coated magnetic bead was very effective to 
selectively trap Ara h3/4 protein in breakfast cereals. The magnetic bead-based sample treatment 
followed by LC-IT-MS/MS method that has been developed can be proposed as a very rapid and 
powerful confirmatory analytical method to verify the reliability of enzyme-linked immunosorbent 
assay (ELISA) screening methods, since the magnetic bead-LC-IT-MS/MS method combines good 
sensitivity to the identification capabilities of mass spectrometry (Careri et al., 2008). The use of a 
selective immunomagnetic extraction procedure combined with LC-MS/MS analysis speeds up the 
procedure compared to the earlier discussed immunodetection or immunoaffinity extraction 
procedures. This could all be automated or robotised and therefore be made high throughput. 
Antibodies need to be raised separately against all known allergens. The method is not quantitative, 
unless the samples are spiked with radiolabeled peptides. Furthermore, this example shows that 
allergens can be detected in processed food. 
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Careri et al. (2009) and Terenghi et al. (2009) have developed a liquid-phase immunoassay for the 
simultaneous determination of five biomarker proteins (antigens). The corresponding antibodies were 
labeled with different lanthanides. The immunocomplexes separated by size exclusion 
chromatography (gel filtration) were determined with inductively coupled plasma mass spectrometer 
(SEC-ICP-MS). The sensitivity of the method was shown to be comparable with that attainable by 
ELISA, with the advantages of multiplexed analysis capacity, virtually no sample preparation, and 
three times less sample than in ELISA. 
 
5.7. Profiling methods to detect modifications in protein expression induced by the 
genetic modification 
 
As already mentioned, the classical proteomic approach including 2-DE followed by immunoblotting 
is a laborious method which requires human sera to detect putative allergens. In order to identify and 
characterise qualitative and quantitative alterations among the pattern of expression of natural 
allergens in a GM plant as compared to its conventional counterpart, it needs to be combined with 
cutting the immuno-reactive spot out of gel or membrane and MS/MS characterisation after tryptic 
digestion of the protein spot for identification. Comparison may not necessarily specifically focus on 
allergens as such but consider the whole set of proteins being expressed, making the use of human sera 
unnecessary. By using DIGE (Difference in Gel Electrophoresis) the protein pattern of a GM plant can 
be compared with that of its conventional counterpart by analysing the protein extracts on one gel. In 
this method different fluorescent labels are used to label proteins and as a consequence different 
extracts can be run and compared on the same 2D gel. With this method a protein extract from a GM 
plant can be compared to that of its conventional counterpart and an internal standard. All up-regulated 
protein spots could be visualised and cut out of the gel for identification. This method analyses more 
proteins than only allergens, but is not high troughput and not quantitative (Teshima et al., 2010). 
 
A non-targeted method using mass spectrometry, i.e. LC-Q-TOF-MS/MS, has been successfully used 
to detect and identify major allergens in processed peanuts by Chassaigne et al. (2007). Before this 
method can be used in a high throughput way to detect allergens in GM food, different allergen-
specific sequence tags need to be identified that can function as markers of the specific allergenic 
proteins using this method. Comparitive LC-TOF-MS/MS could compare tryptic digests of GM plant 
extracts versus appropriate comparators and selectively perform MS/MS on the differentiating mass 
peaks. This method is quantitative (America and Cordewener, 2008), but not high throughput. It will 
give, however, information on all differentiating proteins and peptides in the GM food compared to its 
conventional counterpart. 
 
Profiling techniques for quantifying changes in protein abundance between samples is a key 
requirement. To assess differential protein expression, one approach is to use isotope or mass tag 
labeling of peptides where two samples to be compared are covalently modified by isotopically 
distinguishable but chemically similar adducts (e.g. 1H versus 2H, 12C versus 13C, or 14N versus 15N). 
The samples are proteolysed, mixed and relative changes in protein abundance are determined from 
ratios of intensities between the differentially labeled peptides using MS. Gygi et al (1999) used an 
isotope coded affinity tag (ICAT) reagent with specificity toward sulfhydryl groups. In this case the 
side chains of cysteinyl residues in a reduced protein in a non-GM sample are derivatised with the 
isotopically light form of the ICAT reagent. The equivalent residues in the GM plant are derivatised 
with the isotopically heavy reagent.  The two samples are combined and enzymatically cleaved to 
generate peptide fragments, some of which are tagged. The tagged (cysteine-containing) peptides are 
isolated by avidin affinity chromatography, the isolated peptides separated and analysed by LC-
MS/MS. Both the quantity and sequence identity of the proteins from which the tagged peptides 
originate are automatically determined by multistage MS using the spectrometer in a dual mode 
alternating in successive scans between i) measuring relative quantities of peptides eluting from the 
capillary column and ii) driving sequence information of selected peptides. Peptides are quantified 
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from the relative signal intensities for pairs of peptide ions of identical sequence that are tagged with 
the isotopically light or heavy forms of the reagent, respectively.  
 
The chemical reaction in the ICAT alkylation can be performed in the presence of urea, sodium 
dodecyl sulfate (SDS), salts, and other chemicals that do not contain a reactive thiol group. Therefore, 
proteins are kept in solution with powerful stabilising agents until they are enzymatically digested.  
Studies indicate that the accuracy and variability of such ICAT approaches can reliably detect down to 
an 1.5-fold change in protein abundance over a dynamic range from 10- to 100-fold. Zhou et al (2002) 
describe a method for site-specifc stable isotope labeling of cysteinyl peptides in complex mixtures 
through a solid phase capture and release process and concomitant isolation of labeled peptides using 
LC-MS/MS) to determine their sequence and relative quantities.  The solid phase system appears 
simpler more efficient and more sensitive than the ICAT systems per se.    
 
Disadvantages include cost of isotopic labeling and equipment for pairwise comparisons between 
samples, which prevent retrospective comparisons and complicate large studies.  Not all proteins 
contain cysteinyl residues and are therefore missed by using thiol-specific ICAT reagents but ICAT 
reagents with different specificities make cysteine-free proteins susceptible to analysis by the ICAT 
method.  The ICAT approach provides a broadly applicable means for the quantitative cataloguing and 
comparison of protein expression in a variety of biological samples.  However, to date it has not been 
widely used for plant tissues.    
 
Label-free methods for protein quantitation in shotgun datasets offer an alternative approach to stable 
isotope labeling methods. Peak area intensity and spectral counting methods enable protein ratios 
significant to 2.5-fold to be determined with high confidence. This is a lower sensitivity compared 
with isotopic labeling where protein ratios significant to 1.5-fold have been reported (Old et al., 2005 
and references therein) but neverless biologically relevant. The ability to achieve this without stable 
isotope labeling can be advantageous under conditions where metabolic labeling or chemical 
derivatisation is difficult. Old et al (2005) and others have demonstrated that mass spectral peak 
intensities of peptide ions correlate well with protein abundances in complex samples. Label-free 
methods, termed spectral counting, compare the number of MS/MS spectra assigned to each protein. 
An advantage of the spectral counting approach is that relative abundances of different proteins can in 
principle be measured. Thus, significant correlations have been shown between spectral counts and 
independent estimates of protein copy number.   
 
Comparative LC-MS/MS has also been used to identify which Betv1 allergenic isoforms are expressed 
in different birch species. Not only the presence but also the relative abundance could be determined 
of isoforms with a high and low IgE-reactivity (Schenk et al., 2009). When using MS/MS analysis to 
determine sequence information of the allergens, the availability of DNA sequence information 
(genomic sequences, cDNA or EST sequences) of the allergens is important to be able to identify the 
peptides. Since DNA sequencing has been put to a higher level with the next generation sequencers, 
this type of information is explosively expanding. 
 
5.8. Conclusions and recommendations 
 
Conclusions 
Profiling techniques can employ either targeted approaches in which for example specific antibodies 
(e.g. human IgE) are used for immuno-capture and/or immuno-detection of particular allergens on 
which the analysis is focused, or non-targeted approaches. Allergens in whole plants can be analysed 
based on their immunochemical and biological properties via Enzyme Linked ImmunoSorbent Assay 
(ELISA) and two dimensional electrophoresis in gel (2-DE) followed by immunoblotting. Mass 
spectrometry is commonly used in combination with 2-DE and immuno-detection. Other methods, 
including novel mass spectrometry-based technologies are a potential alternative to the 2-DE approach 
towards multi-dimensional separation of proteins.  In spite of their great performances, ELISA and 2-
DE in gels followed by immunoblotting do have some limitations and critical points with regard to the 
natural heterogeneity of some allergens (isoallergens), allergen extraction, matrix or processing 
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effects, carbohydrates on allergens (CCD), analytical and detection method and availability of human 
sera. Analytical proteomics methods do also have some limitations with regard to the identification of 
proteins, the availability of antibodies against allergens and the identification of allergen-specific 
sequence tags. 
 
Immunoassays such as ELISA and 2-DE combined with immunobloting require human sera from 
clinically well-characterised allergic individuals. These sera have to be available in sufficient 
quantities and sufficient numbers, which might be difficult. The comparison of the allergen repertoire 
of a GM plant with its appropriate comparator(s) could include a pre-screening test with well-
characterised antibodies from sera of animals experimentally sensitised in well-defined conditions as a 
substitute for allergic individual sera. 
 
2-DE followed by immunoblotting and MS analysis is a laborious method. A comparative non-
targeted approach can be done by using DIGE (Difference in Gel Electrophoresis) in which all up-
regulated protein spots are cut out of the gel for identification. A drawback of 2-DE is that highly 
charged and large proteins are difficult to resolve. Furthermore, low abundance proteins are also 
difficult to identify in the presence of highly abundant components. Extra fractionation of sequential 
extraction techniques is therefore needed. For MS/MS identification of a protein spot from the 2D gel 
a relatively high amount of protein is needed. 
 
Other methods may combine immunocapture - when an appropriate set of antibodies is available - and 
different types of MS analyses such as SELDI-TOF-MS, MALDI-TOF-MS or Q-TOF-MS/MS for the 
identification of bound fractions. 
 
A new powerful in vitro analytical method is LC-Q-TOF-MS/MS which has been successfully used to 
detect and identify major allergens in foods. This is a high throughput analytical technique which is 
sensitive, quantitative and not dependent on human sera. Not many laboratories have the apparatus, 
expertise and skilled personnel to perform this type of analysis yet, it appears as a promising technique 
in the future. 
 
Other non-targeted techniques are available which allow the direct comparison of the protein patterns 
in extracts from a GM plant and its conventional counterpart (comparative LC-TOF-MS/MS) and 
selectively perform MS/MS on the differentiating mass peaks. Isotope or mass tag labeling approaches 
and contemporary label-free spectral counting methods need to be assessed for suitability as non-
targeted differential protein analysis tools for plant tissues. 
 
Recommendations 
1-DE and particularly 2-DE followed by immuno-blotting are appropriate in vitro tests to compare the 
levels of endogenous allergens in GM plants and their appropriate comparator(s). If differences are 
detected in the allergen repertoire and they are considered to be of biological significance, more in-
depth sequence analysis is necessary to identify and quantify the allergens and their isoforms. In 
combination with immunodetection using sera from allergic individuals, MS is an option to get 
sequence information and (semi)quantification specifically on allergen spots which differ between the 
GM plant and its appropriate comparator(s). 
• For a comprehensive comparison of the allergenicity of the GM plant and its appropriate 
comparator(s) using ELISA, 2-DE and, if applicable, MS-based techniques, appropriate 
protein extraction procedures need to be tested to cover the different allergenic proteins 
present in the GM plant and its conventional counterpart, including those not easily soluble in 
aqueous buffers. 
• Immunoassays such as ELISA and 2-DE plus immunobloting require human sera from 
clinically well-characterised allergic individuals. In order to avoid the risk to overlook minor 
allergens/isoforms, immunological determinations should be performed using individual sera 
and not pooled sera. These sera have to be available in sufficient quantities and sufficient 
numbers, which might be difficult. Therefore, antibodies with appropriate characteristics of 
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specificity and affinity, obtained from animals experimentally sensitised in well-defined 
conditions, could be used as probes for a pre-screening of potentially allergenic proteins (see 
also Annex 6.3). 
• Future work should study the specificity, sensitivity and feasibility of new profiling 
technologies, particularly those based on so called “-omics” techniques, for the assessment of 
allergenicity. A thorough assessment needs to be made of their advantages and weaknesses in 
order to compare these modern techniques in terms of reliability of interpretation of the results 
with those classically used for targeted analysis, which require the use of human sera. 
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ANNEX 6. ANIMAL MODELS  
 
6.1. Introduction  
 
Animal models of food allergy reproducing the pathophysiology of allergic diseases in humans 
provide a unique strategy for the in vivo detection and screening of proteins as well as chemicals with 
potential allergenicity. Allergic diseases in human encompass a wide variety of clinical symptoms that 
can manifest local reactions affecting the skin, the digestive and respiratory tracts as well as systemic 
reactions that can lead to an anaphylactic shock and even death. Although the pathophysiology of 
allergic diseases is still poorly understood, they can be distinguished by two major types of 
hypersensitivity reactions to one or more allergens, i.e. immediate-type hypersensitivity, (ITH) 
(associated with allergen-specific IgE antibodies in serum) or delayed-type hypersensitivity (DTH) 
(associated with allergen-specific effector T cells). The development of ITH and DTH reactions to a 
given allergen appears within minutes (ITH) to several days (DTH) after allergen exposure. In both 
cases, the symptoms reflect that the individual has been previously sensitised to this 
compound/allergen, although the exact time of sensitisation cannot be precisely determined.  
 
Animal models for food allergy have mainly been used for research purposes focussed on the basic 
mechanisms underlying food allergy, new strategies for prevention and therapy and for identification 
of reliable biomarkers and endpoints of the severity of an allergic reaction. They allow better 
understanding the interactions between the numerous factors involved in the induction or suppression 
of oral tolerance, the relationship between digestibility and allergenicity, the influence of routes and 
doses of administration, duration and timing of exposure on allergic sensitisation. Other factors 
contributing to the propensity to develop an allergic reaction such as the genetic background, the age 
of the subject, physiological, nutritional and environmental conditions at the time of exposure were 
also investigated. Animal models are also developed and evaluated as a systemic approach for hazard 
identification and allergy risk assessment; refined, standardised and validated test procedures are 
aimed to provide reliable tools for evaluating the relative potency of food proteins for sensitisation and 
elicitation of allergic reactions (Bowman and Selgrade, 2009; Selgrade et al., 2003). 
 
The different guidelines available for assessing the allergenicity of (novel) proteins actually focus on 
IgE mediated allergic reactions. They also particularly pertain to the capacity of a novel protein to 
trigger an allergic reaction in allergic consumers already sensitised rather than on the capacity to de 
novo sensitise predisposed atopic individuals. 
 
Bioinformatics and IgE binding studies using sera of allergic individuals are key steps of the 
assessment of the possible sequence homology or structural similarity and cross reactivity of the newly 
expressed protein(s) in a GMO with known allergens. However, as due to several reasons the use of 
human sera is limited and the development of relevant and validated animal models for food allergy 
that can be used as a surrogate or complement is encouraged. They are also necessary because 
sensitisation experiments can not be done in humans. In addition, in vitro tests cannot reproduce the 
complexity of the immune system and account for the interactions between the numerous factors that 
are involved in the regulation of the immune response and the development of a tolerance or allergic 
reaction to a given protein in particular conditions of environment and exposure. 
 
Furthermore, other aspects may be taken into consideration when assessing the allergenicity of GMOs 
as previously emphasised in the document such as the immunogenicity and the adjuvanticity (see 
Annex 1.9.1). 
 
Animal models should thus help in addressing 3 major issues: 
i) is the novel protein a sensitiser, i.e. does it posses intrinsic properties that allow to de novo sensitise 
a predisposed individual? 
ii) is the protein an elicitor i.e. is it able to elicit an allergic reaction in an already sensitised individual 
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to the same or to a cross-reactive protein? 
iii) is the protein an immunogen or an adjuvant, i.e. can it induce an immune response (non IgE) or 
facilitate/enhance the sensitisation to another by-stander protein which is present together with the trait 
protein? 
 
In addition they also should allow a more holistic approach taking into account the impact of the food 
matrix, food processing and different conditions of exposure on the nature of the immune response 
which might be induced. 
 
However, the relevance of using animal models for assessment of allergenicity of GMOs has been 
questioned because none of them completely reproduces the conditions of sensitisation and clinical 
manifestations occurring in humans and because of their variability depending on the animals species 
and protocols used and finally for the lack of sensitivity and specificity (Goodman et al., 2008). 
 
Combination, on a case-by-case basis, of in vivo testing using different animal models such as those 
described below with other tests may certainly improve the weight-of-evidence approach to evaluate 
the likelihood of allergenicity of a GMO.  
 
6.2. Available animal models 
 
6.2.1. Criteria for development of animal models for food allergy 
 
6.2.1.1. Animal species and strains 
 
Allergic individuals have a predisposed (i.e. atopic) genetic background and a close resemblance to 
this scenario in animal models is therefore desirable. This can be achieved by using a strain of an 
animal species that is susceptible for allergic disorders. For instance the Brown Norway rat is a high 
immunoglobulin - especially IgE - responder strain (Atkinson and Miller, 1994), the BALB/c mouse 
shows an immunological responsiveness, which has a propensity towards a Th2 type phenotype and 
IgE production (Hilton et al., 1997). Other strains of mice have also been extensively used including 
mutant strains [e.g. for expression or deficiency of specific toll like receptor (TLR)] or genetically 
modified animals. Alternatively, atopic dogs as well as neonatal swines are used as experimental 
models to test for specific IgE responses (Helm, 2002; Untersmayr and Jensen-Jarolim, 2006). 
 
Besides genetic characteristics, other factors may be involved in the type and intensity of the immune 
response. The normal gut microbiota has been long recognised to play a major role in the 
differentiation of the intestinal immune system and particularly in the induction and maintenance of 
oral tolerance. It has been shown to affect the propensity of the mice to develop an allergic reaction 
when exposed to a foreign protein, which is increased in germ free animals as compared to 
conventional animals (Hazebrouck et al., 2009; Moreau and Gaboriau-Routhiau, 1996). Several 
mechanisms may be involved including the production of lipopolysaccharide (LPS). Indeed, feeding 
mice with ovalbumin (OVA) prior to i.p. immunisation with OVA plus adjuvant, reduces OVA 
specific serum antibody production in normal C3H/HeN mice but not in C3H/HeJ which have a 
spontaneous mutation in the LPS responsive gene, subsequently identified as the TLR4 (see also 
below) (Moreau and Corthier, 1988). 
 
6.2.1.2. Route and methods of administration 
 
Several routes and modes of administration of the allergen are currently used. The oral route, using 
intragastric (i.g.) or oral gavage may be preferred over the intraperitoneal (i.p.), intranasal (i.n.) or 
cutaneous route, because it looks like a more relevant reflection of the situation in humans. Indeed, 
natural barriers such as the acidic and enzymatic conditions in the gastro-intestinal tract and the 
digestibility of proteins influence the allergenicity (Atkinson et al., 1996; Pauwels et al., 1979; Strobel 
and Ferguson, 1984; Turner et al., 1990; Untersmayr et al., 2003). However, exposure to proteins via 
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the oral route normally leads to oral tolerance (Strobel and Ferguson, 1984; Turner et al., 1990). Also 
the possible dietary pre-exposure of the test animals or their parental generations to the protein under 
investigation may have resulted already in tolerance induction (Knippels et al., 1998). Oral 
sensitisation to the protein may thus not always be achieved in this way and other routes of 
administration are used to increase the sensitivity of the test. Proteins can be administered alone or in 
presence of adjuvants, such as cholera toxin (CT) for the oral route, complete or incomplete Freund’s 
adjuvant (CFA/IFA) or alum for i.p. administration. Although natural adjuvant conditions such as 
intestinal inflammation or infections may occur in real-life situations, the use of adjuvants has been a 
point of discussion particularly when assessing the inherent allergenicity of a novel protein because it 
modifies the ability of proteins to induce sensitisation. This may result in false positive results if 
appropriate controls are not included in the test and if the test is misused as the single definite way to 
conclude on the allergenic potential of a protein. However, with respects to the specific and limited 
objectives of the test the use of adjuvants may not be regarded as a problem in the context of the whole 
assessment procedure. Also, it is possible that trace amounts of LPS or various chemicals 
contaminating the allergens preparation exert some adjuvant effect and this could complicate 
interpretation of data generated using distinct allergen sources. 
 
It is noteworthy that presence of the test protein in the animal chow would limit the sensitising 
potential observed when an experimental sensitisation is further performed. 
 
In order to avoid false positive and false negative results due to the genetic background of the animal 
strain and/or conditions of exposure (e.g. diet, microbial environment, structure, presentation and dose 
of the allergen) appropriate controls should be included and the whole immune response (e.g. specific 
IgE and IgG antibody production and cellular response) explored. 
 
The source and quality control required for compounds used as experimental allergens in animal 
models is a crucial question. This issue is also relevant when testing a purified newly expressed 
protein (as expressed in the plant or as a recombinant protein produced in microorganisms) and/or 
crude protein extracts from the whole crop for the allergenicity assessment of a GMO. 
 
6.2.2. Models for investigating the sensitising potential 
 
The sensitising potential of a protein is its capacity to induce the production of specific IgE antibodies. 
It is sometimes confused with its immunogenicity, i.e. the capacity to induce the production of any 
kind of antibodies and particularly those of the IgG class. Immunogenicity does not reflect an 
allergenic potential in the literal sense although it may be associated with a delayed type reaction 
and/or inflammatory diseases (Prescott et al., 2005). Models of experimental sensitisation are mainly 
developed in mice and rats, using different procedures. They have been used for the assessment of 
allergenicity of purified proteins, of protein extracts from foods and also of complex whole foods. 
Other non-rodent animal allergy models like pigs and dogs are often introduced as they show a more 
related physiology and immune system similarity to humans (Helm and Burks, 2002) and may 
therefore contribute further to the knowledge of the allergic responses in humans (Kimber et al., 
2003). For review see also Dearman and Kimber (2009). 
 
Different strains of mice such as BALB/c or C3H mice and Brown Norway (BN) rats are particularly 
used because of their natural propensity to develop a Th2 type immune response which could resemble 
a human atopic genetic background.  
 
6.2.2.1. Mice 
 
Dearman and Kimber developed a model in which 8 to 12 week old adult female BALB/c mice were 
used. Sensitisation was achieved by repeated i.p. administrations of a test protein dose in phosphate 
buffered saline (PBS), without adjuvant. The dose depends on the expected allergenicity of the 
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protein. On day 14, 28 or 42 mice blood samples are tested for protein specific antibody 
determinations (Dearman and Kimber, 2001; Kimber et al., 2003).  
The degree of sensitisation is estimated by the quantification of the IgE (and IgG1) antibodies that 
have been produced after the experimental sensitisation with the test-protein, the capacity to induce a 
specific IgE response in a large proportion of treated animals seems to reflect the sensitising potential 
in humans. Using this model experiments have been performed with OVA and bovine serum albumin 
(Dearman et al., 2000), lipase from the mould Aspergillus oryzae (Hilton et al., 1997), the minor 
peanut allergen: peanut agglutinin and the non-allergenic potato acid phosphatase (Atherton et al., 
2002; Dearman and Kimber, 2001). These experiments show difference in the vigor of specific IgE 
antibody responses induced by OVA and bovine serum albumin (Dearman et al., 2000). Serological 
responses appear to distinguish between strong-, weak- and non-allergenic proteins, with a pattern of 
IgE responses that is consistent with what is known of the relative sensitising potential of the 
corresponding proteins in humans (Atherton et al., 2002; Kimber et al., 2003). 
Adel-Patient et al. (2000; 2001) quantified the intensity and analysed the specificity of IgE, IgG1 and 
IgG2A antibody responses in BALB/c mice that were i.p. immunised against β-lactoglobulin (BLG), a 
cow’s milk allergen. They showed that the IgE epitopes on BLG recognised by the mouse were the 
same as those recognised by the serum IgE antibodies of milk allergic humans. 
 
In other models, developed for food allergy, the mice showed apart from antibody responses (IgE, 
IgG1) also clinical symptoms of food allergy such as diarrhoea, anaphylaxis, and eosinophil and mast 
cell accumulation (Prescott and Hogan, 2006).  
 
Gizzarelli et al. (2006) sensitised BALB/c mice by i.g. gavage of protein extracts from a wild type and 
an herbicide tolerant genetically modified (GM) soybean in the presence of cholera toxin. They indeed 
induced Th2 immune responses that were similar for both kind of soybeans but did not evidence any 
specific response to the newly expressed protein in the GM soybean.  
 
The intranasal route has also proven to be an efficient route for sensitisation in BALB/c mice (Hilton 
et al., 1997). In addition, BALB/c mice have also been used to assess the allergenicity of whole food 
(e.g. milk, peanut) and not only of purified proteins. Adel-Patient et al. (2005) showed that the 
allergens recognised by mouse IgE antibodies were the same as those recognised by serum IgE 
antibodies of humans allergic to milk or peanut.  
 
The model developed by Strid et al. (2004) is derived from those described above, whilst some 
essential parts have been modified in the procedure. Sensitisation is achieved on 6 to 8 week old 
female BALB/c mice using first a single i.g. administration of the protein antigen in PBS followed by 
an injection of the protein in presence of complete Freund’s adjuvant (CFA) and, on day 28, a boost 
injection of the protein solution in PBS is performed in the foot pad. Oral challenge of sensitised mice 
is performed using high doses of protein, in the hundreds milligrams range. This test has been used to 
assess the delayed type hypersensitivity by measuring the food pad swelling after the last boost 
administration. Cell proliferation and cytokine production in spleen and lymph node cells are 
measured by ELISA, after in vitro re-stimulation. Total and specific IgE and specific IgG, IgG1, 
IgG2a were measured using immuno-assays. Performed with both peanut and egg allergens, this 
model confirmed that the the estimated sensitising potential did depend upon the nature of the protein. 
 
In a subsequent paper by Strid et al. (2005) it was concluded that induction of oral tolerance to peanut 
protein can be prevented by epicutaneous exposure to peanut protein, which even might modify 
existing tolerance to peanut. The epidermal exposure to protein allergens would selectively drive Th2-
type responses and might promote sensitisation to food proteins upon oral (gastrointestinal) exposure. 
Similar findings were made by Adel Patient et al. (2007) thus confirming the clinical observations on 
humans allergic to peanut and the fact that exposure via different routes may interact and greatly affect 
the sensitisation. 
 
The oral sensitisation to OVA was studied in different mice strains (e.g. BALB/c, B10.A and ASK) 
and rats by Akiyama et al. (2001). In the different mice strains the effect of age, oral feeding technique 
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and dose of protein were examined. In terms of OVA-specific IgE and IgG1 antibody, the B10.A mice 
were found to exhibit the highest response of the three mice strains tested. Based on the results 
observed it was also suggested that oral sensitisation of mice requires low doses and intermittent 
protein intake. Bodinier et al. (2009) have tested the sensitising potential of wheat gliadins in 3 strains 
of mice and concluded that BALB/c mice were the most appropriate model. 
 
Bowman and Selgrade (2008) subcutaneously (s.c.) or orally sensitised C3H/HeJ mice with extracts 
from most common allergenic foods (e.g. peanut, Brazil nut and egg white), and from non-allergenic 
foods such as turkey and spinach in the presence of cholera toxin. The aim was to establish a spectrum 
of potency of the tested food allergens in order to relate the allergenic potency of a novel protein to 
known food allergens. The oral route of exposure appeared to better discriminate allergenic foods 
from non-allergenic than the s.c. administration. 
 
Birmingham et al. (2007) proposed an adjuvant free transdermal sensitisation protocol on mice with 
subsequent oral challenge and measure of the antibody response and clinical score for anaphylaxis. 
Extracts from most common allergenic food (e.g. peanut, tree nut, egg, fish, milk etc ...) and from non-
allergenic food (e.g. spinach, pinto bean, sorghum etc...) were used which allowed to test the 
sensitivity and specificity (e.g. positive and negative predictive values) of this model. 
 
Transgenic animal (mouse) models 
The use of GM animals, particularly mice, for the assessment of allergenicity is based on the rationale 
that food allergy is the consequence of altered oral tolerance i.e. a physiological mechanism of 
immune suppression to environmental allergens. Indeed, the mucosal-associated immune system 
(MALT), and in particular the intestinal immune system is geared toward induction of immune 
tolerance to exogenous but harmless antigens, such as dietary antigens and components of the bacterial 
flora to which epithelial tissues are constantly exposed (Dubois et al., 2003). This process prevents the 
induction of T cell–mediated inflammatory and allergic reactions that primarily affect surface 
epithelial tissues (buccal mucosa, intestine, skin). Immune tolerance induced by the oral route, 
prevents the outcome of both systemic or local allergic reactions to proteins and chemicals and is 
induced and maintained by regulatory T cells (i.e. Treg) (Desvignes et al., 1996; Desvignes et al., 
1998; Desvignes et al., 2000; Dubois et al., 2003). Most animal models and particularly transgenic 
mice aim at circumventing the mechanisms of normal oral tolerance. 
 
The major histocompatibility complex (MHC) plays an important role in the development and 
polarisation of the immune response which may result in strain dependent qualitative and quantitative 
antibody responses to experimental sensitisations. 
 
Several strains of mice such as the different C3H variants have been used to study the influence of the 
genetic background in the assessment of the sensitising potential of a protein. Altered IgE responses to 
OVA were thus observed in C3H/HeJ, TLR4 deficient and thus LPS-hyporesponsive, strains of mice 
(Vaz et al., 1971). Using 3 different substrains of C3H mice with the same genetic background (H-2k), 
Kaiserlian et al. (2005) have demonstrated that repeated oral immunisations with BLG in presence of 
CT induced variable clinical scores of immediate-type hypersensitivity upon oral challenge with BLG 
alone, reproducing the variable allergic disease severity in human. Wild type normal C3H/HeN mice 
did not develop clinical symptoms, C3H/HeOuJ mice (a substrain of HeN mice) could be sensitised 
after several immunisations but developed only mild clinical symptoms, while C3H/HeJ mice could be 
rapidly sensitised and developed severe systemic symptoms with anaphylaxis. Remarkably, depletion 
of natural Treg increased the severity of symptoms in C3H/HeOuJ mice, which became as susceptible 
as C3H/HeJ mice. 
 
Other studies have pointed out that the C3H/HeJ mouse strain is more susceptible to the induction of 
food allergy than other non-deficient mouse strains which makes it a valuable strain for food allergy 
research (Frossard et al., 2004a; Frossard et al., 2004b; Kaiserlian et al., 2005; Sicherer and Sampson, 
2006). However studies of Bashir et al. (2004) and Berin et al. (2006) on several mouse strains of 
different genetic backgrounds including the TLR4+- and TLR4--C3H, C57Bl/6 or BALB/c mice 
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sensitised either with BLG or peanut extract demonstrated that T-cell responses, propensity to develop 
an allergic reaction and intensity of the IgE response were under H2-linked genetic control and depend 
on both the TLR4 status of the mice and the nature of the antigen. 
 
Advantages of application of transgenic animals to hypersensitivity studies may be that different types 
of genes, the gene product of which influences the immune system, might be introduced or knocked 
out of the genome, and the consequences of the genetic alterations studied. In addition of genetic 
variants of some mouse strains such as the C3H mice, genetically modified mice with impaired 
immune tolerance may also be a useful tool for the assessment of allergenicity. 
 
Data from selected gene-modified mouse have confirmed that Treg play an important role in 
controlling intestinal homeostasis. Indeed, mice with a gene defect affecting Treg number or function 
develop spontaneous chronic inflammatory bowel disease and enteropathy. The Treg compartment 
comprises natural CD4+CD25+Foxp3+ Treg, (which constitutively account for 5-10% of peripheral 
CD4+ T cells) and antigen inducible or antigen-experienced CD4+CD25-Foxp3- Treg. Both types of 
Treg can perform immune suppression of both antigen-specific T and B cell responses, by controlling 
the priming of naive T or B cells in secondary lymphoid organs (spleen, lymph nodes) as well as the 
activation of antigen-specific/memory effectors in target organs or epithelial tissues. Goubier et al. 
(2008) showed that subsets of dendritic cells in mice are tolerogenic and that depletion of these cells 
with specific monoclonal antibodies impairs oral tolerance and renders mice susceptible to in vivo 
sensitisation by the oral route, due to lack of suppressive mechanisms. 
 
Some mouse models with targeted disruption of a single gene essential for Treg differentiation, 
activation or function and which exhibit gut inflammation due to breakdown of oral tolerance to the 
flora and/or dietary antigens are also available. These mouse models include: i) MHC class II 
(Cosgrove et al., 1991) and invariant chain (Ii) (Viville et al., 1993) mice, which respectively harbour 
a complete or partial defect in class II-restricted CD4+ T cells (due to impaired positive selection in the 
thymus); ii) IL-2α chain (CD25) and IL-2R (Desvignes et al., 1998) KO mice, in which survival and 
expansion of Treg is impaired; iii) IL-10 (Desvignes et al., 1996) and TGFß (Cosgrove et al., 1991) 
KO mice, in which Treg function is altered; iv) TcRaß KO mice, which lack T cells and NK-T cells; 
v) Foxp3 KO mice, which have no natural Treg (Hori et al., 2003) 
 
In the future, two types of transgenic animal models are likely to become of most interest in the search 
for GMO allergenicity. The first one uses humanised mice in which major histocompatibility class II 
complexes are entirely of human origin. These will help understanding how a GMO is processed for 
presentation to T cells. Mice carrying specific human T cell receptors are also available, which will be 
useful to evaluate the signalling provided to T cells by GMO presentation. The second model is based 
on the rationale that allergens interact with the innate immune system via multiple mechanisms, which 
constitute the first event occurring when an allergen comes into contact with a living body. The innate 
immune system is highly conserved on an evolutionary basis. The use of some of the many mouse 
strains made deficient in innate immunity components (for example Toll or NOD receptors) will 
provide information likely to be directly extrapolated to the human situation.  
Finally, promoting new developments in constructing transgenic animals for allergenicity testing is in 
accordance with the “three R concept” (Replacement, Reduction, Refinement) based on finding 
replacements for conventional laboratory mice, reduction of amount of laboratory animals and use of 
modern technology. 
 
6.2.2.2. Brown Norway rat 
 
Another important animal model of food allergy is the Brown Norway (BN) rat (Jia et al., 2005; 
Pilegaard and Madsen, 2004). The BN-rat is a high immunoglobulin - especially IgE - responder 
strain, which resembles high IgE responsiveness of atopic individuals. 
 
As reported by Atkinson and Miller (1994) and Miller et al. (1999), 6 to 8 week old male BN rats were 
sensitised by i.p. injection of 10 µg of protein together with carrageenan used as adjuvant. They 
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demonstrated that the pattern of cow’s milk allergens recognised by sensitised rat IgE antibodies was 
the same as the allergen repertoire in allergic humans to milk. Moreover the IgE specificity at the 
epitope level was also very similar. This model was developed as a sensitive model for the 
investigation of allergic reactions to food and to determine the impact of dietary factors on the 
development of oral sensitisation. It was not particularly aimed for predicting the allergenicity of new 
proteins. 
 
This model has also been used to study oral sensitisation to allergenic foods or purified food proteins 
upon administration by gavage of 4 to 6 week old male BN rats in the absence of adjuvant (Knippels 
and Penninks, 2005; Knippels et al., 1999a; Knippels et al., 1998; Knippels et al., 1999b; Knippels et 
al., 2000). In a comparative study with Wistar, Hooded Lister, PVG and BN rats, the latter was found 
to be the most suitable strain of rats for oral sensitisation (Knippels et al., 1999b). The outputs of the 
study by Pilgaard and Madsen (2004) have shown that female rats are more appropriate than male for 
sensitisation studies. 
 
The first experiments in this model, developed in particular for the prediction of potential allergenicity 
of proteins, were performed using OVA (Knippels et al., 1998). In subsequent studies, a whole food 
(cow’s milk), whole protein extracts of hen’s egg white (Knippels and Penninks, 2002; Knippels et al., 
2000) and peanut, and purified strong-allergenic (peanut Arah1 and shrimp Pen a1), weak-allergenic 
(potato Sol t1) and non-allergenic (beef tropomyosin) proteins have been used (Knippels and 
Penninks, 2003). Upon oral application by gavage, rats showed specific IgE and IgG-antibodies to 
OVA (Knippels et al., 1999b), hen’s egg white proteins and cow milk proteins (Knippels et al., 2000). 
Temporary decrease in breathing frequency, blood pressure, and increase in gut permeability, which 
resembles human clinical manifestation, was then observed after oral challenge with OVA (Knippels 
et al., 1999a). Exposure to complex protein mixtures (cow milk, hen egg white) also showed IgE 
antibody responses to a comparable selection of proteins as observed in allergic patients (Knippels et 
al., 2000). 
 
The results obtained with the BN rat indicate that it might be a useful animal model to assess the 
potential allergenicity of novel food proteins. However, a high variability is observed in the induction 
of an IgE response after a well defined protocol of sensitisation. This is due to inherent variability of 
the strain, to environmental conditions to the diet of the animals and their parental generations and to 
the nature of the sensitising antigen. Despite the use of appropriate positive and negative controls, this 
may hamper to conclusively predict the allergenic sensitising potential of a novel protein. 
 
6.2.2.3. Guinea pig 
 
The guinea pig model is by far the oldest animal model for allergenicity. It has been used for 
experiments concerning the allergenicity of chemicals, cosmetics, pharmaceuticals and in particular 
for oral sensitisation studies of cow’s milk and infant formula (Devey et al., 1976; Fritsche, 2003; 
Kitagawa et al., 1995; Piacentini et al., 1994). However it is a less frequently used model for the 
assessment of allergenicity of novel proteins. The guinea pig can be sensitised by the oral route 
without adjuvant but immunologic reactions to proteins are different of those occurring in humans; for 
instance reaginic antibody responses are of the IgG1a subtype (Fritsche, 2003). Drawbacks for the 
further use of the guinea pig in food allergy research are therefore the significant differences in 
immuno-physiology when compared with other species, the limited knowledge of its immune system 
and as a consequence the lack of tools to study its immune system, and finally its questionable 
specificity in allergic sensitisation tests. 
 
6.2.2.4. Non-rodent animals 
 
In several non rodent species, other animal models for food allergy have been developed. As 
examples, the antibody responses observed in dogs and pigs experimentally sensitised to milk or 
wheat flour (Buchanan and Frick, 2002) or to peanut and different nuts (Helm et al., 2002; Teuber et 
al., 2002) partly mimic the pattern of recognition of human IgE antibodies and the elicited clinical 
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manifestations partly reproduce those occurring in allergic humans. In the following paragraphs these 
models in dogs and pigs are presented. 
 
6.2.2.4.1. Atopic Spaniel/basenji dogs 
 
The dogs that have been first introduced to test for food allergy are derived from a colony of inbred 
spaniel/basenji dogs, which have a genetic predisposition to allergy and have history of sensitivity to 
pollen and foods (Buchanan et al., 1997; Buchanan and Frick, 2002; Ermel et al., 1997; Jeffers et al., 
1996). This resembles high IgE responsiveness of allergic patients. Next to this the dog is one of the 
few species other than humans in which food allergies develop naturally and show the same clinical 
symptoms (Buchanan and Frick, 2002; Paterson, 1995). A similar model further developed by 
Buchanan and Frick (2002) uses newborn spaniel/basenji type pups. Sensitisation starts one day after 
birth by s.c. injection of the protein extract with alum as adjuvant and a live vaccine. Then pups are 
boosted by s.c. injections of 10 µg of protein in alum at bimonthly intervals. Allergic responses are 
tested by skin tests and feed challenge. The allergic response is determined by measuring the size of 
the wheal. The allergic response measured by feed challenge is performed by scoring of vomiting and 
number and quality of stools after oral challenge of the dogs with the protein (Buchanan and Frick, 
2002; Teuber et al., 2002). Sera from the animals 1, 2 and sometimes 3 years old were used for IgE 
immunoblotting (Teuber et al., 2002). 
 
This model has been performed using proteins from wheat, cow’s milk and beef extract (Buchanan 
and Frick, 2002) and also peanut, walnut, Brazil nut, barley and soy (Teuber et al., 2002). In the last 
experiment the hierarchy of reactivity by skin testing is similar to the clinical experience in human 
subjects (i.e. peanut, tree nut, wheat, soy, barley). Sligth cross-reactivity between walnut and Brazil 
nut was the only case of cross-reactivity (Teuber et al., 2002). 
 
6.2.2.4.2. Neonatal swine 
 
The model developed by Helm et al. (2002) uses newborn piglets from Large White/Landrace sows. In 
the optimal sensitisation protocol the piglets were i.p. sensitised on days 9, 10 and 11 after birth and 
boosted the same way on day 18 and 25. Sensitisation was performed using crude peanut protein 
extract in presence of cholera toxin. After i.g. challenge, the allergic response was measured using an 
evaluation of clinical manifestations (e.g. cutaneous, respiratory and digestive symptoms), skin testing 
after intradermal injection of protein and histologic examination of the digestive tract. In serum, 
specific IgG antibodies were detected by ELISA whereas specific reaginic antibodies were determined 
by PCA (Helm et al., 2002). 
The physiological and immunological characteristics of pigs are similar to that of humans (Murtaugh, 
1994). They closely resemble humans in gastrointestinal physiology and in the development of 
mucosal immunity. However, piglets are described to be immunodeficient at birth and highly 
dependent upon colostral immune factors delivered from the sow (Stokes et al., 2004). Such passive 
immunity of newborn piglets is followed by a complete development of the immunity. The final 
maturation of the intestinal epithelium reaches the stage of an adult pig after seven weeks (Machado-
Neto et al., 1987; Stokes et al., 2004). Therefore, neonatal piglets have an anatomy, nutritional 
requirements and other characteristics of the digestive tract that are similar to those of the newborn 
human infant (Helm et al., 2003; Untersmayr and Jensen-Jarolim, 2006). Main physical symptoms 
after oral challenge are similar to those observed in humans. Moreover histology of the digestive tract 
shows architectural abnormalities similar to those observed in intestinal mucosa of allergic individuals 
(Helm et al., 2002). Due to limited experimental availabilities the presence of reaginic antibodies 
could only be suggested after exposure to peanut proteins. This model has been tested with peanut 
proteins (Helm et al., 2002) and recently with the chicken ovomucoid (Rupa et al., 2008). 
 
6.2.2.5. Conclusion 
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The models described above mainly concern the sensitisation of the animal to a certain protein, which 
is a most important part of allergenicity testing. When a protein is able to provoke sensitisation, it 
most likely can cause allergic reactions upon re-exposure. This is the reason why most models mainly 
focus on the sensitising potential of proteins. Still, although considerable progress has been made it is 
clear that none of the developed animal models is currently sufficiently evaluated, validated and 
widely accepted 
 
6.2.3. Animal models for investigating the elicitation potential 
 
The assessment of the potency of an allergenic protein/food to elicit an allergic reaction is normally 
studied in animals that have previously been experimentally sensitised to the protein or the whole 
food, using either an i.g. or an i.p. route in presence or absence of adjuvant, in order to qualitatively 
and quantitatively optimise the IgE response. Challenges are then realised in order to reproduce the 
characteristics of the allergic reaction in humans at a serological and cellular level and also with 
regards to systemic clinical manifestations. The challenge may be performed using the sensitising 
protein either under its native structure or after modification, e.g. by processing, a cross reactive 
protein or the whole food in which the protein is present. The main animal models are mice and rats 
but guinea pig and, more recently baby pigs are also used. 
 
The model developed by Li et al. (1999; 2000) used 3 to 5 week old female C3H/HeJ mice. The mice 
were sensitised on day 0 and boosted five times at weekly intervals, by intragastric gavage of protein 
in presence of cholera toxin as adjuvant. On day 42 the mice were i.g. challenged with two doses of 
protein and specific IgE antibodies were measured in blood samples. After challenge clinical 
symptoms occurred including increased vascular permeability, hyper-permeability of the gut mucosa, 
lung inflammation and systemic anaphylaxis symptoms such as anaphylactic shock. They were 
evaluated with a standardised scoring system ranging from no symptoms to death. Other allergic 
responses were determined by for example detection of vascular leakage, determination of plasma 
histamine levels and cutaneous mast cell degranulation. The model mimics the clinical and 
immunological characteristics of peanut and cow’s milk allergy which involve multiple organs in 
human allergic individuals. 
 
Such a model thus allows to analyse different mechanisms involved in the immune-pathology of an 
IgE-mediated allergic reaction, to measure and to grade the severity of the reaction according to the 
serological and clinical manifestations it induces and to study the impact of any change in the structure 
of the protein on its allergenicity. This is an important matter since the production of a heterologous 
foreign protein in a GMO might result in structural modifications. 
 
Adel-Patient et al. (2003) developed a BALB/c mouse model which reproduced the manifestations 
observed during the allergic reaction to BLG and showed that, after challenge, the biochemical and 
clinical manifestations occurring during both the early and late phase of the allergic reaction differ and 
are activated through different metabolic pathways depending on the structure (i.e. native vs. 
denatured) of the allergen. 
 
Other studies in mice (BALB/c, C3H/HeJ) and rat (BN) models have dealt with more mechanistic, 
therapeutic and prophylactic aspects of allergenicity and have been summarised by Knippels et al 
(2004). 
 
6.2.4. Models for investigating the adjuvanticity 
 
In vivo testing of adjuvanticity in relation to food allergens have been successfully performed in a 
number of laboratories using oral immunisation protocols with cholera toxin as adjuvant (Li et al., 
2000), often with slight modifications of the original procedure to ensure good responses (e.g. Vinje et 
al., 2009). The cholera toxin model can serve as a fairly reliable positive control. Peanut extract or 
purified allergenic proteins can be used as a standard allergen. Specific IgE in serum are determined 
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by ELISA or PCA – the former test determines specific IgE antibody levels, while the latter test 
indicates biologically functional IgE levels (for references, see Vinje et al., 2009). Clinical 
anaphylactic reaction can also be used as an outcome (Li et al., 2000; Vinje et al., 2009). To be able to 
detect a possible weaker adjuvant effect than that of cholera toxin, one may want to use more 
extensive immunisation schedules (Brunner et al., 2009; Scholl et al., 2005; Untersmayr et al., 2005; 
Untersmayr et al., 2003). They showed that anti-acid treatment enhanced the IgE response to oral 
administration of fish and hazelnut allergen in mice and also evidenced the adjuvant effect of 
aluminium hydroxyde. A similar effect was also observed in humans (Scholl et al., 2005; Untersmayr 
et al., 2005). 
 
Animal models may also be used to assess the adjuvanticity of a newly expressed protein in a GMO by 
comparing the Th1 and Th2 immune responses induced by a known allergen (e.g. OVA) in presence 
or absence of the protein in question. The adjuvanticity of Cry proteins (i.e. insecticidal proteins from 
Bacillus thuringiensis) has thus been demonstrated in mice (Moreno-Fierros et al., 2003; Vazquez-
Padron et al., 1999). Prescott et al. (2005) reported that a recombinant form of the bean α amylase 
inhibitor was expressed in a GM pea with post-translational modifications (i.e. in the glycosylation 
pattern) which may result in an increased antigenicity and adjuvanticity. Recently using the BALB/c 
mouse model, Guimaraes et al. (2008) have shown that the adjuvanticity of the Cry 1Ab protein as 
expressed in the genetically modified MON 810 maize was much lower than previously described and 
that the mechanism of action would anyway be different from that of the cholera toxin. In addition and 
as for allergenicity, degradation by digestive enzymes may alter the adjuvanticity of a newly expressed 
protein as a consequence of alteration of its structure and biological activity. Also denaturation during 
heat treatments could result in a decrease of immunoreactivity and adjuvanticity of the native protein 
(de Luis et al., 2009). However, this may not be a general rule and for instance, it is recognised that 
receptors for innate immunity are specialised for detecting also denatured adjuvants. 
 
6.3. Conclusions and recommendations 
 
Most animal models are designed in such a way that they circumvent, or at least, try to circumvent the 
mechanism of oral tolerance. Some have an increased susceptibility for allergic disorders, i.e. the BN-
rat model, the BALB/c mouse model, the neonatal swine model and the spaniel/basenji type dog 
model. They may also reproduce, at least partially, the initial changes occurring at the intestinal 
epithelium and the symptoms that accompany the allergic reaction. In addition, several transgenic 
mouse models have been developed and are available for the study of the factors and mechanisms of 
(de)regulation of the immune response and induction of allergy. 
 
A huge variability is observed in allergic responses of humans which may vary depending on 
individual susceptibility based on genotype, exposure and environmental conditions. Like in allergic 
humans, the different animal models reflect the influence of the genetic background on the 
susceptibility for the development of the allergy. However, no “ideal” animal model can mimic the 
heterogeneity of the population of allergic people nor take into account all those factors that interact in 
the induction or repression of an allergic reaction to a protein and consequently reproduce the 
conditions of development of an allergic reaction to food in human consumers. Several animal models, 
including transgenic mice, can contribute to a better understanding of the different mechanisms 
underlying the sensitisation and elicitation which may provide useful additional tools in the risk 
assessment process but a single model is probably not sufficient to cover all requirements for the 
prediction of allergenicity of novel proteins and GM foods. An option would be a combination of 
models with different characteristics and procedures, selected on a case-by-case basis and integrated in 
the whole assessment process to provide a reliable evaluation of the frequency and severity of allergic 
reactions to a novel protein with acceptable sensitivity and specificity.  
 
In addition, combining transgenic mouse models with other approaches for allergenicity testing could 
be a powerful strategy in the future in order to maximise and better characterise the immune response 
in particular conditions. In conjunction with “-omics” technologies studies on transgenic mice could 
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establish a very sensitive assay system using dosages characteristic of human exposure to identify 
potential allergens, and lead to less use of human material and experimental animals.  
 
Finally, to date no single animal model is available for assessing the allergenicity and particularly the 
potential to de novo sensitise atopic individuals of a novel protein or a novel food derived from a 
GMO (Goodman et al., 2008; Knippels et al., 2000; Ladics et al., 2003; Ladics et al., 2010; McClain 
and Bannon, 2006; Selgrade et al., 2009; Thomas et al., 2008; Thomas et al., 2009). Animal models 
are not conclusive per se but they can provide useful information on the different mechanisms 
underlying the induction and development of an allergic reaction. 
 
Conclusions 
Animal models may be used for assessing the potential of a novel protein to elicit an allergic reaction 
in individuals already sensitised when there are indications of a possible cross reactivity with a known 
allergen based on the origin of the source and/or the outcomes of bioinformatics studies. Different 
animal models are available in which they can be efficiently experimentally sensitised before being 
challenged with the test protein. All the different animal models available (e.g. different species and/or 
different procedures of sensitisation) have advantages and pitfalls that preclude any single test to 
provide definite conclusions. However, they may be used in combination in order to reproduce as 
much as possible the different situations of exposure and reaction in at risk groups of the population 
and thus improve both the sensitivity and specificity of the assessment.  
Animal models could be used in addition to or as substitutes of IgE binding studies using allergic 
human sera for assessing the allergenicity of the newly expressed protein or the whole GM plant 
although sera from clinically well characterised allergic individuals are the reference material. In the 
case when the host of the genetic modification is a known food allergen, sera from animals 
experimentally sensitised in appropriate conditions could provide useful information when used in 
western blotting studies for qualitative and quantitative analysis of the allergen repertoire (i.e. the 
pattern of endogenous allergens) of the GM plant vs. its appropriate comparators. 
 
In case there is indication from the origin or from the structure of the newly expressed protein that it 
might act as or like a sensitiser, the potential of the newly expressed protein to sensitise de novo atopic 
individuals could be experimentally investigated only on animal models. Various animal models (e.g. 
using different animal species, including transgenic mice, and different procedures of immunisation) 
are available to study the polarisation of the immune response toward a Th2 type response and the 
development of an allergy. In many cases, animals respond to the same epitopes and in the same way 
as it is found in humans. However the value of any animal model in the prediction of allergenicity of a 
food protein in humans has not been validated. The variability of the human individual immune 
response and conditions of exposure that may be encountered preclude that a single test could be used 
to predict with a sufficient sensitivity and specificity whether or not any protein is likely to be a 
sensitiser in the real life conditions of exposure. 
 
As discussed above useful information could however be obtained by combining different models in 
order to reproduce as much as possible the genetic background as well as different environmental 
factors and conditions of exposure of at risk groups of the population on a case-by-case basis. The 
sensitisation after experimental immunisation should be assessed by a comprehensive analysis of the 
immune response in animals and confirmed upon challenge with the test protein. The same general 
considerations also apply for the assessment of immunogenicity and adjuvanticity of food proteins. 
 
Toxicological studies using multi-transgenic mice have brought significant progress in understanding 
the physiological mechanisms of the response to xenobiotics (Hwang et al., 2001). Therefore, it is also 
expected that the use of multi-transgenic animals in allergenicity testing will help in better 
understanding the role of different factors in the process that results in allergic reaction. 
 
To sum up, many animal models (including transgenic animal models) have been and are currently 
developed for sensitisation, elicitation and adjuvanticity testing using different species and procedures. 
However, none of them fully reproduce either the diversity and variability of the IgE response in 
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heterogeneous populations of allergic humans, or the conditions of sensitisation that occur in the real 
life upon given conditions of exposure and environment. Animal models are therefore frequently 
considered not validated and inconclusive for the assessment of allergenicity (Goodman et al., 2008; 
Knippels et al., 2000; Ladics et al., 2003; Ladics et al., 2010; McClain and Bannon, 2006; Selgrade et 
al., 2009; Thomas et al., 2008; Thomas et al., 2009). Nonetheless, animal models can provide useful 
information on the different mechanisms underlying the induction and development of an allergic 
reaction.  
 
Recommendations 
• Antibodies with appropriate characteristics of specificity and affinity, obtained from animals 
experimentally sensitised in well-defined conditions could be used as a substitute for allergic 
human sera for a (pre-)screening of the immunological cross-reactivity of the newly expressed 
protein with known allergens. They could also provide useful information when used in western 
blotting studies for qualitative and quantitative analysis of the allergen repertoire of the GM plant 
as compared to its appropriate comparator(s). 
• In specific cases such as when indication for sensitisation or adjuvant potential exists, 
additional information gained from (combination of) animal models might be useful for 
clarifying the mechanisms involved and the possible consequences in terms of safety of the 
newly expressed proteins.  
• Future work should aim to improve the sensitivity and specificity of animal models tests as to 
allow consistent and reliable conclusion on sensitising and/or adjuvant potential and explore 
the use of transgenic animals which are likely to develop de novo sensitisations to newly 
expressed proteins and are extrapolable to the human situation. Different species and/or 
different procedures of immunisation/sensitisation may be used in combination, including in 
the presence or absence of an adjuvant, in order to reproduce as much as possible the different 
situations of exposure and reaction observed for at risk groups of human consumers and thus 
improve the sensitivity and specificity of the test. A complete analysis of the whole immune 
reaction occurring after challenge should then be performed including observation and 
measurement of clinical and biological symptoms. In addition, challenges of experimentally 
sensitised animals with different doses of the newly expressed proteins could be performed 
using either purified proteins or whole protein extracts from the GMO in order to assess the 
impact of possible interactions between the newly expressed protein and the food matrix on 
the potential of elicitation. When there is no information on the novel protein or on the food 
derived from a GMO or when specific situations are to be assessed such as the allergy risk in 
young children (see Annex 1.8), specific tests might be developed. In such cases, the use of 
animal pups or of transgenic animals in which immune barriers have been abolished to 
facilitate the development of an immune response towards an allergic sensitisation could be 
considered in the risk assessment process. In a prospective way it is recommended to further 
develop transgenic animal models for allergenicity testing not only with single genes inserted 
or deleted from the animal genome but also containing multiple gene cassettes to modify the 
ability to develop allergenicity more profoundly.  
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ABBREVIATIONS 
 
 
- Ab: Antibody 
- Ag: Antigen 
- APC: Antigen-Presenting Cell 
- BLAST: Basic Local Alignment Search Tool  
- CBB: Coomassie Brilliant Blue, staining 
- CCD: Cross-reactive Carbohydrate Determinant 
- CE: Capillary Electrophoresis 
- CF: Chromatofocusing 
- CV: Cross Validation 
- CZE: Capillary Zone Electrophoresis 
- DBPCFC: Double Blind Placebo Controlled Food Challenge 
- 2-DE: Two Dimensional Electrophoresis 
- DIGE: Difference in Gel Electrophoresis 
- DTH: Delayed-Type Hypersensitivity 
- EAST: Enzyme Allergosorbent Test 
- ELIFA: Enzyme Linked Immuno Filtration Assay 
- ELISA: Enzyme Linked Immunosorbent Assay 
- EST: Expressed Sequence Tag 
- GI: Gastrointestinal 
- IEF: Isoelectric Focusing 
- IFN: Interferon 
- Ig: Immunoglobulin 
- IL: Interleukin (IL-1, IL-2…) 
- ITH: Immediate-Type Hypersensitivity 
- LC: Liquid Chromatography 
- LC-ESI-IT-MS/MS: Liquid Chromatography - Electron Spray Ionisation - Ion-Trap - tandem Mass 
Spectrometry 
- LC-ESI-MS: Liquid Chromatography - Electron Spray Ionisation - Mass Spectrometry 
- LC-MS: Liquid Chromatography - Mass Spectrometry 
- LTP: Lipid-Transfer-Protein 
- MALDI-MS: Matrix Associated Laser Desorption Ionisation Mass Spectrometry 
- MEME: Multiple EM for Motif Elicitation algorithm 
- MHC: Major Histocompatibility Complex 
- MS: Mass Spectrometry 
- NOD: Nucleotide oligomerisation domain 
- nsLTP: non-specific Lipid Transfer Proteins 
- PAG: Poly-Acrylamide Gel 
- PAGE: Poly-Acrylamide Gel Electrophoresis  
- PBMC: Peripheral blood mononuclear cells  
- pI: Isoelectric Point 
- PMF: Peptide Mass Finger printing  
- PR: Pathogenesis-Related 
- Q-TOF-MS/MS: Quadrupole Time Of Flight Mass Spectrometry 
- RAST: Radio Allergosorbent Test 
- RBL: Rat Basophil Leukemias 
- ROC: Receiver Operating Characteristic curves 
- RP: Reversed Phase 
- SDS-PAGE: Sodium Dodecyl Sulphate – Poly-Acrylamide Gel Electrophoresis 
- SELDI-MS: Surface Enhanced Laser Desorption/Ionisation Mass Spectrometry 
- SELDI-TOF-MS: Surface-Enhanced Laser Desorption/Ionisation Time Of Flight Mass Spectrometry 
- SGE: Slab-Gel Electrophoresis 
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- SGF: Simulated Gastric Fluid 
- SPT: Skin Prick Test 
- TGF: Transforming Growth Factor 
- Th cells: T-helper cells 
- TLR: Toll-Like Receptor 
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GLOSSARY 
 
 
- Adjuvants: substances that, when co-administered with an antigen, increase the immune response to 
that antigen. 
- Allergen repertoire: the pattern of expression of endogenous allergens in an allergenic plant. 
- Angio-edema: the swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues. 
- Antigen presentation: the process by which certain cells in the body (antigen-presenting cells) 
express antigen on their surface in a form recognizable by lymphocytes.  
- B cell: lymphocytes that develop in the bone marrow in adults and produce antibody. 
- Basic Local Alignment Search Tool (BLAST): a computer program for comparing DNA and protein 
sequences. 
- Basophils: granulocytic white blood cell with cytosolic granules that stain with basic dyes and 
contain biologically active mediators responsible for the clinical manifestations of the allergic reaction 
when released in the organism after IgE mediated degranulation of basophils. 
- CAPR system: a solid-phase quantitative immunoassay for measuring allergen-specific IgE in human 
serum. 
- CD markers: surface molecules of leukocytes cells used to differentiate cell populations.  
- Coeliac disease: an autoimmune disorder of the small intestine that occurs in genetically predisposed 
people. 
- CpG motifs: components of bacterial DNA. 
- Cross-reactivity: when sensitisation to one allergen causes the immune system to respond to another 
allergen because of shared epitopes (identical or with a high degree of similarity) between the 
allergens. 
- CTLA-4: a protein that plays an important role in the regulation of the immune system. It is also 
known as CD152. 
- Cytokines: a generic term for soluble molecules that mediate interactions between cells. 
- Dendritic cell: a set of cells present in tissues that capture antigens and migrate to the lymph nodes 
and spleen, where they are particularly active in presenting the processed antigen to T cells.  
- E-value: an alignment derived from a FASTA search of a database is accompanied with an E-value, 
which represent the number of times the corresponding alignment score is expected at chance. 
- Eczema: a form of dermatitis or inflammation of the epidermis.   
- ELISPOT assay: a capture assay in which cytokines produced by activated cells are trapped onto 
membranes coated with specific anti-cytokine antibodies. 
- Endosome: a membrane-bound compartment allocated inside cells that is involved in intracellular 
transport. 
- Enzyme Allergosorbent Test (EAST): enzyme solid phase immunoassay used for the determination 
of specific IgE antibodies in serum. 
- Enzyme Linked Immunosorbent Assay (ELISA): a solid phase enzyme immunoassay developed in 
different formats and used for the quantitative measurement of antigens or antibodies. 
- Epitope: an epitope is the part of an antigen that interacts with the antibody.  Epitopes can be either 
conformational (i.e. determined by the 3D structure of the antigen) or linear (i.e. determined by a small 
stretch of contiguous amino acids). 
- FasL: is a type II transmembrane protein that belongs to the TNF family. 
- FASTA: the first widely used algorithm for database similarity searching. The program looks for 
optimal local alignments by scanning the sequence of a query protein and comparison with that of 
known allergens. 
- Glycosylation: process by which sugar residues attach to proteins.  
- GM-CSF: proteins secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. 
- Hapten: a small molecule that can induce a specific immune response when covalently linked to a 
carrier protein and not only by itself. 
- IgE-abs: IgE-antibodies  
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- Immunoglobulins (Ig): serum antibodies, including IgA, IgD, IgE, IgG and IgM that are used by the 
immune system to identify and neutralise antigens. Each of the Ig is made up of two heavy chains and 
two light chains and has two antigen-binding sites.   
- In silico: data generated and analysed using modelling and information technology approaches. 
- In vitro: study in the laboratory usually involving serum, isolated organs, tissues, cells or cellular 
fractions.  
- Inflammation: a series of reactions that bring cells and molecules of the immune system to sites of 
infection or damage. This appears as an increase in blood supply, increased vascular permeability, and 
increased transendothelial migration of leukocytes.  
- Interferons: a group of molecules involved in signaling between cells of the immune system.  
- Interleukins: a group of glycoproteins involved in signaling between cells of the immune system.  
- Isoallergen: Isoallergens are defined (by the IUIS/WHO Allergen Nomenclature Sub-Committee) as 
molecules (from the same species) sharing similar size, identical biological function or feature ≥ 67 % 
amino acid sequence identity. 
- Leucotriene: naturally produced eicosanoid lipid mediators that may be responsible for the effects of 
an inflammatory response. 
- Lymph nodes: an organ formed by many types of cells that is part of the lymphatic system. 
- M cells: specialised epithelial cells of mucosal surfaces lining the respiratory and intestinal tracts. 
They participate in generating mucosal immune protection by sampling and delivering antigens to the 
underlying lymphoid tissue.  
- Major allergens: allergens that are recognised by more than 50% of a population of individuals 
allergic to the food. The concept of major allergens relates only to the frequency of recognition by IgE 
antibodies, and it is not related to the severity of the clinical manifestations of an allergic reaction. 
- Major histocompatibility complex: a genetic region found in most vertebrates that code for proteins 
found on the surfaces of cells that help the immune system recognise foreign substances.   
- Mimotope: a molecular sequence which mimics the epitopic region of a particular antigen, but which 
does not contain the specific amino acid sequence that comprises the epitope.  
- Motif: An amino acid sequence motif can be described as a sequence of amino acids that defines a 
substructure in a protein that can be connected to function or to structural stability. 
- NOD receptors: cytoplasmic proteins that may have a variety of functions in regulation of 
inflammatory and apoptotic responses. 
- Pfam: database with a large collection of protein families, each represented by multiple sequence 
alignments, http://pfam.sanger.ac.uk/ 
- Presumed non-allergens: proteins with presumably low allergenic potential under normal 
conditions/exposure 
- Primary sensitisation: the allergic reaction is elicited by the same allergen that induced the allergic 
sensitisation.  
- Profiling: creation of patterns of the substances within a sample with the aid of analytical techniques, 
such as functional genomics, proteomics, or metabolomics. The identity of the compounds detectable 
within the pattern needs not to be previously recognised. 
- Propensity scales: a propensity score is assigned to every amino acid, based on studies of their 
physico-chemical properties (hydrophobicity, normalised Van der Waals volume, polarity, 
polarizability, charge, surface tension, secondary structure and solvent accessibility) 
- Proteomics: protein profiling using among others 2D-gel electrophoresis and mass spectrometry. 
- Radio Allergosorbent Test (RAST): a solid-phase radioimmunoassay for detecting IgE antibody 
specific for a particular allergen. 
- Ribonucleases: enzymes that catalyse the degradation of RNA 
- Secondary allergy or cross-allergy: the allergic reaction is elicited by an allergen cross-reacting with 
the allergen that caused the sensitisation.  
- Sequence alignment: a method to compare and represent similarities and differences between 
sequences of biomolecules. 
- Skin-prick test: an allergy test that involves placing a small amount of suspected allergen to a scratch 
on the skin. 
- T cell: Lymphocytes that differentiate primarily in the thymus and are central to the control and 
development of immune responses.  
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- T helper (Th1, Th2 and Th17): a sub-group of lymphocytes that play an important role in 
establishing and maximising the immune response. 
- Th (T-helper) cells: different types of T helper lymphocytes characterised by different cytokine 
production profiles: Th1 cells secrete IL-2, IFNγ… whereas Th2 cells secrete IL-4, IL-5… 
- TGF (Transforming growth factors): a group of cytokines with the ability to promote fibroblast 
growth.  
- TNF (tumor necrosis factor): a group of proinflammatory cytokines encoded within the MHC. 
- Tolerance: a state of specific immunological unresponsiveness and therefore, inability to respond to 
antigenic stimulus. 
- Toll-like receptors: a group of cell surface receptors of natural immunity that recognise molecules 
from pathogens.  
- Transcription factor: proteins that bind to specific DNA sequences and control the transcription from 
DNA to RNA. 
 
